{"meta":{"query_hash":"edc9517c5bb8","filters":{"venue":"Clinical Genitourinary Cancer"},"cohort_total":239,"direct_labels_cover":0,"predictions_cover":239,"exported":239,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/edc9517c5bb8","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Genitourinary+Cancer"},"results":[{"id":"W1965322951","doi":"10.1016/j.clgc.2014.06.004","title":"Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Medicine; Perioperative; Urothelial carcinoma; Salvage therapy; Oncology; Chemotherapy; Internal medicine; Urology; Surgery; Bladder cancer; Cancer","score_opus":0.0770716121855227,"score_gpt":0.4207425315289896,"score_spread":0.3436709193434669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965322951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951404,0.026703782,0.005596605,0.0037934238,0.002461159,0.0032844318,0.0006244682,0.00006686178,0.00606526],"genre_scores_gemma":[0.991799,0.000986813,0.0029012598,0.0011916049,0.0005038332,0.0017387158,0.0001891424,0.000023911196,0.0006657384],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.94982505,0.042734336,0.0031910138,0.0021722445,0.0012061293,0.0008712464],"domain_scores_gemma":[0.96220684,0.02813038,0.0042535295,0.0023498815,0.000674861,0.0023843842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033025395,0.00097524404,0.0039678914,0.00035621322,0.0007955999,0.0026241615,0.0011677754,0.002538578,0.0036220779],"category_scores_gemma":[0.04844497,0.00066806347,0.0068767983,0.00076701347,0.0015810039,0.003238471,0.0009925299,0.0042638695,0.0002933099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9247704,0.0024601452,0.018981868,0.0008797868,0.012333322,0.000058157453,0.00014589235,0.002108517,0.0011868721,0.0007621828,0.0005614375,0.035751447],"study_design_scores_gemma":[0.40174344,0.42570043,0.10516921,0.0009292423,0.03815573,0.0002288402,0.00038039067,0.00965285,0.0022619807,0.0072300867,0.00832471,0.00022318955],"about_ca_topic_score_codex":0.0005925077,"about_ca_topic_score_gemma":0.0018496308,"teacher_disagreement_score":0.033025395,"about_ca_system_score_codex":0.0013521746,"about_ca_system_score_gemma":0.0025791458,"threshold_uncertainty_score":0.1746571},"labels":[],"label_agreement":null},{"id":"W1966303504","doi":"10.3816/cgc.2008.n.008","title":"Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer","year":2008,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; Sunnybrook Health Science Centre; Vancouver General Hospital","funders":"Health Canada; Abbott Laboratories","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Internal medicine; Radiation therapy; Population; Androgen suppression; Prospective cohort study; Prostate; Androgen deprivation therapy; Oncology; Urology; Cancer","score_opus":0.11971463573603029,"score_gpt":0.44189972567344477,"score_spread":0.32218508993741446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966303504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989747,0.00032189526,0.00005580412,0.000045318615,0.000010624981,0.00012556047,0.0002973591,0.000004853803,0.00016390189],"genre_scores_gemma":[0.99827635,0.00021048465,0.00014982671,0.00009816771,0.000037624763,0.00019286993,0.0008332645,0.0000045649413,0.00019679948],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99855,0.00086792134,0.00008235699,0.0001696091,0.00013838195,0.00019164833],"domain_scores_gemma":[0.9970599,0.0006950423,0.00077949354,0.00027480282,0.00015928865,0.0010315278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036914516,0.001504559,0.0019339195,0.00046446646,0.00076439837,0.0010224676,0.0010738678,0.0011462932,0.0015091699],"category_scores_gemma":[0.0021762983,0.0006272738,0.002395754,0.00074876327,0.0013445927,0.0008184626,0.000638348,0.0022703758,0.00026156064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7378747,0.05010305,0.1787943,0.00023507173,0.0047080386,0.00012549873,0.0003951129,0.0018286037,0.0050477884,0.00008167324,0.0006855695,0.020120641],"study_design_scores_gemma":[0.1867746,0.2920688,0.5143611,0.000027051978,0.0032867373,0.00016789902,0.00026721024,0.001238266,0.0011571693,0.00010477984,0.0004811289,0.000065231376],"about_ca_topic_score_codex":0.0030560626,"about_ca_topic_score_gemma":0.0037823946,"teacher_disagreement_score":0.0036914516,"about_ca_system_score_codex":0.00089827605,"about_ca_system_score_gemma":0.0011357259,"threshold_uncertainty_score":0.019522488},"labels":[],"label_agreement":null},{"id":"W1972744500","doi":"10.3816/cgc.2006.n.004","title":"The Role of Bisphosphonates in the Treatment of Prostate Cancer: Recommendations from an Expert Panel","year":2006,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec","funders":"","keywords":"Medicine; Prostate cancer; Zoledronic acid; Androgen deprivation therapy; Cancer; Oncology; Bisphosphonate; Prostate; Internal medicine; Bone metastasis; Osteoporosis","score_opus":0.1543635953746926,"score_gpt":0.48967063138232564,"score_spread":0.335307036007633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972744500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035071297,0.9845191,0.00072795164,0.010734082,0.0011363787,0.00010515971,0.00036170447,0.000022097985,0.0020428041],"genre_scores_gemma":[0.0019011055,0.9893995,0.0030621719,0.0039359657,0.00048673654,0.00007468064,0.00031076217,0.0000065815584,0.00082242856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988996,0.0002735271,0.00027797898,0.00012313452,0.00036185762,0.0000639006],"domain_scores_gemma":[0.9965946,0.0017388649,0.00046872787,0.000048846236,0.0009708905,0.00017813516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053524226,0.001174349,0.0032403974,0.0027266198,0.0004340546,0.0012406069,0.0032790222,0.0030992047,0.0026450017],"category_scores_gemma":[0.005133322,0.00050021784,0.0023569355,0.0030015833,0.00048727338,0.0012909356,0.0008358151,0.0033964706,0.0013976037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004427866,0.00008422835,0.00075337564,0.040142115,0.0007762174,0.0003448919,0.00010932689,0.00080470653,0.00095125724,0.0015592743,0.13939223,0.8146397],"study_design_scores_gemma":[0.00038715784,0.0002038255,0.0035591205,0.05650738,0.003729588,0.00094049313,0.0001686712,0.0003856902,0.0006012607,0.0021207663,0.9313321,0.00006392026],"about_ca_topic_score_codex":0.008503348,"about_ca_topic_score_gemma":0.021764223,"teacher_disagreement_score":0.008503348,"about_ca_system_score_codex":0.0016241859,"about_ca_system_score_gemma":0.0048743626,"threshold_uncertainty_score":0.028306663},"labels":[],"label_agreement":null},{"id":"W1976575396","doi":"10.1016/j.clgc.2014.06.015","title":"Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Canadian Centre for Applied Research in Cancer Control","keywords":"Sunitinib; Medicine; Dosing; Renal cell carcinoma; Toxicity; Oncology; Internal medicine; Carcinoma; Pharmacology","score_opus":0.06840083324777685,"score_gpt":0.36831609110235947,"score_spread":0.2999152578545826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976575396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990403,0.00030678016,0.000032557797,0.000093128416,0.0000025985266,0.0000056835247,0.00014561796,0.0000028659235,0.0003703792],"genre_scores_gemma":[0.9996679,0.00008424993,0.000028606617,0.000038512222,0.0000035361616,0.000002466655,0.00011450911,0.0000016528561,0.000058520734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933845,0.00014326633,0.0000887016,0.00014541644,0.00015351745,0.00013054951],"domain_scores_gemma":[0.9976724,0.0004246227,0.0012421804,0.00006361761,0.0002182525,0.00037895617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039989167,0.00010801113,0.00038047714,0.00048669265,0.00047720157,0.00076606683,0.00026659656,0.00039640587,0.0010487379],"category_scores_gemma":[0.0045557977,0.0001476932,0.00040923728,0.0013071875,0.00021218458,0.00053310615,0.0003033616,0.000542303,0.00008411402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000202929,0.00008680569,0.99607074,0.000011413292,0.00006315399,0.00006394762,0.00012696974,0.000069159956,0.00011516447,0.000014941948,0.00010188888,0.0030729463],"study_design_scores_gemma":[0.000020709163,0.00023634227,0.99857223,0.000008584958,0.000038497576,0.00023412182,0.0003727461,0.0002798634,0.0000481716,0.00003949596,0.00014363375,0.0000055911246],"about_ca_topic_score_codex":0.019392893,"about_ca_topic_score_gemma":0.029720858,"teacher_disagreement_score":0.019392893,"about_ca_system_score_codex":0.0011890886,"about_ca_system_score_gemma":0.00090484455,"threshold_uncertainty_score":0.038560033},"labels":[],"label_agreement":null},{"id":"W1979333574","doi":"10.1016/j.clgc.2013.04.025","title":"Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Pazopanib; Docetaxel; Oncology; Chemotherapy; Metastatic Urothelial Carcinoma; Response Evaluation Criteria in Solid Tumors; Context (archaeology); Cyclophosphamide; Gemcitabine; Progressive disease; Cancer; Bladder cancer; Sunitinib; Urothelial carcinoma","score_opus":0.06850117939776647,"score_gpt":0.40310533449699604,"score_spread":0.3346041550992296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979333574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674531,0.01768837,0.00197905,0.004243594,0.0011260393,0.0023098679,0.0006063512,0.000040021467,0.0045535797],"genre_scores_gemma":[0.99484324,0.0008203625,0.0009174036,0.0012095023,0.00038574106,0.0009377165,0.00029569617,0.000015003018,0.0005753173],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9661093,0.02938986,0.001663756,0.0012610615,0.00078933424,0.00078667165],"domain_scores_gemma":[0.97176886,0.020426536,0.003584773,0.0014872613,0.00058135745,0.0021512136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027467674,0.0007416353,0.0031886976,0.000344119,0.0007277383,0.0021288767,0.00082982954,0.0021561976,0.0031688772],"category_scores_gemma":[0.03752556,0.00042323087,0.005162439,0.00070272473,0.0012014615,0.0019455743,0.0009939361,0.0035849614,0.00025280373],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8883143,0.003042154,0.037022084,0.0011578008,0.011172531,0.00008017668,0.00019946604,0.0020095774,0.0014725747,0.0007219323,0.0008613059,0.05394614],"study_design_scores_gemma":[0.36822444,0.3697293,0.20897895,0.00094263116,0.027106449,0.00029423868,0.00040093085,0.007444562,0.00286425,0.005047432,0.008805055,0.00016170392],"about_ca_topic_score_codex":0.00074974285,"about_ca_topic_score_gemma":0.0021260513,"teacher_disagreement_score":0.027467674,"about_ca_system_score_codex":0.0015623621,"about_ca_system_score_gemma":0.0023950771,"threshold_uncertainty_score":0.14526463},"labels":[],"label_agreement":null},{"id":"W1985598595","doi":"10.1016/j.clgc.2013.07.004","title":"Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"Bayer HealthCare","keywords":"Medicine; Clinical trial; Renal cell carcinoma; Intensive care medicine; Clinical study design; Disease; Targeted therapy; Identification (biology); Medical physics; Oncology; Cancer; Internal medicine","score_opus":0.5976262395296403,"score_gpt":0.5387439501577905,"score_spread":0.058882289371849805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985598595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015424068,0.9900226,0.000701614,0.0065201893,0.0008495463,0.00011654684,0.000061446095,0.000018666478,0.0015550215],"genre_scores_gemma":[0.0036744638,0.98015577,0.004631082,0.008486184,0.0016055651,0.00047432608,0.000120321485,0.000012375193,0.00084008824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954572,0.0027691023,0.0007031639,0.0002884483,0.0005948228,0.00018725116],"domain_scores_gemma":[0.9715466,0.023300333,0.0016700724,0.00033255242,0.0025565866,0.0005939007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021971932,0.0010955298,0.0073688077,0.0015965801,0.00067353575,0.0043314095,0.002930544,0.0043403576,0.0077879606],"category_scores_gemma":[0.023223806,0.00060656434,0.002785605,0.0016563453,0.0016074582,0.0041964594,0.0013921042,0.007923217,0.0018203183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083215913,0.00023556445,0.00037661367,0.051441867,0.0006170497,0.00031682444,0.00014292503,0.0013404692,0.00094084174,0.014252351,0.045551598,0.8839517],"study_design_scores_gemma":[0.0015280924,0.001088513,0.0011445724,0.07875182,0.0021325548,0.0009162467,0.00029073207,0.0005752588,0.0003921959,0.02083642,0.8922662,0.00007734315],"about_ca_topic_score_codex":0.0016651342,"about_ca_topic_score_gemma":0.007417703,"teacher_disagreement_score":0.021971932,"about_ca_system_score_codex":0.0019825802,"about_ca_system_score_gemma":0.006422702,"threshold_uncertainty_score":0.11620003},"labels":[],"label_agreement":null},{"id":"W1985605203","doi":"10.1016/j.clgc.2014.10.005","title":"Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Docetaxel; Medicine; Taxane; Paclitaxel; Oncology; Internal medicine; Clinical endpoint; Clinical trial; Chemotherapy; Salvage therapy; Cancer; Breast cancer","score_opus":0.2056236045651798,"score_gpt":0.5066562109203223,"score_spread":0.3010326063551425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985605203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79589134,0.060989574,0.05991718,0.013657691,0.00318527,0.042310834,0.002109122,0.00032604675,0.021613028],"genre_scores_gemma":[0.95013833,0.0025889701,0.021364698,0.004077868,0.00057507044,0.019311251,0.00047055373,0.00007739293,0.0013958715],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.8166259,0.1598546,0.013903545,0.0041971337,0.0042242855,0.0011945671],"domain_scores_gemma":[0.8605661,0.08807095,0.026127381,0.016116846,0.0050246106,0.004094143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.18376744,0.00090787356,0.0032878907,0.00069650845,0.0009968224,0.0030355472,0.0014599208,0.002066876,0.004673364],"category_scores_gemma":[0.1754519,0.0007246303,0.0028029762,0.0012126715,0.0023470917,0.00316056,0.0017817594,0.003704559,0.0006719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50008494,0.003931852,0.04860168,0.009713424,0.022000294,0.00024006795,0.001826197,0.0042346623,0.004895586,0.019261891,0.004957637,0.38025174],"study_design_scores_gemma":[0.3560755,0.294455,0.1356443,0.0071529625,0.034891378,0.0011647327,0.00097616285,0.017293679,0.011314695,0.06234336,0.07833011,0.00035813687],"about_ca_topic_score_codex":0.00028158724,"about_ca_topic_score_gemma":0.00073775684,"teacher_disagreement_score":0.18376744,"about_ca_system_score_codex":0.0021567878,"about_ca_system_score_gemma":0.003094513,"threshold_uncertainty_score":0.9718667},"labels":[],"label_agreement":null},{"id":"W1985646974","doi":"10.1016/j.clgc.2013.04.012","title":"Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; BC Cancer Agency; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Sunitinib; Temsirolimus; Radiosurgery; Brain metastasis; Internal medicine; Targeted therapy; Bevacizumab; Oncology; Sorafenib; Radiation therapy; Pazopanib; Cancer; Metastasis; Chemotherapy; Hepatocellular carcinoma","score_opus":0.05796752178198649,"score_gpt":0.3139130408923284,"score_spread":0.2559455191103419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985646974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667905,0.0010633486,0.00013000717,0.0002218404,0.0000150432825,0.000032994547,0.03063934,0.000012662894,0.0010943145],"genre_scores_gemma":[0.96897864,0.0005174871,0.0001382022,0.00009015418,0.000028480605,0.00005048705,0.029947985,0.000007767016,0.00024077896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993118,0.00013425961,0.00011978983,0.00017321906,0.00016535584,0.00009549267],"domain_scores_gemma":[0.9975299,0.0003959396,0.001273065,0.00013466824,0.00028756607,0.00037880434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007714355,0.00035442607,0.0009078117,0.0014786694,0.0003874218,0.00095560215,0.00073888997,0.0004890817,0.0010559079],"category_scores_gemma":[0.0035167714,0.00017598471,0.00094655564,0.004231467,0.00023037686,0.0006768081,0.0009936378,0.00049820216,0.00020365325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039918735,0.000024323339,0.9968681,0.000029230765,0.0002527521,0.00002762395,0.00003515659,0.00013538227,0.00006870557,0.000023961704,0.0008302334,0.0013054307],"study_design_scores_gemma":[0.000042808682,0.000032028303,0.9989084,0.000008386606,0.00013372734,0.00009262298,0.00007897366,0.0002151851,0.000044526812,0.00002026877,0.00041752608,0.000005709577],"about_ca_topic_score_codex":0.023150748,"about_ca_topic_score_gemma":0.031456646,"teacher_disagreement_score":0.023150748,"about_ca_system_score_codex":0.000968654,"about_ca_system_score_gemma":0.00094890606,"threshold_uncertainty_score":0.046031952},"labels":[],"label_agreement":null},{"id":"W1989955619","doi":"10.1016/j.clgc.2014.09.004","title":"Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Salvage therapy; Urothelial carcinoma; Systemic therapy; End point; Oncology; Internal medicine; Urology; Cancer; Bladder cancer; Chemotherapy","score_opus":0.051355639782387635,"score_gpt":0.3699060234366396,"score_spread":0.3185503836542519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989955619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963062,0.0016280249,0.00023172915,0.00013550081,0.000021510083,0.000021486934,0.00030460922,0.000011514857,0.0013394922],"genre_scores_gemma":[0.9988827,0.00016241288,0.00008623873,0.00007321765,0.000032640077,0.000013764301,0.00050434226,0.0000031814793,0.00024147717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994043,0.00031256664,0.000038488226,0.00005663746,0.0000898827,0.000098230186],"domain_scores_gemma":[0.99855334,0.0005361267,0.0004298192,0.000060519924,0.00006903029,0.00035116368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012667382,0.00028181312,0.00077260484,0.00047235168,0.00021501479,0.00071139133,0.00028844856,0.00048496856,0.00076912035],"category_scores_gemma":[0.0019698648,0.000090204325,0.00083925476,0.00040375165,0.00023717806,0.0004987776,0.00040437275,0.00083904405,0.00012640706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05798074,0.0009195643,0.8761121,0.00027335205,0.00073950086,0.00069033983,0.00023527323,0.0033522134,0.0055781924,0.00032741812,0.0016653906,0.052125867],"study_design_scores_gemma":[0.0005989625,0.011441034,0.97944915,0.000039320024,0.00055856974,0.0006080328,0.00023343593,0.0040456136,0.0011585418,0.00043159732,0.0014139559,0.000021868784],"about_ca_topic_score_codex":0.0006155669,"about_ca_topic_score_gemma":0.0012200228,"teacher_disagreement_score":0.0012667382,"about_ca_system_score_codex":0.00043413322,"about_ca_system_score_gemma":0.00036426558,"threshold_uncertainty_score":0.0066992044},"labels":[],"label_agreement":null},{"id":"W2020496374","doi":"10.1016/j.clgc.2014.02.009","title":"Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Population; Kidney cancer; Cancer; Environmental health","score_opus":0.0668936906804395,"score_gpt":0.36309174508875747,"score_spread":0.296198054408318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020496374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812293,0.015062303,0.00013482422,0.00041412783,0.00003782607,0.000017562981,0.0002621479,0.000008260252,0.0028335853],"genre_scores_gemma":[0.9972294,0.0020547414,0.000043192398,0.00017988357,0.000059953214,0.0000056690906,0.00017996939,0.0000013091301,0.0002459946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998461,0.000057035333,0.000012271584,0.000022392665,0.000029549357,0.000032626504],"domain_scores_gemma":[0.99973303,0.000083622304,0.00008323118,0.000009940148,0.000031354775,0.00005891902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003542445,0.00011061603,0.000553093,0.00017245609,0.00014290023,0.00025141847,0.00008442244,0.00015787447,0.00084383396],"category_scores_gemma":[0.0010031655,0.00003354048,0.00044892286,0.00021459392,0.00009662877,0.00017978117,0.00015185266,0.0002041239,0.00010272793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034723856,0.0018655249,0.516387,0.00091120193,0.0019646923,0.0008556208,0.00034462698,0.002529771,0.013154346,0.0006377752,0.004454177,0.42217147],"study_design_scores_gemma":[0.00095201156,0.016857777,0.96836084,0.00014331438,0.0014287176,0.0012181675,0.00026635826,0.0012993953,0.0020745872,0.00032385346,0.0070572295,0.000017778115],"about_ca_topic_score_codex":0.0013571604,"about_ca_topic_score_gemma":0.002867535,"teacher_disagreement_score":0.0013571604,"about_ca_system_score_codex":0.00038109056,"about_ca_system_score_gemma":0.00029501843,"threshold_uncertainty_score":0.002822876},"labels":[],"label_agreement":null},{"id":"W2021770899","doi":"10.1016/j.clgc.2014.11.001","title":"First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Centre for Applied Research in Cancer Control; GlaxoSmithKline","keywords":"Pazopanib; Medicine; Temsirolimus; Everolimus; Internal medicine; Oncology; Adverse effect; Renal cell carcinoma; Cohort; Nausea; Clinical trial; Sunitinib; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.04026818035067124,"score_gpt":0.31459013582231826,"score_spread":0.274321955471647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021770899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963483,0.0016599897,0.00008438182,0.00029717843,0.00002199605,0.000046550453,0.00026192263,0.000011222575,0.0012684487],"genre_scores_gemma":[0.99890697,0.00040263083,0.0001296531,0.00018894681,0.000024193932,0.000013124491,0.0002066901,0.000002498595,0.0001252617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996333,0.000084297884,0.000031375635,0.000088670255,0.00006244696,0.00009991871],"domain_scores_gemma":[0.99938524,0.00011325855,0.00019581868,0.000015587368,0.00005306712,0.00023700051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025333095,0.00017745708,0.0005751484,0.00039592755,0.00070146646,0.0005672903,0.00027709865,0.00038008866,0.0012490863],"category_scores_gemma":[0.001571579,0.00017519562,0.0004873396,0.0008416256,0.00022509054,0.00050427514,0.0002609449,0.0007171886,0.00009518282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052864784,0.0011577781,0.94482905,0.00015121723,0.0002799593,0.00065779866,0.00013304413,0.00051519775,0.002498623,0.00008079692,0.001557074,0.042853016],"study_design_scores_gemma":[0.000596397,0.0046279845,0.9868507,0.00006312146,0.00040742755,0.0023953929,0.0006279744,0.0015312163,0.0008413337,0.00019505476,0.00184095,0.000022330265],"about_ca_topic_score_codex":0.008919069,"about_ca_topic_score_gemma":0.037569538,"teacher_disagreement_score":0.008919069,"about_ca_system_score_codex":0.0011636203,"about_ca_system_score_gemma":0.002177823,"threshold_uncertainty_score":0.01773429},"labels":[],"label_agreement":null},{"id":"W2023072606","doi":"10.1016/j.clgc.2014.06.001","title":"A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"National Cancer Institute","keywords":"Bicalutamide; Medicine; Pazopanib; Prostate cancer; Castration; Oncology; Internal medicine; Cancer; Urology; Androgen receptor; Hormone","score_opus":0.06198738149956967,"score_gpt":0.42551997177265527,"score_spread":0.3635325902730856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023072606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001837,0.0028321438,0.00054938026,0.00070001004,0.00036789075,0.0018025591,0.0012075115,0.00016724115,0.0023549756],"genre_scores_gemma":[0.98753184,0.0030584268,0.0014999354,0.0009952561,0.00036773784,0.0018442986,0.0021526818,0.00006458885,0.0024851973],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994388,0.00025109333,0.000026485037,0.000110063505,0.000038140963,0.0001353817],"domain_scores_gemma":[0.9993591,0.00009546031,0.00008326363,0.000060589908,0.0000271589,0.00037446714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011288368,0.001862266,0.0039293333,0.00066913967,0.0004925278,0.0011231621,0.0012720979,0.0014293452,0.0051701143],"category_scores_gemma":[0.00095943327,0.00096282014,0.0020297389,0.0007921748,0.0014961938,0.0014812055,0.00049735996,0.004680798,0.0013412685],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8836404,0.031501457,0.0017284105,0.0006357536,0.0012477622,0.00014655133,0.00013443331,0.0014799552,0.021294132,0.00021645834,0.0026820002,0.055292778],"study_design_scores_gemma":[0.78662485,0.20506884,0.0043307394,0.00001791574,0.00052662264,0.00013351352,0.00004142257,0.000593416,0.0011864427,0.00014728103,0.0012975262,0.0000314066],"about_ca_topic_score_codex":0.0019028779,"about_ca_topic_score_gemma":0.0050297547,"teacher_disagreement_score":0.0051701143,"about_ca_system_score_codex":0.00093346724,"about_ca_system_score_gemma":0.001996328,"threshold_uncertainty_score":0.017295718},"labels":[],"label_agreement":null},{"id":"W2027791854","doi":"10.1016/j.clgc.2014.12.003","title":"Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Hormonal therapy; Population; Androgen; Cancer; Hormone","score_opus":0.0790272422180056,"score_gpt":0.3952314846535048,"score_spread":0.3162042424354992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027791854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991542,0.00023560882,0.00005372408,0.000029665862,0.000007769477,0.000008966541,0.00024995758,0.0000023414257,0.00025779643],"genre_scores_gemma":[0.9991897,0.00015206063,0.00003779811,0.00004269698,0.000027016877,0.000011572492,0.00040843105,0.0000018076546,0.00012894662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993942,0.00016773595,0.000058217018,0.00019037542,0.00009554427,0.00009385304],"domain_scores_gemma":[0.9992323,0.0001210968,0.00021987394,0.00008240555,0.00008228133,0.0002619825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050235394,0.0006184932,0.0009876878,0.0010736018,0.0010198734,0.0011832217,0.00062131556,0.0012640198,0.0013715749],"category_scores_gemma":[0.0012753255,0.0007623487,0.0014492894,0.0022736585,0.00055626594,0.0012706346,0.00068187946,0.0013353938,0.00027657527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005131074,0.00016710642,0.997924,0.000010768083,0.00028627925,0.000119037046,0.00008264089,0.000033913424,0.0003013808,0.0000131939105,0.00005921706,0.0004893328],"study_design_scores_gemma":[0.000033991328,0.00028862225,0.99891424,0.0000030142621,0.00011190049,0.00021722802,0.00022686952,0.000088136956,0.00002303786,0.000018443632,0.00006737155,0.0000071570457],"about_ca_topic_score_codex":0.0068419534,"about_ca_topic_score_gemma":0.007811741,"teacher_disagreement_score":0.0068419534,"about_ca_system_score_codex":0.00046080045,"about_ca_system_score_gemma":0.0004334108,"threshold_uncertainty_score":0.013604283},"labels":[],"label_agreement":null},{"id":"W2029168581","doi":"10.1016/j.clgc.2013.09.002","title":"Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Oncology; Urothelial carcinoma; Internal medicine; Overall survival; Primary (astronomy); Urothelial cancer; Carcinoma; Second line; First line; Cancer; Clinical trial; Bladder cancer","score_opus":0.1740494188975193,"score_gpt":0.4790419817274608,"score_spread":0.3049925628299415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029168581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008979062,0.9984004,0.00008817751,0.00006737074,0.000064313885,0.000022020029,0.00006336663,0.0000029291123,0.00039346752],"genre_scores_gemma":[0.008205031,0.99040973,0.00045760142,0.00022387569,0.00007131768,0.000039260223,0.00016076241,0.0000027213712,0.00042965685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965084,0.000112305024,0.00007199554,0.00004371667,0.000102624464,0.000018566798],"domain_scores_gemma":[0.9993781,0.0003788285,0.0001239781,0.000010139638,0.00008905714,0.000019784502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011452133,0.0008080809,0.003128802,0.001418955,0.00011615535,0.0005891327,0.0010226269,0.0006126769,0.0023003006],"category_scores_gemma":[0.0008960885,0.00020699344,0.0019627467,0.0013148015,0.00022052666,0.00057894475,0.00025862633,0.0012071443,0.00041040953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011190402,0.0002131302,0.000843411,0.07340023,0.0030524966,0.00009597694,0.00006234627,0.00063549366,0.0016895309,0.000685602,0.008025401,0.9101773],"study_design_scores_gemma":[0.0044801394,0.008507696,0.036033154,0.07976041,0.03425026,0.0039062477,0.0005198599,0.0023796088,0.0051820325,0.0028960733,0.82181627,0.00026823627],"about_ca_topic_score_codex":0.0010320782,"about_ca_topic_score_gemma":0.004298051,"teacher_disagreement_score":0.003128802,"about_ca_system_score_codex":0.00048687204,"about_ca_system_score_gemma":0.00061886734,"threshold_uncertainty_score":0.0076952577},"labels":[],"label_agreement":null},{"id":"W2030980371","doi":"10.3816/cgc.2006.n.043","title":"A Randomized Phase III Study of Neoadjuvant Hormonal Therapy in Patients with Localized Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hormonal therapy; Radiation therapy; Randomized controlled trial; Prostate cancer; Oncology; Prostate; Neoadjuvant therapy; Hormone therapy; Internal medicine; Bicalutamide; Cancer; Urology; Breast cancer","score_opus":0.03350345570443808,"score_gpt":0.37200553265588315,"score_spread":0.3385020769514451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030980371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98939383,0.0029810457,0.0006148009,0.00091792597,0.0005399828,0.0026391996,0.00079103914,0.000091308335,0.002030953],"genre_scores_gemma":[0.9859505,0.0023873383,0.0016635391,0.0013869609,0.0004958812,0.0037923134,0.0012491132,0.00003893435,0.0030353903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991773,0.0005508802,0.00003129649,0.00009557629,0.000038059814,0.00010682193],"domain_scores_gemma":[0.9983853,0.0005107823,0.0002467984,0.00015976377,0.00005941945,0.00063789147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016715371,0.0014669131,0.003257801,0.00041075496,0.00056871003,0.00095247355,0.0009474678,0.0014583638,0.0075041284],"category_scores_gemma":[0.0018434048,0.00066415576,0.0013637741,0.00058296695,0.0018978908,0.0011111981,0.00048754076,0.003013293,0.0010467621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9771081,0.008706452,0.0007167115,0.00020697393,0.00034642193,0.000024652341,0.000044551594,0.0003915479,0.0021337229,0.0000777815,0.000515318,0.009727813],"study_design_scores_gemma":[0.907923,0.089387834,0.0014181195,0.000015124631,0.00019239835,0.00002813633,0.000029615752,0.00020637276,0.00024250512,0.00009759967,0.00044866957,0.000010512696],"about_ca_topic_score_codex":0.0016545579,"about_ca_topic_score_gemma":0.0043936167,"teacher_disagreement_score":0.0075041284,"about_ca_system_score_codex":0.0010094403,"about_ca_system_score_gemma":0.002268291,"threshold_uncertainty_score":0.025103807},"labels":[],"label_agreement":null},{"id":"W2032147926","doi":"10.3816/cgc.2007.n.022","title":"Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases","year":2007,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Hôpital Notre-Dame; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Zoledronic acid; Medicine; Placebo; Prostate cancer; Internal medicine; Incidence (geometry); Surgery; Urology; Cancer; Pathology","score_opus":0.032306235641630716,"score_gpt":0.3783189155830735,"score_spread":0.3460126799414428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032147926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7568883,0.21111736,0.0005392249,0.016222175,0.00052536844,0.00011222078,0.0012680709,0.00009271216,0.013234612],"genre_scores_gemma":[0.96913177,0.02500985,0.00079914066,0.0019947903,0.00074288325,0.000024403345,0.0006802212,0.0000072516964,0.001609718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997861,0.000056525998,0.000032411557,0.00002025984,0.00006538747,0.00003935695],"domain_scores_gemma":[0.9990125,0.00044393793,0.00013119288,0.000040455077,0.00014815517,0.00022376866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007834171,0.00017509876,0.0008517583,0.0003226342,0.00027121976,0.0003851202,0.0002358611,0.000643401,0.002934112],"category_scores_gemma":[0.003473289,0.00008878021,0.0006063271,0.00053050905,0.0001753482,0.0003970274,0.000177349,0.0008873999,0.00024068325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074659355,0.001127193,0.14989601,0.0011816588,0.0009268924,0.0007415316,0.00029684312,0.0009122817,0.005309957,0.0006191588,0.0066174306,0.7577117],"study_design_scores_gemma":[0.013282009,0.023853743,0.92907715,0.000442114,0.0029179943,0.0021849955,0.00034244085,0.0009922382,0.0018212394,0.0010217298,0.024026563,0.000037750633],"about_ca_topic_score_codex":0.005430288,"about_ca_topic_score_gemma":0.013621739,"teacher_disagreement_score":0.005430288,"about_ca_system_score_codex":0.00043897337,"about_ca_system_score_gemma":0.0010301155,"threshold_uncertainty_score":0.010797322},"labels":[],"label_agreement":null},{"id":"W2032898069","doi":"10.1016/j.clgc.2014.03.016","title":"Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma","year":2014,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Accrual; Oncology; Salvage therapy; Metastatic Urothelial Carcinoma; Internal medicine; Urothelial carcinoma; Disease; Intensive care medicine; Chemotherapy; Cancer; Bladder cancer","score_opus":0.1872850933706951,"score_gpt":0.47635958257400335,"score_spread":0.28907448920330825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032898069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075874045,0.98719144,0.00075756945,0.0010709326,0.00037724036,0.0007226417,0.00040928027,0.000010726835,0.00187278],"genre_scores_gemma":[0.1393469,0.84576905,0.0032002362,0.0049362727,0.0008612026,0.0031518955,0.0013266741,0.000016090524,0.0013916731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974063,0.0016183216,0.00052968477,0.00017837652,0.00018657329,0.00008069057],"domain_scores_gemma":[0.9958046,0.0034948324,0.00046645335,0.00007243829,0.00008869851,0.000073056726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005286289,0.0003589294,0.0034780228,0.00047364028,0.00022266376,0.0008092792,0.00089846185,0.0014311048,0.0066424217],"category_scores_gemma":[0.011321176,0.00017664388,0.0020105813,0.00068735867,0.00047239423,0.00081758836,0.00037222638,0.0011656188,0.0003171013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015120097,0.00031923602,0.0021627573,0.1415056,0.0033593206,0.00019208115,0.00010688551,0.00089498196,0.0008728264,0.0039531523,0.009958737,0.82155436],"study_design_scores_gemma":[0.105622284,0.01778267,0.043176416,0.3036421,0.052952237,0.0037974257,0.00057611725,0.0033019409,0.002680863,0.04336487,0.42285347,0.00024954643],"about_ca_topic_score_codex":0.00048870186,"about_ca_topic_score_gemma":0.001513014,"teacher_disagreement_score":0.0066424217,"about_ca_system_score_codex":0.00052359677,"about_ca_system_score_gemma":0.0018218793,"threshold_uncertainty_score":0.027956903},"labels":[],"label_agreement":null},{"id":"W2033476800","doi":"10.1016/j.clgc.2014.03.005","title":"Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group","funders":"Pfizer","keywords":"Medicine; Docetaxel; Prostate cancer; Neutrophil to lymphocyte ratio; Internal medicine; Oncology; Proportional hazards model; Clinical endpoint; Urology; Gastroenterology; Prostate-specific antigen; Cancer; Lymphocyte; Clinical trial","score_opus":0.031524767388623295,"score_gpt":0.37021621365111523,"score_spread":0.3386914462624919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033476800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539435,0.002884982,0.00011701505,0.0001610334,0.00003090656,0.0000063498355,0.00022951592,0.000010098093,0.001165877],"genre_scores_gemma":[0.9995047,0.00017728751,0.000042236567,0.000027109496,0.000027705466,0.0000018620154,0.0001044503,0.0000013332311,0.00011327792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997917,0.00007272743,0.000022991497,0.000031088035,0.000041075244,0.000040408406],"domain_scores_gemma":[0.9991949,0.00023904716,0.00027027624,0.000039089417,0.000075354146,0.00018123646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003729547,0.00028979813,0.0003759402,0.0005116647,0.0002850202,0.0004930663,0.00027240615,0.00037091342,0.0011342528],"category_scores_gemma":[0.0020049375,0.00013501066,0.00025524336,0.00059943245,0.00027635545,0.00039732427,0.00030118955,0.00048308336,0.0001797037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070149906,0.000024694944,0.9947501,0.000012691869,0.00005628769,0.000105828985,0.00001985684,0.00013120647,0.00040259928,0.00002379217,0.00011400688,0.0036576015],"study_design_scores_gemma":[0.000013774302,0.0002397389,0.99783784,0.0000066182984,0.00007150755,0.000527842,0.0000825379,0.00065078976,0.00021193454,0.000056986115,0.00029365078,0.000006727139],"about_ca_topic_score_codex":0.0015548503,"about_ca_topic_score_gemma":0.002911205,"teacher_disagreement_score":0.0015548503,"about_ca_system_score_codex":0.0002218147,"about_ca_system_score_gemma":0.00024521467,"threshold_uncertainty_score":0.0037944317},"labels":[],"label_agreement":null},{"id":"W2034053985","doi":"10.1016/j.clgc.2013.07.010","title":"Population-Based Referrals for Adjuvant Radiotherapy After Radical Prostatectomy in Men With Prostate Cancer: Impact of Randomized Trials","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Randomized controlled trial; Radiation therapy; Oncology; Adjuvant radiotherapy; Urology; Population; Prostate; Adjuvant; Cancer; Internal medicine","score_opus":0.06761566883305067,"score_gpt":0.4357410631022356,"score_spread":0.3681253942691849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034053985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8041884,0.17163154,0.0018356941,0.008133489,0.0041550514,0.0037017206,0.0016838192,0.00011047701,0.004559794],"genre_scores_gemma":[0.975128,0.015373625,0.001495581,0.0044443374,0.00097077375,0.0012389806,0.0009044607,0.00001960093,0.00042469075],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9761121,0.017630795,0.0022869457,0.0020652777,0.0012312933,0.00067350315],"domain_scores_gemma":[0.9648143,0.024107993,0.006423592,0.0014825035,0.0011716675,0.0019999011],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016743384,0.0010441794,0.005069682,0.00088099984,0.0008706059,0.0021306116,0.0020226105,0.005178693,0.005281189],"category_scores_gemma":[0.049906563,0.00095046195,0.007940822,0.0019265927,0.002289027,0.0026725943,0.0012663074,0.0040499927,0.00034959472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8204549,0.004746981,0.043941353,0.013176574,0.05076136,0.00008916617,0.00035614514,0.0014448973,0.00048418675,0.00089770905,0.00296841,0.060678367],"study_design_scores_gemma":[0.8035771,0.048173405,0.070888005,0.004868559,0.06405514,0.00014867862,0.00043163594,0.0012001664,0.0003157871,0.0021916758,0.004040548,0.000109237575],"about_ca_topic_score_codex":0.0048704348,"about_ca_topic_score_gemma":0.007894285,"teacher_disagreement_score":0.98325664,"about_ca_system_score_codex":0.0021730412,"about_ca_system_score_gemma":0.003134794,"threshold_uncertainty_score":0.08854848},"labels":[],"label_agreement":null},{"id":"W2037252326","doi":"10.1016/j.clgc.2013.05.004","title":"Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Luteinizing hormone; Hormone; Adverse effect; Hormone receptor; Internal medicine; Oncology; Bioinformatics; Physiology; Cancer; Breast cancer","score_opus":0.1516322326945628,"score_gpt":0.454092749034244,"score_spread":0.3024605163396812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037252326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013262955,0.99881077,0.00009342205,0.00025263123,0.00010979919,0.000009744656,0.00021061099,0.000007865654,0.00037245062],"genre_scores_gemma":[0.0016733874,0.9968497,0.00044055836,0.00038077746,0.00013693329,0.00001735519,0.00028231263,0.0000028320626,0.00021619872],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.998548,0.00027420901,0.0005457887,0.00016320685,0.00041408156,0.00005470213],"domain_scores_gemma":[0.99653196,0.0019786323,0.0008561071,0.000051491297,0.00051380997,0.00006792697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019070158,0.001156668,0.0032609333,0.007790939,0.00019576128,0.001407004,0.0010129953,0.0011333773,0.004414076],"category_scores_gemma":[0.0042268885,0.00044505674,0.0018951684,0.0072704037,0.00051189086,0.0013476888,0.00093905185,0.0015035564,0.0011054387],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018894246,0.000049121485,0.0022620603,0.107531115,0.0012983629,0.00016440015,0.00009147026,0.00022156388,0.00073459005,0.0012422416,0.030323094,0.85589296],"study_design_scores_gemma":[0.00022416744,0.0003137803,0.02639049,0.16185279,0.007313395,0.003931221,0.0004446425,0.0003698759,0.0012288499,0.0023789888,0.7953769,0.00017485986],"about_ca_topic_score_codex":0.003205267,"about_ca_topic_score_gemma":0.005366502,"teacher_disagreement_score":0.007790939,"about_ca_system_score_codex":0.0008919006,"about_ca_system_score_gemma":0.0018058298,"threshold_uncertainty_score":0.014766574},"labels":[],"label_agreement":null},{"id":"W2039105660","doi":"10.1016/j.clgc.2015.02.008","title":"Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Leukocytosis; Urothelial carcinoma; Internal medicine; Carcinoma; Oncology; Pathology; Cancer; Bladder cancer","score_opus":0.06281715259500498,"score_gpt":0.3149987794033473,"score_spread":0.25218162680834233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039105660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977303,0.0007373971,0.00013500162,0.00015189154,0.000020706015,0.0000058308274,0.00011293844,0.000012507854,0.0010933627],"genre_scores_gemma":[0.9996001,0.00013943993,0.000046411245,0.000039902836,0.000043411426,0.0000025143192,0.000073815114,0.0000014800528,0.000052890155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999741,0.000060791594,0.00004238493,0.000041077317,0.000052775264,0.000061825405],"domain_scores_gemma":[0.99813855,0.0007115331,0.0006753932,0.00010493873,0.000106528256,0.0002631164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022142862,0.0004363226,0.00038812144,0.0011068613,0.0005235848,0.00063242106,0.000364046,0.00076796167,0.0014282016],"category_scores_gemma":[0.0033824907,0.00026102999,0.000251822,0.0010701356,0.00060601154,0.0006590428,0.00043307687,0.0005735546,0.00025958655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028864434,0.000031666124,0.97679406,0.000022120736,0.000024752202,0.01822972,0.0000805903,0.00006399351,0.0020939948,0.000055298384,0.0001894285,0.0021257747],"study_design_scores_gemma":[0.000015985377,0.00019163059,0.93708074,0.000015526764,0.000057591413,0.0609494,0.00033609808,0.00040493155,0.00039640494,0.00017380042,0.00036535814,0.000012524242],"about_ca_topic_score_codex":0.000699012,"about_ca_topic_score_gemma":0.000755483,"teacher_disagreement_score":0.0014282016,"about_ca_system_score_codex":0.00014580347,"about_ca_system_score_gemma":0.00031838662,"threshold_uncertainty_score":0.004777789},"labels":[],"label_agreement":null},{"id":"W2044493544","doi":"10.1016/j.clgc.2015.02.001","title":"Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Cystectomy; Neutrophil to lymphocyte ratio; Oncology; Pathological; Gastroenterology; Stage (stratigraphy); Neoadjuvant therapy; Chemotherapy; Cisplatin; Retrospective cohort study; Lymphocyte; Urology; Cancer; Breast cancer","score_opus":0.040634914403198726,"score_gpt":0.348950956030141,"score_spread":0.30831604162694226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044493544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980229,0.0010931911,0.00006177981,0.00009001692,0.000015666841,0.0000056161025,0.00009889914,0.000004173963,0.00060775015],"genre_scores_gemma":[0.99951196,0.00013504758,0.000043089105,0.00003490837,0.000012822307,0.000006424647,0.00012559758,9.682216e-7,0.0001292017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998135,0.000055757475,0.000035637884,0.000029296394,0.000028924695,0.00003681785],"domain_scores_gemma":[0.99929273,0.00023445167,0.00024138675,0.00002918125,0.00006512885,0.00013709461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031019264,0.00020296626,0.00039210287,0.00041601673,0.00025529056,0.00043915122,0.00020580106,0.0003741607,0.00067843776],"category_scores_gemma":[0.0019629772,0.00013538956,0.00022780013,0.00045373317,0.00023486112,0.00039096727,0.00025753258,0.0004141785,0.00013314131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010480618,0.00003809773,0.99539113,0.000015265237,0.000038058508,0.000124438,0.000026102183,0.0000943275,0.00080942817,0.000012566748,0.00007334521,0.002329194],"study_design_scores_gemma":[0.000017063197,0.00036765847,0.997586,0.000008802215,0.00007053396,0.00061389006,0.00013092825,0.00050320715,0.0003655487,0.000038905033,0.00029111875,0.0000063670036],"about_ca_topic_score_codex":0.00072041707,"about_ca_topic_score_gemma":0.0013072074,"teacher_disagreement_score":0.00072041707,"about_ca_system_score_codex":0.00035004277,"about_ca_system_score_gemma":0.00028957496,"threshold_uncertainty_score":0.002539754},"labels":[],"label_agreement":null},{"id":"W2046474914","doi":"10.1016/j.clgc.2014.03.003","title":"First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Genentech; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Cancer research; Cell culture; Internal medicine; Biology","score_opus":0.059614904111763366,"score_gpt":0.3511681714682748,"score_spread":0.29155326735651144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046474914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96997315,0.0080079045,0.00053253205,0.0011968907,0.000026697391,0.00007993235,0.017196864,0.000034760338,0.002951206],"genre_scores_gemma":[0.98648214,0.0022004428,0.0006488955,0.00047072183,0.00003117905,0.00007195868,0.009908946,0.000019481638,0.00016624379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99470985,0.0010675336,0.0012699444,0.0011924364,0.0013565632,0.00040370546],"domain_scores_gemma":[0.9726678,0.0066206018,0.016160822,0.000947814,0.0020999874,0.00150302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022505545,0.00021464875,0.001038672,0.0029483892,0.00054440263,0.0012892417,0.00096817105,0.0006316777,0.0013589568],"category_scores_gemma":[0.015642922,0.00028042853,0.00093698734,0.011404439,0.0004459233,0.00094940886,0.0014397749,0.0007468036,0.00021519302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016019992,0.000022489561,0.993036,0.000104203034,0.000183529,0.000046520196,0.00010700436,0.00011054137,0.00009508709,0.00010274211,0.0012078579,0.0048238374],"study_design_scores_gemma":[0.00005208168,0.000077079574,0.9958007,0.00012779761,0.00019537663,0.00050793204,0.000570588,0.0006093372,0.00016646774,0.00009569745,0.0017838334,0.000013036883],"about_ca_topic_score_codex":0.016792173,"about_ca_topic_score_gemma":0.034635503,"teacher_disagreement_score":0.016792173,"about_ca_system_score_codex":0.002157156,"about_ca_system_score_gemma":0.0030857567,"threshold_uncertainty_score":0.033388853},"labels":[],"label_agreement":null},{"id":"W2054379162","doi":"10.1016/j.clgc.2012.12.007","title":"Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Urothelial carcinoma; Oncology; Cisplatin; Urothelial cancer; Pooled analysis; Internal medicine; Metastatic Urothelial Carcinoma; Carcinoma; Bladder cancer; Cancer; Chemotherapy; Meta-analysis","score_opus":0.20872856748471622,"score_gpt":0.5079691153930224,"score_spread":0.2992405479083061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054379162","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47078827,0.49964175,0.007957717,0.001051457,0.002206771,0.0035871647,0.009151883,0.0004017769,0.0052131503],"genre_scores_gemma":[0.9595171,0.03030602,0.0023400087,0.0009818905,0.0005066967,0.001495506,0.0032622034,0.00008551278,0.0015049273],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98928785,0.007718233,0.0012907205,0.0009038898,0.00047935758,0.00031988457],"domain_scores_gemma":[0.98764986,0.007308361,0.0029262465,0.0009272732,0.00073445425,0.00045379013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017502898,0.0029375623,0.012469902,0.001733642,0.00035424094,0.0024489756,0.0010136459,0.00145273,0.0038396465],"category_scores_gemma":[0.024354804,0.0012382051,0.022251591,0.0020728044,0.0007038611,0.0015327381,0.0012238135,0.0022424562,0.00043893213],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48914227,0.00021058468,0.0036566034,0.012201098,0.4753955,0.00008498683,0.000051310668,0.0023782842,0.0014740453,0.000098778524,0.0011023647,0.01420417],"study_design_scores_gemma":[0.21871458,0.022486087,0.0193823,0.0011721976,0.7321613,0.00015916827,0.00009259833,0.0014134954,0.0008284087,0.0005906475,0.0029149603,0.00008425805],"about_ca_topic_score_codex":0.0012568574,"about_ca_topic_score_gemma":0.0029370107,"teacher_disagreement_score":0.017502898,"about_ca_system_score_codex":0.0012026586,"about_ca_system_score_gemma":0.0012167605,"threshold_uncertainty_score":0.0925653},"labels":[],"label_agreement":null},{"id":"W2066355838","doi":"10.1016/j.clgc.2013.12.003","title":"A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Baker Hughes (Canada); Western University; Alberta Cancer Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Temsirolimus; Hazard ratio; Everolimus; Renal cell carcinoma; Internal medicine; Oncology; Confidence interval; Population; Clear cell renal cell carcinoma; Urology; Gastroenterology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","score_opus":0.124437901460307,"score_gpt":0.39399840166557637,"score_spread":0.26956050020526934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066355838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95259815,0.020865833,0.008622593,0.00086570374,0.00007703265,0.00009665405,0.009177306,0.00009000036,0.0076068463],"genre_scores_gemma":[0.98702765,0.0065542483,0.0015655247,0.00018393908,0.00007197128,0.0000628007,0.0039588534,0.000029456896,0.0005454731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998591,0.000545827,0.00018217081,0.0003489808,0.00021935177,0.00011263213],"domain_scores_gemma":[0.9971917,0.00093494286,0.0007106764,0.0001914625,0.0007588806,0.0002123843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017262661,0.00016902384,0.0004617339,0.0016754264,0.00029014202,0.00063101784,0.0003848088,0.00035206016,0.0021229882],"category_scores_gemma":[0.0050473437,0.00019324983,0.0005313405,0.0024927466,0.00026808024,0.0005261856,0.00044337672,0.00045997958,0.00030088672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004367681,0.000065335735,0.931371,0.0001817289,0.00051471667,0.00012993129,0.00028787425,0.0020767467,0.0011151626,0.00094896636,0.0017732923,0.0610984],"study_design_scores_gemma":[0.000013767405,0.00030271368,0.9881236,0.000079879916,0.00024824886,0.0010452197,0.00040218123,0.0019022117,0.00030821326,0.000715206,0.0068395166,0.000019206956],"about_ca_topic_score_codex":0.0074500293,"about_ca_topic_score_gemma":0.008335932,"teacher_disagreement_score":0.0074500293,"about_ca_system_score_codex":0.00071313855,"about_ca_system_score_gemma":0.0008898846,"threshold_uncertainty_score":0.014813364},"labels":[],"label_agreement":null},{"id":"W2076483997","doi":"10.1016/j.clgc.2014.03.009","title":"Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; McMaster University","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Radiation therapy; Oncology; Stage (stratigraphy); Mucositis; Proportional hazards model; Chemotherapy","score_opus":0.03276988785044034,"score_gpt":0.3731778031250632,"score_spread":0.3404079152746229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076483997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540968,0.02952212,0.00067530107,0.00067950983,0.00020115565,0.00023873705,0.00047716725,0.00007566718,0.014033424],"genre_scores_gemma":[0.9945298,0.003705186,0.00027734504,0.00013686158,0.00008984346,0.0000350674,0.00019333867,0.0000074849313,0.0010250895],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998853,0.000026109794,0.000010997661,0.000024253175,0.00002564041,0.000027761493],"domain_scores_gemma":[0.9998259,0.000045233857,0.00003541252,0.00001750277,0.0000157324,0.000060304075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016524924,0.00023241698,0.00048744594,0.0003477618,0.0006349307,0.00038416366,0.00027300572,0.000239886,0.003308282],"category_scores_gemma":[0.0007135542,0.00020107854,0.00057801517,0.0004954903,0.0002671869,0.00026918642,0.00034536264,0.0003848853,0.00021802368],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030841174,0.0020618152,0.44910842,0.0021536457,0.00199939,0.0065739793,0.0008139824,0.004262913,0.055953156,0.00073365314,0.0066638654,0.438834],"study_design_scores_gemma":[0.0039331242,0.021551142,0.9066419,0.00047122044,0.0032002036,0.01421125,0.00061661896,0.0033644747,0.012855715,0.000648615,0.032430507,0.00007524414],"about_ca_topic_score_codex":0.0061129755,"about_ca_topic_score_gemma":0.023532981,"teacher_disagreement_score":0.0061129755,"about_ca_system_score_codex":0.0007067106,"about_ca_system_score_gemma":0.001049799,"threshold_uncertainty_score":0.012154758},"labels":[],"label_agreement":null},{"id":"W2077860755","doi":"10.3816/cgc.2009.n.035","title":"Tolerance of Sunitinib in Dialyzed Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre","funders":"","keywords":"Sunitinib; Medicine; Renal cell carcinoma; Hemodialysis; Dialysis; Peritoneal dialysis; Internal medicine; Toxicity; Oncology; Urology","score_opus":0.042401785770641985,"score_gpt":0.3333178607955501,"score_spread":0.2909160750249081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077860755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996476,0.0021460308,0.00016932432,0.00012470924,0.000017142413,0.00000642006,0.00004549156,0.000010011398,0.001004925],"genre_scores_gemma":[0.999602,0.00018804858,0.00002404374,0.00006488956,0.000008815008,0.0000017037154,0.000037894173,0.0000013128431,0.000071242925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998148,0.000061385086,0.000027057147,0.000020936477,0.000035173623,0.000040631727],"domain_scores_gemma":[0.9995758,0.00012481965,0.00012283657,0.000019491381,0.00003587483,0.00012115265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034610974,0.00013755806,0.00048848276,0.00016942578,0.00021154762,0.0003224654,0.00012704897,0.00015006016,0.0005604014],"category_scores_gemma":[0.0014103994,0.000051872765,0.0002935578,0.0002702768,0.00012604284,0.00024506229,0.0001464391,0.000373135,0.00008391342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029107137,0.0009898177,0.7681578,0.00035898818,0.00072742585,0.002868755,0.0007405149,0.0027078942,0.024726495,0.00034644335,0.001641425,0.16762729],"study_design_scores_gemma":[0.0006042991,0.016184216,0.96558404,0.000037445698,0.00035387155,0.007100803,0.00037219565,0.0019467984,0.004584225,0.0002687124,0.0029416017,0.00002194314],"about_ca_topic_score_codex":0.00076568546,"about_ca_topic_score_gemma":0.0009359582,"teacher_disagreement_score":0.00076568546,"about_ca_system_score_codex":0.0004508211,"about_ca_system_score_gemma":0.00023984551,"threshold_uncertainty_score":0.003270924},"labels":[],"label_agreement":null},{"id":"W2079168970","doi":"10.1016/j.clgc.2014.09.003","title":"Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; Western University; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Dana-Farber/Harvard Cancer Center","keywords":"Medicine; Renal cell carcinoma; Term (time); Oncology; Internal medicine; Carcinoma; Database","score_opus":0.0563195451303097,"score_gpt":0.32547690014645964,"score_spread":0.26915735501614996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079168970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711911,0.0007198625,0.00009149162,0.00013101398,0.0000096019985,0.000030077224,0.026735313,0.000012092448,0.0010794097],"genre_scores_gemma":[0.97160494,0.00031557574,0.000057688176,0.00009777918,0.000017356171,0.000047114394,0.027506536,0.000009344923,0.00034362054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998678,0.00019069618,0.00033111603,0.0003079937,0.00027089103,0.00022129311],"domain_scores_gemma":[0.9941849,0.0006866046,0.0031040437,0.0003127561,0.00068884704,0.0010228818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010457833,0.00026474573,0.0008412869,0.002212341,0.0004826861,0.0011280972,0.0008413021,0.000673523,0.0018071997],"category_scores_gemma":[0.005091391,0.00020088325,0.00084224535,0.005297383,0.00031336717,0.0009265918,0.0010917026,0.0005432806,0.0003283832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015552188,0.000020879601,0.99843854,0.00001659482,0.00009283094,0.000034348726,0.000050205635,0.000058630096,0.000043927408,0.000013873812,0.00039817623,0.00067647756],"study_design_scores_gemma":[0.000008012632,0.000044559703,0.9992623,0.0000071782038,0.00004225674,0.00011443438,0.00015572857,0.00005343892,0.00002319204,0.000006363164,0.00027757202,0.000005035847],"about_ca_topic_score_codex":0.025047693,"about_ca_topic_score_gemma":0.021548826,"teacher_disagreement_score":0.025047693,"about_ca_system_score_codex":0.0012343634,"about_ca_system_score_gemma":0.001058209,"threshold_uncertainty_score":0.049803793},"labels":[],"label_agreement":null},{"id":"W2080771641","doi":"10.1016/j.clgc.2013.04.008","title":"Use of a Clinical Assistant to Screen Patients With Genitourinary Cancer to Encourage Entry into Clinical Trials and Use of Supportive Medication: A Pilot Project at a Canadian Cancer Center","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Queen's University","funders":"Sanofi","keywords":"Medicine; Clinical trial; Prostate cancer; Retrospective cohort study; Psychological intervention; Cancer; Referral; Genitourinary system; Prospective cohort study; Internal medicine; Family medicine; Nursing","score_opus":0.2792360679714213,"score_gpt":0.49305666692671674,"score_spread":0.21382059895529543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080771641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078405,0.00070502,0.0107270535,0.013861143,0.00033155188,0.040746856,0.0011103151,0.0012696425,0.023407904],"genre_scores_gemma":[0.79245174,0.0017784775,0.14869113,0.012952632,0.00024934727,0.01527969,0.001203587,0.00033776008,0.02705558],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9871494,0.0069112163,0.0006775858,0.0009051087,0.0023343326,0.002022286],"domain_scores_gemma":[0.9442067,0.014168165,0.0036231796,0.0027417904,0.013978143,0.021282073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015696494,0.00065763894,0.00066034327,0.0019265192,0.00942795,0.0024875728,0.0033441368,0.0016533785,0.007187661],"category_scores_gemma":[0.027561547,0.00097161223,0.0008368794,0.0012233788,0.0019990145,0.0010393343,0.0028045427,0.0027619163,0.0013710383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052338126,0.050768577,0.31773773,0.0010331534,0.00023253003,0.004571798,0.043685135,0.001345708,0.021681538,0.0006088288,0.0615488,0.49155238],"study_design_scores_gemma":[0.0075222035,0.044486385,0.70179474,0.0007311215,0.0006581609,0.0042909193,0.064169355,0.0113288555,0.014725652,0.0008255266,0.14873625,0.00073088304],"about_ca_topic_score_codex":0.39025292,"about_ca_topic_score_gemma":0.67680246,"teacher_disagreement_score":0.60974705,"about_ca_system_score_codex":0.013229419,"about_ca_system_score_gemma":0.09513973,"threshold_uncertainty_score":0.77596277},"labels":[],"label_agreement":null},{"id":"W2093356247","doi":"10.1016/j.clgc.2014.08.011","title":"Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Queen Elizabeth II Health Sciences Centre; Western University; Sunnybrook Health Science Centre; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Carcinoma; Internal medicine; Sarcomatoid carcinoma; Database; Pathology","score_opus":0.06455312898978038,"score_gpt":0.3293076878502526,"score_spread":0.2647545588604722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093356247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98416543,0.0007030668,0.00006638492,0.00033129938,0.000011640649,0.000017407452,0.013095194,0.000008877123,0.0016006718],"genre_scores_gemma":[0.9861102,0.00032278275,0.000038651848,0.00009508548,0.000016175116,0.000015486141,0.013205272,0.000004748506,0.00019149102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887997,0.00024774577,0.00017119134,0.00025511667,0.00026301722,0.00018285196],"domain_scores_gemma":[0.99764353,0.00030237727,0.0011177195,0.00011356323,0.00033573693,0.00048708482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009196729,0.00033593265,0.0007659208,0.0013560021,0.0005616519,0.0012605266,0.0007011497,0.0005382123,0.0012442813],"category_scores_gemma":[0.0043623177,0.0001745044,0.00086985005,0.0036867633,0.00034499116,0.0010423205,0.0015064082,0.0005601429,0.00024371268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001563096,0.000023307291,0.997809,0.00001657775,0.00013247541,0.000047725505,0.000051368625,0.000121628895,0.000039404888,0.00004008173,0.0006923339,0.00086992007],"study_design_scores_gemma":[0.000016312782,0.00003851135,0.9988972,0.000010669684,0.00007057449,0.00015116532,0.00021092349,0.0002128153,0.000031927244,0.000029203211,0.0003248012,0.000005820846],"about_ca_topic_score_codex":0.031032067,"about_ca_topic_score_gemma":0.036135733,"teacher_disagreement_score":0.031032067,"about_ca_system_score_codex":0.0014684539,"about_ca_system_score_gemma":0.0010242468,"threshold_uncertainty_score":0.061702847},"labels":[],"label_agreement":null},{"id":"W2093984374","doi":"10.1016/j.clgc.2014.03.006","title":"Metastatic Large-Cell Neuroendocrine Prostate Carcinoma: Successful Treatment With Androgen Deprivation Therapy","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostate; Neuroendocrine differentiation; Context (archaeology); Adenocarcinoma; Neuroendocrine tumors; Oncology; Small-cell carcinoma; Internal medicine; Androgen; Carcinoma; Cancer research; Cancer; Pathology; Hormone; Biology","score_opus":0.06053790294127071,"score_gpt":0.37806420833724846,"score_spread":0.31752630539597776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093984374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.872465,0.04336719,0.0135243,0.021066695,0.0024961592,0.0008504044,0.002386167,0.0008165766,0.043027423],"genre_scores_gemma":[0.9824843,0.006155078,0.0019527713,0.0017385376,0.0012969131,0.00008942088,0.0006435606,0.00006544717,0.005574069],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99981695,0.000031055308,0.000019752668,0.000035381716,0.00004512225,0.00005166276],"domain_scores_gemma":[0.9996282,0.00012681549,0.000020159627,0.00003674012,0.000020617317,0.00016752629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033928512,0.00079638464,0.0011551342,0.0006790173,0.000808612,0.0005021273,0.0006528968,0.0015659991,0.0012449429],"category_scores_gemma":[0.0010712893,0.00020078829,0.0013322085,0.00048479918,0.0006775051,0.00036863863,0.0004749894,0.0012559067,0.00064434577],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010384307,0.002835478,0.026430054,0.00096864265,0.0006252208,0.68332976,0.0004316155,0.009623997,0.05895122,0.0027054988,0.010099902,0.1936144],"study_design_scores_gemma":[0.0039435904,0.017186368,0.13879496,0.00020008122,0.00087337394,0.7490286,0.00028292474,0.012880787,0.0310194,0.005967691,0.03958895,0.00023322612],"about_ca_topic_score_codex":0.002181943,"about_ca_topic_score_gemma":0.0059216614,"teacher_disagreement_score":0.002181943,"about_ca_system_score_codex":0.0007465944,"about_ca_system_score_gemma":0.00070053554,"threshold_uncertainty_score":0.0054169297},"labels":[],"label_agreement":null},{"id":"W2128675949","doi":"10.1016/j.clgc.2013.04.020","title":"Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"Cancer Institute NSW; Sanofi","keywords":"Medicine; Docetaxel; Prostate cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.04536099101820812,"score_gpt":0.3538127279444684,"score_spread":0.30845173692626027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128675949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634945,0.0020697056,0.000092620096,0.0002219981,0.000038017628,0.000009430821,0.00018033847,0.000008229529,0.0010302144],"genre_scores_gemma":[0.9994875,0.0001797304,0.000044157838,0.000024075081,0.000022917919,0.0000024939675,0.0001300964,0.0000016078295,0.00010737393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997919,0.00006770241,0.000021586739,0.000022137085,0.00004483155,0.00005186772],"domain_scores_gemma":[0.9990339,0.00022071131,0.00034846464,0.00003710464,0.00008861861,0.0002711703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003170874,0.00025324474,0.00038631228,0.0004967727,0.00021668222,0.0005410639,0.0002576787,0.0002817296,0.0008406855],"category_scores_gemma":[0.0023302753,0.00010161946,0.00035421882,0.00086039514,0.0002456909,0.0002771161,0.00024918333,0.0004901668,0.00011158858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002879713,0.00006646764,0.98703104,0.000026641079,0.00013284382,0.0002961718,0.000050831015,0.00033409297,0.000758001,0.000056964745,0.0005259364,0.00784129],"study_design_scores_gemma":[0.0000585261,0.00067868293,0.9966485,0.000012302733,0.0001911397,0.00046871876,0.00009394987,0.00095559185,0.00020059198,0.00008841232,0.0005937302,0.000009830638],"about_ca_topic_score_codex":0.0044269487,"about_ca_topic_score_gemma":0.00654171,"teacher_disagreement_score":0.0044269487,"about_ca_system_score_codex":0.0004633156,"about_ca_system_score_gemma":0.0006779501,"threshold_uncertainty_score":0.008802354},"labels":[],"label_agreement":null},{"id":"W2137336295","doi":"10.1016/j.clgc.2012.06.004","title":"Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Neutropenia; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Placebo; Chemotherapy; Cancer; Confidence interval; Pathology","score_opus":0.05422431967467393,"score_gpt":0.4329186536417635,"score_spread":0.37869433396708957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137336295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063265,0.006400837,0.00054385787,0.0002933468,0.000036726637,0.000030300702,0.00021654204,0.000016068643,0.0018296177],"genre_scores_gemma":[0.99889874,0.00041094684,0.00029754103,0.00007701434,0.000029004585,0.000006973299,0.000092362134,0.000002833749,0.00018454756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994734,0.00024858446,0.00005131279,0.00005238141,0.00014139581,0.000032905828],"domain_scores_gemma":[0.99801636,0.0009408859,0.00068476016,0.000049849794,0.00012221654,0.00018585923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081521296,0.0002348074,0.00041896937,0.0004760601,0.00020880644,0.0005927512,0.00025315516,0.00035114022,0.0004115643],"category_scores_gemma":[0.003784206,0.00015420861,0.0003145957,0.0005709474,0.00019552492,0.00035561403,0.0001844853,0.00059754465,0.00006181909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073521957,0.0001681452,0.9522638,0.00008927535,0.00026249772,0.00044506628,0.00007130234,0.0013831068,0.0052490784,0.0001997444,0.00039176104,0.032124028],"study_design_scores_gemma":[0.00009859281,0.0022240493,0.987513,0.000030052339,0.00028164856,0.0013095257,0.00007041999,0.0050699348,0.0020103739,0.00018735627,0.0011845075,0.000020441115],"about_ca_topic_score_codex":0.0018810012,"about_ca_topic_score_gemma":0.0048659393,"teacher_disagreement_score":0.0018810012,"about_ca_system_score_codex":0.0005824069,"about_ca_system_score_gemma":0.0005489659,"threshold_uncertainty_score":0.004311323},"labels":[],"label_agreement":null},{"id":"W2158732258","doi":"10.1016/j.clgc.2013.07.013","title":"Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment","year":2013,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Malignancy; Cancer; Tumor progression; Adipose tissue; Prostate; Obesity; Tumor microenvironment; Insulin resistance; Oncology; Internal medicine; Cancer research; Bioinformatics; Biology","score_opus":0.03440061590890456,"score_gpt":0.379315280825505,"score_spread":0.3449146649166004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158732258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050098646,0.99918824,0.00009258303,0.00025952558,0.00014444208,0.000001405346,0.0000094493325,0.000003677636,0.00025052406],"genre_scores_gemma":[0.00036491815,0.99883753,0.0001043766,0.00017589606,0.00023521451,0.0000027697286,0.000014738514,8.082045e-7,0.00026382724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979883,0.000029540859,0.000021985292,0.00003791154,0.00008802995,0.000023710276],"domain_scores_gemma":[0.999582,0.00017074909,0.000057907768,0.000011699626,0.00012639585,0.000051260402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007641114,0.0009831712,0.0016957023,0.0016564693,0.00029198045,0.0013639826,0.0010309254,0.0016066679,0.002837188],"category_scores_gemma":[0.0007846308,0.00032061234,0.00043356494,0.0023195546,0.00074943394,0.0014837711,0.0010585816,0.0022691577,0.0015402348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013480746,0.000073446434,0.0002992983,0.01002107,0.00008735207,0.00030211153,0.00003652265,0.00040729492,0.0024136582,0.0033557033,0.0438666,0.9390021],"study_design_scores_gemma":[0.000039299797,0.00008537852,0.0010950279,0.0023509138,0.00012738466,0.0015839835,0.000070177026,0.00014447643,0.0006027837,0.0023322352,0.9915386,0.000029653815],"about_ca_topic_score_codex":0.0013926054,"about_ca_topic_score_gemma":0.0029280905,"teacher_disagreement_score":0.002837188,"about_ca_system_score_codex":0.00089340046,"about_ca_system_score_gemma":0.0015497819,"threshold_uncertainty_score":0.009491324},"labels":[],"label_agreement":null},{"id":"W2159738538","doi":"10.1016/j.clgc.2014.08.010","title":"Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy","year":2014,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cisplatin; Hazard ratio; Perioperative; Internal medicine; Proportional hazards model; Gemcitabine; Chemotherapy; Oncology; Confidence interval; Anemia; Urology; Gastroenterology; Surgery","score_opus":0.05456261629408484,"score_gpt":0.37659038282777574,"score_spread":0.3220277665336909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159738538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9343276,0.050612275,0.0028705369,0.0016687685,0.00075491593,0.00020882774,0.0003207245,0.00011062785,0.009125771],"genre_scores_gemma":[0.99016505,0.007061993,0.0009470966,0.00039757972,0.00014532552,0.00003373972,0.0003303941,0.000011588189,0.0009072691],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999018,0.000019892008,0.000014958291,0.000016841732,0.000022329936,0.000024245988],"domain_scores_gemma":[0.9998203,0.000037584185,0.000033390406,0.000018528814,0.000023920215,0.000066250155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029383975,0.00018507763,0.000556855,0.00033515325,0.00045865207,0.00039700847,0.0003771844,0.00025118943,0.001100999],"category_scores_gemma":[0.00074703427,0.00009948022,0.0006752892,0.0003301996,0.00021930003,0.00035036576,0.0002452308,0.00092383835,0.00025620617],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013081711,0.0021306626,0.15896907,0.0027069908,0.0016924286,0.016582495,0.00054947886,0.0041596573,0.06150944,0.0015162196,0.009996111,0.7271057],"study_design_scores_gemma":[0.0022167384,0.04547632,0.69609445,0.0011816777,0.0026991835,0.07857915,0.0005014891,0.008200709,0.06655485,0.0016967828,0.096642986,0.00015566967],"about_ca_topic_score_codex":0.00081508985,"about_ca_topic_score_gemma":0.003392004,"teacher_disagreement_score":0.001100999,"about_ca_system_score_codex":0.00051148457,"about_ca_system_score_gemma":0.0007711327,"threshold_uncertainty_score":0.0037111044},"labels":[],"label_agreement":null},{"id":"W2167903555","doi":"10.1016/j.clgc.2013.11.017","title":"Extensive Necrotizing Fasciitis Associated With Sunitinib Therapy","year":2013,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Foothills Medical Centre; University of Calgary; Island Health; University of Toronto","funders":"","keywords":"Sunitinib; Medicine; Tyrosine-kinase inhibitor; Renal cell carcinoma; Angiogenesis; Fasciitis; GiST; Toxicity; Internal medicine; Vascular endothelial growth factor; Oncology; Cancer research; Stromal cell; Cancer; VEGF receptors; Surgery","score_opus":0.07610663729308634,"score_gpt":0.36627617883622204,"score_spread":0.2901695415431357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167903555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95139796,0.00995689,0.0038880087,0.0011740914,0.00022197116,0.00032909453,0.00024067321,0.0002915881,0.032499805],"genre_scores_gemma":[0.99773824,0.0008697199,0.00032688497,0.00020391877,0.00008077209,0.000012127645,0.000052256473,0.000005400345,0.00071062124],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996704,0.00009196711,0.000040330513,0.00004008476,0.000063627616,0.00009364649],"domain_scores_gemma":[0.9988053,0.00033212733,0.00044723248,0.00011913865,0.000078846686,0.00021745368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040378553,0.0005322544,0.00042962865,0.0004917209,0.00046283915,0.00036880653,0.00022861129,0.0006872801,0.0014880905],"category_scores_gemma":[0.0013414104,0.00021726107,0.0005230924,0.000406988,0.0003964278,0.00035994503,0.0003108807,0.0009433001,0.00028186417],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020388903,0.00025782725,0.058985643,0.0005586842,0.00021865683,0.8668868,0.0002469408,0.0012618041,0.029591432,0.00048026166,0.0015225954,0.03795049],"study_design_scores_gemma":[0.00021738341,0.0022030117,0.1335807,0.00014413372,0.00018579411,0.8422302,0.0002149957,0.002061606,0.01192802,0.0003662935,0.0068422104,0.000025720858],"about_ca_topic_score_codex":0.0009271827,"about_ca_topic_score_gemma":0.002387124,"teacher_disagreement_score":0.0014880905,"about_ca_system_score_codex":0.00077126455,"about_ca_system_score_gemma":0.0003622178,"threshold_uncertainty_score":0.005595982},"labels":[],"label_agreement":null},{"id":"W2196142402","doi":"10.1016/j.clgc.2015.10.005","title":"Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Cisplatin; Chemotherapy; Oncology; Internal medicine; Regimen; Proportional hazards model; Chemotherapy regimen; Perioperative; Confidence interval; Retrospective cohort study; Surgery","score_opus":0.09136507234050824,"score_gpt":0.3933785982598038,"score_spread":0.3020135259192956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2196142402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695396,0.0018499542,0.00013529134,0.00011489103,0.00013989565,0.000059657625,0.000053725948,0.000008480922,0.00068417017],"genre_scores_gemma":[0.9984744,0.0008997536,0.00014942829,0.00008401407,0.00006660603,0.000031575422,0.00008946476,0.0000035222558,0.00020111995],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996512,0.0001586089,0.00004199392,0.000040865532,0.000031431424,0.00007588903],"domain_scores_gemma":[0.9994155,0.00021423114,0.00008279804,0.00005587264,0.000023569595,0.0002079594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079602306,0.00027817997,0.0010909152,0.00024523336,0.0001821789,0.00044636728,0.00042772907,0.00034033734,0.0015052045],"category_scores_gemma":[0.0016035073,0.00018063051,0.0009795555,0.00026218282,0.00042611282,0.0007063305,0.00029551925,0.0011197275,0.00013182886],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74694175,0.0114401365,0.017144505,0.0010900119,0.0022194705,0.0005337026,0.0003597427,0.007943399,0.030927718,0.00087673083,0.0017701769,0.17875265],"study_design_scores_gemma":[0.052770454,0.7596813,0.14634481,0.00032715307,0.0034593767,0.0016271024,0.00042631745,0.00953074,0.01847561,0.000908522,0.006347573,0.00010112822],"about_ca_topic_score_codex":0.0008464532,"about_ca_topic_score_gemma":0.0024321608,"teacher_disagreement_score":0.0015052045,"about_ca_system_score_codex":0.000532649,"about_ca_system_score_gemma":0.00072036183,"threshold_uncertainty_score":0.0050354004},"labels":[],"label_agreement":null},{"id":"W2198033618","doi":"10.1016/j.clgc.2015.12.023","title":"Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute","keywords":"Prostate cancer; Medicine; Androgen receptor; Prostate; Cancer; Cancer research; Androgen deprivation therapy; Oncology; Androgen; Adenocarcinoma; Internal medicine; Hormone","score_opus":0.12458159150662867,"score_gpt":0.45912500398680195,"score_spread":0.3345434124801733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198033618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757749,0.0018298979,0.0036224688,0.0084972745,0.0002526166,0.00016372722,0.0003065977,0.00019009072,0.009362373],"genre_scores_gemma":[0.99644333,0.00039231294,0.0011945026,0.0009274484,0.0004043473,0.000013740984,0.00011418635,0.00004038168,0.00046973708],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994036,0.000070140195,0.00006454172,0.00015521176,0.00010736994,0.00019914118],"domain_scores_gemma":[0.9980236,0.0006823671,0.00026226396,0.00013649404,0.00015354008,0.00074167934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040504118,0.0011255628,0.00093049736,0.0022837296,0.0023614932,0.001605022,0.001733056,0.004878775,0.0018575026],"category_scores_gemma":[0.004397818,0.0006835952,0.0013939735,0.0011673599,0.001867549,0.0015484073,0.0013182573,0.0036475025,0.000653986],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008647349,0.000036441972,0.013865023,0.000017960621,0.0000058191167,0.9834616,0.00007878631,0.00018135918,0.0006743135,0.00010265231,0.00027276826,0.0012167846],"study_design_scores_gemma":[0.000012511579,0.000119778575,0.009246853,0.000020995018,0.000018709703,0.9871709,0.00016103373,0.0015708086,0.0010998484,0.00028093354,0.00028217272,0.000015502459],"about_ca_topic_score_codex":0.0047237063,"about_ca_topic_score_gemma":0.0059109093,"teacher_disagreement_score":0.004878775,"about_ca_system_score_codex":0.0023122488,"about_ca_system_score_gemma":0.0011294854,"threshold_uncertainty_score":0.016776562},"labels":[],"label_agreement":null},{"id":"W2212423693","doi":"10.1016/j.clgc.2015.12.026","title":"Desmoplastic Small Round Cell Tumor Presenting as an Isolated Testicular Mass in an Adult With Multiple Previous Malignancies","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Desmoplastic small-round-cell tumor; Testicular cancer; Pathology; Oncology; Internal medicine; Cancer research; Cancer; Immunohistochemistry","score_opus":0.07605188571086151,"score_gpt":0.3530543778406104,"score_spread":0.27700249212974887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2212423693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97714466,0.0048751594,0.001832374,0.0024708828,0.00028286723,0.00013448902,0.0006368198,0.00027738945,0.01234541],"genre_scores_gemma":[0.9954129,0.0013173338,0.000898087,0.0004163131,0.0007672399,0.000012593718,0.00022898955,0.000028071281,0.0009184757],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9993881,0.00004460248,0.00010447597,0.00014206578,0.00011212625,0.00020864319],"domain_scores_gemma":[0.99791604,0.00044146765,0.0005649573,0.00010829092,0.00012261073,0.00084654515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030170023,0.0018524651,0.0011259457,0.00398624,0.0016208313,0.0016686057,0.0012823311,0.003660662,0.004828649],"category_scores_gemma":[0.0028326658,0.0013816027,0.0011249402,0.0021327345,0.0012749406,0.0022737419,0.001420017,0.0019613972,0.001644845],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045979974,0.000023421178,0.018267531,0.000021102362,0.000008447181,0.9799152,0.00005348328,0.000058539852,0.00059925945,0.000058883248,0.00016523984,0.0007829566],"study_design_scores_gemma":[0.000008458497,0.000053907515,0.010664785,0.000011547069,0.000017837896,0.9882449,0.00010969073,0.00024344376,0.00029198796,0.000054421223,0.0002912557,0.00000771941],"about_ca_topic_score_codex":0.0020388162,"about_ca_topic_score_gemma":0.0038144013,"teacher_disagreement_score":0.004828649,"about_ca_system_score_codex":0.0011286819,"about_ca_system_score_gemma":0.0009698749,"threshold_uncertainty_score":0.016153455},"labels":[],"label_agreement":null},{"id":"W2214412695","doi":"10.1016/j.clgc.2015.12.007","title":"Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Renal mass; Renal pathology; Pathology; Biopsy; Hematologic Neoplasms; Hematologic malignancy; Internal medicine; Kidney; Cancer; Nephrectomy","score_opus":0.1399516400823857,"score_gpt":0.3901498421154825,"score_spread":0.2501982020330968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214412695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802601,0.00986758,0.0013946893,0.0010047165,0.00019196603,0.00005385866,0.0005780867,0.00008137148,0.0065676295],"genre_scores_gemma":[0.9973278,0.00075273373,0.00084337284,0.0001731167,0.00011309504,0.000011077475,0.00030072744,0.0000082230345,0.00046990102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995894,0.00012418078,0.00006603001,0.00005043507,0.00011516343,0.00005491911],"domain_scores_gemma":[0.9974553,0.001013547,0.00057132007,0.00013511328,0.00043589468,0.00038876073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011285293,0.00052736705,0.0004939269,0.0020700505,0.00039154408,0.0015131984,0.0004868184,0.0006956497,0.002193142],"category_scores_gemma":[0.0058004195,0.00020850482,0.00034456022,0.0011630999,0.00041271193,0.0008262805,0.00043068355,0.0008358689,0.0005984617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003182308,0.00005147709,0.9886785,0.000025996671,0.000056713543,0.00018692807,0.000020552354,0.00017030825,0.00077002426,0.00006692099,0.0005143237,0.00913997],"study_design_scores_gemma":[0.00004221958,0.00047629527,0.98374534,0.00011366535,0.0003104631,0.0025814197,0.00028017876,0.0057170205,0.00297413,0.0005941031,0.0031481315,0.000017123448],"about_ca_topic_score_codex":0.0010580911,"about_ca_topic_score_gemma":0.0027148654,"teacher_disagreement_score":0.002193142,"about_ca_system_score_codex":0.00038502674,"about_ca_system_score_gemma":0.00046813436,"threshold_uncertainty_score":0.007336855},"labels":[],"label_agreement":null},{"id":"W2216703724","doi":"10.1016/j.clgc.2015.10.011","title":"Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses","year":2015,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal","funders":"","keywords":"Medicine; Ethnic group; Charlson comorbidity index; Socioeconomic status; Comorbidity; Subgroup analysis; Epidemiology; Internal medicine; Surveillance, Epidemiology, and End Results; Population; African american; Cancer; Demography; Gerontology; Cancer registry; Confidence interval","score_opus":0.19242303712189826,"score_gpt":0.4041198364005924,"score_spread":0.21169679927869414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216703724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946932,0.0010898784,0.00009676589,0.0011008848,0.000024916155,0.000007652888,0.00043486882,0.0000028336165,0.0025490406],"genre_scores_gemma":[0.99932146,0.0002780248,0.000033083918,0.00010186191,0.000020232299,0.0000026897635,0.00013922222,0.0000017686663,0.000101775295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947065,0.0001345807,0.00007479144,0.00007155247,0.000098554905,0.00014989055],"domain_scores_gemma":[0.99735606,0.0006628861,0.0012271424,0.000080035,0.00015036017,0.00052357727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039465143,0.0000714896,0.00016050434,0.00049225555,0.00041310024,0.00046322623,0.00026787687,0.00040742123,0.003506488],"category_scores_gemma":[0.0044228337,0.00015916636,0.0002947578,0.0008609769,0.0002376643,0.00039384468,0.00037157934,0.00071038294,0.00016492385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003600557,0.000059981845,0.99723,0.000012147204,0.000036206417,0.000055371278,0.00011709967,0.000033896107,0.0000756446,0.0001754834,0.00024166184,0.0019264151],"study_design_scores_gemma":[0.000002303589,0.000017005174,0.99896944,0.0000135909495,0.0000103771945,0.000106050684,0.00039509076,0.000110672976,0.000022813583,0.00009432487,0.00025553716,0.0000027756473],"about_ca_topic_score_codex":0.013631982,"about_ca_topic_score_gemma":0.02444633,"teacher_disagreement_score":0.013631982,"about_ca_system_score_codex":0.00044122094,"about_ca_system_score_gemma":0.00080032076,"threshold_uncertainty_score":0.027105272},"labels":[],"label_agreement":null},{"id":"W2397377428","doi":"10.1016/j.clgc.2016.05.003","title":"Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Docetaxel; Oncology; Taxane; Meta-analysis; Paclitaxel; Chemotherapy; Cisplatin; Cancer; Urology; Breast cancer","score_opus":0.17177038917727194,"score_gpt":0.4438781869271826,"score_spread":0.2721077977499107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397377428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076469285,0.9915549,0.00018760069,0.00007186734,0.00008205599,0.00006634218,0.00020479273,0.000008521311,0.00017704515],"genre_scores_gemma":[0.20350023,0.7936474,0.0010234128,0.000729304,0.00017344225,0.00015662702,0.00046736025,0.000015005259,0.00028726994],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9974552,0.0009736435,0.0007904516,0.00038973455,0.00029099005,0.00009998244],"domain_scores_gemma":[0.9952603,0.0031995897,0.0010264365,0.00013553645,0.00028245716,0.00009565902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043612346,0.0017853294,0.010842351,0.0023143685,0.00034850807,0.0017110101,0.0015223491,0.0014949918,0.002345787],"category_scores_gemma":[0.010645839,0.00093947334,0.021513311,0.0031172852,0.00046924857,0.0012185937,0.0009047415,0.0016647666,0.0002077975],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006200168,0.00008641062,0.005524178,0.354831,0.6017576,0.00015668444,0.000115742936,0.0008231461,0.0005434433,0.000119280434,0.00078083586,0.029061554],"study_design_scores_gemma":[0.001096989,0.0005309928,0.005031817,0.011640362,0.97912383,0.00014474816,0.000058797163,0.00015437689,0.00016083104,0.00013104896,0.0018935979,0.00003263087],"about_ca_topic_score_codex":0.0037637223,"about_ca_topic_score_gemma":0.013005222,"teacher_disagreement_score":0.010842351,"about_ca_system_score_codex":0.0014144765,"about_ca_system_score_gemma":0.0014460317,"threshold_uncertainty_score":0.023064673},"labels":[],"label_agreement":null},{"id":"W2401517553","doi":"10.1016/j.clgc.2016.05.019","title":"Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Papillary renal cell carcinomas; Leiomyomatosis; Fumarase; Germline mutation; Cancer research; Tyrosine kinase; Renal cell carcinoma; Metastasis; Pathogenesis; Tyrosine-kinase inhibitor; Germline; Pathology; Internal medicine; Carcinoma; Oncology; Cancer; Mutation; Receptor; Gene; Biology; Genetics","score_opus":0.049069436257547165,"score_gpt":0.33576451621007697,"score_spread":0.2866950799525298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401517553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897894,0.0034312191,0.0008664417,0.00025411806,0.000018608322,0.00006858855,0.00040491164,0.000035983838,0.005130671],"genre_scores_gemma":[0.99801457,0.00045495477,0.0003259055,0.0000611086,0.000009716936,0.000017079386,0.00043215093,0.000006371324,0.0006779767],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968815,0.00006101117,0.000027127247,0.000042138094,0.00010237971,0.000079155085],"domain_scores_gemma":[0.9996369,0.00011494637,0.00006911534,0.00004885193,0.00006545132,0.00006480686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089340855,0.00020518151,0.00061056874,0.0006567996,0.00024574008,0.0007713127,0.00030423483,0.0002900303,0.0015194627],"category_scores_gemma":[0.00072589755,0.00015061724,0.000369769,0.00045842107,0.00036841683,0.00035523385,0.0002107926,0.00045138915,0.00021805405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011495922,0.0006559058,0.3479305,0.00046801678,0.00049979595,0.0019836621,0.00036489533,0.0046587065,0.46691865,0.0019353282,0.0016909573,0.1613978],"study_design_scores_gemma":[0.0003399247,0.0072366493,0.8421122,0.000039666913,0.00057791965,0.0055104187,0.00059783144,0.0052605863,0.122723706,0.0011335937,0.014438509,0.000028932533],"about_ca_topic_score_codex":0.0018059288,"about_ca_topic_score_gemma":0.0029781612,"teacher_disagreement_score":0.0018059288,"about_ca_system_score_codex":0.00096345233,"about_ca_system_score_gemma":0.00071365654,"threshold_uncertainty_score":0.006990373},"labels":[],"label_agreement":null},{"id":"W2404852579","doi":"10.1016/j.clgc.2016.05.009","title":"Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Bone metastasis; Docetaxel; Radiology; Metastasis; Lesion; Nuclear medicine; Proportional hazards model; Cancer; Confidence interval; Internal medicine; Surgery","score_opus":0.14115413462752094,"score_gpt":0.4419744133769954,"score_spread":0.3008202787494745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404852579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98546,0.009172773,0.0014184294,0.000197419,0.00004674556,0.00009132528,0.00020242973,0.000051900126,0.0033589997],"genre_scores_gemma":[0.99559516,0.0016730834,0.002092754,0.000059227463,0.000034908462,0.00001928941,0.00016000887,0.000012515188,0.00035314378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994931,0.00017081469,0.00004689231,0.00004054957,0.00018904055,0.000059513757],"domain_scores_gemma":[0.9993018,0.00018944523,0.00012504523,0.000025814117,0.00025661898,0.00010123826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014157797,0.0005804606,0.00058905804,0.0021431635,0.00026506168,0.001006391,0.000486064,0.0005702586,0.00056390883],"category_scores_gemma":[0.0028517612,0.00044027588,0.0004342526,0.0012005589,0.00033115866,0.0005552203,0.0004606516,0.0005790124,0.00017337974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037969523,0.00029664286,0.89977,0.00019542268,0.00037444284,0.0015810651,0.00019180393,0.0016322752,0.025439959,0.000104993596,0.0005086156,0.066107884],"study_design_scores_gemma":[0.000090102614,0.0011847198,0.97580385,0.00006133282,0.0005108603,0.0037794814,0.00038118823,0.0104145,0.006183043,0.00014205836,0.0014208093,0.000028075365],"about_ca_topic_score_codex":0.007808475,"about_ca_topic_score_gemma":0.023014594,"teacher_disagreement_score":0.007808475,"about_ca_system_score_codex":0.0005183153,"about_ca_system_score_gemma":0.0006176729,"threshold_uncertainty_score":0.015526056},"labels":[],"label_agreement":null},{"id":"W2469882367","doi":"10.1016/j.clgc.2016.05.001","title":"Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Taxane; Carboplatin; Salvage therapy; Hazard ratio; Internal medicine; Oncology; Cisplatin; Chemotherapy; Confidence interval; Gemcitabine; Surgery; Urology; Cancer; Breast cancer","score_opus":0.07187810949543827,"score_gpt":0.4065238027753753,"score_spread":0.33464569327993704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469882367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891284,0.0050803865,0.00005493202,0.0012941742,0.00012362852,0.000015675945,0.00031922903,0.0000075453236,0.0039761555],"genre_scores_gemma":[0.99818724,0.00075440115,0.000032469186,0.0002428276,0.00010599473,0.0000037718526,0.00028988475,0.0000034092557,0.0003799229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995772,0.00014732411,0.00003749472,0.000050733648,0.000080310914,0.00010683382],"domain_scores_gemma":[0.99822515,0.0005995053,0.00044173608,0.000059191283,0.000118202006,0.00055624504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040618106,0.00017956068,0.00061388715,0.00022864701,0.00047939867,0.0008680861,0.00032480073,0.00056189526,0.00275432],"category_scores_gemma":[0.004667561,0.000098066856,0.0011533058,0.0004567781,0.00029065175,0.00061474607,0.00042055015,0.0011259377,0.00018442812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011767199,0.0007873692,0.9215285,0.00012253875,0.0007920231,0.0006205575,0.00012826479,0.00094328827,0.0013760949,0.00016220624,0.0013290481,0.0604429],"study_design_scores_gemma":[0.00010028308,0.0020765697,0.9949045,0.000038024704,0.0004635727,0.00037229384,0.00020448872,0.00046839102,0.00014771562,0.0001326369,0.0010815343,0.000009954695],"about_ca_topic_score_codex":0.004233207,"about_ca_topic_score_gemma":0.013186319,"teacher_disagreement_score":0.004233207,"about_ca_system_score_codex":0.0008242068,"about_ca_system_score_gemma":0.0011085141,"threshold_uncertainty_score":0.009214163},"labels":[],"label_agreement":null},{"id":"W2479114272","doi":"10.1016/j.clgc.2016.07.023","title":"A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Agence Nationale de la Recherche","keywords":"Medicine; Confidence interval; Testicular cancer; Germ cell tumors; Statistical significance; Surgery; Cure rate; Internal medicine; Cancer; Oncology; Chemotherapy","score_opus":0.0460010595576425,"score_gpt":0.36150168405096955,"score_spread":0.31550062449332705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479114272","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08733666,0.0020342781,0.9049687,0.0014947903,0.0004373044,0.0010635953,0.00067278335,0.00067159673,0.001320351],"genre_scores_gemma":[0.50274724,0.00051892526,0.49226877,0.0005880376,0.00046478308,0.0017129998,0.00052364677,0.00016965774,0.0010060137],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.95089936,0.038622506,0.0027985729,0.0032613834,0.003825679,0.00059253327],"domain_scores_gemma":[0.7225944,0.25278494,0.008174692,0.008128066,0.0064030397,0.0019148934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10043915,0.0011103135,0.0042451373,0.0037695335,0.001557648,0.0017067785,0.0027681985,0.0018341786,0.005668271],"category_scores_gemma":[0.1788968,0.00061483635,0.0044435696,0.003671075,0.0017075635,0.0016833905,0.0016482726,0.0029381379,0.00031363947],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010022561,0.0017649878,0.17150196,0.0026093067,0.0119571,0.000658732,0.0008848827,0.06320632,0.005784111,0.030622918,0.005675447,0.6953117],"study_design_scores_gemma":[0.0015858997,0.011523475,0.097124934,0.0006296604,0.0071532535,0.00092353806,0.0009268901,0.8281729,0.0042071003,0.03567247,0.011854868,0.00022502238],"about_ca_topic_score_codex":0.003259875,"about_ca_topic_score_gemma":0.0035591982,"teacher_disagreement_score":0.10043915,"about_ca_system_score_codex":0.0014872801,"about_ca_system_score_gemma":0.0047563575,"threshold_uncertainty_score":0.53117937},"labels":[],"label_agreement":null},{"id":"W2481386596","doi":"10.1016/j.clgc.2016.06.008","title":"Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Metformin; Propensity score matching; Hazard ratio; Internal medicine; Confidence interval; Proportional hazards model; Retrospective cohort study; Diabetes mellitus; Cancer; Kidney cancer; Nephrectomy; Renal cell carcinoma; Population; Kidney disease; Oncology; Surgery; Kidney; Endocrinology","score_opus":0.04497834636614622,"score_gpt":0.3087816892335585,"score_spread":0.26380334286741225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481386596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873513,0.000372559,0.0002678224,0.000045802095,0.000014243534,0.000007311791,0.00029498863,0.000004453873,0.0002576495],"genre_scores_gemma":[0.9993955,0.0000881389,0.0000786153,0.000018634666,0.000015956306,0.0000055670334,0.0003008401,0.0000023082337,0.00009446667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923146,0.00022276874,0.0001090402,0.00020333446,0.000107108666,0.00012633347],"domain_scores_gemma":[0.9981833,0.0003415564,0.0008427735,0.00027561688,0.00010236177,0.0002543234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001003861,0.00039075955,0.0007331476,0.0010920438,0.0005782441,0.0010237454,0.0004416769,0.0007951515,0.0016865828],"category_scores_gemma":[0.0023154654,0.0004555725,0.0021846187,0.00211261,0.0003195681,0.00068919634,0.00079332606,0.001051659,0.0002040161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007402373,0.00004637442,0.9971271,0.00000814856,0.0006765719,0.000042372434,0.000016613902,0.00017850642,0.00015399417,0.000040660005,0.00008193698,0.00088749593],"study_design_scores_gemma":[0.00008449009,0.00026500112,0.9963575,0.0000062271674,0.0005567831,0.00022149889,0.00009683438,0.001966781,0.00008231028,0.00014477308,0.00020479869,0.000013008458],"about_ca_topic_score_codex":0.0032061264,"about_ca_topic_score_gemma":0.00368371,"teacher_disagreement_score":0.0032061264,"about_ca_system_score_codex":0.00039391546,"about_ca_system_score_gemma":0.00046713406,"threshold_uncertainty_score":0.006374955},"labels":[],"label_agreement":null},{"id":"W2488303827","doi":"10.1016/j.clgc.2016.07.018","title":"A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Taxane; myalgia; Prostate cancer; Incidence (geometry); Internal medicine; Cabazitaxel; Cancer; Clinical trial; Oncology; Chemotherapy; Observational study; Breast cancer; Androgen deprivation therapy","score_opus":0.0528981432978041,"score_gpt":0.4295533392958634,"score_spread":0.3766551959980593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488303827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008861568,0.99828666,0.00006514654,0.00009165859,0.000057478297,0.00008841275,0.00036843354,0.000004380371,0.00015161924],"genre_scores_gemma":[0.007872112,0.99117744,0.00032116685,0.00026567632,0.000036197453,0.000082123224,0.00016033575,0.0000023466612,0.00008271232],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99792445,0.00045164092,0.0009918315,0.00021462385,0.00034139343,0.00007609901],"domain_scores_gemma":[0.9944518,0.003459312,0.0015031138,0.000074958836,0.00042512538,0.000085678046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002335916,0.0011538387,0.006244696,0.005425785,0.00037168936,0.0015111053,0.0012447087,0.0011349677,0.0041208304],"category_scores_gemma":[0.010683895,0.00075534696,0.008163314,0.0066458397,0.00045374574,0.0012639728,0.0010711576,0.0010377349,0.00024163425],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029360852,0.000022384356,0.0011148317,0.9377459,0.019205173,0.00010468275,0.00011168838,0.00009725297,0.00021850076,0.00012943594,0.0016205134,0.039335918],"study_design_scores_gemma":[0.0006602098,0.00047189632,0.013734435,0.651413,0.2861832,0.00093234674,0.00030299494,0.00011359422,0.00025192706,0.0004108549,0.045430254,0.00009525384],"about_ca_topic_score_codex":0.007540982,"about_ca_topic_score_gemma":0.026212681,"teacher_disagreement_score":0.007540982,"about_ca_system_score_codex":0.0013680701,"about_ca_system_score_gemma":0.0049614,"threshold_uncertainty_score":0.014994144},"labels":[],"label_agreement":null},{"id":"W2500670690","doi":"10.1016/j.clgc.2016.07.022","title":"A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Germ cell tumors; Etoposide; Oncology; Concordance; Internal medicine; Proportional hazards model; Cisplatin; Chemotherapy","score_opus":0.031256571530880475,"score_gpt":0.3418429633400645,"score_spread":0.310586391809184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500670690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98853314,0.001618698,0.0024851137,0.0009851769,0.00023822996,0.000041051597,0.00075038173,0.000076692,0.0052715926],"genre_scores_gemma":[0.9982626,0.00009820802,0.0006441214,0.000049523624,0.00009474931,0.000008018139,0.0004268587,0.0000103706325,0.00040556525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920076,0.00023865838,0.00010219286,0.0001557741,0.00013095133,0.00017174105],"domain_scores_gemma":[0.99736917,0.0007523372,0.0004021874,0.0003287213,0.00062570645,0.0005217692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017121328,0.0005718177,0.00041305262,0.0016814027,0.00070758676,0.0014553476,0.00069938984,0.00059592223,0.0037591958],"category_scores_gemma":[0.00693275,0.00013296684,0.0008995334,0.0009892776,0.00050231826,0.00069933385,0.0006832578,0.00083589676,0.00070965994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042952056,0.000026869495,0.98059756,0.000036743586,0.00011572919,0.00025455287,0.00010106534,0.00032448885,0.0010797966,0.0003477972,0.00072309887,0.015962712],"study_design_scores_gemma":[0.00005424978,0.00038509583,0.9826067,0.000056212895,0.00052193727,0.001746089,0.0005320593,0.00622275,0.0017321804,0.0025564872,0.0035585104,0.000027764578],"about_ca_topic_score_codex":0.0016662483,"about_ca_topic_score_gemma":0.0024536196,"teacher_disagreement_score":0.0037591958,"about_ca_system_score_codex":0.00047058548,"about_ca_system_score_gemma":0.0007350347,"threshold_uncertainty_score":0.012575805},"labels":[],"label_agreement":null},{"id":"W2522935852","doi":"10.1016/j.clgc.2016.08.012","title":"Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"American Society for Radiation Oncology; Prostate Cancer Foundation","keywords":"Prostatectomy; Medicine; Prostate cancer; Radiation therapy; Cost effectiveness; Oncology; Adjuvant therapy; Internal medicine; Cancer; Intensive care medicine","score_opus":0.1608032523094253,"score_gpt":0.4728689907432387,"score_spread":0.31206573843381336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522935852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245754,0.0066107484,0.04453057,0.008366019,0.00050527125,0.00035711474,0.0035649904,0.0005862669,0.010903591],"genre_scores_gemma":[0.9804385,0.0005538449,0.015402352,0.00046679,0.0001542565,0.000059403443,0.0013672176,0.00004319628,0.001514449],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99852777,0.0008033482,0.00008288511,0.00020542454,0.00027050177,0.000110202534],"domain_scores_gemma":[0.9915475,0.00707701,0.00028235593,0.00037364796,0.0004844988,0.00023489997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002691311,0.00072810275,0.0011630484,0.0009850571,0.0002778187,0.0016101304,0.00077819725,0.0011051381,0.005327397],"category_scores_gemma":[0.016450383,0.00028433654,0.0009127712,0.00072721933,0.00032734952,0.0014351939,0.0007106074,0.0009109558,0.0005073923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012528525,0.0015134463,0.123840146,0.00028217587,0.0008710217,0.00042872882,0.00007122694,0.3214316,0.0030282368,0.004451717,0.010814587,0.5207385],"study_design_scores_gemma":[0.000635197,0.0016421394,0.029592972,0.00006256466,0.00072784454,0.0005251437,0.00013671527,0.95302606,0.0025455782,0.008853057,0.0021961692,0.000056457266],"about_ca_topic_score_codex":0.0065921694,"about_ca_topic_score_gemma":0.008328183,"teacher_disagreement_score":0.0065921694,"about_ca_system_score_codex":0.0012706037,"about_ca_system_score_gemma":0.001712405,"threshold_uncertainty_score":0.017821968},"labels":[],"label_agreement":null},{"id":"W2562774782","doi":"10.1016/j.clgc.2016.12.014","title":"Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Univariate analysis; Performance status; Multivariate analysis; Oncology; Proportional hazards model; Gastroenterology; Toxicity; Adverse effect; Cancer; Urothelial carcinoma; Bladder cancer","score_opus":0.054823167612941544,"score_gpt":0.3807051565461041,"score_spread":0.32588198893316256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562774782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5604495,0.43270236,0.0012987149,0.00016606136,0.00023454658,0.00025008604,0.0033691402,0.000046780515,0.0014828551],"genre_scores_gemma":[0.9661165,0.030300764,0.000424942,0.00032126697,0.00015170425,0.00010674857,0.0022433014,0.000017536657,0.00031714066],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996747,0.0015637393,0.0005706971,0.00062428945,0.00033049475,0.00016378064],"domain_scores_gemma":[0.9946737,0.0024140277,0.001921368,0.00043858646,0.000364018,0.00018827351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004411137,0.001206195,0.0048135337,0.00193036,0.00026441173,0.0014085338,0.00052254973,0.0009005775,0.0012792563],"category_scores_gemma":[0.0061323233,0.00056879787,0.013223464,0.0022832637,0.00023991549,0.0007789072,0.00079237565,0.0008119978,0.000106870546],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049604524,0.00011960527,0.28190994,0.010628352,0.6242327,0.00033033226,0.00011352698,0.0014371645,0.0021020798,0.00009481066,0.0010904963,0.028336555],"study_design_scores_gemma":[0.006522468,0.003723322,0.45540747,0.0011934832,0.5269553,0.00077048247,0.00015581022,0.00085017877,0.00066647603,0.00017921747,0.0034981777,0.00007760697],"about_ca_topic_score_codex":0.0026930189,"about_ca_topic_score_gemma":0.0068890606,"teacher_disagreement_score":0.0048135337,"about_ca_system_score_codex":0.00074666913,"about_ca_system_score_gemma":0.0005326731,"threshold_uncertainty_score":0.023328543},"labels":[],"label_agreement":null},{"id":"W2565985412","doi":"10.1016/j.clgc.2016.12.025","title":"Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population","year":2016,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Gemcitabine; Bladder cancer; Carboplatin; Regimen; Internal medicine; Oncology; Vinblastine; Population; Chemotherapy; Cancer registry; Cancer; Cisplatin","score_opus":0.08039182811776317,"score_gpt":0.4279513018811414,"score_spread":0.3475594737633782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565985412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951645,0.0024307305,0.000056237026,0.0006872766,0.0000104087085,0.000008337925,0.00039827684,0.0000032958376,0.0012408837],"genre_scores_gemma":[0.99884063,0.0006698413,0.00002154371,0.0001204186,0.00000882326,0.0000028969764,0.00019252491,0.0000014310662,0.00014194449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995072,0.00018109783,0.000041334784,0.00006411661,0.00007533969,0.00013089909],"domain_scores_gemma":[0.9988514,0.0001771914,0.00059248105,0.0000291633,0.00012253455,0.00022718587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038712632,0.00007513843,0.0002376663,0.0002997669,0.00028403278,0.00054055155,0.00019940964,0.00034792678,0.0019190757],"category_scores_gemma":[0.0035647033,0.0000988233,0.00035372376,0.0010668229,0.00021054532,0.0005113339,0.0005194249,0.00038098235,0.00015804362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029597752,0.00010710808,0.9810493,0.00005288508,0.00011078452,0.00015878868,0.0003614896,0.00017628663,0.00017304173,0.00013154406,0.0008293845,0.016553318],"study_design_scores_gemma":[0.000013420348,0.0001676759,0.9982003,0.000025805713,0.00003525316,0.00020499538,0.0006877295,0.0001381364,0.00002593863,0.00010217275,0.00039389473,0.0000047884637],"about_ca_topic_score_codex":0.013463182,"about_ca_topic_score_gemma":0.021236904,"teacher_disagreement_score":0.013463182,"about_ca_system_score_codex":0.0010345461,"about_ca_system_score_gemma":0.0007383519,"threshold_uncertainty_score":0.026769638},"labels":[],"label_agreement":null},{"id":"W2573089847","doi":"10.1016/j.clgc.2017.01.005","title":"Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of British Columbia; BC Cancer Agency; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Toxicity; VEGF receptors; Internal medicine; Targeted therapy; Second-line therapy; Cancer; Chemotherapy","score_opus":0.11363597456475641,"score_gpt":0.4247044064405806,"score_spread":0.3110684318758242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573089847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292856,0.0049923956,0.00012949585,0.0003326539,0.000041987056,0.000011070596,0.00012687132,0.0000071211102,0.001429733],"genre_scores_gemma":[0.99896896,0.00042778204,0.00004599594,0.00011916795,0.000037113023,0.0000041496905,0.0001444258,0.0000031412353,0.00024926473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934953,0.00021784166,0.00005728369,0.00008621274,0.00014625113,0.00014285151],"domain_scores_gemma":[0.9972606,0.0011476803,0.00090999284,0.00010930651,0.00019044496,0.00038193766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013471697,0.000119272394,0.00050571945,0.0001752145,0.0002833739,0.000727184,0.00026707308,0.0003812463,0.0012345331],"category_scores_gemma":[0.0054298835,0.00005809238,0.0008364899,0.0002951394,0.00023260941,0.0005831748,0.00023228982,0.00096797687,0.00010125335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023932287,0.0014016427,0.7524954,0.00023593887,0.0013529649,0.00028748118,0.0003087853,0.0017850656,0.0057628066,0.00050602714,0.001798934,0.21013266],"study_design_scores_gemma":[0.00023826573,0.005804348,0.98809147,0.000050673178,0.0006436378,0.00035319955,0.00013245457,0.0009553088,0.0012076349,0.000381117,0.0021278812,0.000013870461],"about_ca_topic_score_codex":0.002153576,"about_ca_topic_score_gemma":0.005175974,"teacher_disagreement_score":0.002153576,"about_ca_system_score_codex":0.0010939081,"about_ca_system_score_gemma":0.00090687285,"threshold_uncertainty_score":0.007936895},"labels":[],"label_agreement":null},{"id":"W2585144179","doi":"10.1016/j.clgc.2017.01.016","title":"Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Cancer Agency; Pfizer","keywords":"Medicine; Sunitinib; Dosing; Discontinuation; Renal cell carcinoma; Regimen; Internal medicine; Oncology; Adverse effect; Population; Renal function; Urology","score_opus":0.08856902812750578,"score_gpt":0.4031532497966694,"score_spread":0.3145842216691636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585144179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979867,0.0002010819,0.000030168972,0.00008353564,0.00000221326,0.0000090655585,0.0013034358,0.0000022854988,0.00038139996],"genre_scores_gemma":[0.9990188,0.00010642015,0.000025320986,0.000021373366,0.0000032033658,0.000005284732,0.00072775624,0.0000020681596,0.0000897534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899143,0.00015959253,0.00009942789,0.00017846211,0.00026542158,0.00030566155],"domain_scores_gemma":[0.99773335,0.00023127833,0.0010301347,0.00015736009,0.00037462072,0.00047316408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045672298,0.00029554882,0.0005177564,0.0008094786,0.0009005676,0.0008867326,0.00087370776,0.0005850655,0.0014187417],"category_scores_gemma":[0.0028398186,0.00045688346,0.0014587763,0.0037094604,0.000507864,0.0006197424,0.0007863175,0.0010035927,0.00014872839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027761105,0.000059680635,0.9981007,0.000017122777,0.00014805482,0.000076031916,0.00008231719,0.00018657288,0.0000974104,0.000029691611,0.00017182918,0.0007530326],"study_design_scores_gemma":[0.000024417706,0.00007058668,0.9991431,0.0000048541674,0.00005986034,0.00008668486,0.00018822163,0.00028415633,0.000018390803,0.000022596065,0.000090636044,0.0000064812384],"about_ca_topic_score_codex":0.542239,"about_ca_topic_score_gemma":0.5746109,"teacher_disagreement_score":0.542239,"about_ca_system_score_codex":0.0082779955,"about_ca_system_score_gemma":0.0044479463,"threshold_uncertainty_score":0.9209137},"labels":[],"label_agreement":null},{"id":"W2592873754","doi":"10.1016/j.clgc.2017.02.002","title":"Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Chemotherapy; Internal medicine; Perioperative; Oncology; Lymph node; Stage (stratigraphy); Proportional hazards model; Penile cancer; Retrospective cohort study; Surgery; Cancer","score_opus":0.03055347263178582,"score_gpt":0.39558978975928033,"score_spread":0.3650363171274945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592873754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883586,0.00056777574,0.000055436863,0.000031550364,0.000003655544,0.0000144547585,0.00033888375,0.0000017455156,0.0001505824],"genre_scores_gemma":[0.99886453,0.00021248612,0.00006820504,0.000037259397,0.000013937592,0.000017363322,0.00074131985,0.0000028558684,0.000042073472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845195,0.0006855799,0.00020549241,0.00028207124,0.00021236128,0.00016264613],"domain_scores_gemma":[0.997042,0.0005460419,0.0015219828,0.00021065788,0.0003423694,0.00033686412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016879364,0.00043346864,0.0007890185,0.00079751044,0.0003716507,0.0009351622,0.00047343757,0.0003704989,0.00069686165],"category_scores_gemma":[0.0036798723,0.00023692085,0.0010574069,0.0016346206,0.0003910791,0.00068402954,0.00067093247,0.00039062227,0.00011957109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016924964,0.00011599356,0.994292,0.000024524228,0.00065788726,0.00005541466,0.00006576099,0.000095099014,0.00031172638,0.00001570007,0.00012595401,0.0025472664],"study_design_scores_gemma":[0.00012446834,0.0005738147,0.997884,0.000010271568,0.0004768384,0.00016977296,0.0002334554,0.00017562763,0.00015899548,0.000014546196,0.00016913946,0.000009021721],"about_ca_topic_score_codex":0.0023217085,"about_ca_topic_score_gemma":0.0026564368,"teacher_disagreement_score":0.0023217085,"about_ca_system_score_codex":0.0007643608,"about_ca_system_score_gemma":0.0006359169,"threshold_uncertainty_score":0.008926749},"labels":[],"label_agreement":null},{"id":"W2602722441","doi":"10.1016/j.clgc.2017.03.007","title":"Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non–muscle-invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Bladder cancer; Neutrophil to lymphocyte ratio; Lymphocyte; Oncology; Internal medicine; Primary (astronomy); Cancer; Immunology; Pathology","score_opus":0.0354414923943765,"score_gpt":0.3702700535807678,"score_spread":0.3348285611863913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464285,0.0033036587,0.00021203991,0.00017448183,0.000042485502,0.000008648312,0.0002582777,0.000016663906,0.0013409727],"genre_scores_gemma":[0.9993992,0.00017617029,0.00007761994,0.000022031882,0.000024467234,0.0000035429368,0.0001276443,0.0000015453668,0.0001679122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969363,0.00010453064,0.000044808596,0.000041925512,0.00004360591,0.00007150615],"domain_scores_gemma":[0.9989361,0.0003369122,0.00030674698,0.00006117996,0.00014778049,0.00021125562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006201445,0.0002774992,0.00043172782,0.0005268242,0.00027612105,0.00071160024,0.0003219208,0.00044294054,0.0014440425],"category_scores_gemma":[0.0024489372,0.00013605463,0.00026043886,0.00061729393,0.0003169789,0.0005364717,0.00041489792,0.00051427475,0.0002822089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050696015,0.000024912035,0.9943077,0.00002104721,0.00004536799,0.00012466202,0.000023673498,0.00008501657,0.0006519472,0.000022436432,0.00015193468,0.0040343045],"study_design_scores_gemma":[0.000011694903,0.00022080391,0.99612635,0.000015518119,0.00010007538,0.0008628868,0.0001559966,0.001129211,0.0006497578,0.000100981255,0.00061903725,0.000007714394],"about_ca_topic_score_codex":0.00075505656,"about_ca_topic_score_gemma":0.0013297823,"teacher_disagreement_score":0.0014440425,"about_ca_system_score_codex":0.00026970793,"about_ca_system_score_gemma":0.00027142026,"threshold_uncertainty_score":0.0048307776},"labels":[],"label_agreement":null},{"id":"W2606962296","doi":"10.1016/j.clgc.2017.04.006","title":"Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Confidence interval; Prostatectomy; Incidence (geometry); Internal medicine; Proportional hazards model; Oncology; Epidemiology; Surveillance, Epidemiology, and End Results; Confounding; Cancer; Cancer registry","score_opus":0.09925951799187302,"score_gpt":0.4456136316898717,"score_spread":0.34635411369799873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606962296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778169,0.002434091,0.00016510629,0.00015419994,0.000011827853,0.000014365442,0.018370807,0.000014280577,0.0010185294],"genre_scores_gemma":[0.9839273,0.0007389006,0.000105829095,0.00005849579,0.000021749736,0.000013531947,0.014985494,0.0000072691896,0.00014141336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982843,0.0002844701,0.00031256967,0.0005230774,0.00033467854,0.00026090659],"domain_scores_gemma":[0.9966577,0.0005306817,0.001737508,0.00037556217,0.0004442579,0.00025434914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011376814,0.00026450527,0.0007653634,0.0019772209,0.00030141015,0.0011520534,0.00069133757,0.0005013033,0.0012117028],"category_scores_gemma":[0.0035272795,0.00034748012,0.0016454903,0.005203742,0.00023724273,0.0011338638,0.0009729535,0.0007445836,0.00023738369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020047522,0.000022624077,0.99677724,0.000039616054,0.00048176243,0.00005262117,0.00004122157,0.00016108144,0.0000799656,0.00006437438,0.00053129176,0.0015477753],"study_design_scores_gemma":[0.000010646412,0.000029921199,0.9988223,0.000009093818,0.00017934274,0.00016582,0.00012772265,0.0002417681,0.00002909822,0.000027058555,0.00035257053,0.000004661842],"about_ca_topic_score_codex":0.018312816,"about_ca_topic_score_gemma":0.022695657,"teacher_disagreement_score":0.018312816,"about_ca_system_score_codex":0.0009217576,"about_ca_system_score_gemma":0.0007954494,"threshold_uncertainty_score":0.036412418},"labels":[],"label_agreement":null},{"id":"W2612397142","doi":"10.1016/j.clgc.2017.05.014","title":"Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institutes of Health; National Cancer Institute; Sanofi; Abbott Laboratories","keywords":"Medicine; Prostate cancer; Docetaxel; Hazard ratio; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Enzalutamide; Prostate-specific antigen; Cancer; Progressive disease; Disease","score_opus":0.11292832206148902,"score_gpt":0.43059886480570775,"score_spread":0.31767054274421874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612397142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728715,0.00012704238,0.00007792519,0.000047618094,0.000013690724,0.000014595759,0.0014765564,0.000011590414,0.000943976],"genre_scores_gemma":[0.996452,0.0000510917,0.00010870133,0.000037954735,0.000017125723,0.000016987442,0.0028403017,0.0000109477805,0.0004648959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900144,0.00045237894,0.000079025696,0.00018013861,0.00017153478,0.00011553537],"domain_scores_gemma":[0.99764675,0.000568402,0.00071812194,0.00042173275,0.0003890353,0.00025594977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016940202,0.00042852716,0.00055262505,0.00066399877,0.00048765464,0.0007830566,0.00055701536,0.00044339788,0.0016230629],"category_scores_gemma":[0.0037936447,0.0001973351,0.0005718651,0.0010462417,0.00033046637,0.00039847588,0.0005213855,0.0005277002,0.0004968319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027019081,0.000099396835,0.99097484,0.0000153645,0.00020031357,0.00003789536,0.00007856401,0.00016588488,0.001033035,0.000029668996,0.0005195853,0.0041435896],"study_design_scores_gemma":[0.000071387454,0.0007627214,0.9973959,0.0000030137187,0.00009016049,0.00013368196,0.00006955351,0.00031113572,0.00029208264,0.000026548852,0.000838738,0.0000051196675],"about_ca_topic_score_codex":0.0049134423,"about_ca_topic_score_gemma":0.008939083,"teacher_disagreement_score":0.0049134423,"about_ca_system_score_codex":0.00038563434,"about_ca_system_score_gemma":0.0005742022,"threshold_uncertainty_score":0.009769678},"labels":[],"label_agreement":null},{"id":"W2613354668","doi":"10.1016/j.clgc.2017.05.007","title":"Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Cystectomy; Cystoprostatectomy; Radiation therapy; Surgery; Genitourinary system; Urology; Urinary diversion; Internal medicine; Bladder cancer; Cancer","score_opus":0.09100725329578864,"score_gpt":0.43840633249904226,"score_spread":0.34739907920325364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613354668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994697,0.0001431928,0.000060364804,0.000005400644,0.0000021452224,0.00000409684,0.0000808144,0.0000010533863,0.00023331317],"genre_scores_gemma":[0.9996973,0.000058748537,0.000020968184,0.000013110097,0.0000033836347,0.0000034216564,0.00013508678,0.000001846715,0.0000662103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939847,0.00015981309,0.0001008792,0.00014961553,0.00007585784,0.0001152658],"domain_scores_gemma":[0.99795544,0.000393473,0.00095325,0.00021328911,0.00017286505,0.00031165185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005590791,0.00026720625,0.00037004228,0.00077870686,0.00046613882,0.00071105716,0.0003411041,0.0003779237,0.0016986545],"category_scores_gemma":[0.0016357268,0.00028208006,0.0006758818,0.0011036015,0.0004834687,0.0005281908,0.0005345025,0.00032118137,0.00028301968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020857812,0.00004189088,0.9982173,0.000008492551,0.00004168639,0.00024054405,0.00010731747,0.0000360474,0.0003044241,0.000010121093,0.000020495712,0.0007631657],"study_design_scores_gemma":[0.0000060732223,0.00042614658,0.9967193,0.0000057463326,0.000056570098,0.001580244,0.00068327243,0.00007273219,0.00017756682,0.000018669629,0.00024720092,0.000006412815],"about_ca_topic_score_codex":0.0011779155,"about_ca_topic_score_gemma":0.0013236804,"teacher_disagreement_score":0.0016986545,"about_ca_system_score_codex":0.00032008582,"about_ca_system_score_gemma":0.0002831484,"threshold_uncertainty_score":0.005682528},"labels":[],"label_agreement":null},{"id":"W2613761563","doi":"10.1016/j.clgc.2017.05.006","title":"Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Interquartile range; Medicine; Cystectomy; Quartile; Odds ratio; Confidence interval; Bladder cancer; Internal medicine; Surgery; Cancer","score_opus":0.11917036530780481,"score_gpt":0.4432306947105458,"score_spread":0.324060329402741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613761563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993799,0.0001036614,0.00005655862,0.00004145845,0.000004968458,0.0000061178507,0.00026684432,0.0000015737944,0.0001388126],"genre_scores_gemma":[0.9995011,0.000038833936,0.00003310318,0.00002612227,0.0000072578855,0.0000062838667,0.00032020133,0.0000016561635,0.0000654644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979522,0.0006369833,0.00025359832,0.0004425734,0.00019207725,0.0005223791],"domain_scores_gemma":[0.9919878,0.001161743,0.003851017,0.0006168994,0.00064760156,0.0017349105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015097405,0.00042283605,0.000659686,0.0012971874,0.0013150778,0.00147168,0.0011213933,0.00094422576,0.0019188137],"category_scores_gemma":[0.0052310843,0.0005562432,0.0015757642,0.003222553,0.0009237019,0.0015332849,0.0020649796,0.0013836233,0.0002096339],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100404286,0.00006204677,0.9993069,0.000004089303,0.00012374378,0.000026835483,0.000069590016,0.000026143212,0.000034291144,0.000008418775,0.00003854839,0.00019896342],"study_design_scores_gemma":[0.000009329754,0.00013180893,0.99892515,0.0000050806666,0.000060720788,0.00006795187,0.0005938809,0.000103651684,0.000019083696,0.000015660873,0.000059304515,0.000008376308],"about_ca_topic_score_codex":0.01909034,"about_ca_topic_score_gemma":0.021034677,"teacher_disagreement_score":0.01909034,"about_ca_system_score_codex":0.0011306077,"about_ca_system_score_gemma":0.0012390811,"threshold_uncertainty_score":0.037958443},"labels":[],"label_agreement":null},{"id":"W2659875471","doi":"10.1016/j.clgc.2017.06.004","title":"Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Astellas Pharma; Sanofi","keywords":"Medicine; Prostate cancer; Internal medicine; Androgen receptor; Docetaxel; Hazard ratio; Androgen deprivation therapy; Prostate-specific antigen; Oncology; Taxane; Enzalutamide; Cancer; Breast cancer; Confidence interval","score_opus":0.062336598362176865,"score_gpt":0.3819573128623433,"score_spread":0.31962071450016644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2659875471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988765,0.0001845007,0.000029913808,0.00010376591,0.000007969734,0.000008956854,0.0005496946,0.000001983803,0.00023656223],"genre_scores_gemma":[0.99931467,0.000053239975,0.000016130376,0.000034585217,0.0000101373325,0.00000503061,0.00052826543,0.0000013714103,0.000036515754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900204,0.0003265978,0.000097816606,0.0002113671,0.000085771,0.00027645053],"domain_scores_gemma":[0.9958978,0.00067151716,0.0018589331,0.00012313631,0.00021987416,0.0012287301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007145651,0.00025517424,0.00048365447,0.0005510537,0.000578814,0.0011568101,0.0005961265,0.0008915837,0.0024108342],"category_scores_gemma":[0.0054788357,0.00022769351,0.00086181134,0.001203518,0.00058422686,0.0012417572,0.00091432704,0.0011296608,0.00021935398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010644596,0.00016935516,0.99671835,0.00001800983,0.00014967092,0.00009039901,0.00010518881,0.0001798521,0.000059971484,0.00003951614,0.00025931967,0.001146045],"study_design_scores_gemma":[0.00006890974,0.0007619613,0.9968182,0.000012827373,0.00007503825,0.00026687072,0.0010507823,0.0005727316,0.00003170182,0.00010598835,0.00021240741,0.000022628114],"about_ca_topic_score_codex":0.01239811,"about_ca_topic_score_gemma":0.016090458,"teacher_disagreement_score":0.01239811,"about_ca_system_score_codex":0.0011449488,"about_ca_system_score_gemma":0.00066320854,"threshold_uncertainty_score":0.024651945},"labels":[],"label_agreement":null},{"id":"W2719550704","doi":"10.1016/j.clgc.2017.06.003","title":"Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Proportional hazards model; Lymphovascular invasion; Hazard ratio; Thrombocytosis; Stage (stratigraphy); Internal medicine; T-stage; Cohort; Oncology; Urology; Lymph node; Carcinoma; Cancer; Metastasis; Confidence interval; Platelet","score_opus":0.048477951581277025,"score_gpt":0.3851021898531702,"score_spread":0.33662423827189314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719550704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695045,0.0017624997,0.00015359189,0.0001341162,0.00003940907,0.000006324862,0.00015389142,0.000008567059,0.00079119095],"genre_scores_gemma":[0.9995894,0.00015615915,0.000069461144,0.000015281452,0.000034415843,0.0000022565046,0.0000702989,0.0000012664909,0.00006146737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995732,0.000139199,0.00007606185,0.000043268323,0.00007781483,0.00009054639],"domain_scores_gemma":[0.9970106,0.0013277818,0.00066937105,0.00016406662,0.00031198902,0.00051611674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072812435,0.00030205768,0.00040808105,0.0011104177,0.00044098674,0.00084481103,0.00035896015,0.0006877551,0.0017072514],"category_scores_gemma":[0.005637053,0.00021534225,0.00037837215,0.0013287511,0.00060346635,0.0004754324,0.00038498658,0.0007766644,0.00020436382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026413676,0.000021767772,0.99746335,0.000011087099,0.000029818577,0.00013376522,0.000019182273,0.00011623664,0.0002665816,0.00001997904,0.00006298029,0.0015911205],"study_design_scores_gemma":[0.000015071103,0.00015472643,0.9958776,0.000019022827,0.00013351068,0.0009649591,0.00023544593,0.001665902,0.0004470836,0.00011885743,0.0003590553,0.00000886921],"about_ca_topic_score_codex":0.0014787595,"about_ca_topic_score_gemma":0.0017262923,"teacher_disagreement_score":0.0017072514,"about_ca_system_score_codex":0.00029725337,"about_ca_system_score_gemma":0.00044856008,"threshold_uncertainty_score":0.005711317},"labels":[],"label_agreement":null},{"id":"W2737333498","doi":"10.1016/j.clgc.2017.07.014","title":"Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Proportional hazards model; Hazard ratio; Internal medicine; Progression-free survival; Oncology; Chemotherapy; Univariate analysis; Urology; Cancer; Confidence interval; Gastroenterology; Multivariate analysis; Androgen deprivation therapy","score_opus":0.12033434774859395,"score_gpt":0.44305116817026297,"score_spread":0.32271682042166905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737333498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95203394,0.0023740227,0.025097644,0.002199508,0.00051789323,0.00016410745,0.013308827,0.00076907803,0.003535002],"genre_scores_gemma":[0.9918566,0.00027090346,0.0022847226,0.000073227304,0.00008415833,0.00006380375,0.0037054678,0.000020993983,0.0016401075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99967253,0.00010743385,0.000025871863,0.0000753487,0.0000513784,0.000067433044],"domain_scores_gemma":[0.9983504,0.000973115,0.00021489758,0.00008539277,0.00021955295,0.00015656362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017961747,0.00092797406,0.00103106,0.0008835037,0.0002888214,0.001172431,0.0010304345,0.00052464334,0.004006172],"category_scores_gemma":[0.0044636987,0.00021351877,0.0013650345,0.000543865,0.00017358005,0.0003501776,0.00046324916,0.0010761367,0.0009858918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009725701,0.00076375506,0.68117243,0.00024831347,0.002458871,0.0004378974,0.00011639406,0.2035493,0.0015654955,0.0014926457,0.011318073,0.08715111],"study_design_scores_gemma":[0.0003258455,0.00077122037,0.099001445,0.00005561891,0.0010438741,0.00022237108,0.00006587981,0.8946506,0.00050151587,0.0016153705,0.0017032189,0.000043010125],"about_ca_topic_score_codex":0.016835054,"about_ca_topic_score_gemma":0.011206226,"teacher_disagreement_score":0.016835054,"about_ca_system_score_codex":0.00091520644,"about_ca_system_score_gemma":0.0015028215,"threshold_uncertainty_score":0.033474147},"labels":[],"label_agreement":null},{"id":"W2737755444","doi":"10.1016/j.clgc.2017.07.018","title":"Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Positron emission tomography; Confidence interval; Odds ratio; Bladder cancer; Magnetic resonance imaging; Stage (stratigraphy); Logistic regression; Radiology; Nuclear medicine; Cancer; Computed tomography; Internal medicine","score_opus":0.03682113614610499,"score_gpt":0.3799245230723125,"score_spread":0.3431033869262075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737755444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97294384,0.012082076,0.00022889015,0.006183955,0.00012309298,0.000016469297,0.0017846047,0.000007705588,0.006629454],"genre_scores_gemma":[0.99624866,0.0025667662,0.00010782477,0.00031243666,0.000081612394,0.000004333878,0.00040493545,0.0000018385831,0.00027159028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999385,0.0002870305,0.000058740156,0.000032577664,0.000106293795,0.00013042579],"domain_scores_gemma":[0.9972867,0.00066338,0.0013430039,0.000050003444,0.0002492454,0.00040755444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054930453,0.00014415206,0.00014282449,0.00085917563,0.00025259293,0.00084849424,0.00027405904,0.00054004247,0.0031066432],"category_scores_gemma":[0.005191333,0.00011444233,0.0005343792,0.001265683,0.0002607606,0.00044406383,0.0005501523,0.0007168299,0.00017303358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003025396,0.00010639989,0.9825295,0.00006828601,0.00016488261,0.00045898062,0.000034857796,0.0003576995,0.00017083564,0.00032656724,0.00088002335,0.014599492],"study_design_scores_gemma":[0.000014039331,0.00008013186,0.995432,0.00006866819,0.00014597265,0.0008134995,0.00035893466,0.00094983546,0.00009896134,0.00026868793,0.0017630254,0.0000063092034],"about_ca_topic_score_codex":0.009583493,"about_ca_topic_score_gemma":0.011894465,"teacher_disagreement_score":0.009583493,"about_ca_system_score_codex":0.0011438265,"about_ca_system_score_gemma":0.00092678523,"threshold_uncertainty_score":0.019055426},"labels":[],"label_agreement":null},{"id":"W2742727144","doi":"10.1016/j.clgc.2017.07.026","title":"Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Prostate Cancer Foundation","keywords":"Medicine; Prostatectomy; Prostate cancer; Prostate-specific antigen; Proportional hazards model; Univariate analysis; Confidence interval; Stage (stratigraphy); Urology; Internal medicine; Oncology; Surgery; Cancer; Multivariate analysis","score_opus":0.07020088189698086,"score_gpt":0.42518401383945753,"score_spread":0.35498313194247666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742727144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993049,0.00019777611,0.000083416075,0.000016809461,0.0000034852058,0.0000130241015,0.00013286027,0.0000033128088,0.00024443297],"genre_scores_gemma":[0.9991528,0.0001812587,0.00010474455,0.000019888428,0.000014203969,0.000012310871,0.00033441465,0.0000038382054,0.00017660133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992543,0.00019178295,0.00007348501,0.00017006106,0.0001524448,0.00015788218],"domain_scores_gemma":[0.99803156,0.0004369344,0.0005288979,0.00019249339,0.00035257323,0.00045758855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011645589,0.00043357635,0.00063718605,0.0009846869,0.0010474479,0.00100497,0.0005859006,0.00058558985,0.0010804983],"category_scores_gemma":[0.0026262389,0.00025645204,0.0008846994,0.0012007607,0.00066754187,0.0009226974,0.0009470333,0.0007085564,0.00034826098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049039593,0.0008883506,0.9888461,0.000015782098,0.000091718124,0.0005019308,0.00082655414,0.00018299269,0.00041997083,0.000012344205,0.000121135825,0.0076026153],"study_design_scores_gemma":[0.00003331741,0.0017728846,0.99468,0.000016359687,0.00011823723,0.001239359,0.0013257604,0.00023428282,0.00030343037,0.000020447484,0.00022918852,0.000026724405],"about_ca_topic_score_codex":0.008430434,"about_ca_topic_score_gemma":0.008378215,"teacher_disagreement_score":0.008430434,"about_ca_system_score_codex":0.00088137144,"about_ca_system_score_gemma":0.0008115971,"threshold_uncertainty_score":0.016762674},"labels":[],"label_agreement":null},{"id":"W2748271565","doi":"10.1016/j.clgc.2017.07.001","title":"Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Bladder cancer; Internal medicine; Proportional hazards model; Lymph node; Oncology; Tissue microarray; Cystectomy; Stage (stratigraphy); Cancer; Confidence interval; Cadherin; Biomarker; Survival analysis; Cell","score_opus":0.037392255950071576,"score_gpt":0.36233653435889096,"score_spread":0.3249442784088194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748271565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967278,0.0012934072,0.000099090066,0.00015341546,0.000022844964,0.0000037571074,0.00020047884,0.000006528429,0.001492757],"genre_scores_gemma":[0.999241,0.00018682738,0.00004799735,0.000027523316,0.000020753272,0.0000023126622,0.00020067368,0.0000013165723,0.000271541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997297,0.00006653697,0.000029884788,0.000041850886,0.000045679113,0.00008634808],"domain_scores_gemma":[0.9991874,0.0002449409,0.00023327462,0.000042233587,0.00011504655,0.00017717664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042690808,0.00026359595,0.00034896386,0.0006287846,0.00038390487,0.0006970529,0.00032837444,0.0005576767,0.0016833512],"category_scores_gemma":[0.0021022123,0.00016816396,0.00034800492,0.0009404585,0.0004241121,0.000564605,0.0004304781,0.0005353405,0.00021223514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022348817,0.000019728828,0.9960347,0.000013997681,0.000040753042,0.00012418212,0.000036541875,0.000071162605,0.00057551573,0.000027815342,0.0001724968,0.0026596063],"study_design_scores_gemma":[0.000006292805,0.00005686499,0.99824417,0.000007969437,0.000056423865,0.00043000668,0.00013332092,0.00041633623,0.0001708466,0.000058955346,0.00041401185,0.0000048550896],"about_ca_topic_score_codex":0.0021350493,"about_ca_topic_score_gemma":0.005403447,"teacher_disagreement_score":0.0021350493,"about_ca_system_score_codex":0.00037231526,"about_ca_system_score_gemma":0.00035273944,"threshold_uncertainty_score":0.0056313872},"labels":[],"label_agreement":null},{"id":"W2748372943","doi":"10.1016/j.clgc.2017.08.002","title":"External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Prostatectomy; Prostate cancer; Interquartile range; Stage (stratigraphy); Cohort; Lymph node; Prostate-specific antigen; Population; Dissection (medical); Lymphadenectomy; Urology; Prostate; Cancer; Radiology; Oncology; Surgery; Internal medicine","score_opus":0.11332004871470644,"score_gpt":0.43751846598963035,"score_spread":0.32419841727492393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748372943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658185,0.0002245341,0.001345468,0.00004612119,0.000038454124,0.00013412403,0.0006020178,0.00001675068,0.0010106873],"genre_scores_gemma":[0.9971552,0.00006687983,0.00048332315,0.000079787,0.000041455332,0.00015099542,0.001714605,0.000028740584,0.00027898295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877543,0.0067810058,0.00074250175,0.002429079,0.0017650829,0.0005280677],"domain_scores_gemma":[0.98012656,0.006940751,0.0022508686,0.0055490225,0.0043258592,0.0008069196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013223742,0.0009822068,0.0010488734,0.0011609929,0.0013880725,0.0015413822,0.0017786387,0.0016475721,0.0015856328],"category_scores_gemma":[0.026720777,0.0007937904,0.0012815362,0.0013948685,0.0021561433,0.00096774165,0.0018292823,0.0011906708,0.00091059424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010064829,0.00038836154,0.9925781,0.000039310322,0.0005829611,0.00009500917,0.00056915113,0.00023196927,0.0012068301,0.00010408209,0.000592534,0.0026052084],"study_design_scores_gemma":[0.00021354039,0.00079071615,0.9951827,0.000019125588,0.00042320025,0.0003647249,0.0002984282,0.0006940921,0.00038316436,0.00011862258,0.0014928855,0.000018777482],"about_ca_topic_score_codex":0.003460847,"about_ca_topic_score_gemma":0.00421553,"teacher_disagreement_score":0.013223742,"about_ca_system_score_codex":0.0008490717,"about_ca_system_score_gemma":0.0010678626,"threshold_uncertainty_score":0.069934666},"labels":[],"label_agreement":null},{"id":"W2750977739","doi":"10.1016/j.clgc.2017.08.008","title":"Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Etoposide; Germ cell tumors; Bleomycin; Cisplatin; Oncology; Internal medicine; Chemotherapy; Germinoma; Seminoma; Testicular cancer; Germ cell","score_opus":0.07880990781772557,"score_gpt":0.41848480532497623,"score_spread":0.33967489750725066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750977739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95878386,0.0042728223,0.0021742515,0.010492497,0.00075180933,0.0002172212,0.0006776795,0.0003410781,0.022288758],"genre_scores_gemma":[0.99420494,0.0010558726,0.00067848514,0.0012114423,0.0010202623,0.000012980675,0.00015647257,0.000033281493,0.0016263607],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99968815,0.000029463456,0.000033903372,0.00006486899,0.000060215316,0.00012349503],"domain_scores_gemma":[0.9982815,0.00049906736,0.00024171048,0.00010659505,0.00008791781,0.00078326295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018830378,0.0010880159,0.0010343677,0.002420018,0.0018021555,0.0010515096,0.0011826172,0.0043987427,0.003616364],"category_scores_gemma":[0.002387707,0.00073627837,0.0012852779,0.0014351726,0.0012366463,0.0014831193,0.000826099,0.0036403877,0.00089883903],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057115434,0.00002818669,0.0036874984,0.000014201747,0.0000051105276,0.9948939,0.00004331328,0.000061805935,0.00036076846,0.000055776713,0.00014588304,0.0006464063],"study_design_scores_gemma":[0.000022885748,0.00015470815,0.009694481,0.000010791376,0.0000187463,0.98848313,0.00009650968,0.00039054116,0.00062746234,0.00010427187,0.0003835909,0.0000128929305],"about_ca_topic_score_codex":0.0027764721,"about_ca_topic_score_gemma":0.0035926602,"teacher_disagreement_score":0.0043987427,"about_ca_system_score_codex":0.001532682,"about_ca_system_score_gemma":0.0008823036,"threshold_uncertainty_score":0.012097955},"labels":[],"label_agreement":null},{"id":"W2751039941","doi":"10.1016/j.clgc.2017.08.019","title":"Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Genitourinary system; Oncology; Internal medicine; Clinical trial; Randomized controlled trial","score_opus":0.6998276852707463,"score_gpt":0.6579835191735466,"score_spread":0.041844166097199764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751039941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7786011,0.1706384,0.017595401,0.009681191,0.0014777865,0.003659547,0.0036330374,0.00034064663,0.0143728405],"genre_scores_gemma":[0.98583174,0.005354095,0.0021660565,0.0029280987,0.00031380585,0.001402032,0.0011903625,0.00009106571,0.0007227829],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.901147,0.082001425,0.0062576663,0.0045098313,0.0051260325,0.00095809693],"domain_scores_gemma":[0.7229424,0.22147815,0.033736885,0.012716645,0.006160194,0.0029657737],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10452699,0.00066875684,0.0027706574,0.00095903117,0.00089601596,0.0026656522,0.00094010914,0.0025432743,0.0026689833],"category_scores_gemma":[0.18247586,0.0006817641,0.0047733556,0.001438573,0.003112976,0.0029764783,0.0014213461,0.0032983567,0.00044203832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49392018,0.0017764098,0.14067425,0.0065488564,0.025666922,0.00021762494,0.0012903201,0.005510297,0.0025078715,0.007493247,0.015787054,0.29860693],"study_design_scores_gemma":[0.20183933,0.119206585,0.52978134,0.0046236045,0.05318824,0.002125749,0.0009728351,0.013291843,0.008555053,0.020064969,0.045966145,0.00038424358],"about_ca_topic_score_codex":0.00088548166,"about_ca_topic_score_gemma":0.0011803567,"teacher_disagreement_score":0.895473,"about_ca_system_score_codex":0.0023784859,"about_ca_system_score_gemma":0.0022827631,"threshold_uncertainty_score":0.55279815},"labels":[],"label_agreement":null},{"id":"W2751103497","doi":"10.1016/j.clgc.2017.09.003","title":"Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer","year":2017,"lang":"en","type":"letter","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Psychosocial; Penile cancer; Distress; Cancer; Quality of life (healthcare); Prostate cancer; Psychosexual development; Psychiatry; Clinical psychology; Internal medicine; Psychology","score_opus":0.07036041780127776,"score_gpt":0.4219131222647663,"score_spread":0.3515527044634885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751103497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6014683,0.004106475,0.0005206232,0.37196285,0.003763221,0.00012642043,0.0003014613,0.000034731387,0.017715868],"genre_scores_gemma":[0.8968887,0.002378858,0.00086491386,0.09151142,0.005434527,0.00008483289,0.00011931827,0.000010373389,0.00270707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990402,0.0003793514,0.00017777384,0.00006030204,0.00015140498,0.00019095518],"domain_scores_gemma":[0.997621,0.0011832193,0.00026993983,0.00005534072,0.00040570504,0.0004648582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000877774,0.00021874037,0.00054284633,0.00046251077,0.001037475,0.0010184544,0.00032852663,0.0035733704,0.0011081863],"category_scores_gemma":[0.008906315,0.00020702266,0.0003312104,0.0006269176,0.00052413676,0.00074672926,0.0005879343,0.0029583136,0.00035829024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026846927,0.0002901021,0.8413391,0.00014623646,0.000045251898,0.05131045,0.0019171573,0.0001947386,0.0010558176,0.00048652416,0.056003455,0.04694266],"study_design_scores_gemma":[0.00028406508,0.0013086667,0.7573651,0.0008110696,0.00020210657,0.13771504,0.022580693,0.0030909334,0.0010424595,0.0048895823,0.07056826,0.0001419649],"about_ca_topic_score_codex":0.0030817415,"about_ca_topic_score_gemma":0.007670403,"teacher_disagreement_score":0.0035733704,"about_ca_system_score_codex":0.0008214907,"about_ca_system_score_gemma":0.0009610471,"threshold_uncertainty_score":0.006127596},"labels":[],"label_agreement":null},{"id":"W2751215168","doi":"10.1016/j.clgc.2017.08.005","title":"Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Biochemical recurrence; Internal medicine; Gynecology; Cancer","score_opus":0.17808546896709068,"score_gpt":0.47745107562301586,"score_spread":0.29936560665592515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751215168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977272,0.0012814839,0.00008076928,0.00006958624,0.000013563115,0.000025491763,0.00009977727,0.0000028954532,0.0006992392],"genre_scores_gemma":[0.9989599,0.00043434315,0.00009710963,0.00007167165,0.00001732488,0.000024862233,0.00030383724,0.0000026329196,0.000088354675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789447,0.0011252766,0.00021156028,0.00027494656,0.0002486948,0.00024506173],"domain_scores_gemma":[0.9964863,0.0016326512,0.00093151146,0.00017904192,0.00038045357,0.00038999275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029049583,0.00023266641,0.00059250434,0.000624074,0.00041621228,0.000909149,0.0004970922,0.0007449949,0.0012091973],"category_scores_gemma":[0.006658556,0.0001369252,0.0009265349,0.000907324,0.0005656338,0.0007078461,0.0006657591,0.0003576359,0.000087738954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06494034,0.0019161035,0.83957505,0.00042992443,0.0022422543,0.00021527926,0.0015915574,0.0021792382,0.0017102215,0.00065196154,0.0008056372,0.0837424],"study_design_scores_gemma":[0.001217404,0.009349409,0.98389417,0.000114963164,0.00078182516,0.00028585433,0.0015788664,0.00075253425,0.0004444025,0.00016104443,0.0013990276,0.000020512125],"about_ca_topic_score_codex":0.0031373117,"about_ca_topic_score_gemma":0.0036001615,"teacher_disagreement_score":0.0031373117,"about_ca_system_score_codex":0.0010758092,"about_ca_system_score_gemma":0.0009916476,"threshold_uncertainty_score":0.015363038},"labels":[],"label_agreement":null},{"id":"W2751687881","doi":"10.1016/j.clgc.2017.08.020","title":"The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Bayer HealthCare","keywords":"Medicine; Radium-223; Enzalutamide; Prostate cancer; Docetaxel; Radium; Oncology; Abiraterone; Internal medicine; Abiraterone acetate; Cancer; Bone metastasis; Androgen deprivation therapy","score_opus":0.3042373536338288,"score_gpt":0.49066077146474124,"score_spread":0.18642341783091243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751687881","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1429482,0.8292931,0.0019610857,0.012717934,0.00070855534,0.000021663767,0.00026461075,0.00006198058,0.012022888],"genre_scores_gemma":[0.7373357,0.25314352,0.0014784761,0.0037071512,0.0022940766,0.000024677165,0.00033363616,0.000055995984,0.0016267656],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990908,0.00031689834,0.00012437394,0.00012745144,0.00026601486,0.000074468204],"domain_scores_gemma":[0.9985342,0.0005199424,0.0004866631,0.000097462194,0.00024044655,0.000121354045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020513027,0.0002088801,0.00070117105,0.0006621715,0.00033175395,0.0014161519,0.00054067007,0.00038790057,0.0013752078],"category_scores_gemma":[0.0032269154,0.00016226273,0.0006418594,0.0013869077,0.0007744919,0.00063922344,0.0003914532,0.0009900433,0.00034348597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020040523,0.00017394204,0.038082775,0.0017124338,0.00051346584,0.0004342126,0.00031036124,0.0020546403,0.008651167,0.0027459287,0.005720276,0.9375967],"study_design_scores_gemma":[0.00051100017,0.0076545244,0.49103418,0.0022435216,0.0027271714,0.015197332,0.0009050999,0.0028238662,0.010985295,0.00400394,0.4618068,0.000107343905],"about_ca_topic_score_codex":0.0023896045,"about_ca_topic_score_gemma":0.010338188,"teacher_disagreement_score":0.0023896045,"about_ca_system_score_codex":0.0016824261,"about_ca_system_score_gemma":0.0013170086,"threshold_uncertainty_score":0.012206972},"labels":[],"label_agreement":null},{"id":"W2753069614","doi":"10.1016/j.clgc.2017.08.011","title":"Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université de Sherbrooke; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Cancer; Radiation therapy; Prostate; Oncology; Surgery; Internal medicine","score_opus":0.1549085546321779,"score_gpt":0.4554041013892394,"score_spread":0.3004955467570615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753069614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936931,0.0053629903,0.00006626268,0.0001624276,0.00004860056,0.00001289099,0.00006263892,0.0000022785957,0.00058884325],"genre_scores_gemma":[0.99881506,0.000879207,0.00003613751,0.000048138074,0.000043559314,0.0000041559815,0.00004521231,0.0000013152106,0.00012730948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885213,0.00066061306,0.0000705189,0.00011083013,0.00013118408,0.00017475915],"domain_scores_gemma":[0.9972916,0.0017430907,0.00044246417,0.000072893505,0.000067823865,0.00038211187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016875184,0.00029946756,0.0007022819,0.00050171895,0.00026046444,0.00074160984,0.00047928767,0.00080649275,0.0016666378],"category_scores_gemma":[0.005296893,0.00026026956,0.00206193,0.000549498,0.0004687682,0.0006558307,0.0004839164,0.00094360486,0.000094374744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13237897,0.0016779766,0.80730385,0.0005992681,0.0032160336,0.00036756354,0.00054434803,0.0019081188,0.001618781,0.0004200298,0.00035316162,0.04961187],"study_design_scores_gemma":[0.0024049333,0.03358086,0.9560844,0.00012930945,0.002777337,0.00038556362,0.0015142388,0.0013248501,0.0004925117,0.0004624752,0.0007955665,0.00004800195],"about_ca_topic_score_codex":0.0025209517,"about_ca_topic_score_gemma":0.0054810653,"teacher_disagreement_score":0.0025209517,"about_ca_system_score_codex":0.00046769725,"about_ca_system_score_gemma":0.00069779,"threshold_uncertainty_score":0.008924544},"labels":[],"label_agreement":null},{"id":"W2753901771","doi":"10.1016/j.clgc.2017.08.012","title":"Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Bleomycin; Chemotherapy; Odds ratio; Pneumonitis; Chemotherapy regimen; Germ cell tumors; Adverse effect; Asymptomatic; Risk factor; Regimen; Gastroenterology; Oncology; Surgery; Lung","score_opus":0.0646788704708834,"score_gpt":0.4267789825561201,"score_spread":0.36210011208523674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753901771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571276,0.0031028101,0.000061555686,0.00014637185,0.000050113336,0.000019391962,0.00004464949,0.00001075984,0.00085165247],"genre_scores_gemma":[0.9992342,0.00038356244,0.00005456881,0.0000381457,0.00002369422,0.0000046850287,0.00005723122,0.0000021950518,0.00020168784],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99975747,0.00013352394,0.0000144253845,0.000013528024,0.000032899206,0.00004819788],"domain_scores_gemma":[0.999566,0.00016320366,0.00006270353,0.000029637473,0.000035604608,0.0001428796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034777127,0.00013848775,0.0003915691,0.0001982012,0.00015266087,0.00024100381,0.00014795213,0.00024813827,0.0010155675],"category_scores_gemma":[0.0008677999,0.00003938215,0.00029346152,0.00012273296,0.00023268661,0.0001418577,0.00011255295,0.00043308781,0.0000853085],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17619847,0.011684979,0.077148244,0.00070819334,0.0011382956,0.0021281969,0.00024596648,0.0021638097,0.4335944,0.0006670153,0.0020911996,0.2922312],"study_design_scores_gemma":[0.005760681,0.20200777,0.5609254,0.00014565622,0.0018424494,0.002718883,0.00033053165,0.0039543486,0.21274352,0.0003106414,0.00922448,0.00003569633],"about_ca_topic_score_codex":0.00079256814,"about_ca_topic_score_gemma":0.0016440089,"teacher_disagreement_score":0.0010155675,"about_ca_system_score_codex":0.00017827828,"about_ca_system_score_gemma":0.00034810163,"threshold_uncertainty_score":0.0033974051},"labels":[],"label_agreement":null},{"id":"W2761290291","doi":"10.1016/j.clgc.2017.09.011","title":"Analysis of Suicide Risk in Patients with Penile Cancer and Review of the Literature","year":2017,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Penile cancer; Penectomy; Cancer; Population; Surveillance, Epidemiology, and End Results; Epidemiology; Depression (economics); Internal medicine; Surgery; Psychiatry; Cancer registry","score_opus":0.09241422617241636,"score_gpt":0.479554176809179,"score_spread":0.38713995063676265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761290291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006762798,0.99893516,0.000021096157,0.0001175504,0.000038297487,0.000004011065,0.00007206582,0.0000012478472,0.00013416601],"genre_scores_gemma":[0.005388064,0.9942159,0.00008023036,0.00013104461,0.00007008502,0.0000070324477,0.00006984169,5.830574e-7,0.00003717388],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993697,0.00011523291,0.00024425704,0.00010107737,0.00014101583,0.00002878195],"domain_scores_gemma":[0.9977881,0.001419237,0.0005718418,0.000022500735,0.00015470556,0.000043537526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008224478,0.0007297748,0.001959202,0.0048127547,0.00030061722,0.0012839638,0.00085679087,0.0009138145,0.002285945],"category_scores_gemma":[0.0039150505,0.00033051803,0.0017444745,0.005785746,0.0004549482,0.0012650393,0.0006992379,0.00085141225,0.00018851162],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039583992,0.00010212508,0.034734797,0.3081708,0.0046091955,0.0010470261,0.00053794764,0.0004662887,0.00023868754,0.001041353,0.013790338,0.6348655],"study_design_scores_gemma":[0.00020481308,0.00056084833,0.1559523,0.5154964,0.031260952,0.028358435,0.0032075164,0.00069921464,0.0006111599,0.0029790853,0.2603522,0.0003170734],"about_ca_topic_score_codex":0.0032308889,"about_ca_topic_score_gemma":0.0063956343,"teacher_disagreement_score":0.0048127547,"about_ca_system_score_codex":0.00058834767,"about_ca_system_score_gemma":0.00163661,"threshold_uncertainty_score":0.007647276},"labels":[],"label_agreement":null},{"id":"W2767182382","doi":"10.1016/j.clgc.2017.10.012","title":"Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Metastatic Urothelial Carcinoma; Chemotherapy; Internal medicine; Oncology; Bone metastasis; Retrospective cohort study; Proportional hazards model; Metastasis; Cancer; Urothelial carcinoma; Bladder cancer","score_opus":0.038967938103646564,"score_gpt":0.3499311026994399,"score_spread":0.3109631645957933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767182382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95821226,0.0276033,0.00033890927,0.0024912723,0.00010612269,0.000030784013,0.00033827187,0.000016631755,0.010862471],"genre_scores_gemma":[0.98963857,0.009028445,0.00014661126,0.00034791775,0.00027648732,0.000007318081,0.00019232104,0.000006913465,0.00035537005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997944,0.000047753292,0.00001485438,0.00003637715,0.000040253166,0.0000662401],"domain_scores_gemma":[0.9996176,0.00008899925,0.0001301945,0.000009835037,0.000048548452,0.00010485145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024089034,0.00017419319,0.00043960317,0.00074432045,0.00037694408,0.00067451445,0.00021273557,0.0004299714,0.0032399816],"category_scores_gemma":[0.00093275995,0.000107944514,0.00023626507,0.00086251163,0.00030827546,0.00057894445,0.0004944081,0.0003314998,0.00026465513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002762333,0.000064453474,0.94405514,0.00024366139,0.00005409064,0.0029061628,0.00043098975,0.00014099255,0.0015299367,0.0005371591,0.002485012,0.047276024],"study_design_scores_gemma":[0.00001758265,0.00024677473,0.97056705,0.00018368568,0.00011247568,0.0191951,0.0028988393,0.00030480142,0.00023275673,0.00045151202,0.0057762926,0.000013080266],"about_ca_topic_score_codex":0.0022012386,"about_ca_topic_score_gemma":0.006325834,"teacher_disagreement_score":0.0032399816,"about_ca_system_score_codex":0.00026264318,"about_ca_system_score_gemma":0.00065221946,"threshold_uncertainty_score":0.010838866},"labels":[],"label_agreement":null},{"id":"W2767678806","doi":"10.1016/j.clgc.2017.10.015","title":"Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Proportional hazards model; Prostatectomy; Biochemical recurrence; Internal medicine; Urology; Oncology; Cumulative incidence; Cumulative dose; Metastasis; Cancer; Surgery; Cohort; Confidence interval","score_opus":0.04245840618537775,"score_gpt":0.40280566478281105,"score_spread":0.3603472585974333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767678806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976671,0.0011136823,0.000033021963,0.00009184095,0.000022233417,0.0000045915613,0.0001403762,0.0000032827586,0.0009238722],"genre_scores_gemma":[0.99945194,0.00016445048,0.000013207712,0.00003426003,0.000023309229,0.0000012052665,0.00010385302,0.0000016628156,0.00020605163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976116,0.00009622276,0.00001708371,0.000032595217,0.00003507671,0.000057893845],"domain_scores_gemma":[0.99900705,0.00036426148,0.0002411567,0.00006599003,0.00006411179,0.00025751474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033925634,0.00017282713,0.00035678557,0.0003122944,0.00029128755,0.00057057803,0.00026626152,0.00040377438,0.002281639],"category_scores_gemma":[0.0021970952,0.00013185514,0.0009729962,0.00031036363,0.00023904805,0.0002490957,0.0003338964,0.00056702836,0.00013959041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005695254,0.00023756888,0.98385805,0.000032323434,0.0004710449,0.00028476963,0.00008607827,0.00048805276,0.0009253337,0.000052052008,0.00016680566,0.0077026323],"study_design_scores_gemma":[0.000032140615,0.00084667205,0.99804425,0.000006519078,0.00023725403,0.00018147664,0.0001000248,0.00021051499,0.00010317267,0.00003833847,0.00019486711,0.0000047859075],"about_ca_topic_score_codex":0.005364988,"about_ca_topic_score_gemma":0.010973609,"teacher_disagreement_score":0.005364988,"about_ca_system_score_codex":0.00047512457,"about_ca_system_score_gemma":0.0004958759,"threshold_uncertainty_score":0.010667503},"labels":[],"label_agreement":null},{"id":"W2773593291","doi":"10.1016/j.clgc.2017.11.004","title":"Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Multidisciplinary approach; Medicine; Bladder cancer; Family medicine; Nursing; Cancer; Internal medicine","score_opus":0.05583987742814905,"score_gpt":0.38280239173580316,"score_spread":0.3269625143076541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773593291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818091,0.0040824246,0.00040001742,0.0058654733,0.0000792882,0.000029347579,0.0009180272,0.000013470968,0.006802952],"genre_scores_gemma":[0.9972071,0.0011871248,0.00022374355,0.0006066635,0.00004445551,0.000026937876,0.00038643644,0.000006103205,0.00031151145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984224,0.00041592476,0.00023894095,0.00020956955,0.00025775924,0.00045534084],"domain_scores_gemma":[0.9958146,0.0006328128,0.0017740338,0.00007836351,0.00052020187,0.0011800269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006377037,0.00009192277,0.0002131144,0.00088326767,0.0010382057,0.001103949,0.000589331,0.0005350592,0.0038516056],"category_scores_gemma":[0.005505354,0.00015796693,0.00031311397,0.0025470948,0.0004087817,0.00085829024,0.0014690806,0.000715812,0.00021671157],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001026778,0.00008113641,0.97672844,0.00008150976,0.00006690859,0.00024117195,0.0017894437,0.0002256669,0.0002267823,0.00069411995,0.0025578155,0.017204301],"study_design_scores_gemma":[0.000011304399,0.0000594712,0.9821598,0.00021032056,0.00001909098,0.00095646124,0.011726885,0.00049003185,0.00007607331,0.00049273117,0.0037829084,0.0000149791085],"about_ca_topic_score_codex":0.021770017,"about_ca_topic_score_gemma":0.06425528,"teacher_disagreement_score":0.021770017,"about_ca_system_score_codex":0.0024827751,"about_ca_system_score_gemma":0.0023270196,"threshold_uncertainty_score":0.04328662},"labels":[],"label_agreement":null},{"id":"W2776594178","doi":"10.1016/j.clgc.2017.12.012","title":"Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Enzalutamide; Medicine; Prostate cancer; Abiraterone acetate; Docetaxel; Androgen deprivation therapy; Oncology; Internal medicine; Cancer; Androgen receptor","score_opus":0.18384847412308658,"score_gpt":0.4752861645697759,"score_spread":0.2914376904466893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776594178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98865104,0.007822759,0.00010991595,0.00024027916,0.000089045425,0.000046857815,0.0008434089,0.000015699954,0.0021809589],"genre_scores_gemma":[0.99728143,0.00092294684,0.00004087646,0.00012022374,0.00006784931,0.00001692348,0.0011424975,0.0000040355003,0.0004031281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956733,0.00012925357,0.000046365178,0.000060759474,0.00008899487,0.000107258245],"domain_scores_gemma":[0.9984357,0.00036499073,0.00037147108,0.00006350328,0.0001375479,0.00062671374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007903633,0.00031902714,0.00091725925,0.00037003824,0.00028817615,0.0007689353,0.00038423514,0.00045096205,0.0013714418],"category_scores_gemma":[0.0025315194,0.0001239843,0.0016592353,0.00050357793,0.0003147355,0.0005964382,0.0002933113,0.0011173445,0.0002853511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25629738,0.004975914,0.5040642,0.00075391884,0.0036957548,0.0014585105,0.00036075528,0.005595611,0.0065702708,0.00030289884,0.005138201,0.21078661],"study_design_scores_gemma":[0.006501567,0.05886834,0.92338526,0.00014370409,0.003130331,0.0013162799,0.00025894257,0.0016138145,0.0014018102,0.0004049398,0.0028973338,0.000077765275],"about_ca_topic_score_codex":0.0027919621,"about_ca_topic_score_gemma":0.007029251,"teacher_disagreement_score":0.0027919621,"about_ca_system_score_codex":0.0010075523,"about_ca_system_score_gemma":0.0008460927,"threshold_uncertainty_score":0.0073103905},"labels":[],"label_agreement":null},{"id":"W2777354357","doi":"10.1016/j.clgc.2017.12.009","title":"Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio","year":2017,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Neutrophil to lymphocyte ratio; Internal medicine; Urothelial cancer; Proportional hazards model; Cancer; Mean time between failures; Hazard ratio; Lymphocyte; Gastroenterology; Oncology; Urology; Bladder cancer; Confidence interval","score_opus":0.03096370431593965,"score_gpt":0.3955360637080628,"score_spread":0.3645723593921232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777354357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624735,0.0015076541,0.00023469674,0.00024638546,0.000026173064,0.000007944483,0.0009675445,0.0000095550695,0.00075275986],"genre_scores_gemma":[0.99932146,0.00014192954,0.00005965638,0.000025909903,0.00001641134,0.000005628942,0.00037356923,0.0000019184413,0.000053476906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878734,0.00059636356,0.00016843423,0.000174681,0.00012915174,0.00014393128],"domain_scores_gemma":[0.99598515,0.0012740536,0.0018786262,0.00019924762,0.00028673,0.00037622545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013475463,0.00026964466,0.0004639372,0.00075781235,0.0003092545,0.0015142953,0.0004080367,0.0006904063,0.0011909798],"category_scores_gemma":[0.007304361,0.00012397816,0.0003859569,0.0012803583,0.0004589098,0.0011390678,0.0007337728,0.0007227134,0.0002739556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002924381,0.000024274523,0.99714893,0.0000218751,0.00008594181,0.000056562214,0.00004747692,0.00016635677,0.000084354404,0.000046541234,0.00013621507,0.0018890599],"study_design_scores_gemma":[0.00001126358,0.00022720694,0.99678767,0.000015228261,0.00008602463,0.0003687662,0.0003637843,0.0011320796,0.00015526814,0.0002728057,0.00056618534,0.000013810774],"about_ca_topic_score_codex":0.0010723603,"about_ca_topic_score_gemma":0.0012002924,"teacher_disagreement_score":0.0015142953,"about_ca_system_score_codex":0.00039937772,"about_ca_system_score_gemma":0.00024954687,"threshold_uncertainty_score":0.0071265697},"labels":[],"label_agreement":null},{"id":"W2778808609","doi":"10.1016/j.clgc.2017.12.006","title":"Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies","year":2017,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Prednisone; Medicine; Docetaxel; Prostate cancer; Internal medicine; Oncology; Placebo; Randomized controlled trial; Abiraterone acetate; Cancer; Androgen deprivation therapy; Pathology","score_opus":0.25017454742995576,"score_gpt":0.539170911552819,"score_spread":0.2889963641228633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778808609","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043797866,0.9948525,0.00013994829,0.00004148071,0.000041897805,0.000032062308,0.00034980048,0.000005638361,0.00015702772],"genre_scores_gemma":[0.099923104,0.8977044,0.00071747915,0.00026009348,0.00014702053,0.00007591338,0.0009820488,0.000013171766,0.00017671257],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99704534,0.0009560481,0.0010552852,0.00044726414,0.00039886826,0.00009709402],"domain_scores_gemma":[0.9920976,0.0055939844,0.0014776577,0.0002647213,0.0004435959,0.00012241119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058254884,0.0012693747,0.0079153115,0.0028815863,0.00022433186,0.0016153106,0.0011626009,0.00087692996,0.0021508827],"category_scores_gemma":[0.010950257,0.0006182477,0.013446618,0.004514239,0.00036067222,0.0009705625,0.00096447545,0.0011789179,0.00016665453],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011781053,0.00007692162,0.016819905,0.25314453,0.55037624,0.00015483331,0.0001088487,0.001272614,0.00068258867,0.0002060401,0.0019872868,0.16338922],"study_design_scores_gemma":[0.0023717438,0.0011369423,0.04261515,0.020964516,0.9209718,0.00037581427,0.00013060143,0.00028100147,0.0003884738,0.0005964536,0.010091866,0.000075680946],"about_ca_topic_score_codex":0.002658952,"about_ca_topic_score_gemma":0.006563062,"teacher_disagreement_score":0.0079153115,"about_ca_system_score_codex":0.0009081613,"about_ca_system_score_gemma":0.0013354854,"threshold_uncertainty_score":0.030808508},"labels":[],"label_agreement":null},{"id":"W2781546173","doi":"10.1016/j.clgc.2017.12.016","title":"Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Epidemiology; Population; Hazard ratio; Odds ratio; Logistic regression; Internal medicine; Cancer; Confidence interval; Environmental health","score_opus":0.07452605924954833,"score_gpt":0.39969779965112495,"score_spread":0.3251717404015766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781546173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643755,0.0003403869,0.0000942834,0.00006966936,0.0000095697815,0.000010264732,0.0026004405,0.0000131004645,0.000424714],"genre_scores_gemma":[0.9967997,0.00016560136,0.00007490344,0.00003577134,0.000010008111,0.000012082682,0.0026652932,0.0000048771544,0.00023185855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992649,0.00014042172,0.000113860006,0.0002296154,0.00009044408,0.00016080543],"domain_scores_gemma":[0.99875116,0.000116695235,0.0005856001,0.00013352535,0.00019201444,0.00022085516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007882103,0.0003698034,0.0006182966,0.0013173618,0.00050643703,0.00092770136,0.00054424856,0.0008565358,0.0021208297],"category_scores_gemma":[0.0019456067,0.0004955787,0.0027216582,0.0027551176,0.00023465071,0.0011832154,0.0008904257,0.0012486005,0.00035434583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019386986,0.00002815714,0.99843174,0.000012963844,0.0003421008,0.000033013188,0.000042250213,0.000083845196,0.000053156265,0.000011556692,0.00014923037,0.00061799964],"study_design_scores_gemma":[0.000006538093,0.0000729036,0.99921775,0.000004074403,0.00011222104,0.000077574245,0.00015452971,0.00020653251,0.000013061998,0.000011610637,0.000118084514,0.000005138449],"about_ca_topic_score_codex":0.026027398,"about_ca_topic_score_gemma":0.032302387,"teacher_disagreement_score":0.026027398,"about_ca_system_score_codex":0.0006848557,"about_ca_system_score_gemma":0.0006621693,"threshold_uncertainty_score":0.051751852},"labels":[],"label_agreement":null},{"id":"W2789859592","doi":"10.1016/j.clgc.2018.01.011","title":"Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Testicular cancer; Framingham Risk Score; Cisplatin; Internal medicine; Oncology; Disease; Cancer; Chemotherapy","score_opus":0.02383816253581744,"score_gpt":0.30989196123904555,"score_spread":0.2860537987032281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789859592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678445,0.0010052869,0.0007146794,0.00017443796,0.000037456273,0.000026534019,0.00032230827,0.000014363477,0.0009205139],"genre_scores_gemma":[0.9987494,0.00026387896,0.0005288308,0.000023172246,0.000044347555,0.0000097764405,0.00022834272,0.000002068712,0.00015022069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996792,0.00012404658,0.000030309382,0.000059749145,0.0000631479,0.00004361077],"domain_scores_gemma":[0.9992223,0.00019849723,0.0002687151,0.0000573875,0.00011670275,0.00013634205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010963588,0.00044596876,0.00045787383,0.0009727519,0.00028859184,0.00069780624,0.00028160418,0.00038497135,0.0007031571],"category_scores_gemma":[0.0024437867,0.00017762146,0.00064582005,0.00077518524,0.00015382121,0.00039632103,0.000471224,0.00067010813,0.00009142222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013180745,0.00003586476,0.9941451,0.000008893691,0.00013003008,0.000022149352,0.000024355646,0.00015243808,0.00013288305,0.000038085615,0.00012691392,0.0050513595],"study_design_scores_gemma":[0.000013803301,0.000276834,0.99643445,0.000011476759,0.00027789472,0.00014297293,0.00007372429,0.00222183,0.00013589514,0.00010786843,0.00029510955,0.000008097071],"about_ca_topic_score_codex":0.0029961076,"about_ca_topic_score_gemma":0.0040399903,"teacher_disagreement_score":0.0029961076,"about_ca_system_score_codex":0.00023027278,"about_ca_system_score_gemma":0.0004571649,"threshold_uncertainty_score":0.005957365},"labels":[],"label_agreement":null},{"id":"W2791728754","doi":"10.1016/j.clgc.2018.02.005","title":"Revisiting the Prognostic Heterogeneity of AJCC Stage IV Carcinomas of the Upper Urinary Tract","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; AJCC staging system; Hazard ratio; Proportional hazards model; Stage (stratigraphy); Renal pelvis; Oncology; Confidence interval; Cancer staging; Cancer; Surveillance, Epidemiology, and End Results; Cancer registry; Survival analysis; Internal medicine; Urinary system; Staging system","score_opus":0.08032134750045948,"score_gpt":0.3931273802920347,"score_spread":0.3128060327915752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791728754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97122407,0.019604137,0.0014334518,0.0025629823,0.0002546715,0.000022148568,0.001181315,0.000028920864,0.0036883],"genre_scores_gemma":[0.99699366,0.0014030287,0.0002480233,0.00017682526,0.0002834482,0.000005212386,0.00063764234,0.000014080492,0.00023808828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986021,0.00045794446,0.00016898182,0.00025166044,0.0002714849,0.0002476849],"domain_scores_gemma":[0.99616843,0.0015111044,0.00081465195,0.0006906909,0.00054548646,0.00026970106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00259355,0.00038261787,0.0007588595,0.0023372632,0.0006195008,0.0021623948,0.0008024154,0.00038972218,0.0017776393],"category_scores_gemma":[0.008978748,0.00012788667,0.0007263439,0.0033974359,0.00065248564,0.001060988,0.00096245314,0.00076614454,0.0003053658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040598208,0.000019689931,0.94140166,0.00010447938,0.0003136449,0.00022165035,0.00041121157,0.00037863225,0.002874574,0.0005326601,0.0018419252,0.051493876],"study_design_scores_gemma":[0.000018561122,0.00011258734,0.9859315,0.00006913744,0.00044464925,0.00080286514,0.000883489,0.000999442,0.00070959784,0.0018145575,0.008195459,0.00001811002],"about_ca_topic_score_codex":0.005153596,"about_ca_topic_score_gemma":0.010361935,"teacher_disagreement_score":0.005153596,"about_ca_system_score_codex":0.00063851464,"about_ca_system_score_gemma":0.0010206263,"threshold_uncertainty_score":0.013716161},"labels":[],"label_agreement":null},{"id":"W2793249623","doi":"10.1016/j.clgc.2018.01.003","title":"Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature","year":2018,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Renal cell carcinoma; Sorafenib; Adjuvant therapy; Nephrectomy; Oncology; Kidney cancer; Internal medicine; Adjuvant; Bevacizumab; Placebo; Tyrosine-kinase inhibitor; Cancer; Kidney; Chemotherapy; Pathology; Hepatocellular carcinoma; Alternative medicine","score_opus":0.09971389070820243,"score_gpt":0.4146607554077169,"score_spread":0.3149468646995145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793249623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011863619,0.9995727,0.000021097103,0.0000723692,0.000030431675,0.0000029802443,0.000019976278,0.0000010721352,0.00016072967],"genre_scores_gemma":[0.00077041,0.9989506,0.00007350641,0.000097464246,0.00004205371,0.0000031278632,0.000017045557,3.391676e-7,0.00004554816],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99969923,0.000059251393,0.00010493935,0.000051131552,0.00006930018,0.000016083917],"domain_scores_gemma":[0.998901,0.0007599052,0.00020867422,0.000013088226,0.00009138846,0.000026065341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006845326,0.00064662495,0.0019124309,0.002498493,0.0002543702,0.0010081456,0.00087859854,0.0008815348,0.0033623227],"category_scores_gemma":[0.0019065501,0.00029339382,0.001028965,0.0028540348,0.00034417826,0.0012682901,0.0005345051,0.0009294761,0.0003695269],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022393891,0.0001003803,0.0009891589,0.20972988,0.0007676095,0.00048023544,0.00015088152,0.0004489936,0.0009552166,0.0010606222,0.013321064,0.77177197],"study_design_scores_gemma":[0.00014738584,0.00040821714,0.007571378,0.1916349,0.0068660993,0.007126345,0.00046582575,0.00033257063,0.00077324547,0.0017587559,0.78283656,0.00007872536],"about_ca_topic_score_codex":0.0015973184,"about_ca_topic_score_gemma":0.0039729285,"teacher_disagreement_score":0.0033623227,"about_ca_system_score_codex":0.00047523715,"about_ca_system_score_gemma":0.0014372973,"threshold_uncertainty_score":0.011248112},"labels":[],"label_agreement":null},{"id":"W2796329816","doi":"10.1016/j.clgc.2018.03.016","title":"Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group","funders":"National Cancer Institute","keywords":"Medicine; Nomogram; Oncology; Docetaxel; Internal medicine; Pazopanib; Sunitinib; Confidence interval; Carboplatin; Renal cell carcinoma; Urology; Chemotherapy; Cisplatin","score_opus":0.18361739499181,"score_gpt":0.45337110015947707,"score_spread":0.26975370516766706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796329816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7261353,0.076704234,0.10403492,0.007341035,0.0030488628,0.00145024,0.029085536,0.0025473267,0.049652494],"genre_scores_gemma":[0.96301025,0.004352575,0.018012041,0.00090432225,0.00060180784,0.0005150275,0.009253912,0.00018844736,0.0031616003],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99875057,0.0005018334,0.00014746729,0.00016319031,0.000308076,0.00012880542],"domain_scores_gemma":[0.99439913,0.0032717658,0.0007899854,0.00025282244,0.00076582906,0.00052050233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050862757,0.0015295175,0.0025526308,0.003313632,0.0005790071,0.0019886815,0.0010292772,0.0012815355,0.003914084],"category_scores_gemma":[0.0104534235,0.00023755532,0.0036079476,0.0010884549,0.00052127347,0.0013967275,0.001075656,0.001928786,0.0011698],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011704712,0.00057658815,0.47529012,0.0029648317,0.0060554678,0.0006544197,0.00032824517,0.07772465,0.004461676,0.0042183124,0.03161762,0.3844034],"study_design_scores_gemma":[0.0019093934,0.009710923,0.56864446,0.0015537313,0.013767003,0.005226117,0.0011242018,0.27849668,0.0069210846,0.01631742,0.09592242,0.0004064761],"about_ca_topic_score_codex":0.0016790783,"about_ca_topic_score_gemma":0.0024166175,"teacher_disagreement_score":0.0050862757,"about_ca_system_score_codex":0.0010532417,"about_ca_system_score_gemma":0.0009054603,"threshold_uncertainty_score":0.0268991},"labels":[],"label_agreement":null},{"id":"W2800033280","doi":"10.1016/j.clgc.2018.04.003","title":"Two Cases of Arterioureteral Fistula in the Setting of Previous Radiation Therapy and Indwelling Ureteral Stents: Results of Endovascular Management","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Infectious Aortic and Vascular Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Urinary Fistula; Radiology; Fistula; Surgery","score_opus":0.05202607944733138,"score_gpt":0.37306959088257374,"score_spread":0.32104351143524235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800033280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844552,0.002770477,0.003639029,0.0010829754,0.00029786656,0.00026412652,0.00026259947,0.00013883968,0.0070888745],"genre_scores_gemma":[0.99411255,0.0009618668,0.002306577,0.000482052,0.00074492185,0.000068237794,0.00020178183,0.0000371473,0.0010849553],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99842715,0.0002865222,0.0002656385,0.00021326094,0.00017944163,0.00062798505],"domain_scores_gemma":[0.99334383,0.0028875836,0.0010739509,0.0010800329,0.0003113409,0.0013033077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096664974,0.0030320396,0.0016458029,0.0043564667,0.003779404,0.0027589013,0.0024534971,0.010803395,0.0030372317],"category_scores_gemma":[0.01376312,0.0020834594,0.0027998125,0.0026634664,0.0033512819,0.0025688086,0.0025511151,0.003995907,0.0015272646],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018167592,0.0003950085,0.017962806,0.00004650741,0.000027088963,0.978686,0.00029984105,0.00013788683,0.00042428108,0.00013197165,0.00010073893,0.0016062832],"study_design_scores_gemma":[0.000080080885,0.0003883215,0.012872712,0.000024985358,0.000041265805,0.9845339,0.00029873615,0.0003269649,0.00080278015,0.00015543417,0.00043673528,0.000038015478],"about_ca_topic_score_codex":0.0018940171,"about_ca_topic_score_gemma":0.0019450735,"teacher_disagreement_score":0.010803395,"about_ca_system_score_codex":0.00156894,"about_ca_system_score_gemma":0.0010970696,"threshold_uncertainty_score":0.0113835335},"labels":[],"label_agreement":null},{"id":"W2805011737","doi":"10.1016/j.clgc.2018.03.003","title":"Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Nephrectomy; Interquartile range; Renal cell carcinoma; Proportional hazards model; Disease; Retrospective cohort study; Regimen; Internal medicine; Cancer; Localized disease; Surgery; Urology; Oncology; Kidney; Prostate cancer","score_opus":0.019548714726438352,"score_gpt":0.3043169565525032,"score_spread":0.2847682418260648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805011737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99592304,0.0024684614,0.00022028586,0.00025138893,0.000050696486,0.0000047369394,0.00022569891,0.000010927954,0.0008447106],"genre_scores_gemma":[0.99931264,0.0001940496,0.00004608414,0.000025055322,0.000046823745,0.0000023087493,0.00018304985,0.0000043154264,0.00018567109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921846,0.00026072765,0.000083507635,0.00012516284,0.00009196779,0.00022012812],"domain_scores_gemma":[0.9954731,0.002077493,0.0010418313,0.00031926786,0.0002643859,0.0008239348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014077948,0.00042755686,0.00072208483,0.00067602773,0.00046217535,0.0009372454,0.000690375,0.0009834334,0.002271841],"category_scores_gemma":[0.0064934413,0.00024272667,0.001957058,0.0010843772,0.00048097686,0.0010942286,0.00065217534,0.0014300947,0.0002830701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007257974,0.000040198,0.9960343,0.000013061935,0.00019786903,0.00009185089,0.000039755567,0.00024499738,0.0001564412,0.0000357945,0.00009530382,0.0023245492],"study_design_scores_gemma":[0.00001376748,0.00024748695,0.99754816,0.000011874605,0.0002855436,0.00027547908,0.00013868853,0.0010419536,0.00009092761,0.00009085143,0.0002458757,0.000009378172],"about_ca_topic_score_codex":0.005038303,"about_ca_topic_score_gemma":0.0052334373,"teacher_disagreement_score":0.005038303,"about_ca_system_score_codex":0.00036760533,"about_ca_system_score_gemma":0.00077678956,"threshold_uncertainty_score":0.010017931},"labels":[],"label_agreement":null},{"id":"W2807085990","doi":"10.1016/j.clgc.2018.05.016","title":"Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cancer; Prostate cancer; Prostate; Oncology; Internal medicine","score_opus":0.17179034212278158,"score_gpt":0.4655013243474023,"score_spread":0.2937109822246208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807085990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837399,0.010656841,0.0005497796,0.0008914239,0.00007783907,0.000009830339,0.0007216193,0.000024189982,0.0033284929],"genre_scores_gemma":[0.99774325,0.0013651473,0.00011838981,0.00008478184,0.00009109922,0.0000024012,0.00023106502,0.0000065904883,0.00035734914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999716,0.0000798464,0.000026683541,0.00006683554,0.00005359903,0.00005693515],"domain_scores_gemma":[0.9989008,0.00026838767,0.00050677196,0.000049331502,0.0000936184,0.0001810558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002662935,0.00026387555,0.0004014242,0.0006166068,0.00031750154,0.0007868112,0.0003642312,0.000533674,0.0055539976],"category_scores_gemma":[0.0025438562,0.00021559681,0.00045595173,0.0009777802,0.0003086881,0.0006817517,0.0005539968,0.0006202973,0.000581416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014579999,0.000019442816,0.9869501,0.00003947342,0.00009870468,0.00016256541,0.000054232183,0.00012785583,0.000513824,0.00007749983,0.00035461475,0.011455962],"study_design_scores_gemma":[0.000005097136,0.00005439331,0.99750817,0.00002096393,0.00008987881,0.0010510264,0.00020469702,0.00017068091,0.000077300225,0.00015089323,0.0006602988,0.000006521065],"about_ca_topic_score_codex":0.0030532163,"about_ca_topic_score_gemma":0.007876732,"teacher_disagreement_score":0.0055539976,"about_ca_system_score_codex":0.0002706902,"about_ca_system_score_gemma":0.0003801269,"threshold_uncertainty_score":0.01857996},"labels":[],"label_agreement":null},{"id":"W2859836197","doi":"10.1016/j.clgc.2018.07.002","title":"Prognostic Value of Serum Cholinesterase in Non–muscle-invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Bladder cancer; Cholinesterase; Internal medicine; Oncology; Cancer; Urology","score_opus":0.06080499678222432,"score_gpt":0.4219349544516621,"score_spread":0.3611299576694378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2859836197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959245,0.002189443,0.00014425916,0.00015267322,0.000032234653,0.0000049899704,0.00025675612,0.000011713281,0.0012834249],"genre_scores_gemma":[0.9994147,0.00019254393,0.00004648888,0.000017051703,0.00002413477,0.0000017686929,0.00015815393,0.0000015034569,0.00014350863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970704,0.000081047336,0.00004204147,0.00004273384,0.000045986315,0.000081100065],"domain_scores_gemma":[0.99828374,0.0005746605,0.00041997773,0.000112291746,0.00024076158,0.0003686319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006280988,0.0003740184,0.00044617627,0.0007304341,0.00038377568,0.00076410634,0.0003844601,0.0006629204,0.0015765602],"category_scores_gemma":[0.003715381,0.00016700067,0.0004923555,0.0009809134,0.00040143335,0.00051529665,0.00044736915,0.0006406112,0.0002493711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036730507,0.000013050732,0.9971552,0.000012781355,0.00004665555,0.00010446976,0.000016351203,0.00007066263,0.00032111353,0.000013039821,0.00006374316,0.0018156026],"study_design_scores_gemma":[0.000010161598,0.00011556519,0.9976283,0.000011460731,0.00011593588,0.00055248896,0.00013259816,0.00078998815,0.00028813197,0.00008111525,0.00026714875,0.0000072035773],"about_ca_topic_score_codex":0.0029950507,"about_ca_topic_score_gemma":0.0040890053,"teacher_disagreement_score":0.0029950507,"about_ca_system_score_codex":0.0003573704,"about_ca_system_score_gemma":0.00044119594,"threshold_uncertainty_score":0.0059552193},"labels":[],"label_agreement":null},{"id":"W2884972285","doi":"10.1016/j.clgc.2018.07.007","title":"Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Proportional hazards model; Internal medicine; Androgen deprivation therapy; Docetaxel; Survival analysis; Prostate; Prostate-specific antigen; Progression-free survival; Performance status; Cancer; Overall survival","score_opus":0.06612133646766608,"score_gpt":0.4508892951953859,"score_spread":0.38476795872771985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884972285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707183,0.021832237,0.0010288425,0.0006047066,0.000862733,0.0017960933,0.0011078863,0.000074785145,0.0019744087],"genre_scores_gemma":[0.99316496,0.0028324123,0.00062166876,0.00043122107,0.0005286697,0.0009817139,0.0006587113,0.000014788341,0.00076576654],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99519604,0.0031856792,0.00033112886,0.0006294923,0.00028741744,0.00037022232],"domain_scores_gemma":[0.9921634,0.004221794,0.0017202772,0.00070520863,0.00037916147,0.0008100461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048984955,0.0016219706,0.005251117,0.0004764584,0.0005514199,0.0015952954,0.0012546314,0.0020711883,0.0055404925],"category_scores_gemma":[0.009672318,0.0006242433,0.0067505925,0.00074086775,0.0015313457,0.0013731825,0.000680118,0.004098226,0.00044484506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9804844,0.0017938844,0.0017087576,0.0014403274,0.00889119,0.000031070624,0.000021262858,0.00034635753,0.0003468735,0.000075488344,0.00030851288,0.0045518656],"study_design_scores_gemma":[0.91066825,0.06040806,0.009238691,0.0002064231,0.017211182,0.000052502448,0.000042864,0.0009199154,0.0004107869,0.00035460806,0.00044730573,0.000039415216],"about_ca_topic_score_codex":0.0016701166,"about_ca_topic_score_gemma":0.0022681789,"teacher_disagreement_score":0.0055404925,"about_ca_system_score_codex":0.001018482,"about_ca_system_score_gemma":0.0013119633,"threshold_uncertainty_score":0.025905967},"labels":[],"label_agreement":null},{"id":"W2890747191","doi":"10.1016/j.clgc.2018.09.006","title":"Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Kidney cancer; Carcinoma; Targeted therapy; Cancer","score_opus":0.05160311231907259,"score_gpt":0.32438790381401117,"score_spread":0.27278479149493856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890747191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076205,0.005351219,0.00020658567,0.0005541986,0.000108374996,0.000012997182,0.000413368,0.000012584908,0.0025785794],"genre_scores_gemma":[0.99760926,0.0010428261,0.00007138108,0.00014516331,0.000102170496,0.0000056848417,0.0003175085,0.0000040320488,0.0007020037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973184,0.000047659312,0.000025799725,0.000055275752,0.00006774736,0.00007172956],"domain_scores_gemma":[0.99916685,0.00012929166,0.00036399643,0.00003392627,0.00010121542,0.00020470972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026013335,0.00017958961,0.00045113082,0.00038160774,0.00047999102,0.0007470566,0.0003042067,0.00046216743,0.0033430785],"category_scores_gemma":[0.0014437394,0.0001302018,0.0007533237,0.00085938437,0.00024857066,0.0003892213,0.00032025826,0.00076822884,0.0002609449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043891257,0.00009218362,0.9896125,0.000045501787,0.00026096817,0.0001716337,0.00004169983,0.000050811188,0.00096896925,0.00005709925,0.00031932344,0.007940392],"study_design_scores_gemma":[0.000012811683,0.000118292744,0.9976538,0.000020626656,0.00026809148,0.00038528652,0.00010280766,0.00021399611,0.0001602419,0.00013402675,0.000924115,0.0000060796115],"about_ca_topic_score_codex":0.00290821,"about_ca_topic_score_gemma":0.0054651857,"teacher_disagreement_score":0.0033430785,"about_ca_system_score_codex":0.00032637696,"about_ca_system_score_gemma":0.0005464986,"threshold_uncertainty_score":0.011183679},"labels":[],"label_agreement":null},{"id":"W2891104247","doi":"10.1016/j.clgc.2018.09.008","title":"Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Cystectomy; Nomogram; Bladder cancer; Proportional hazards model; Retrospective cohort study; Concordance; Perioperative; Lymph node; Cumulative incidence; Stage (stratigraphy); Confidence interval; Cancer; Hazard ratio; Urology; Internal medicine; Oncology; Cohort; Surgery","score_opus":0.03668717770792943,"score_gpt":0.3472813592159894,"score_spread":0.31059418150805995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891104247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935855,0.000674715,0.002523369,0.0004150029,0.0001503304,0.00010312241,0.00081573625,0.00006131702,0.0016709319],"genre_scores_gemma":[0.9958794,0.00018498627,0.0023812803,0.00006565658,0.00008095676,0.000071695606,0.0009350723,0.0000073678407,0.0003935598],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99895215,0.00033468724,0.00016813731,0.00015274326,0.0002161936,0.00017615278],"domain_scores_gemma":[0.9958845,0.0020689806,0.0007312354,0.00013583906,0.0007938621,0.00038561007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024933943,0.00083355,0.0009663145,0.0030162425,0.00068128377,0.0017798168,0.00091595796,0.0010313243,0.0013733519],"category_scores_gemma":[0.009295282,0.00036745833,0.0011790735,0.0015012217,0.00035037077,0.0013921632,0.0010023677,0.0010481817,0.00034609024],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021759716,0.00012153187,0.9900913,0.00002269526,0.000105330946,0.00005444959,0.00005032494,0.00038037976,0.00012257608,0.00006513854,0.0004508211,0.0083178505],"study_design_scores_gemma":[0.00009353051,0.00061223813,0.9608058,0.000089566325,0.00079792755,0.00051746744,0.00063753227,0.032882333,0.0008694932,0.00062626344,0.002018031,0.000049836668],"about_ca_topic_score_codex":0.0024744857,"about_ca_topic_score_gemma":0.0049054427,"teacher_disagreement_score":0.0030162425,"about_ca_system_score_codex":0.00054572587,"about_ca_system_score_gemma":0.001203466,"threshold_uncertainty_score":0.013186514},"labels":[],"label_agreement":null},{"id":"W2891539948","doi":"10.1016/j.clgc.2018.09.005","title":"Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"Kidney Cancer Association; National Cancer Institute; Conquer Cancer Foundation; National Institutes of Health; Cancer Prevention and Research Institute of Texas; Johnson Foundation","keywords":"Medicine; Sickle cell trait; Clinical trial; Renal cell carcinoma; Disease; Dosing; Internal medicine; Chemotherapy; Intensive care medicine; Oncology; Nephrectomy; Kidney","score_opus":0.13382681391219975,"score_gpt":0.4528119512202993,"score_spread":0.3189851373080996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891539948","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013601528,0.14544703,0.039407168,0.62160915,0.03616235,0.008972545,0.029545207,0.0019661011,0.10328895],"genre_scores_gemma":[0.07311341,0.08253774,0.1953112,0.52295285,0.04062127,0.018781932,0.038210522,0.0010225651,0.027448526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9802413,0.008067974,0.006916677,0.000670593,0.003045597,0.0010578277],"domain_scores_gemma":[0.910943,0.047698047,0.010253977,0.0016685082,0.023912918,0.0055235852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02585414,0.0013612269,0.004113592,0.004236099,0.0017560399,0.003989869,0.0043558194,0.012513965,0.009817185],"category_scores_gemma":[0.08568507,0.0013123895,0.0075562545,0.003406811,0.0010940821,0.0032138298,0.0019685342,0.015701741,0.0044017946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014182031,0.00051198975,0.010693332,0.0040444504,0.0008563049,0.0003888293,0.0002675894,0.0018774562,0.0009322027,0.004622137,0.77176964,0.20261784],"study_design_scores_gemma":[0.0070204046,0.0005778609,0.05359788,0.03460762,0.0049501476,0.0021836641,0.00060743705,0.0047313673,0.0016106804,0.020547004,0.8691353,0.00043053736],"about_ca_topic_score_codex":0.012898222,"about_ca_topic_score_gemma":0.029486317,"teacher_disagreement_score":0.02585414,"about_ca_system_score_codex":0.003127703,"about_ca_system_score_gemma":0.009416703,"threshold_uncertainty_score":0.13673139},"labels":[],"label_agreement":null},{"id":"W2893134098","doi":"10.1016/j.clgc.2018.09.016","title":"Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Metformin; Docetaxel; Prostate cancer; Internal medicine; Oncology; Prednisone; Diabetes mellitus; Proportional hazards model; Cancer; Endocrinology; Insulin","score_opus":0.03945590755046969,"score_gpt":0.3818552045301798,"score_spread":0.3423992969797101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893134098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76430833,0.22813183,0.0014788868,0.0002720051,0.00024200366,0.00025259034,0.0037558048,0.000054821474,0.0015036952],"genre_scores_gemma":[0.9847088,0.012503034,0.0003114392,0.00022319665,0.00012583857,0.00008731734,0.0018149628,0.000018379986,0.0002069534],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9929604,0.004166769,0.0009663671,0.0009301783,0.00066099723,0.00031530278],"domain_scores_gemma":[0.9923475,0.00358037,0.0024722053,0.00084078143,0.00047921267,0.00027997664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009568375,0.0016397507,0.0056173964,0.0013608276,0.000377988,0.0020876275,0.00071746757,0.0010098668,0.0007940877],"category_scores_gemma":[0.008138047,0.00077313144,0.01650425,0.0025899373,0.0004881886,0.00080827426,0.0009926386,0.0012206511,0.000100695856],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12231264,0.00019110506,0.20606597,0.004468157,0.640393,0.00017608078,0.00008294329,0.00253477,0.0014165937,0.00009555431,0.0007647316,0.021498384],"study_design_scores_gemma":[0.01129038,0.0055668703,0.37065956,0.00043856612,0.60818696,0.00023694907,0.00012868072,0.0010150692,0.00058511493,0.00029098935,0.0015128468,0.00008813659],"about_ca_topic_score_codex":0.0026934813,"about_ca_topic_score_gemma":0.00496309,"teacher_disagreement_score":0.009568375,"about_ca_system_score_codex":0.0007632145,"about_ca_system_score_gemma":0.0007513708,"threshold_uncertainty_score":0.050603032},"labels":[],"label_agreement":null},{"id":"W2893828074","doi":"10.1016/j.clgc.2018.09.011","title":"Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Logistic regression; Prostate cancer; Epidemiology; Internal medicine; Population; Prostate-specific antigen; Demography; Stage (stratigraphy); Cancer; Gynecology; Environmental health","score_opus":0.04762448794292119,"score_gpt":0.41928996364143567,"score_spread":0.3716654756985145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893828074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791497,0.000572368,0.00006985854,0.00013127003,0.0000125903,0.000007655267,0.00033592264,0.000006093755,0.00094925205],"genre_scores_gemma":[0.99929094,0.00017820163,0.000035374705,0.000069558184,0.000020370342,0.0000055361265,0.00023680441,0.0000027026585,0.00016042101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991509,0.00024319277,0.00007626442,0.00023329146,0.00015673818,0.00013965787],"domain_scores_gemma":[0.99755824,0.00046842013,0.0010309976,0.00020461515,0.0002941907,0.00044352296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059698906,0.0002245069,0.00046498675,0.0010141477,0.00065683125,0.0010354483,0.00075897155,0.0009176492,0.0021318253],"category_scores_gemma":[0.0030248093,0.00039855507,0.00074826076,0.0015549843,0.00034093455,0.00086068816,0.00048124036,0.0011914456,0.0002239158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048934235,0.000056240355,0.99893755,0.00000681425,0.000041613956,0.000042971627,0.00005702917,0.000011526643,0.00007602951,0.000011923041,0.00009371215,0.00061566755],"study_design_scores_gemma":[0.00000273662,0.000035437013,0.99943703,0.0000034957102,0.000023897208,0.00013771474,0.0001829487,0.00007555752,0.000013500891,0.000008567085,0.00007650797,0.0000024952737],"about_ca_topic_score_codex":0.0128171295,"about_ca_topic_score_gemma":0.017746704,"teacher_disagreement_score":0.0128171295,"about_ca_system_score_codex":0.0004989818,"about_ca_system_score_gemma":0.0005957383,"threshold_uncertainty_score":0.025485098},"labels":[],"label_agreement":null},{"id":"W2894543473","doi":"10.1016/j.clgc.2018.09.017","title":"Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Urology; Cohort; Internal medicine; Oncology; Chemotherapy; Population; Cancer","score_opus":0.05022373847367602,"score_gpt":0.4042056028138359,"score_spread":0.3539818643401599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894543473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933715,0.00453307,0.000072858275,0.00024785838,0.000053058375,0.00001821681,0.00015346699,0.000010610207,0.0015394816],"genre_scores_gemma":[0.99809176,0.00092798204,0.00004031516,0.00006382196,0.0000308945,0.000008266136,0.00017205262,0.0000032689572,0.0006615846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999861,0.00006517017,0.0000067948586,0.000015363104,0.000011427021,0.000040204588],"domain_scores_gemma":[0.99961674,0.0001536412,0.000048356374,0.000026879949,0.0000243031,0.00013004526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003712649,0.00016343602,0.0004929115,0.00015990261,0.00018440332,0.00020020292,0.00013873068,0.00023189349,0.0027333184],"category_scores_gemma":[0.0009759064,0.000058687052,0.00043963816,0.00017939946,0.0002079053,0.00022644862,0.00017282186,0.00042307537,0.000117844334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33283556,0.010141113,0.11715044,0.0013755284,0.0016790176,0.0009043763,0.0007271984,0.01609907,0.06876692,0.0017691046,0.006665601,0.44188604],"study_design_scores_gemma":[0.009972681,0.23355749,0.71314555,0.0002482276,0.0023757906,0.0011741986,0.00034819415,0.006824219,0.018586451,0.0009403842,0.01278456,0.0000422291],"about_ca_topic_score_codex":0.002123334,"about_ca_topic_score_gemma":0.005375423,"teacher_disagreement_score":0.0027333184,"about_ca_system_score_codex":0.00046379547,"about_ca_system_score_gemma":0.00039962813,"threshold_uncertainty_score":0.009143889},"labels":[],"label_agreement":null},{"id":"W2894922686","doi":"10.1016/j.clgc.2018.09.021","title":"Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Gemcitabine; Cisplatin; Chemoradiotherapy; Radiation therapy; Chemotherapy; Confidence interval; Oncology; Stage (stratigraphy); Internal medicine; Urology; External beam radiotherapy; Cancer; Surgery; Brachytherapy","score_opus":0.028054779955515932,"score_gpt":0.3492026512342951,"score_spread":0.3211478712787792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894922686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96858585,0.021918563,0.00040635027,0.002089539,0.00041349992,0.000059659746,0.00033585262,0.000029984274,0.006160743],"genre_scores_gemma":[0.99452883,0.0033503987,0.00031191987,0.00044874632,0.00014378977,0.000045465666,0.00046298132,0.0000058545747,0.00070193224],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980813,0.00007962798,0.000022082852,0.00002714624,0.000021265365,0.000041895462],"domain_scores_gemma":[0.9996153,0.00014241118,0.00007955426,0.000015667778,0.000021758096,0.00012522172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023072705,0.0002056567,0.0006318625,0.00020293529,0.00032523886,0.0003736417,0.00013419129,0.00037328337,0.0016582339],"category_scores_gemma":[0.0015355758,0.0001798019,0.0003082837,0.00030094842,0.00020480371,0.00037613825,0.00013109217,0.00047922277,0.00019850835],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0606181,0.0018837972,0.6519926,0.0011055268,0.00055757136,0.002085631,0.00035330074,0.0033434457,0.026786264,0.0005862652,0.009078699,0.2416087],"study_design_scores_gemma":[0.0016337789,0.015610314,0.95514905,0.000427997,0.00087119744,0.0030965793,0.00042567673,0.0022371728,0.004263187,0.00072138204,0.015512345,0.000051399744],"about_ca_topic_score_codex":0.0014279268,"about_ca_topic_score_gemma":0.0075959777,"teacher_disagreement_score":0.0016582339,"about_ca_system_score_codex":0.0005409273,"about_ca_system_score_gemma":0.0009037697,"threshold_uncertainty_score":0.0055473447},"labels":[],"label_agreement":null},{"id":"W2895612504","doi":"10.1016/j.clgc.2018.09.024","title":"Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Proportional hazards model; Incidence (geometry); Epidemiology; Hazard ratio; Urology; Internal medicine; Surgical margin; Mortality rate; Propensity score matching; Cancer; Demography; Oncology; Confidence interval","score_opus":0.03634812508401912,"score_gpt":0.38369164269377554,"score_spread":0.3473435176097564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895612504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958075,0.0020108342,0.00012265367,0.00026130202,0.000037032492,0.0000047063036,0.0005284969,0.000014310328,0.0012132446],"genre_scores_gemma":[0.99931467,0.00018549715,0.00003081599,0.000026275538,0.000038026796,0.0000023267373,0.0001896997,0.000002972465,0.00020984249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893945,0.00050160196,0.000084363906,0.00015181131,0.00014260483,0.00018011165],"domain_scores_gemma":[0.9910278,0.004769586,0.0022896817,0.0006010238,0.0002813008,0.0010306457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018076529,0.00032431958,0.00036110278,0.0006287187,0.00025952296,0.0008777748,0.00069906935,0.0008234968,0.0036171544],"category_scores_gemma":[0.011121074,0.00044503255,0.001639464,0.0006018052,0.0004782644,0.00086775114,0.0008199957,0.00149041,0.00030173763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010450269,0.00005469216,0.99474597,0.000020650086,0.0002605333,0.00005776511,0.0000530175,0.00030325865,0.00007942597,0.000066098866,0.00019959424,0.0031140256],"study_design_scores_gemma":[0.000013696944,0.00014004954,0.99883896,0.0000089510695,0.00013398216,0.00011646222,0.00013693946,0.00037520129,0.00003731306,0.00008215306,0.0001074759,0.0000087149965],"about_ca_topic_score_codex":0.004384959,"about_ca_topic_score_gemma":0.007116538,"teacher_disagreement_score":0.004384959,"about_ca_system_score_codex":0.00041730423,"about_ca_system_score_gemma":0.0004913121,"threshold_uncertainty_score":0.012100637},"labels":[],"label_agreement":null},{"id":"W2897938485","doi":"10.1016/j.clgc.2018.10.007","title":"Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer","year":2018,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Fundação para a Ciência e a Tecnologia","keywords":"Medicine; Testicular cancer; Cancer; Oncology; Disease; Precision medicine; Biomarker; Germ cell tumors; Internal medicine; Prostate cancer; Genitourinary system; Clinical trial; Narrative review; Intensive care medicine; Pathology; Chemotherapy","score_opus":0.16430088471697618,"score_gpt":0.5135315118760754,"score_spread":0.3492306271590992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897938485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000747874,0.9972088,0.00017774028,0.0013998548,0.0003642953,0.0000040572827,0.00004057792,0.000010369066,0.0007195555],"genre_scores_gemma":[0.0018194199,0.9945551,0.0005399108,0.0018216405,0.00078760413,0.0000089402965,0.00005889728,0.0000033113974,0.00040512762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917895,0.00024406277,0.00012124819,0.00014194018,0.00025370577,0.00006012808],"domain_scores_gemma":[0.995814,0.0028547093,0.0003969588,0.0000982915,0.000717029,0.00011893702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022925232,0.0008422069,0.0021101364,0.0027705138,0.00035808742,0.0024049515,0.0010793477,0.0018910888,0.0048172832],"category_scores_gemma":[0.004742192,0.00029019406,0.0010781839,0.0024410181,0.0011471567,0.0019805639,0.0011697196,0.0026683474,0.0011702807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010728626,0.000057979076,0.0010215066,0.02293012,0.00030633013,0.00023039628,0.000085682936,0.0004831631,0.000652422,0.011079656,0.052429143,0.9106163],"study_design_scores_gemma":[0.000039783874,0.000111413305,0.0016233205,0.012202703,0.00048515142,0.0009152726,0.00014139003,0.00023920457,0.0004067071,0.007528321,0.9762639,0.000042874097],"about_ca_topic_score_codex":0.0020976288,"about_ca_topic_score_gemma":0.0040690457,"teacher_disagreement_score":0.0048172832,"about_ca_system_score_codex":0.0012964285,"about_ca_system_score_gemma":0.0036397614,"threshold_uncertainty_score":0.016115427},"labels":[],"label_agreement":null},{"id":"W2901812877","doi":"10.1016/j.clgc.2018.11.003","title":"More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Hazard ratio; Propensity score matching; Proportional hazards model; Urology; Bladder cancer; Lymph node; Dissection (medical); Internal medicine; Overall survival; Surgery; Oncology; Cancer; Confidence interval","score_opus":0.04512874150609205,"score_gpt":0.36884425104176705,"score_spread":0.323715509535675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901812877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937115,0.004918524,0.000088906476,0.0002012366,0.00003403195,0.000008994533,0.0000726053,0.000011610722,0.0009527799],"genre_scores_gemma":[0.9978356,0.001478601,0.00008172501,0.0000879363,0.000040537492,0.0000025400625,0.000112495094,0.0000021432372,0.00035836958],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999416,0.000021370699,0.0000040332507,0.00000852131,0.000010306193,0.000014265337],"domain_scores_gemma":[0.9998672,0.000046367368,0.000024082505,0.000010336205,0.0000063108073,0.000045637236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023432722,0.00015004458,0.00032876286,0.00011503117,0.00009601494,0.00019429724,0.00011309766,0.00014042333,0.0020378802],"category_scores_gemma":[0.00060464744,0.000056301997,0.00031183386,0.00016136722,0.00013126315,0.00020825965,0.00018651117,0.0002972341,0.000118763506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055404484,0.0047799656,0.24067235,0.001378921,0.0013047272,0.00081368064,0.00036182866,0.011337402,0.10502297,0.00052756333,0.0042673377,0.5741288],"study_design_scores_gemma":[0.0017160196,0.019933693,0.9663057,0.00009411937,0.00076630065,0.00065067725,0.00014851436,0.0013526713,0.0043044747,0.0006155837,0.0040889154,0.000023361188],"about_ca_topic_score_codex":0.0007574795,"about_ca_topic_score_gemma":0.0031900166,"teacher_disagreement_score":0.0020378802,"about_ca_system_score_codex":0.00016018601,"about_ca_system_score_gemma":0.00029337592,"threshold_uncertainty_score":0.0068174005},"labels":[],"label_agreement":null},{"id":"W2905972441","doi":"10.1016/j.clgc.2018.12.006","title":"How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?","year":2018,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; University of Toronto; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia","funders":"Prostate Cancer Canada; Astellas Pharma Canada","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Psychological intervention; Erectile dysfunction; Attendance; Side effect (computer science); Sexual dysfunction; Physical therapy; Intensive care medicine; Cancer; Internal medicine; Psychiatry","score_opus":0.02916770483972373,"score_gpt":0.331082178830633,"score_spread":0.30191447399090926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905972441","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26549593,0.06313228,0.001723979,0.57894874,0.005164837,0.00017061029,0.000506964,0.00013125483,0.084725454],"genre_scores_gemma":[0.8443959,0.052246943,0.003481442,0.08615252,0.004332663,0.00015183738,0.000453521,0.000054507313,0.008730636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99869376,0.00051516143,0.00013181524,0.00009116948,0.0003398362,0.00022839598],"domain_scores_gemma":[0.9951239,0.0013300459,0.00089610013,0.00009521208,0.0008764972,0.0016781708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012979975,0.00016009607,0.00050417037,0.0003755757,0.0016143472,0.002912206,0.0005022132,0.0021710445,0.0058206664],"category_scores_gemma":[0.016859094,0.00019648891,0.0004714981,0.00055964,0.00103714,0.0032918153,0.0010029189,0.0024522243,0.0011054623],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038006695,0.0008878254,0.19633336,0.00085907086,0.00021012322,0.0022684198,0.005600796,0.00041319584,0.0005779976,0.0029433016,0.12670481,0.6628211],"study_design_scores_gemma":[0.00041217316,0.0021715257,0.3858946,0.0052521066,0.00083197135,0.019651758,0.06893896,0.0009726499,0.0010102231,0.026099723,0.48847246,0.0002918122],"about_ca_topic_score_codex":0.0029633613,"about_ca_topic_score_gemma":0.0073104696,"teacher_disagreement_score":0.0058206664,"about_ca_system_score_codex":0.00075009733,"about_ca_system_score_gemma":0.0034548268,"threshold_uncertainty_score":0.019472063},"labels":[],"label_agreement":null},{"id":"W2907881473","doi":"10.1016/j.clgc.2018.12.009","title":"Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Janssen Biotech; Orionin Tutkimussäätiö; Cilag; Astellas Pharma; Eisai; Sanofi; F. Hoffmann-La Roche; Roche; Novartis; British Microcirculation Society; Amgen; Pfizer; Bristol-Myers Squibb; International Parkinson and Movement Disorder Society; Bayer","keywords":"Medicine; Abiraterone; Prostate cancer; Metformin; Abiraterone acetate; Oncology; Internal medicine; Disease; Cancer; Androgen deprivation therapy; Insulin; Androgen receptor","score_opus":0.05126263416340064,"score_gpt":0.39075892055386896,"score_spread":0.3394962863904683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907881473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741024,0.0007022094,0.00011996609,0.00019679476,0.00008183497,0.0006242421,0.00032751382,0.000038240814,0.00049905],"genre_scores_gemma":[0.9944311,0.0011238055,0.0009144712,0.00039694016,0.00025258763,0.0008379088,0.00083623163,0.00002234334,0.0011846343],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99933213,0.00033593687,0.000037031325,0.00010925844,0.0000495678,0.00013603985],"domain_scores_gemma":[0.99870133,0.00025813386,0.00023051574,0.00010553718,0.00006258145,0.00064186164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015128079,0.0019010006,0.0023135485,0.00059548253,0.00053920713,0.0013913488,0.0011194572,0.0013977748,0.0035037033],"category_scores_gemma":[0.0016886492,0.0007360833,0.0020128118,0.0005855804,0.0013654206,0.0013545183,0.00061799027,0.0037394452,0.0006023398],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88243794,0.064261444,0.002634832,0.00025459265,0.00072220387,0.000104196944,0.00018584807,0.0011169702,0.009894953,0.00008425156,0.0006785216,0.03762426],"study_design_scores_gemma":[0.33920297,0.6487056,0.008381554,0.000024005561,0.00056720997,0.000088170025,0.00008808815,0.00054168893,0.0015056613,0.00010539525,0.00075527315,0.000034399793],"about_ca_topic_score_codex":0.002318404,"about_ca_topic_score_gemma":0.0058021555,"teacher_disagreement_score":0.0035037033,"about_ca_system_score_codex":0.00086925476,"about_ca_system_score_gemma":0.002315689,"threshold_uncertainty_score":0.011721075},"labels":[],"label_agreement":null},{"id":"W2912199505","doi":"10.1016/j.clgc.2019.01.015","title":"COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; University of British Columbia","funders":"Janssen Biotech; National Cancer Institute; Eisai; Ipsen Biopharmaceuticals; Prometheus; North Carolina GlaxoSmithKline Foundation; Novartis; GlaxoSmithKline Australia; Exelixis; Sanofi; GlaxoSmithKline; Merck; Astellas Pharma Global Development; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Memorial Sloan-Kettering Cancer Center; Roche; Astellas Pharma US; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Pazopanib; Medicine; Post-hoc analysis; Oncology; Renal cell carcinoma; Internal medicine; Post hoc; Sunitinib","score_opus":0.03562386660572312,"score_gpt":0.33030507837456136,"score_spread":0.2946812117688382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912199505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99045837,0.00092939974,0.0028740452,0.00021440405,0.00023755642,0.0009400396,0.0028155332,0.0000971805,0.0014334986],"genre_scores_gemma":[0.99063313,0.00012532473,0.00190643,0.0003552871,0.00014311142,0.0018477443,0.003343541,0.00006868382,0.0015767779],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99042004,0.006672503,0.00048618775,0.001241601,0.00072962843,0.00045006763],"domain_scores_gemma":[0.98768425,0.008446647,0.0016025082,0.0012941025,0.0006032397,0.00036928974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009481032,0.00090754626,0.0022061844,0.000645234,0.00034042416,0.00090751855,0.00089729665,0.000792584,0.008479861],"category_scores_gemma":[0.010618227,0.0002692103,0.0040586395,0.0005953097,0.00064580806,0.00086797395,0.00071510125,0.0013418365,0.0005627611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.843869,0.0037386096,0.08471502,0.001163172,0.018461684,0.0004233302,0.00025031276,0.0032656519,0.009111541,0.00044755536,0.0055391216,0.029015025],"study_design_scores_gemma":[0.07541799,0.37163505,0.45501947,0.00013151125,0.019185124,0.001462414,0.00067658914,0.028984386,0.024584843,0.0023663144,0.020342272,0.00019401268],"about_ca_topic_score_codex":0.00042078734,"about_ca_topic_score_gemma":0.0005241023,"teacher_disagreement_score":0.009481032,"about_ca_system_score_codex":0.0007582306,"about_ca_system_score_gemma":0.000786789,"threshold_uncertainty_score":0.050141096},"labels":[],"label_agreement":null},{"id":"W2912754254","doi":"10.1016/j.clgc.2019.01.009","title":"Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Brigham Research Institute","keywords":"Medicine; Bladder cancer; Cancer therapy; Cancer; Oncology; Internal medicine","score_opus":0.1357726139639858,"score_gpt":0.4188765261547862,"score_spread":0.28310391219080044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912754254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92746884,0.04054142,0.0019882685,0.0021865843,0.00025034658,0.000030177825,0.010056298,0.00012450224,0.017353509],"genre_scores_gemma":[0.99011564,0.004033546,0.00017522696,0.00019009301,0.0001444,0.000017221484,0.004562578,0.000017615763,0.00074378296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999567,0.000070382106,0.00005482327,0.0001148268,0.000081334285,0.00011156515],"domain_scores_gemma":[0.99771464,0.0006918626,0.00087450526,0.0001689067,0.0002670995,0.00028292296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009231156,0.00015055161,0.0004280697,0.0009898212,0.00026122743,0.0009590773,0.000466375,0.00056979305,0.00348728],"category_scores_gemma":[0.0038124651,0.00011209794,0.0012674998,0.0017838598,0.0004569403,0.0006387192,0.00056635024,0.00071103347,0.0004146915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049091573,0.000105218714,0.82442105,0.0006952759,0.0011722844,0.00023433683,0.00083978527,0.004522704,0.001194937,0.00247402,0.008835548,0.1505957],"study_design_scores_gemma":[0.000055941437,0.00050642056,0.98866194,0.00014007483,0.00049515086,0.0006852255,0.00033643507,0.00074941205,0.00024352186,0.0006496484,0.007454929,0.000021172493],"about_ca_topic_score_codex":0.0042353864,"about_ca_topic_score_gemma":0.007650242,"teacher_disagreement_score":0.0042353864,"about_ca_system_score_codex":0.0012030333,"about_ca_system_score_gemma":0.000570079,"threshold_uncertainty_score":0.011666119},"labels":[],"label_agreement":null},{"id":"W2922172159","doi":"10.1016/j.clgc.2019.03.005","title":"A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; CancerCare Manitoba; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Castration; Clinical trial; Gynecology; Hormone","score_opus":0.15472136721313998,"score_gpt":0.4811174060029069,"score_spread":0.326396038789767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922172159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713343,0.007082245,0.0006780374,0.0017179208,0.00033888957,0.0040062717,0.006819911,0.0002544101,0.0077678985],"genre_scores_gemma":[0.96309984,0.007266697,0.0023465364,0.0024304132,0.0003610179,0.0025972724,0.009765716,0.00010698408,0.012025642],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993142,0.00032347094,0.000016173315,0.000076955155,0.00007772822,0.00019146275],"domain_scores_gemma":[0.9991241,0.00011279592,0.00012105413,0.000053327985,0.00005272751,0.0005359456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017981705,0.0020856645,0.002750659,0.00061271543,0.0007942633,0.0011663807,0.00148531,0.0014153072,0.0073762885],"category_scores_gemma":[0.0010333562,0.0006483337,0.0023182153,0.00100674,0.0015163776,0.0005999083,0.00044886983,0.004101824,0.0012756932],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8441087,0.03189373,0.00665093,0.0013196802,0.002687447,0.00028059963,0.00036818846,0.0037063498,0.012681332,0.0006851257,0.015683286,0.07993462],"study_design_scores_gemma":[0.78829455,0.185313,0.017995337,0.00005270499,0.00086594257,0.00023763374,0.000113865244,0.00090399565,0.00092054135,0.0002086042,0.0050404123,0.000053351887],"about_ca_topic_score_codex":0.053396836,"about_ca_topic_score_gemma":0.14691885,"teacher_disagreement_score":0.053396836,"about_ca_system_score_codex":0.0028007699,"about_ca_system_score_gemma":0.007868584,"threshold_uncertainty_score":0.106172025},"labels":[],"label_agreement":null},{"id":"W2933596744","doi":"10.1016/j.clgc.2019.03.003","title":"Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Urology; Proportional hazards model; Cohort; Upper urinary tract; Internal medicine; Population; Oncology; Epidemiology; Chemotherapy; Urinary system","score_opus":0.04144192562534474,"score_gpt":0.38248303098953385,"score_spread":0.3410411053641891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933596744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220264,0.005703236,0.000080841535,0.00022920714,0.000059676102,0.000012695709,0.000178137,0.000010128275,0.0015233603],"genre_scores_gemma":[0.9981679,0.0009819384,0.000036711466,0.00006311866,0.000038232763,0.000004006845,0.00017882453,0.0000017310444,0.0005275626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99985194,0.00006008635,0.000008393576,0.00001754104,0.000016897135,0.000045088687],"domain_scores_gemma":[0.9996575,0.00010549488,0.000051529205,0.00002020468,0.000017331527,0.0001480896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005265127,0.0001941528,0.00041916815,0.00013054816,0.00015065874,0.00015994426,0.00016169436,0.00019554078,0.002037978],"category_scores_gemma":[0.0007819571,0.00005163453,0.00078247854,0.000107073734,0.00022458546,0.0002017655,0.00020643193,0.00038212558,0.00009081954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32096365,0.006269487,0.19613682,0.0017779665,0.0034140407,0.0010679774,0.0005476942,0.013349635,0.06974226,0.0013523488,0.0050147935,0.38036343],"study_design_scores_gemma":[0.004153098,0.110094145,0.8689165,0.000111500856,0.0016130183,0.0009978496,0.00026898284,0.0028146687,0.0064493944,0.00036633085,0.0041836696,0.000030699633],"about_ca_topic_score_codex":0.0027022723,"about_ca_topic_score_gemma":0.010861442,"teacher_disagreement_score":0.0027022723,"about_ca_system_score_codex":0.0003208634,"about_ca_system_score_gemma":0.00042522638,"threshold_uncertainty_score":0.0068176985},"labels":[],"label_agreement":null},{"id":"W2936749762","doi":"10.1016/j.clgc.2019.04.009","title":"Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Hazard ratio; Oncology; Internal medicine; Population; Proportional hazards model; Urology; Prostate; Adenocarcinoma; Cancer; Surveillance, Epidemiology, and End Results; Confidence interval; Cancer registry","score_opus":0.0909769474591462,"score_gpt":0.40316706546182113,"score_spread":0.31219011800267493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936749762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985347,0.00046583955,0.00012413897,0.000042884465,0.000008743081,0.0000055207215,0.00035502735,0.0000035397034,0.00045968717],"genre_scores_gemma":[0.99919206,0.00015324485,0.000036225483,0.000029563673,0.000023027242,0.0000054757643,0.00050297636,0.0000025090276,0.000054906544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985374,0.0004238072,0.0001446531,0.0005122,0.00021554853,0.00016641818],"domain_scores_gemma":[0.99789643,0.0005127369,0.00061272364,0.0003053536,0.00033813136,0.00033459382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013530924,0.00028545616,0.00062948343,0.0015422227,0.0006637435,0.00110143,0.00065343187,0.00075462897,0.0015989388],"category_scores_gemma":[0.0033325045,0.00035796213,0.0006649728,0.0025842316,0.0007585377,0.0012427848,0.0008307319,0.0007041543,0.00030220574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020781788,0.00003572587,0.9982564,0.000006985183,0.00011143299,0.000060607264,0.00007500769,0.000021227239,0.00020336303,0.000025144513,0.00006549996,0.0009308206],"study_design_scores_gemma":[0.000009866335,0.00010027764,0.99902725,0.0000024590306,0.000048620062,0.00023705211,0.00030257265,0.00006645258,0.000028123279,0.000036411308,0.00013672386,0.0000042060724],"about_ca_topic_score_codex":0.0039964765,"about_ca_topic_score_gemma":0.0036627601,"teacher_disagreement_score":0.0039964765,"about_ca_system_score_codex":0.0005654039,"about_ca_system_score_gemma":0.00041160456,"threshold_uncertainty_score":0.007946432},"labels":[],"label_agreement":null},{"id":"W2942671874","doi":"10.1016/j.clgc.2019.04.015","title":"Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Seminoma; Stage (stratigraphy); Orchiectomy; Propensity score matching; Surveillance, Epidemiology, and End Results; Hazard ratio; Testicular cancer; Proportional hazards model; Internal medicine; Incidence (geometry); Epidemiology; Population; Cumulative incidence; Urology; Oncology; Chemotherapy; Confidence interval; Cancer registry; Cohort","score_opus":0.06811372294504209,"score_gpt":0.4375365370072789,"score_spread":0.3694228140622368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942671874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984341,0.00071479974,0.00008848832,0.000043273747,0.0000059741546,0.0000033926474,0.0002894163,0.000003884514,0.00041673565],"genre_scores_gemma":[0.9994815,0.00014003422,0.000020836927,0.000012638381,0.000010032816,0.0000020358716,0.00029359641,0.0000010956884,0.00003820674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993649,0.00021609449,0.00006898014,0.00015814969,0.0001132394,0.00007854224],"domain_scores_gemma":[0.99824655,0.0004871032,0.0006927294,0.00013133607,0.00024612012,0.00019623249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012895057,0.00019114384,0.00043162864,0.0013724361,0.00030640283,0.0007637707,0.00040433614,0.0005023137,0.00075958297],"category_scores_gemma":[0.0032558443,0.00012454251,0.00058365864,0.0012564163,0.0004113084,0.0007097522,0.00048757147,0.00042037418,0.00011763595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005221186,0.000036346883,0.9962244,0.0000143511215,0.0001107947,0.000022795568,0.00012326213,0.000058951704,0.00018020341,0.000026547652,0.000056110282,0.0026240866],"study_design_scores_gemma":[0.000007433599,0.0002889796,0.99893564,0.000004205314,0.00006557541,0.00011292121,0.00029367066,0.00011608759,0.000046307076,0.000024633782,0.00010150516,0.0000031126879],"about_ca_topic_score_codex":0.0036989104,"about_ca_topic_score_gemma":0.004775823,"teacher_disagreement_score":0.0036989104,"about_ca_system_score_codex":0.000423177,"about_ca_system_score_gemma":0.00025446698,"threshold_uncertainty_score":0.007354796},"labels":[],"label_agreement":null},{"id":"W2945029662","doi":"10.1016/j.clgc.2019.05.015","title":"Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Cancer; Incidence (geometry); Oncology; Prostate; Internal medicine; Gynecology; Family history","score_opus":0.10185653789288218,"score_gpt":0.3954380661042507,"score_spread":0.2935815282113685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945029662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874994,0.006225025,0.00014159984,0.0007437998,0.00014373304,0.000058584552,0.0024865523,0.00002649401,0.0026748285],"genre_scores_gemma":[0.9964533,0.00087742833,0.00005862853,0.00030354722,0.00021751548,0.00004698632,0.0013713734,0.000008452525,0.0006627799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880636,0.00065106305,0.000059700506,0.00020593523,0.00011285632,0.00016408662],"domain_scores_gemma":[0.9973803,0.00070884096,0.00104256,0.00029295767,0.00008646732,0.000488868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023323814,0.00066315767,0.00120531,0.00030831163,0.00051281194,0.0015830721,0.0006597948,0.0010761824,0.0024622022],"category_scores_gemma":[0.0044538863,0.00042130717,0.0020533907,0.0010903816,0.0007598465,0.0010657584,0.0007300086,0.002362265,0.00027319737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3812626,0.0014071536,0.5769308,0.0010883278,0.015692612,0.00040566392,0.0002245128,0.0011274692,0.0009753791,0.0006135655,0.00668572,0.0135862315],"study_design_scores_gemma":[0.06781638,0.0074553266,0.9018921,0.00016742497,0.015153986,0.00039031444,0.00035608877,0.0012378488,0.0003541518,0.0008189683,0.0042725517,0.00008482208],"about_ca_topic_score_codex":0.0053385952,"about_ca_topic_score_gemma":0.009159923,"teacher_disagreement_score":0.0053385952,"about_ca_system_score_codex":0.0006330805,"about_ca_system_score_gemma":0.00106495,"threshold_uncertainty_score":0.012334943},"labels":[],"label_agreement":null},{"id":"W2945646193","doi":"10.1016/j.clgc.2019.05.019","title":"Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cyclophosphamide; Chemotherapy; Sarcomatoid carcinoma; Urothelial carcinoma; Radiation therapy; Oncology; Disease; Histology; Internal medicine; Cancer; Carcinoma","score_opus":0.030470337433298546,"score_gpt":0.33155655983775306,"score_spread":0.30108622240445454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945646193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984492,0.00025048826,0.00018986667,0.00015288693,0.0000066718876,0.000005448324,0.0003120899,0.000009924261,0.0006234703],"genre_scores_gemma":[0.9993895,0.000046363562,0.000085888416,0.000048158323,0.0000043027017,0.0000019912584,0.00022997959,0.00000348878,0.00019039994],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9997408,0.000050597944,0.00002408589,0.00008196629,0.000048273345,0.000054302567],"domain_scores_gemma":[0.9996164,0.00014521113,0.00009621855,0.000039193725,0.00005336856,0.000049667087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021489592,0.00014571258,0.00023129002,0.00056235417,0.0003044504,0.0004883917,0.00019134553,0.0003773955,0.0018180236],"category_scores_gemma":[0.0010136879,0.00009814908,0.00024654623,0.00053823896,0.0002571464,0.00017044548,0.0002010565,0.00025291127,0.00017871756],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023928757,0.00021206588,0.8442289,0.00006464623,0.0002698604,0.0046828752,0.00040155262,0.0009371606,0.115392864,0.00035474412,0.0006288772,0.03043357],"study_design_scores_gemma":[0.000029073573,0.0006182694,0.9805982,0.000008729304,0.00015652213,0.005973267,0.00035761073,0.0013445081,0.009035657,0.00024871065,0.0016200867,0.000009393477],"about_ca_topic_score_codex":0.0023062397,"about_ca_topic_score_gemma":0.002489539,"teacher_disagreement_score":0.0023062397,"about_ca_system_score_codex":0.00034991628,"about_ca_system_score_gemma":0.00017425898,"threshold_uncertainty_score":0.0060819387},"labels":[],"label_agreement":null},{"id":"W2946472581","doi":"10.1016/j.clgc.2019.05.017","title":"Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Eisai; Fondazione Internazionale Menarini; British Microcirculation Society; M.S.I. Foundation; Ipsen Biopharmaceuticals; Pfizer; Intuitive Surgical; Takeda Pharmaceutical Company; Exelixis; Meso Scale Diagnostics; Ipsen; Olympus; Medtronic; Roche; Baxter International; Novartis Pharma; Novartis","keywords":"Medicine; Renal cell carcinoma; Real world evidence; Oncology; Internal medicine; Real world data; Data science","score_opus":0.27979379609309263,"score_gpt":0.45433514373646267,"score_spread":0.17454134764337004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946472581","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44976398,0.48920125,0.0018513751,0.0030638136,0.0004152907,0.0004898158,0.041396342,0.00004584724,0.013772217],"genre_scores_gemma":[0.94011873,0.03641905,0.0012582714,0.0018414133,0.0002667135,0.00032242187,0.019045254,0.000045647448,0.0006824786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9841755,0.0092940405,0.003038165,0.0012527477,0.0017070872,0.00053251756],"domain_scores_gemma":[0.9705641,0.017389676,0.009051933,0.0013495117,0.0011302044,0.0005145611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009882556,0.0005849606,0.0029155891,0.0023203637,0.00021190962,0.0021413595,0.00057616516,0.0009803828,0.003873146],"category_scores_gemma":[0.036859248,0.00036654048,0.005760957,0.0031632653,0.0005666051,0.0011106012,0.0010804156,0.0013136256,0.0005353262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078192584,0.00077742094,0.32646635,0.09073264,0.20378639,0.0007009648,0.00069633615,0.014806814,0.0016687169,0.0042098504,0.022644186,0.25531778],"study_design_scores_gemma":[0.026298368,0.008588356,0.64050597,0.04226285,0.18069698,0.0027991452,0.00089130644,0.0024769153,0.0014851694,0.0035254122,0.09021525,0.00025435598],"about_ca_topic_score_codex":0.0021651385,"about_ca_topic_score_gemma":0.004187715,"teacher_disagreement_score":0.009882556,"about_ca_system_score_codex":0.0015929586,"about_ca_system_score_gemma":0.0017095543,"threshold_uncertainty_score":0.05226457},"labels":[],"label_agreement":null},{"id":"W2946957740","doi":"10.1016/j.clgc.2021.05.004","title":"Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; McMaster University; Sunnybrook Health Science Centre; University of Manitoba; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; University of Ottawa","funders":"Genentech; Ipsen; Amgen Astellas Biopharma; Astellas Pharma; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; AbbVie; Exelixis; Sanofi; Roche; Karyopharm Therapeutics; Novartis; MedImmune; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Hazard ratio; Renal cell carcinoma; Internal medicine; Kidney cancer; Systemic therapy; Cancer; Cohort study; Confidence interval; Oncology; Breast cancer","score_opus":0.05802921157147152,"score_gpt":0.32756667941217094,"score_spread":0.26953746784069943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946957740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79936147,0.007000303,0.00029426118,0.0044419663,0.000103698396,0.0002640957,0.16668883,0.000092316885,0.021753082],"genre_scores_gemma":[0.953845,0.0027515148,0.00043637748,0.0006402367,0.000048007267,0.000060255796,0.04005361,0.000018479985,0.0021465144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973291,0.00022312545,0.00017589645,0.00020824572,0.0014666233,0.00059702585],"domain_scores_gemma":[0.992469,0.00048515399,0.0010329598,0.00012031754,0.0047268094,0.0011657457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019790912,0.0004877123,0.00057775,0.0034852657,0.0013904705,0.0013785397,0.0013575921,0.00056084787,0.0023877602],"category_scores_gemma":[0.009338692,0.00021913658,0.0008785416,0.009955505,0.00033841,0.00058913324,0.0011579732,0.00073871575,0.00025750214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019480665,0.00005269633,0.97347397,0.000192628,0.00013637554,0.000041635256,0.0003114189,0.00040036472,0.000096982,0.00015796775,0.011886247,0.013054793],"study_design_scores_gemma":[0.000014441684,0.000020146916,0.9961486,0.000059684346,0.00007596858,0.0000252158,0.00032093748,0.00045319778,0.00005740428,0.000020218497,0.002793686,0.000010432334],"about_ca_topic_score_codex":0.9936293,"about_ca_topic_score_gemma":0.9955699,"teacher_disagreement_score":0.02679486,"about_ca_system_score_codex":0.02679486,"about_ca_system_score_gemma":0.046596244,"threshold_uncertainty_score":0.19441122},"labels":[],"label_agreement":null},{"id":"W2946986050","doi":"10.1016/j.clgc.2019.05.012","title":"Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; Orionin Tutkimussäätiö; Cilag; Astellas Pharma; Ipsen; Astellas Pharma Canada; Bristol-Myers Squibb; Bayer Corporation; Janssen Canada; Meso Scale Diagnostics; Sanofi; Roche; Novartis; Amgen; Pfizer; Johnson and Johnson; Takeda Pharmaceutical Company; Active Biotech; Bayer","keywords":"Medicine; Prostate cancer; Radium-223; Oncology; Disease; Internal medicine; Radium; Castration; Urology; Cancer; Hormone; Bone metastasis","score_opus":0.06678858482934684,"score_gpt":0.420381723733961,"score_spread":0.35359313890461413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946986050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99937755,0.00017141517,0.000040501134,0.00003599069,0.000003017245,0.000011147408,0.00014916902,0.0000023369444,0.00020900226],"genre_scores_gemma":[0.9995912,0.000045146535,0.000039215647,0.00002324585,0.000008155168,0.000010503828,0.00018341439,0.0000012182661,0.000098084616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979407,0.00007200792,0.000016666696,0.000039979186,0.000044135675,0.000033168068],"domain_scores_gemma":[0.99857926,0.00026492422,0.0006700592,0.00003602699,0.00004947036,0.00040016556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005319121,0.00015314331,0.00027134418,0.00029750087,0.00026748434,0.00036064282,0.00019769104,0.00029193924,0.0014537645],"category_scores_gemma":[0.0013233431,0.00012596053,0.00030786867,0.00048129744,0.00014203014,0.000258238,0.00017601524,0.00049253483,0.00015718007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002630491,0.0003096397,0.9933228,0.000016832002,0.00007337193,0.000069927766,0.000040688275,0.00015870116,0.0005421157,0.000012149539,0.00016299012,0.0026602992],"study_design_scores_gemma":[0.00011983365,0.0009848349,0.99811316,0.0000041215117,0.000035791436,0.00019416247,0.000037364218,0.0002063282,0.00007209598,0.000011091571,0.00021758003,0.0000036190836],"about_ca_topic_score_codex":0.001238365,"about_ca_topic_score_gemma":0.0017722675,"teacher_disagreement_score":0.0014537645,"about_ca_system_score_codex":0.00027914118,"about_ca_system_score_gemma":0.00032335139,"threshold_uncertainty_score":0.004863322},"labels":[],"label_agreement":null},{"id":"W2947434657","doi":"10.1016/j.clgc.2019.05.022","title":"Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Prostate; Cancer; Cytoreductive surgery; Oncology; Internal medicine; Ovarian cancer","score_opus":0.20192312562868442,"score_gpt":0.5194030736804688,"score_spread":0.31747994805178437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947434657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835865,0.011330163,0.0006380636,0.00020246596,0.00036851823,0.00014096587,0.0002627248,0.000035069577,0.0034355656],"genre_scores_gemma":[0.99657285,0.001902669,0.00037117605,0.00010534943,0.00024606954,0.00003944885,0.00016796672,0.000005464161,0.00058916985],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993643,0.00029238235,0.000059831866,0.00010084142,0.000102302525,0.00008038544],"domain_scores_gemma":[0.9990044,0.00059284945,0.00015272954,0.000065427266,0.000040146784,0.00014454297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008430889,0.0006042387,0.0010631147,0.0003012777,0.00016802788,0.00058276363,0.0005504899,0.00045985793,0.0028363261],"category_scores_gemma":[0.0023813138,0.00021973581,0.001597021,0.00022840148,0.00054978934,0.0006647773,0.00038288528,0.000745116,0.00023006999],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70973307,0.004715829,0.00872542,0.0023054492,0.0028892914,0.00026469503,0.00030675202,0.005771035,0.009831781,0.00047626838,0.00091479515,0.25406548],"study_design_scores_gemma":[0.087516755,0.588911,0.2965509,0.0005243417,0.004886442,0.0014911344,0.00059808366,0.007024204,0.004005125,0.0015037607,0.006806459,0.00018178957],"about_ca_topic_score_codex":0.0011291642,"about_ca_topic_score_gemma":0.003375154,"teacher_disagreement_score":0.0028363261,"about_ca_system_score_codex":0.0005258221,"about_ca_system_score_gemma":0.00053819356,"threshold_uncertainty_score":0.009488404},"labels":[],"label_agreement":null},{"id":"W2950152297","doi":"10.1016/j.clgc.2019.06.003","title":"Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Hazard ratio; Seminoma; Internal medicine; Incidence (geometry); Proportional hazards model; Epidemiology; Odds ratio; Logistic regression; Germ cell tumors; Oncology; Mortality rate; Gynecology; Demography; Confidence interval; Biology; Chemotherapy","score_opus":0.029922654611996943,"score_gpt":0.3494134939490125,"score_spread":0.31949083933701555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950152297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786258,0.012804643,0.00032350575,0.0008018479,0.00008127883,0.000008143606,0.0030417189,0.000036832294,0.004276255],"genre_scores_gemma":[0.9944218,0.0034783927,0.000095855285,0.000074155614,0.000117526484,0.0000063595985,0.0015956254,0.000005226461,0.00020511552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996928,0.000056193843,0.000046304714,0.000054976987,0.000077881836,0.00007178315],"domain_scores_gemma":[0.9988482,0.00024017673,0.00048327626,0.00005800128,0.00018321132,0.00018705927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003640262,0.00013980847,0.0002950519,0.0013293441,0.00034368035,0.00090688025,0.00031450271,0.00041366497,0.0018081357],"category_scores_gemma":[0.0018657004,0.00012230304,0.0004336199,0.0028507377,0.00031384706,0.0006351698,0.00042124352,0.0005113583,0.000310641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007442068,0.000011556014,0.9936173,0.00002343216,0.000043486765,0.00006002587,0.000073044066,0.00007399747,0.00006841435,0.00009073098,0.00048085084,0.0053826505],"study_design_scores_gemma":[0.0000029057314,0.00002991787,0.9978467,0.000015861298,0.00003503559,0.0005148425,0.00037614384,0.00013935538,0.000046622503,0.00008694379,0.00090172724,0.0000038489256],"about_ca_topic_score_codex":0.0042609307,"about_ca_topic_score_gemma":0.005532543,"teacher_disagreement_score":0.0042609307,"about_ca_system_score_codex":0.00046483384,"about_ca_system_score_gemma":0.00045003387,"threshold_uncertainty_score":0.008472264},"labels":[],"label_agreement":null},{"id":"W2964142510","doi":"10.1016/j.clgc.2019.07.008","title":"A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Period (music); Oncology; Cancer; Prostate; Internal medicine","score_opus":0.067928409871219,"score_gpt":0.41973478168077677,"score_spread":0.35180637180955776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964142510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972734,0.0008487613,0.000082380284,0.000033780983,0.000008901841,0.0000061287915,0.0014827031,0.000004558868,0.00025938443],"genre_scores_gemma":[0.9980254,0.00022933517,0.00003538001,0.000016858387,0.000013149374,0.0000052649416,0.0014613218,0.000002406547,0.0002108391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994868,0.00015199275,0.00005535103,0.00011378,0.00005797607,0.00013396169],"domain_scores_gemma":[0.99882954,0.00026135173,0.00043389818,0.00011898621,0.000120898476,0.00023539393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010339929,0.00037851068,0.00054252153,0.0017839684,0.00040845352,0.00079976884,0.00040792002,0.0004456887,0.0013557225],"category_scores_gemma":[0.0018495402,0.0002914598,0.0023656546,0.0020963796,0.00019285279,0.0004806013,0.00063402666,0.0006598696,0.00018148696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012641271,0.00005509939,0.9956226,0.000030860007,0.00063656626,0.00013516608,0.000031922584,0.00037806993,0.00032325732,0.000020289699,0.00016138276,0.0013406663],"study_design_scores_gemma":[0.000009249253,0.00008989069,0.9993197,0.0000026258724,0.00013324837,0.00006338258,0.000041238916,0.00022586537,0.000025534351,0.0000053618137,0.00008108032,0.000002730064],"about_ca_topic_score_codex":0.024746468,"about_ca_topic_score_gemma":0.024900578,"teacher_disagreement_score":0.024746468,"about_ca_system_score_codex":0.0007959442,"about_ca_system_score_gemma":0.0007971757,"threshold_uncertainty_score":0.049204886},"labels":[],"label_agreement":null},{"id":"W2965386530","doi":"10.1016/j.clgc.2019.07.016","title":"Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Pharmaceuticals; Janssen Biotech; Fonds de Recherche du Québec - Santé; Amgen; AbbVie Canada; AstraZeneca; Innocrin Pharmaceuticals; Ferring Pharmaceuticals; Astellas Pharma Canada; Bayer; Merck; MedImmune; Roche; Sanofi","keywords":"Medicine; Cystectomy; 5 Alpha-Reductase Inhibitor; Bladder cancer; Receipt; Alpha (finance); Oncology; Internal medicine; Urology; Cancer; Finasteride; Surgery; World Wide Web","score_opus":0.035415946778967325,"score_gpt":0.3493478301064011,"score_spread":0.31393188332743377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965386530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97642297,0.008892525,0.000225403,0.007438675,0.0003523595,0.000018057473,0.0003306295,0.000024692801,0.006294743],"genre_scores_gemma":[0.9960729,0.0018556038,0.00013569319,0.00095829525,0.0002823798,0.000003170186,0.00015244323,0.0000049739365,0.00053454685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995735,0.00011600264,0.00003057978,0.000058921367,0.00009926197,0.00012168582],"domain_scores_gemma":[0.99798775,0.0006043684,0.00075916556,0.00007051811,0.00014620123,0.0004319566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051887665,0.00014930117,0.0005599844,0.00028157758,0.00031313245,0.00090606266,0.0003416743,0.001008947,0.003513176],"category_scores_gemma":[0.0047816965,0.00013722935,0.00050841377,0.0004909507,0.00037310354,0.00059195206,0.00013423109,0.0009272542,0.00040982835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004207191,0.0007455103,0.8928979,0.00016108756,0.0004981233,0.0005333091,0.00014928829,0.00024251577,0.0035584455,0.0006617347,0.0023197795,0.094025046],"study_design_scores_gemma":[0.00012539038,0.0008754682,0.9943282,0.000054334923,0.0003002476,0.00059079734,0.00027978895,0.00017314716,0.0004577677,0.00046406587,0.0023387065,0.00001218595],"about_ca_topic_score_codex":0.0026572365,"about_ca_topic_score_gemma":0.0072931983,"teacher_disagreement_score":0.003513176,"about_ca_system_score_codex":0.00044540098,"about_ca_system_score_gemma":0.0009089222,"threshold_uncertainty_score":0.011752784},"labels":[],"label_agreement":null},{"id":"W2969581577","doi":"10.1016/j.clgc.2019.08.004","title":"Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Pfizer Canada; Ipsen Biopharmaceuticals; Novartis; Pfizer","keywords":"Medicine; Renal cell carcinoma; Clinical trial; Oncology; Clinical decision making; Intensive care medicine; Genitourinary system; Kidney cancer; Internal medicine; Overall survival","score_opus":0.2945977963045506,"score_gpt":0.483884615773327,"score_spread":0.1892868194687764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969581577","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05137067,0.0789784,0.2904095,0.48487696,0.018562218,0.008666809,0.011789179,0.0007871473,0.054559056],"genre_scores_gemma":[0.4512372,0.024645396,0.35735214,0.12385674,0.022373622,0.0103982985,0.0072894986,0.00057498226,0.0022721784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.15203616,0.6751438,0.1361823,0.0074528325,0.027118567,0.0020663997],"domain_scores_gemma":[0.020128008,0.7924874,0.067320876,0.06776207,0.049232308,0.0030693347],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.77917844,0.0015536745,0.0063280608,0.010120366,0.002438132,0.03528058,0.008824212,0.01181523,0.0030194677],"category_scores_gemma":[0.9111308,0.0024716554,0.005038539,0.008859293,0.010469378,0.027478082,0.010839058,0.021292027,0.0013792274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005868669,0.0007651731,0.061255116,0.017250072,0.009701496,0.0010579019,0.0076416023,0.011541331,0.0013635274,0.08181494,0.11186811,0.689872],"study_design_scores_gemma":[0.0041746693,0.002590804,0.04233438,0.06886312,0.010071893,0.0016851779,0.003569538,0.049026348,0.0065935203,0.5265198,0.28345627,0.0011144599],"about_ca_topic_score_codex":0.0028930535,"about_ca_topic_score_gemma":0.0040592817,"teacher_disagreement_score":0.22082156,"about_ca_system_score_codex":0.0060666436,"about_ca_system_score_gemma":0.029073684,"threshold_uncertainty_score":0.27231234},"labels":[],"label_agreement":null},{"id":"W2969582517","doi":"10.1016/j.clgc.2019.08.009","title":"Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Orchiectomy; Propensity score matching; Retroperitoneal lymph node dissection; Surveillance, Epidemiology, and End Results; Hazard ratio; Proportional hazards model; Testicular cancer; Population; Stage (stratigraphy); Germ cell tumors; Cumulative incidence; Relative survival; Internal medicine; Epidemiology; Surgery; Gynecology; Oncology; Chemotherapy; Confidence interval; Cancer registry; Cohort","score_opus":0.03828911427823522,"score_gpt":0.38667993397473727,"score_spread":0.34839081969650204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969582517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984511,0.0007534529,0.00006746855,0.000055436547,0.000006808282,0.000002885754,0.00031259656,0.000003887356,0.00034640872],"genre_scores_gemma":[0.9994035,0.00015266135,0.000018081422,0.000016785423,0.000011254304,0.0000017613005,0.0003611479,8.67267e-7,0.000034078108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956614,0.00013085126,0.00005159328,0.000119584474,0.00007117558,0.00006069072],"domain_scores_gemma":[0.99834394,0.00043063122,0.00064798415,0.00010565801,0.0002360657,0.0002356379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089910795,0.0001590902,0.00040171822,0.0010364575,0.0003057585,0.0007425924,0.0003387021,0.0005086026,0.0006092881],"category_scores_gemma":[0.0027310709,0.00012553236,0.00047855833,0.0011308764,0.0003993088,0.0006696928,0.00038417906,0.0004266308,0.000111669055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033100543,0.000024594985,0.9977144,0.000008377909,0.0000669803,0.000021100863,0.00005493075,0.000040497256,0.00011684936,0.000010894035,0.000041354004,0.0015688997],"study_design_scores_gemma":[0.000007472276,0.00021683873,0.9991411,0.0000029425394,0.00005195541,0.0001286003,0.00018993934,0.000118327174,0.00003716479,0.000017562874,0.00008520535,0.0000028881143],"about_ca_topic_score_codex":0.0045693507,"about_ca_topic_score_gemma":0.0046037976,"teacher_disagreement_score":0.0045693507,"about_ca_system_score_codex":0.0004511519,"about_ca_system_score_gemma":0.00026961046,"threshold_uncertainty_score":0.009085536},"labels":[],"label_agreement":null},{"id":"W2975223270","doi":"10.1016/j.clgc.2019.09.004","title":"Impact of Patients’ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien","keywords":"Medicine; Meta-analysis; Internal medicine; Hazard ratio; Kidney cancer; Oncology; Confidence interval; Cancer; Immunotherapy; Randomized controlled trial; Cochrane Library; Systematic review; MEDLINE","score_opus":0.1967646823354452,"score_gpt":0.4571831977062537,"score_spread":0.2604185153708085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975223270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070056394,0.991732,0.00027953947,0.00013229996,0.00014641548,0.00007702753,0.00039513072,0.000014962933,0.00021682454],"genre_scores_gemma":[0.30152285,0.69352794,0.0014091001,0.0016079334,0.0003200998,0.0003049662,0.00072286895,0.000036885394,0.0005473675],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960801,0.0015936557,0.0011414129,0.0005987256,0.00038046684,0.00020559436],"domain_scores_gemma":[0.99286824,0.0051757223,0.0011972752,0.0002653492,0.0003595129,0.00013383658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051712864,0.0019370238,0.011828689,0.0020682407,0.0004558916,0.0020945012,0.0015764469,0.0022652044,0.003935955],"category_scores_gemma":[0.014291188,0.0012087552,0.03230495,0.0035669415,0.00064865046,0.0013889591,0.001298018,0.0023385186,0.00032136208],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037342296,0.000040534615,0.008587663,0.22537519,0.7479779,0.00011980588,0.00009454288,0.00047501735,0.0002676898,0.000111405854,0.0007521212,0.012463914],"study_design_scores_gemma":[0.00070406793,0.00019626564,0.005173974,0.00797132,0.9843076,0.00006288858,0.000042682193,0.00010338695,0.00006041796,0.00013178863,0.0012237701,0.000021855409],"about_ca_topic_score_codex":0.0075675696,"about_ca_topic_score_gemma":0.022272293,"teacher_disagreement_score":0.011828689,"about_ca_system_score_codex":0.0014245707,"about_ca_system_score_gemma":0.002026899,"threshold_uncertainty_score":0.027348697},"labels":[],"label_agreement":null},{"id":"W2975300000","doi":"10.1016/j.clgc.2019.09.008","title":"Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Urology; Hazard ratio; Stage (stratigraphy); Proportional hazards model; Dissection (medical); Lymph node; Bladder cancer; Logistic regression; Cohort; Internal medicine; Surgery; Confidence interval; Cancer","score_opus":0.02686335273150627,"score_gpt":0.33224553994996825,"score_spread":0.305382187218462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975300000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994155,0.003119127,0.00009945787,0.00024017661,0.000029286886,0.00001009136,0.0011543522,0.000005325675,0.001187177],"genre_scores_gemma":[0.997635,0.0010215258,0.000051748764,0.000060414295,0.000029971518,0.000004811292,0.0009297839,0.000002074098,0.00026476485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998425,0.00001967939,0.0000147724495,0.000034258253,0.000026166805,0.00006247754],"domain_scores_gemma":[0.9994116,0.00008677258,0.00030996525,0.00003339344,0.000046096087,0.00011216706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027609864,0.000109423934,0.00016013195,0.0004324439,0.0002909093,0.00046929222,0.00026018146,0.0002699881,0.0018728925],"category_scores_gemma":[0.0014363464,0.00013107891,0.00044955453,0.0011883514,0.00020654021,0.00076654804,0.00040588726,0.00041502668,0.00013325129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052725204,0.000036758647,0.9917031,0.000046730096,0.000113239716,0.00012824438,0.00005058987,0.00009995829,0.00021955797,0.000041298954,0.0003253027,0.006707907],"study_design_scores_gemma":[0.000011625498,0.00011235173,0.9986236,0.000015620515,0.000058364847,0.00027690985,0.00020925309,0.00014183151,0.000053578056,0.000050673934,0.00044295564,0.000003249706],"about_ca_topic_score_codex":0.011061149,"about_ca_topic_score_gemma":0.026470186,"teacher_disagreement_score":0.011061149,"about_ca_system_score_codex":0.00045572777,"about_ca_system_score_gemma":0.0009689369,"threshold_uncertainty_score":0.021993577},"labels":[],"label_agreement":null},{"id":"W2976600478","doi":"10.1016/j.clgc.2019.09.007","title":"Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Hazard ratio; Biochemical recurrence; Proportional hazards model; Prostate cancer; Internal medicine; Confidence interval; Oncology; Cancer; Urology; Surgery","score_opus":0.050618921630573264,"score_gpt":0.4138482882475533,"score_spread":0.3632293666169801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976600478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940024,0.0014149336,0.000066664754,0.0018171667,0.000079013764,0.000016731481,0.00023763557,0.000004535672,0.0023608857],"genre_scores_gemma":[0.9990433,0.00019729695,0.00007932197,0.000264774,0.000045103116,0.000006039365,0.00016481947,0.0000021912967,0.00019707053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754286,0.0012110595,0.0002610265,0.00022770502,0.00036531835,0.0003920193],"domain_scores_gemma":[0.9921766,0.0027493448,0.0031088034,0.0002547822,0.0004921816,0.0012183099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016232004,0.00016352706,0.0005076535,0.00039099634,0.00071500486,0.00112351,0.00048277611,0.0008420315,0.0028033974],"category_scores_gemma":[0.019781059,0.00016539836,0.0011004017,0.00070083665,0.0002693936,0.00061959383,0.00081553386,0.0014673077,0.00013598069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005113836,0.00034195167,0.9844148,0.000043979082,0.00037445498,0.000053312215,0.00018023668,0.00021880344,0.00004472451,0.00006465425,0.00046901178,0.013282559],"study_design_scores_gemma":[0.00003308592,0.0003200142,0.9977792,0.00005385643,0.000194703,0.0000893014,0.00052943,0.00047650834,0.000027684078,0.00011201995,0.00037390905,0.000010178043],"about_ca_topic_score_codex":0.014121465,"about_ca_topic_score_gemma":0.02294894,"teacher_disagreement_score":0.014121465,"about_ca_system_score_codex":0.00070193724,"about_ca_system_score_gemma":0.0013939018,"threshold_uncertainty_score":0.028078556},"labels":[],"label_agreement":null},{"id":"W2981079561","doi":"10.1016/j.clgc.2019.10.012","title":"Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Urology; Hazard ratio; Bladder cancer; Proportional hazards model; Perioperative; Confidence interval; Population; Internal medicine; Oncology; Cancer; Surgery","score_opus":0.036086200905455966,"score_gpt":0.34745412947923465,"score_spread":0.3113679285737787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981079561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856769,0.010718359,0.00032336143,0.00053072424,0.00008222656,0.000009525544,0.00043620687,0.000019483976,0.0022032678],"genre_scores_gemma":[0.99623007,0.0025525931,0.000194268,0.00015622427,0.0000710475,0.0000054973684,0.00032044319,0.0000043611158,0.0004655181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998104,0.000050650713,0.000026829885,0.00003003876,0.000044617966,0.00003758837],"domain_scores_gemma":[0.99868923,0.00021377679,0.00083138933,0.000060173737,0.00009229988,0.00011319716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027210973,0.00015764327,0.00026324735,0.0003102867,0.00024175225,0.0005956355,0.00019379251,0.00028694462,0.0016714893],"category_scores_gemma":[0.002337272,0.0001357189,0.00042090332,0.00086482696,0.0001933381,0.00043553693,0.0002985448,0.00051624695,0.00015219126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044238995,0.000055830522,0.9859446,0.00006332306,0.00017016301,0.00009071726,0.00003988658,0.00010929054,0.00071519427,0.000048390888,0.0002578637,0.012062385],"study_design_scores_gemma":[0.00000634041,0.00010996429,0.99851316,0.000014497061,0.00012210108,0.00021775506,0.00009047677,0.0001445827,0.00021845062,0.000040883333,0.00051856466,0.0000031921038],"about_ca_topic_score_codex":0.001225068,"about_ca_topic_score_gemma":0.0030423976,"teacher_disagreement_score":0.0016714893,"about_ca_system_score_codex":0.00018091232,"about_ca_system_score_gemma":0.00031828982,"threshold_uncertainty_score":0.0055916905},"labels":[],"label_agreement":null},{"id":"W2981238229","doi":"10.1016/j.clgc.2019.10.016","title":"Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urothelial carcinoma; Urothelial cancer; Histology; Oncology; Urology; Population; Internal medicine; Cancer","score_opus":0.04974038611521558,"score_gpt":0.3695354914271372,"score_spread":0.3197951053119216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981238229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992299,0.00025579645,0.00003951753,0.000026167761,0.0000076341075,0.0000032156538,0.0002484867,0.000002082329,0.00018711058],"genre_scores_gemma":[0.9995484,0.00008491068,0.000009692347,0.000016252445,0.000011603937,0.0000033775568,0.000248324,0.0000015889187,0.0000758478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991567,0.00021537718,0.000069519396,0.00029524267,0.000082164705,0.00018091266],"domain_scores_gemma":[0.99869126,0.00024592283,0.0004497971,0.00016247253,0.000109440254,0.0003411467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007502818,0.00045208394,0.00079799804,0.0010487679,0.00065327616,0.0010319586,0.00057933363,0.0012742833,0.00170623],"category_scores_gemma":[0.0020972844,0.00051817036,0.0017104173,0.0018133223,0.0005893509,0.0010772716,0.0007641842,0.000998812,0.0002675147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088906364,0.000065339394,0.99751055,0.000011237884,0.00036508715,0.00012393751,0.000084659376,0.000046883415,0.00027341678,0.000014637422,0.00006134135,0.00055377855],"study_design_scores_gemma":[0.000020999065,0.00028614927,0.9989598,0.0000028721659,0.00014289183,0.00017703477,0.00021734528,0.000084697036,0.000018864359,0.000020776577,0.000061761304,0.0000067904825],"about_ca_topic_score_codex":0.0058899964,"about_ca_topic_score_gemma":0.004919767,"teacher_disagreement_score":0.0058899964,"about_ca_system_score_codex":0.00043605868,"about_ca_system_score_gemma":0.00039154186,"threshold_uncertainty_score":0.011711419},"labels":[],"label_agreement":null},{"id":"W2985526546","doi":"10.1016/j.clgc.2019.10.024","title":"Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AbbVie Canada; Elekta; Varian Medical Systems; Roche; Eisai; AbbVie; Merck; Ipsen; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Interquartile range; Systemic therapy; Renal cell carcinoma; Cohort; Internal medicine; Retrospective cohort study; Cancer; Oncology; Surgery; Breast cancer","score_opus":0.026376206283059863,"score_gpt":0.34590948857936804,"score_spread":0.3195332822963082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985526546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799042,0.011250904,0.00019540514,0.0007867378,0.00010974414,0.00003874337,0.00024691442,0.000017011103,0.0074503953],"genre_scores_gemma":[0.9969907,0.0016774583,0.00011324965,0.00020990566,0.000114020484,0.000012081574,0.00026268227,0.0000058882915,0.0006141528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99985397,0.00006254127,0.000008687555,0.000022801902,0.00002042784,0.00003153485],"domain_scores_gemma":[0.99970394,0.0001225573,0.00005176502,0.000010113157,0.000021902557,0.00008970016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020495706,0.00016858138,0.0006286057,0.00013182132,0.00020775964,0.0003546109,0.00013878057,0.00018746142,0.0020871637],"category_scores_gemma":[0.0010096394,0.000052190666,0.00048242693,0.00019513624,0.00015444466,0.00027524948,0.00018554657,0.00043452944,0.0001124476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061957367,0.0033942303,0.41593575,0.0007436549,0.0016920656,0.0027870694,0.00026047198,0.004406932,0.016509349,0.0007171335,0.0047118263,0.48688412],"study_design_scores_gemma":[0.0022898696,0.031822592,0.9485976,0.00015943509,0.0017230933,0.0029402662,0.00037257187,0.0027152074,0.0020612676,0.0005492184,0.006744202,0.000024752038],"about_ca_topic_score_codex":0.0026007697,"about_ca_topic_score_gemma":0.009985979,"teacher_disagreement_score":0.0026007697,"about_ca_system_score_codex":0.00040765764,"about_ca_system_score_gemma":0.0006092036,"threshold_uncertainty_score":0.0069823265},"labels":[],"label_agreement":null},{"id":"W2992439077","doi":"10.1016/j.clgc.2019.11.010","title":"A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; McGill University Health Centre; Université de Montréal; Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Renal cell carcinoma; Nivolumab; Kidney cancer; Internal medicine; Oncology; Nephrectomy; Ipilimumab; Pembrolizumab; Cancer; Adjuvant therapy; Immunotherapy; Kidney","score_opus":0.18648242834762796,"score_gpt":0.4384022978983788,"score_spread":0.25191986955075085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992439077","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40412158,0.111528,0.15544368,0.27236342,0.007905993,0.008369134,0.0029445866,0.0009907485,0.036332786],"genre_scores_gemma":[0.7737596,0.012942157,0.14010236,0.057907272,0.0052017304,0.004597745,0.0021350528,0.00047613733,0.0028779223],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9627511,0.029658161,0.0033732543,0.0017301319,0.0015930091,0.0008943525],"domain_scores_gemma":[0.95609605,0.02747793,0.0057981634,0.004561111,0.0036519836,0.002414785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.078682885,0.0010699725,0.003275105,0.0011846399,0.0010199371,0.0047841817,0.0016327718,0.0017967419,0.004964129],"category_scores_gemma":[0.076011896,0.00059713837,0.0031813385,0.0014248346,0.0014954231,0.004107467,0.0017973002,0.005715335,0.0014267076],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024984995,0.0017989262,0.12649262,0.0018151753,0.0043496042,0.00014605894,0.00070542825,0.016093828,0.007130147,0.012752258,0.029879622,0.7738514],"study_design_scores_gemma":[0.01787063,0.059207477,0.37189284,0.008734036,0.0109000625,0.0015680221,0.0022740983,0.06947523,0.013376323,0.1330448,0.31085533,0.00080119283],"about_ca_topic_score_codex":0.0012451006,"about_ca_topic_score_gemma":0.0032869284,"teacher_disagreement_score":0.078682885,"about_ca_system_score_codex":0.0022665737,"about_ca_system_score_gemma":0.0040128366,"threshold_uncertainty_score":0.4161198},"labels":[],"label_agreement":null},{"id":"W2995419061","doi":"10.1016/j.clgc.2019.12.002","title":"Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Subgroup analysis; Cancer; Cochrane Library; Confidence interval","score_opus":0.2286906265936641,"score_gpt":0.496953248459781,"score_spread":0.26826262186611693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995419061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005087493,0.99377394,0.00024952323,0.000116278585,0.00010566255,0.00005094749,0.00044415158,0.000017324655,0.00015463328],"genre_scores_gemma":[0.22338045,0.77243793,0.0013869455,0.0010030752,0.0002756846,0.00021900234,0.00083019777,0.00003253758,0.00043421148],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964755,0.0013366851,0.0009993152,0.00060567237,0.00039015483,0.00019259364],"domain_scores_gemma":[0.9925337,0.0054412605,0.0011308728,0.00029691687,0.0004456128,0.00015165709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004988739,0.0022415698,0.012576272,0.003734574,0.00050418597,0.002275128,0.0019105404,0.002131715,0.0040757237],"category_scores_gemma":[0.014029789,0.0014359464,0.029074155,0.0058107213,0.00063913176,0.0015256724,0.0016112891,0.0021020863,0.00037905015],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019995943,0.000033030094,0.011292085,0.24887656,0.7229879,0.00014476803,0.000097174016,0.00046772306,0.00027923108,0.00012190166,0.0010379968,0.012661964],"study_design_scores_gemma":[0.0003955363,0.00010084431,0.0065237894,0.00972664,0.9816259,0.000073425916,0.000046632307,0.00012375915,0.00005956712,0.00013754814,0.0011588758,0.00002743004],"about_ca_topic_score_codex":0.011255015,"about_ca_topic_score_gemma":0.029910978,"teacher_disagreement_score":0.012576272,"about_ca_system_score_codex":0.0015163796,"about_ca_system_score_gemma":0.0022771433,"threshold_uncertainty_score":0.02638334},"labels":[],"label_agreement":null},{"id":"W2996164021","doi":"10.1016/j.clgc.2019.12.007","title":"Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Foundation Medicine; Genentech; Ipsen; Bayer; Calithera Biosciences; Bristol-Myers Squibb Canada; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; F. Hoffmann-La Roche; Pfizer Canada; Alexion Pharmaceuticals; Dana-Farber Cancer Institute; Roche; Novartis; Exelixis; Sanofi; Merck; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Hazard ratio; Discontinuation; Renal cell carcinoma; Internal medicine; Odds ratio; Oncology; Confidence interval; Retrospective cohort study; Kidney cancer","score_opus":0.03917808895234826,"score_gpt":0.3492407280194261,"score_spread":0.31006263906707787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996164021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018127,0.0066622323,0.000112111724,0.00032844482,0.00008111195,0.000023416358,0.0006709936,0.000010572815,0.0019297893],"genre_scores_gemma":[0.9980262,0.0006149463,0.000032076,0.00012568891,0.000060937633,0.000009353755,0.0008490311,0.0000025916343,0.00027906024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996562,0.000060821985,0.000040177307,0.00006552597,0.00006137084,0.00011596743],"domain_scores_gemma":[0.9989599,0.00022215178,0.00035351844,0.00003324048,0.000117535834,0.0003135876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049271324,0.00021137082,0.0008852088,0.0002929667,0.00038580789,0.0008264777,0.00025766937,0.00042495813,0.0013188877],"category_scores_gemma":[0.0022657767,0.00010783331,0.0016623861,0.000455665,0.00021086898,0.00063794653,0.00032977492,0.0008670258,0.00017517274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024328357,0.000730398,0.9043726,0.00037060597,0.0015093789,0.0006774625,0.00013454897,0.0024459483,0.0013236386,0.00016440617,0.002432888,0.06150983],"study_design_scores_gemma":[0.00076253474,0.006550737,0.98524284,0.00011035836,0.0014199466,0.0010639991,0.00020918043,0.0016411952,0.0006157887,0.00030244119,0.0020413962,0.000039600884],"about_ca_topic_score_codex":0.0025248516,"about_ca_topic_score_gemma":0.005596635,"teacher_disagreement_score":0.0025248516,"about_ca_system_score_codex":0.0011494905,"about_ca_system_score_gemma":0.0008018712,"threshold_uncertainty_score":0.00834018},"labels":[],"label_agreement":null},{"id":"W2996730987","doi":"10.1016/j.clgc.2019.12.001","title":"Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Cystectomy; Bladder cancer; Internal medicine; Oncology; Hazard ratio; Transitional cell carcinoma; Cancer; Urology; Surgery; Confidence interval","score_opus":0.07390756539667452,"score_gpt":0.3492164704109788,"score_spread":0.2753089050143043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996730987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719584,0.00093092653,0.00007052568,0.000050122544,0.000009399209,0.0000035409462,0.0006000008,0.0000029263513,0.0011367319],"genre_scores_gemma":[0.9987871,0.00029177577,0.000016885515,0.000023561131,0.000015886999,0.0000037468637,0.00068866886,0.0000013594929,0.00017113445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998054,0.000030465013,0.00001747956,0.000054494456,0.000022322396,0.00006981356],"domain_scores_gemma":[0.99959034,0.00010684592,0.00013032477,0.000027571852,0.00004669003,0.00009823385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026718128,0.00018131192,0.00037591832,0.00054959307,0.00041756904,0.0007035422,0.00026955162,0.00042457972,0.0020030607],"category_scores_gemma":[0.000877477,0.000087649816,0.00057539874,0.0010272576,0.00034320087,0.00045153286,0.00045930065,0.00041560942,0.0002688945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033686957,0.00009434442,0.98303115,0.000048528047,0.00030892156,0.00036640748,0.0002703798,0.0007196914,0.00073550525,0.00018621306,0.00033194528,0.010538169],"study_design_scores_gemma":[0.000029103006,0.0006069421,0.99677306,0.000010023899,0.00015856016,0.0006680842,0.0003463979,0.0003085917,0.00009371997,0.0001413655,0.00085460756,0.000009517193],"about_ca_topic_score_codex":0.0030349134,"about_ca_topic_score_gemma":0.003856532,"teacher_disagreement_score":0.0030349134,"about_ca_system_score_codex":0.00048965967,"about_ca_system_score_gemma":0.00023206402,"threshold_uncertainty_score":0.006700933},"labels":[],"label_agreement":null},{"id":"W2999047517","doi":"10.1016/j.clgc.2019.12.019","title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Pharmaceuticals; Bristol-Myers Squibb Canada; EMD Serono; Ipsen; Ferring Pharmaceuticals; Sanofi Genzyme; Merck Sharp and Dohme; Ferring; AstraZeneca; Invitae; Innocrin Pharmaceuticals; Astellas Pharma US; Flatiron Health; Dendreon Pharmaceuticals; Bayer Fund; Astellas Pharma Canada; F. Hoffmann-La Roche; Exelixis; Sanofi; Celgene; Novartis; Merck; Roche; American Association for Cancer Research; Amgen; Janssen Biotech; Johnson and Johnson; AcelRx Pharmaceuticals; Myovant Sciences; Pfizer; Bristol-Myers Squibb; Bayer; Calithera Biosciences; Constellation Energy Group","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Docetaxel; Prednisone; Abiraterone acetate; Internal medicine; Oncology; Confidence interval; Abiraterone; Clinical trial; Androgen deprivation therapy; Cancer","score_opus":0.10347877718998197,"score_gpt":0.4589470104597338,"score_spread":0.35546823326975185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999047517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963133,0.0008147964,0.00014861481,0.00034431674,0.00000805407,0.00003104518,0.0018699944,0.0000070628657,0.00046280463],"genre_scores_gemma":[0.99811363,0.00028676898,0.00018055634,0.00015413035,0.00001157341,0.000026414678,0.0011629706,0.0000026257417,0.00006131023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979145,0.00065036205,0.0004215168,0.0004914849,0.00034597385,0.00017621652],"domain_scores_gemma":[0.9914693,0.0010515283,0.0060214465,0.00026658285,0.00053796417,0.0006530682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013600269,0.00014923526,0.00034387683,0.0012375496,0.00047932393,0.0009329289,0.0004980538,0.00041166286,0.001098717],"category_scores_gemma":[0.0061507584,0.00025567712,0.00031432108,0.0029914945,0.00047209446,0.0007669692,0.0007069919,0.00058371003,0.00016456663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042300053,0.000032426327,0.99848145,0.000019187137,0.000041851003,0.000042570795,0.000109794084,0.000042884105,0.00002506341,0.00001912971,0.00022051773,0.0009227558],"study_design_scores_gemma":[0.000017305118,0.00008747175,0.99776316,0.000036136542,0.000024937532,0.00034636783,0.0007626578,0.0003737902,0.000041004536,0.00004570157,0.00049186376,0.000009575514],"about_ca_topic_score_codex":0.017973706,"about_ca_topic_score_gemma":0.027234558,"teacher_disagreement_score":0.017973706,"about_ca_system_score_codex":0.0013778388,"about_ca_system_score_gemma":0.0012773698,"threshold_uncertainty_score":0.03573823},"labels":[],"label_agreement":null},{"id":"W3000018687","doi":"10.1016/j.clgc.2019.12.018","title":"Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pfizer Canada; EMD Serono; Eisai; Bayer Canada; Bayer; Ipsen Biopharmaceuticals; Astellas Pharma Canada; AstraZeneca Canada; Janssen Canada; Sanofi; Bristol-Myers Squibb; AstraZeneca; Pfizer; Janssen Biotech; Canadian Institutes of Health Research; ESSA Pharma; BC Cancer Foundation; Roche; Astellas Pharma US","keywords":"Renal cell carcinoma; Medicine; BAP1; Somatic cell; Liquid biopsy; Cell-free fetal DNA; Germline; Oncology; Concordance; Germline mutation; Cancer research; Cancer; Internal medicine; Gene; Mutation; Biology; Genetics","score_opus":0.042431672381923524,"score_gpt":0.3125762196046652,"score_spread":0.27014454722274167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000018687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979284,0.00057217374,0.00019702867,0.00007840556,0.000009224007,0.00000433155,0.000081634695,0.000014231947,0.0011145462],"genre_scores_gemma":[0.99944526,0.00008157808,0.000116795156,0.000029482659,0.000020584963,0.0000026745029,0.00005269629,0.0000035106627,0.0002473287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983263,0.000037901475,0.000014946918,0.000028853228,0.000052035317,0.000033579003],"domain_scores_gemma":[0.99898773,0.0005432859,0.00016761225,0.00004361815,0.00008784436,0.00016987386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033478026,0.00016301067,0.00021059091,0.0012524406,0.00028774785,0.00048338066,0.0003145,0.00058182125,0.0025502453],"category_scores_gemma":[0.002463014,0.00018638013,0.000082378145,0.00070617266,0.00031678253,0.00034399683,0.00023722668,0.0004256938,0.00021021074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002361113,0.00017440639,0.9210192,0.000075505326,0.00004941566,0.0084158005,0.0005761268,0.00042210153,0.04355551,0.00043043826,0.00049484393,0.022425583],"study_design_scores_gemma":[0.000043150463,0.0005669553,0.9683132,0.000018075283,0.000056035566,0.019263344,0.00046745385,0.001929801,0.0076747355,0.00050405104,0.0011509643,0.000012143449],"about_ca_topic_score_codex":0.0013120414,"about_ca_topic_score_gemma":0.0012776922,"teacher_disagreement_score":0.0025502453,"about_ca_system_score_codex":0.00032158213,"about_ca_system_score_gemma":0.00026126305,"threshold_uncertainty_score":0.008531392},"labels":[],"label_agreement":null},{"id":"W3000024629","doi":"10.1016/j.clgc.2019.12.020","title":"A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Impact; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre","funders":"Sanofi","keywords":"Medicine; Brachytherapy; Prostate cancer; External beam radiotherapy; Dose fractionation; Radiation therapy; Randomized controlled trial; Prostate; Androgen deprivation therapy; Urology; Oncology; Nuclear medicine; Internal medicine; Cancer","score_opus":0.04768839545873921,"score_gpt":0.39801358100444806,"score_spread":0.35032518554570885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000024629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659999,0.004028288,0.0017527271,0.0019566605,0.0016501282,0.010069933,0.005008275,0.00045301818,0.009081108],"genre_scores_gemma":[0.944218,0.0038493236,0.0049955,0.004044378,0.0009899603,0.015927387,0.0070357276,0.00016587255,0.018773763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99942636,0.000313334,0.0000181443,0.00013087814,0.00003019268,0.00008114119],"domain_scores_gemma":[0.9993399,0.00014518554,0.00011796725,0.000068189605,0.000034011715,0.000294864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018037218,0.0028361373,0.003003936,0.00053421856,0.00050680665,0.0011428223,0.0014068875,0.0017619972,0.019987734],"category_scores_gemma":[0.0015161248,0.00079936907,0.0017520013,0.0006362161,0.0017538287,0.0012117358,0.0006674032,0.004713034,0.0027148318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9724401,0.008360545,0.00032664082,0.00035137899,0.00051179953,0.0000218926,0.000057481575,0.00049994874,0.002065623,0.00025599764,0.002236342,0.012872218],"study_design_scores_gemma":[0.96550614,0.03244199,0.0005612704,0.000015271831,0.00014823843,0.000016747348,0.000016518285,0.00023403458,0.00015322023,0.00022265514,0.00067558564,0.000008362753],"about_ca_topic_score_codex":0.0020020553,"about_ca_topic_score_gemma":0.004689052,"teacher_disagreement_score":0.019987734,"about_ca_system_score_codex":0.001001834,"about_ca_system_score_gemma":0.0021166378,"threshold_uncertainty_score":0.06686562},"labels":[],"label_agreement":null},{"id":"W3004761772","doi":"10.1016/j.clgc.2020.02.001","title":"Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa; Surgical Specialties (Canada); McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Chromophobe cell; Renal cell carcinoma; Logistic regression; Nephrectomy; Internal medicine; Carcinoma; Clear cell; Gastroenterology; Urology; Pathology; Oncology; Kidney","score_opus":0.09900866393972269,"score_gpt":0.3375998677825703,"score_spread":0.2385912038428476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004761772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976012,0.00057545834,0.00029268823,0.00013966484,0.00002169012,0.000007812913,0.00013877806,0.000009106588,0.0012135813],"genre_scores_gemma":[0.99916303,0.00015254371,0.00019104425,0.000030432291,0.000028207283,0.000003891757,0.00014172474,0.000005896222,0.00028319104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971527,0.000099007055,0.000033456447,0.000039241284,0.000066302164,0.000046751746],"domain_scores_gemma":[0.9987379,0.00042263008,0.0003111428,0.000082053535,0.00017761957,0.00026871546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006468111,0.00030584566,0.00048603318,0.00038898466,0.00030539755,0.000570905,0.0002693109,0.00040609317,0.001227881],"category_scores_gemma":[0.0034312247,0.00019122424,0.00042115658,0.0005126687,0.00022835944,0.00040803125,0.00025761192,0.00042424633,0.00024778294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017097822,0.000022575314,0.99562246,0.00000580483,0.000026581429,0.000062831925,0.000012002919,0.00017248052,0.00041676324,0.000009944488,0.00008975982,0.0033878414],"study_design_scores_gemma":[0.0000101084215,0.00012451292,0.996268,0.000006185433,0.00009335438,0.0005076212,0.00008077861,0.0021140072,0.00036021008,0.000087950175,0.00034221454,0.000005227039],"about_ca_topic_score_codex":0.0037741456,"about_ca_topic_score_gemma":0.012498076,"teacher_disagreement_score":0.0037741456,"about_ca_system_score_codex":0.00025524065,"about_ca_system_score_gemma":0.00048458917,"threshold_uncertainty_score":0.007504344},"labels":[],"label_agreement":null},{"id":"W3004971171","doi":"10.1016/j.clgc.2020.01.007","title":"Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Cystectomy; Bladder cancer; Hazard ratio; Oncology; Internal medicine; Odds ratio; Proportional hazards model; Chemotherapy; Cancer; Adenocarcinoma; Neoadjuvant therapy; Urology; Population; Gastroenterology; Confidence interval","score_opus":0.038623644687281564,"score_gpt":0.32093572236471685,"score_spread":0.28231207767743527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004971171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994286,0.00015368072,0.00002513532,0.000016159764,0.0000045335983,0.0000038608327,0.00020862042,0.0000012191987,0.00015826945],"genre_scores_gemma":[0.9994363,0.00006556587,0.000017457965,0.000017702254,0.000010536853,0.0000045909783,0.00036736444,0.0000012117929,0.00007922569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951386,0.00012723003,0.000053699674,0.00012489097,0.00005157966,0.0001286889],"domain_scores_gemma":[0.9988085,0.00018177295,0.00048728913,0.000102817554,0.00009518941,0.0003244331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047635168,0.00040849167,0.000536678,0.00081322016,0.00072495494,0.0008354895,0.00042363835,0.00062550616,0.0015944184],"category_scores_gemma":[0.0013710539,0.00037985956,0.00095998147,0.0015089536,0.00047213765,0.00076106936,0.00074934534,0.00061271107,0.00021420757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030159668,0.000031029398,0.99906653,0.000004128069,0.000065279986,0.000046219207,0.000029260857,0.000029078785,0.00010518795,0.000006237683,0.000032452568,0.00028297876],"study_design_scores_gemma":[0.000012063222,0.000114659146,0.9992009,0.000002854153,0.0000635702,0.00017814817,0.0001935629,0.000089145775,0.000036917754,0.000014850743,0.0000877827,0.000005542093],"about_ca_topic_score_codex":0.0050057885,"about_ca_topic_score_gemma":0.0065789456,"teacher_disagreement_score":0.0050057885,"about_ca_system_score_codex":0.00056061725,"about_ca_system_score_gemma":0.00071063783,"threshold_uncertainty_score":0.00995326},"labels":[],"label_agreement":null},{"id":"W3009221479","doi":"10.1016/j.clgc.2020.02.011","title":"Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Biochemical recurrence; Prostate cancer; Meta-analysis; Hazard ratio; Surgical margin; Confidence interval; Oncology; Radiation therapy; Internal medicine; Systematic review; MEDLINE; Urology; Cancer","score_opus":0.14183398920565934,"score_gpt":0.4451487956099993,"score_spread":0.30331480640433994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009221479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039222757,0.99484456,0.00029325386,0.00011379458,0.00010806412,0.00006796015,0.00046449905,0.000020413727,0.00016509948],"genre_scores_gemma":[0.14273752,0.85339046,0.001309189,0.0009401776,0.00023015468,0.00024518237,0.00068312284,0.000030991392,0.00043326998],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99708277,0.0011083429,0.0008010672,0.00051951426,0.00031990703,0.000168493],"domain_scores_gemma":[0.9939335,0.0043527037,0.00095399533,0.00023214586,0.00039377384,0.00013382923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004644854,0.002464234,0.012944132,0.003697772,0.00051220664,0.0023717256,0.0019905432,0.0023195578,0.0048847473],"category_scores_gemma":[0.012821546,0.0015440608,0.027756618,0.005731741,0.00063100253,0.0017915409,0.0017378067,0.0022667213,0.0005084232],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017552654,0.00003485044,0.0076682237,0.32006562,0.6543227,0.00015645972,0.00010944139,0.00046308083,0.0003004595,0.00011522926,0.0010316537,0.013977022],"study_design_scores_gemma":[0.00043389513,0.000107659354,0.005482057,0.012280624,0.9798797,0.00007919482,0.000050403618,0.000108297085,0.000059810467,0.00014882545,0.0013395587,0.000030016394],"about_ca_topic_score_codex":0.01046955,"about_ca_topic_score_gemma":0.02853998,"teacher_disagreement_score":0.012944132,"about_ca_system_score_codex":0.0013680859,"about_ca_system_score_gemma":0.002482181,"threshold_uncertainty_score":0.024564624},"labels":[],"label_agreement":null},{"id":"W3009812442","doi":"10.1016/j.clgc.2020.02.005","title":"A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer","year":2020,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Mount Sinai Hospital; University of Calgary","funders":"Janssen Biotech; Astellas Pharma Canada; Bayer","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Meta-analysis; Oncology; Enzalutamide; Subgroup analysis; Androgen deprivation therapy; Randomized controlled trial; Placebo; Confidence interval; Androgen receptor; Cancer; Pathology","score_opus":0.22681532087135517,"score_gpt":0.4784924576525275,"score_spread":0.2516771367811723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009812442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002564319,0.9956709,0.0003805859,0.00015064992,0.00014044488,0.00013148169,0.00063350395,0.000021436508,0.00030658348],"genre_scores_gemma":[0.11840061,0.87681943,0.0016214593,0.0011925327,0.00020622564,0.00040125567,0.0008587591,0.000033090164,0.00046657913],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99467164,0.002415874,0.0014770908,0.00064510544,0.0005704359,0.00021986243],"domain_scores_gemma":[0.99277264,0.0051451013,0.001204124,0.00022412982,0.0005157063,0.0001383646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061842063,0.0022164593,0.014287506,0.0043792585,0.0004832393,0.0023416781,0.0017868512,0.0014973197,0.0051109116],"category_scores_gemma":[0.018782893,0.0011323823,0.02324442,0.0065687257,0.0004992228,0.0015900885,0.0016065959,0.0019073852,0.0004298614],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018381026,0.000022414519,0.002682636,0.4000329,0.5774101,0.00012181967,0.000077535115,0.0004945608,0.00026276713,0.00016976851,0.001276568,0.015610803],"study_design_scores_gemma":[0.0007689466,0.00011921695,0.0029276283,0.021676615,0.97125816,0.00007916992,0.000035635538,0.00010968398,0.00005676292,0.00021132786,0.0027326886,0.000024080706],"about_ca_topic_score_codex":0.012168537,"about_ca_topic_score_gemma":0.036460355,"teacher_disagreement_score":0.014287506,"about_ca_system_score_codex":0.0023488766,"about_ca_system_score_gemma":0.0032010572,"threshold_uncertainty_score":0.032705605},"labels":[],"label_agreement":null},{"id":"W3024665518","doi":"10.1016/j.clgc.2020.05.004","title":"Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Eisai; Astellas Pharma; British Microcirculation Society; Merck Sharp and Dohme; Janssen Biotech; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Ipsen; Pharmacyclics; Astellas Pharma Canada; Sanofi España; Sanofi; GlaxoSmithKline Japan; Boehringer Ingelheim; Roche; Novartis; Bayer; University of Bristol; Merck; Novartis Farmacéutica; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Pfizer; Takeda Pharmaceutical Company","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Internal medicine; Urothelial cancer; Overall survival; Cancer; Bladder cancer","score_opus":0.08429556182043416,"score_gpt":0.40567108539705654,"score_spread":0.32137552357662236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024665518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916897,0.0046310956,0.00031118575,0.00024784944,0.00008362881,0.00015031883,0.0020968816,0.000028477538,0.00076086575],"genre_scores_gemma":[0.99262625,0.00090899656,0.00044403208,0.00031239237,0.00006797093,0.00014558536,0.004886247,0.000037009188,0.00057155715],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99847883,0.0010614522,0.00005802342,0.00014960149,0.00009363412,0.00015843468],"domain_scores_gemma":[0.99853706,0.00054932234,0.00023253726,0.00015966193,0.000089884816,0.00043150224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054861205,0.0010463154,0.0025114003,0.00054662494,0.00029124203,0.0012684949,0.0008389518,0.0008466049,0.00141047],"category_scores_gemma":[0.0026162758,0.00036308318,0.004192215,0.0005739828,0.0005119648,0.00083441293,0.00072398357,0.0016725655,0.00020494885],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8300577,0.002743216,0.076770335,0.0009784065,0.014288075,0.00012899633,0.00021722188,0.008059281,0.0071995743,0.00032188906,0.004699727,0.05453565],"study_design_scores_gemma":[0.20532145,0.2138057,0.5316792,0.00029816132,0.027201677,0.0004267064,0.00035292795,0.009695917,0.003097642,0.0010147265,0.006962227,0.00014366991],"about_ca_topic_score_codex":0.001865171,"about_ca_topic_score_gemma":0.0046196342,"teacher_disagreement_score":0.0054861205,"about_ca_system_score_codex":0.00095068564,"about_ca_system_score_gemma":0.0012410318,"threshold_uncertainty_score":0.029013693},"labels":[],"label_agreement":null},{"id":"W3024966661","doi":"10.1016/j.clgc.2020.05.006","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Bristol-Myers Squibb Canada; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Daiichi-Sankyo; Pfizer; Moderna; Five Prime Therapeutics; Mirati Therapeutics; Clovis Oncology; Roche; Karyopharm Therapeutics; Novartis; AbbVie; Sanofi; MedImmune; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Chromophobe cell; Nivolumab; Internal medicine; Renal cell carcinoma; Adverse effect; Regimen; Gastroenterology; Clinical endpoint; Phases of clinical research; Rash; Clear cell; Urology; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","score_opus":0.03434760163426389,"score_gpt":0.31876612176908636,"score_spread":0.2844185201348225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024966661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421126,0.0029878104,0.00015919677,0.00014971562,0.000027655202,0.00030151778,0.0009850917,0.000026497542,0.0011512825],"genre_scores_gemma":[0.99466574,0.00086143013,0.00038037903,0.0003828779,0.00003808387,0.00020113924,0.0027897682,0.000010974611,0.00066961517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996008,0.00018343558,0.000027544571,0.000059861948,0.00008328766,0.000045053726],"domain_scores_gemma":[0.99920744,0.00016410933,0.00020024541,0.00007063055,0.00011778614,0.00023979567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017272186,0.0003536368,0.0007053884,0.00015442065,0.00022017474,0.0005870484,0.00043113806,0.00044780155,0.0015777901],"category_scores_gemma":[0.0010304124,0.00014257045,0.0007251709,0.00018474934,0.0002981858,0.00027007973,0.0002032457,0.00072232547,0.00030274098],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42916533,0.013699951,0.22775951,0.0023181036,0.0056009004,0.00039302706,0.00043985216,0.00510671,0.067750424,0.00043660912,0.014649269,0.23268034],"study_design_scores_gemma":[0.2103009,0.23856595,0.4953885,0.00028924795,0.0039829784,0.00113255,0.00019117795,0.005768894,0.01868092,0.00051353296,0.025067043,0.00011834936],"about_ca_topic_score_codex":0.0022820495,"about_ca_topic_score_gemma":0.0048430855,"teacher_disagreement_score":0.0022820495,"about_ca_system_score_codex":0.0013317328,"about_ca_system_score_gemma":0.0015034046,"threshold_uncertainty_score":0.009662449},"labels":[],"label_agreement":null},{"id":"W3026350312","doi":"10.1016/j.clgc.2020.05.009","title":"Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal","funders":"","keywords":"Medicine; Propensity score matching; Renal cell carcinoma; Hazard ratio; Cohort; Nephrectomy; Internal medicine; Proportional hazards model; Clinical endpoint; Urology; Oncology; Population; Surgery; Randomized controlled trial; Kidney; Confidence interval","score_opus":0.1313542326888146,"score_gpt":0.3565032904072205,"score_spread":0.2251490577184059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026350312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9443111,0.044329785,0.0013777951,0.0020410842,0.0003444803,0.000030430956,0.0002184146,0.00006248863,0.0072844843],"genre_scores_gemma":[0.992698,0.0055766134,0.00037033894,0.00024284582,0.00025088433,0.0000060098782,0.00028317192,0.0000073845895,0.00056479155],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99994576,0.000012258233,0.0000038660664,0.000011675746,0.000016312488,0.000010102915],"domain_scores_gemma":[0.9998963,0.000033211407,0.000019750241,0.000012856729,0.000011340852,0.000026575208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020812407,0.00015630289,0.00029098697,0.00011920895,0.0001468638,0.0002852763,0.00016388905,0.00015663503,0.0015693868],"category_scores_gemma":[0.0005003299,0.000051326962,0.00028164499,0.00020860106,0.00022594116,0.00024233495,0.000118107346,0.000442068,0.00012984734],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0151591655,0.0015004326,0.062673226,0.0013150537,0.00076018326,0.0011075003,0.00023164554,0.011036135,0.061608594,0.0025958873,0.009401681,0.8326105],"study_design_scores_gemma":[0.0032283752,0.028822917,0.85262656,0.00033021535,0.0014987725,0.0065542185,0.00043664564,0.013033545,0.020870468,0.0047454904,0.067800395,0.000052410196],"about_ca_topic_score_codex":0.001502425,"about_ca_topic_score_gemma":0.00613505,"teacher_disagreement_score":0.0015693868,"about_ca_system_score_codex":0.0004813716,"about_ca_system_score_gemma":0.00028197546,"threshold_uncertainty_score":0.005250156},"labels":[],"label_agreement":null},{"id":"W3029830108","doi":"10.1016/j.clgc.2020.05.013","title":"A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Astellas Pharma; Bayer Fund; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Genentech; Valeant Pharmaceuticals International; Merck; Astellas Pharma US; Society for Immunotherapy of Cancer; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Sunitinib; Dasatinib; Prostate cancer; Hazard ratio; Internal medicine; Oncology; Abiraterone acetate; Clinical endpoint; Randomized controlled trial; Androgen deprivation therapy; Urology; Docetaxel; Confidence interval; Cancer; Tyrosine kinase","score_opus":0.12002647259925224,"score_gpt":0.45093749650814924,"score_spread":0.330911023908897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029830108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98712677,0.0016431342,0.000847927,0.0010711938,0.0008251343,0.004220964,0.0010812136,0.00020961261,0.0029741344],"genre_scores_gemma":[0.98617804,0.0008894022,0.0020984977,0.0010397729,0.00038371567,0.004286164,0.0010782204,0.000050921768,0.003995211],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99911684,0.00041936047,0.000040595118,0.0002026669,0.000049986116,0.00017049817],"domain_scores_gemma":[0.9987929,0.0003079633,0.00018006066,0.0001284801,0.000053514214,0.00053720974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018240189,0.0020095787,0.0025495212,0.0005912675,0.000603232,0.0011105081,0.000876534,0.0017685352,0.01034382],"category_scores_gemma":[0.0024039575,0.00079589715,0.0019011996,0.0004403495,0.0013406071,0.0012884162,0.000527668,0.004220924,0.0016091786],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9745831,0.008579963,0.0003675974,0.0001553903,0.0003559288,0.000027282864,0.00005889778,0.00058943435,0.0016725528,0.00011485474,0.00075626717,0.0127387475],"study_design_scores_gemma":[0.928213,0.069115326,0.0010172015,0.000011244981,0.00013486343,0.00003309291,0.000021328848,0.00044793394,0.00027575783,0.00023240634,0.00048140145,0.000016465787],"about_ca_topic_score_codex":0.0015888566,"about_ca_topic_score_gemma":0.0038866007,"teacher_disagreement_score":0.01034382,"about_ca_system_score_codex":0.0010601948,"about_ca_system_score_gemma":0.00205199,"threshold_uncertainty_score":0.034603536},"labels":[],"label_agreement":null},{"id":"W3036074908","doi":"10.1016/j.clgc.2020.06.005","title":"Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Interquartile range; Hazard ratio; Bladder cancer; Internal medicine; Chemoradiotherapy; Cancer; Urology; Surgery; Confidence interval","score_opus":0.09806510995669171,"score_gpt":0.4090351033570236,"score_spread":0.3109699934003319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036074908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888621,0.0059397165,0.00020337224,0.002255921,0.000094029085,0.000015545464,0.00028234845,0.000007520279,0.002339432],"genre_scores_gemma":[0.9984694,0.00088879955,0.00006701781,0.0001866671,0.000048043235,0.000005921748,0.00018991722,0.000002829491,0.00014132414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966204,0.00007026527,0.000033008448,0.000055384702,0.000042158536,0.0001371275],"domain_scores_gemma":[0.9985839,0.0002825382,0.00062732166,0.000039300485,0.00010502461,0.00036190127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041900255,0.00011245746,0.0002881418,0.00019655468,0.00048308427,0.0008315453,0.0002980454,0.0003659788,0.0016339234],"category_scores_gemma":[0.004357677,0.00007711551,0.00047365853,0.00043917305,0.00019359305,0.00067718263,0.00060068694,0.0007017225,0.0000885548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033072906,0.00045447197,0.89052534,0.00025896553,0.00036995785,0.00050046085,0.00048309134,0.0018402289,0.0011336581,0.0004948127,0.0026844156,0.09794725],"study_design_scores_gemma":[0.00013494982,0.0019583441,0.9869263,0.00025096867,0.00030597826,0.0011492985,0.0017472334,0.0019002656,0.00050202187,0.00083132286,0.0042669764,0.000026400267],"about_ca_topic_score_codex":0.005478594,"about_ca_topic_score_gemma":0.011636086,"teacher_disagreement_score":0.005478594,"about_ca_system_score_codex":0.0011757823,"about_ca_system_score_gemma":0.0015513699,"threshold_uncertainty_score":0.0108934045},"labels":[],"label_agreement":null},{"id":"W3043096196","doi":"10.1016/j.clgc.2020.07.011","title":"Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Cystectomy; Bladder cancer; Oncology; Internal medicine; Cancer; Hazard ratio; Urinary bladder; Carcinoma; Adenocarcinoma; Urology; Confidence interval","score_opus":0.14080938582434996,"score_gpt":0.42606383480198334,"score_spread":0.2852544489776334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043096196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861661,0.008359391,0.0004670464,0.00019493766,0.00005961319,0.000040815354,0.0018263691,0.000014503201,0.0028712398],"genre_scores_gemma":[0.9979243,0.00065304403,0.0001254659,0.00005962731,0.000025941872,0.000008647963,0.0007765136,0.000008194335,0.00041825676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986909,0.00040258386,0.00013364086,0.00029303812,0.0002523657,0.00022740274],"domain_scores_gemma":[0.99815,0.00049678533,0.0007304141,0.0001345673,0.0002514899,0.00023671615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016056914,0.0002811063,0.00075804966,0.0013348286,0.00032126528,0.0009388716,0.00050673157,0.0004605293,0.003582418],"category_scores_gemma":[0.0037703146,0.00015858933,0.0016985615,0.0013629885,0.00030594863,0.0011063141,0.0011121124,0.00045655432,0.0002498926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009660462,0.00013304573,0.95431185,0.00036732602,0.0027568454,0.00012479945,0.00022029222,0.0004055223,0.0023921356,0.00020616414,0.0006347194,0.02878701],"study_design_scores_gemma":[0.00004872912,0.0009116365,0.99641955,0.000050156606,0.0006537355,0.00021070735,0.00041311898,0.00018205939,0.00013861065,0.00011324016,0.00085102045,0.000007324444],"about_ca_topic_score_codex":0.003940882,"about_ca_topic_score_gemma":0.009279807,"teacher_disagreement_score":0.003940882,"about_ca_system_score_codex":0.00046767786,"about_ca_system_score_gemma":0.00042342133,"threshold_uncertainty_score":0.011984408},"labels":[],"label_agreement":null},{"id":"W3093155264","doi":"10.1016/j.clgc.2020.10.001","title":"Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chemotherapy; Adverse effect; Bladder cancer; Perioperative; Gemcitabine; Internal medicine; Oncology; Urology; Cancer; Surgery","score_opus":0.13380061401930163,"score_gpt":0.4132333197204557,"score_spread":0.2794327057011541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093155264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98427606,0.0006930112,0.01054579,0.00037273683,0.00005882157,0.00009552382,0.00024347847,0.000026699709,0.0036878856],"genre_scores_gemma":[0.9931463,0.00042544075,0.0023830868,0.00013827183,0.000021565851,0.0001587659,0.00015030865,0.00000801411,0.0035683687],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998882,0.000040536906,0.0000031878692,0.000020689578,0.000008514242,0.00003884116],"domain_scores_gemma":[0.9996401,0.00019655122,0.00009151891,0.000013930679,0.000014945038,0.00004301842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035398453,0.00056144904,0.0006133977,0.00017758133,0.000121241384,0.00045016085,0.0005868817,0.00038561394,0.0029385695],"category_scores_gemma":[0.00064633694,0.00014220564,0.0005883126,0.00012213021,0.00028272704,0.0003387428,0.00027619637,0.0005680437,0.00019192384],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010549992,0.0044653527,0.004627243,0.0003873759,0.00032381382,0.0002795054,0.00009273865,0.84630346,0.07609324,0.022053579,0.0015324742,0.03329121],"study_design_scores_gemma":[0.00086481246,0.00889072,0.0026048599,0.000028848364,0.0004440246,0.00008216175,0.00006581835,0.97172076,0.008979746,0.004739007,0.0015480514,0.00003116748],"about_ca_topic_score_codex":0.002029899,"about_ca_topic_score_gemma":0.0017610766,"teacher_disagreement_score":0.0029385695,"about_ca_system_score_codex":0.00051866524,"about_ca_system_score_gemma":0.00070832885,"threshold_uncertainty_score":0.009830475},"labels":[],"label_agreement":null},{"id":"W3098898455","doi":"10.1016/j.clgc.2020.11.003","title":"Improving the Stratification of Patients With Intermediate-risk Prostate Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Risk stratification; Prostate cancer; Stratification (seeds); Prostate; Cancer; Oncology; Internal medicine","score_opus":0.035170907386635294,"score_gpt":0.33033798943828435,"score_spread":0.29516708205164904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3098898455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93752384,0.017771332,0.0050111776,0.016296452,0.00096350594,0.00033119065,0.0016992583,0.00018690887,0.020216452],"genre_scores_gemma":[0.99068636,0.0018913456,0.003164123,0.0016507208,0.0005148828,0.000045930756,0.0009947348,0.000018789928,0.0010330849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987814,0.00052307145,0.00013801146,0.00014767505,0.00022433542,0.0001855616],"domain_scores_gemma":[0.9981316,0.0005942126,0.00030075922,0.00013213599,0.00046274546,0.00037859494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018000287,0.0005383798,0.00088608265,0.0009365366,0.0007526213,0.0019467162,0.00078894035,0.0008751075,0.0031337286],"category_scores_gemma":[0.009024356,0.00020808855,0.00082399166,0.0007591253,0.00021325405,0.00097466813,0.0011285926,0.001782361,0.00065575074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012207634,0.0005255452,0.829447,0.00016588959,0.00024053105,0.00014716822,0.00018708743,0.0010329073,0.0007632574,0.00051160617,0.010315704,0.15544257],"study_design_scores_gemma":[0.0002711455,0.0012426566,0.9619084,0.00036741406,0.0009624676,0.00060851086,0.0009551628,0.0097244205,0.0014426443,0.0042853956,0.018167397,0.00006432659],"about_ca_topic_score_codex":0.00618705,"about_ca_topic_score_gemma":0.0138856815,"teacher_disagreement_score":0.00618705,"about_ca_system_score_codex":0.00073285634,"about_ca_system_score_gemma":0.001495822,"threshold_uncertainty_score":0.012302101},"labels":[],"label_agreement":null},{"id":"W3100270977","doi":"10.1016/j.clgc.2020.10.008","title":"Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Incidence (geometry); Obesity; Life expectancy; Population; Kidney cancer; Artificial neural network; Renal cell carcinoma; Demography; Environmental health; Internal medicine; Machine learning; Computer science; Mathematics","score_opus":0.07402055290459694,"score_gpt":0.373951521271211,"score_spread":0.29993096836661404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100270977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96985483,0.0029146753,0.0062144557,0.0038921814,0.00029232577,0.000039447612,0.008602132,0.00017113786,0.008018836],"genre_scores_gemma":[0.9950777,0.00062609394,0.0013221061,0.000125744,0.000045394034,0.000012944432,0.0018427626,0.000006154145,0.0009410021],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997522,0.00011161892,0.000019656907,0.000037297414,0.000056318004,0.000022802322],"domain_scores_gemma":[0.9984829,0.0008395756,0.00025564496,0.000038715614,0.00028559237,0.0000975645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078234804,0.00022569892,0.00018834669,0.0010543962,0.00014982512,0.0006117585,0.00033854521,0.0004074012,0.0012720113],"category_scores_gemma":[0.0045366054,0.00012860169,0.00029889194,0.001023903,0.00012205489,0.00041177587,0.00025805488,0.0006498558,0.000200474],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030401573,0.00025749195,0.89778155,0.00005651953,0.00023903922,0.00006940985,0.000045623176,0.059029687,0.00014007221,0.0007216549,0.0065887994,0.034766093],"study_design_scores_gemma":[0.000056844958,0.00018188615,0.37936455,0.0000777197,0.00016696971,0.00009793147,0.00026779016,0.6133776,0.00048119598,0.0027472083,0.0031544848,0.000025906134],"about_ca_topic_score_codex":0.044909377,"about_ca_topic_score_gemma":0.06607627,"teacher_disagreement_score":0.044909377,"about_ca_system_score_codex":0.00087664556,"about_ca_system_score_gemma":0.0007092502,"threshold_uncertainty_score":0.08929598},"labels":[],"label_agreement":null},{"id":"W3108115906","doi":"10.1016/j.clgc.2020.11.004","title":"Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Urology; Upper urinary tract; Adenocarcinoma; Internal medicine; Odds ratio; Oncology; Cancer; Urinary system","score_opus":0.10736175486310746,"score_gpt":0.38198908150011895,"score_spread":0.2746273266370115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108115906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9021721,0.07751767,0.0010042016,0.001585212,0.0003839619,0.000020543735,0.00057019887,0.000029751833,0.01671641],"genre_scores_gemma":[0.9923666,0.0057373736,0.00037990828,0.00020328548,0.00023121075,0.0000023654075,0.00018483141,0.0000052127552,0.00088919955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977905,0.00007305085,0.000021921422,0.000034593366,0.0000491028,0.000042264965],"domain_scores_gemma":[0.99949753,0.00012715977,0.00018792064,0.000019653771,0.0000638519,0.00010388045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045991683,0.00018512088,0.0003740498,0.00056985626,0.00019192658,0.0009720363,0.00019747477,0.00027400628,0.003123518],"category_scores_gemma":[0.0013879925,0.00006314297,0.00022941439,0.001136208,0.00040009452,0.0004600015,0.00026253678,0.00030476143,0.00022478472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021742727,0.000107455424,0.8293653,0.0004630777,0.00024472317,0.001008181,0.00018702085,0.00037297132,0.0044701486,0.0024369436,0.0022731735,0.15689668],"study_design_scores_gemma":[0.00010772297,0.0012940294,0.97357583,0.00035952684,0.00034083266,0.006831853,0.001010852,0.00089610263,0.00095014484,0.0022191873,0.012389424,0.000024335468],"about_ca_topic_score_codex":0.0016824483,"about_ca_topic_score_gemma":0.004427468,"teacher_disagreement_score":0.003123518,"about_ca_system_score_codex":0.00035478236,"about_ca_system_score_gemma":0.0003687582,"threshold_uncertainty_score":0.010449231},"labels":[],"label_agreement":null},{"id":"W3120326425","doi":"10.1016/j.clgc.2020.12.001","title":"Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Cumulative incidence; Cancer; Incidence (geometry); Adenocarcinoma; Epidemiology; Proportional hazards model; Disease; Cancer registry; Oncology; Gynecology; Cohort","score_opus":0.061875441818343604,"score_gpt":0.3911019798275126,"score_spread":0.329226538009169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120326425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996974,0.001178846,0.000038994385,0.00014314396,0.000022048707,0.0000030157205,0.00030620664,0.0000031434106,0.0013305527],"genre_scores_gemma":[0.99899715,0.00022310807,0.000015267067,0.000059737544,0.000016867016,0.0000014774288,0.00018394581,0.0000024093638,0.0004999622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999767,0.000046098452,0.000023213006,0.000042092695,0.00002742665,0.0000941875],"domain_scores_gemma":[0.9992613,0.0001838536,0.0002460822,0.000042442844,0.000058187634,0.00020819539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024475428,0.00013905809,0.00024974108,0.00035636674,0.0003204904,0.0005486005,0.00017746403,0.00036089597,0.0050396724],"category_scores_gemma":[0.0019672166,0.0001445398,0.00056708645,0.00062418793,0.0001666957,0.0004172227,0.00033163285,0.0004352414,0.0003272578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032284894,0.000025315832,0.9957711,0.000009724455,0.00006529939,0.00010190281,0.00006942353,0.00003282101,0.0002226637,0.00003936493,0.00015278107,0.003186713],"study_design_scores_gemma":[0.000006593181,0.000082395156,0.9990023,0.0000070552537,0.00003237796,0.00021910104,0.00020045973,0.000080355785,0.00004330886,0.00006528551,0.0002575324,0.0000032933208],"about_ca_topic_score_codex":0.0027953095,"about_ca_topic_score_gemma":0.006926538,"teacher_disagreement_score":0.0050396724,"about_ca_system_score_codex":0.00021011957,"about_ca_system_score_gemma":0.00036760097,"threshold_uncertainty_score":0.016859353},"labels":[],"label_agreement":null},{"id":"W3126428342","doi":"10.1016/j.clgc.2021.01.007","title":"The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University Health Centre; Ministère de la Santé et des Services sociaux; McGill University","keywords":"Medicine; Bladder cancer; Cystectomy; Hazard ratio; Proportional hazards model; Propensity score matching; Internal medicine; Retrospective cohort study; Confidence interval; Surgery; Cancer; Oncology; Urology","score_opus":0.05813035974551425,"score_gpt":0.36739308850707963,"score_spread":0.3092627287615654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126428342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980888,0.005791526,0.000084903266,0.0028724428,0.00015636919,0.00004699175,0.0024306965,0.000015738766,0.007713386],"genre_scores_gemma":[0.9967257,0.0010623346,0.00004956551,0.00040244803,0.00004052721,0.000005946973,0.0006666862,0.0000034523046,0.0010433224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954826,0.000080957136,0.000029578216,0.00006164653,0.00011087554,0.00016865565],"domain_scores_gemma":[0.99808097,0.00022418215,0.00048413972,0.000039104943,0.0005323298,0.0006392491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040076402,0.0002000789,0.00052817573,0.00031237182,0.0011031979,0.00084285834,0.00065836764,0.00046917392,0.0036362163],"category_scores_gemma":[0.002340893,0.00013418528,0.0007237535,0.0011026501,0.00033889204,0.00028781316,0.00027070747,0.00068669085,0.00021396097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078683964,0.00008772177,0.98537153,0.00006541978,0.0001699772,0.0001456865,0.00011731452,0.00018970865,0.00025758825,0.00006807876,0.0026185035,0.010121577],"study_design_scores_gemma":[0.000052025123,0.00012508858,0.9984668,0.000037901747,0.00011601629,0.00004137607,0.00028522685,0.00018908792,0.000031407537,0.000016211341,0.00063090015,0.000007834075],"about_ca_topic_score_codex":0.9394546,"about_ca_topic_score_gemma":0.9831154,"teacher_disagreement_score":0.060545385,"about_ca_system_score_codex":0.009727616,"about_ca_system_score_gemma":0.013673,"threshold_uncertainty_score":0.12180382},"labels":[],"label_agreement":null},{"id":"W3136768966","doi":"10.1016/j.clgc.2021.03.006","title":"Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Pfizer Canada; Genentech; Astellas Pharma; Bristol-Myers Squibb Canada; Eisai; Ipsen; Astellas Pharma Canada; Roche; EMD Serono; Novartis; AstraZeneca; Amgen; Pfizer; Exelixis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Clinical Oncology; Kidney cancer; Cancer","score_opus":0.0731584245030044,"score_gpt":0.40543841801258984,"score_spread":0.3322799935095854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136768966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986922,0.0007923752,0.000037094287,0.000023838169,0.0000034292655,0.000018647092,0.00025384806,0.0000024769517,0.00017606565],"genre_scores_gemma":[0.9991935,0.00020135252,0.000048579346,0.000032109754,0.000014502871,0.0000137034785,0.00046327536,0.0000011664564,0.000031770367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858356,0.00051792955,0.00017398554,0.00033938317,0.00026429398,0.00012090028],"domain_scores_gemma":[0.99510396,0.0008652742,0.0031347945,0.00019049327,0.00026201297,0.00044341854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016414039,0.0002861125,0.0007623397,0.00051090133,0.0003520316,0.0009999927,0.00043040529,0.0005372208,0.00089569925],"category_scores_gemma":[0.0034005484,0.00017606678,0.0009045398,0.00070352474,0.00035157785,0.0005960242,0.0003657401,0.0004277868,0.0002024141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019218732,0.00023466747,0.99350834,0.000074614545,0.00025878297,0.00014051575,0.0000555991,0.00015582256,0.00023180127,0.000009176027,0.00009492642,0.0033138865],"study_design_scores_gemma":[0.00031473907,0.0030997759,0.99342984,0.000025310588,0.00025102138,0.0012326018,0.000117617805,0.000610346,0.0002852162,0.000014722929,0.0006041175,0.000014749701],"about_ca_topic_score_codex":0.0016671846,"about_ca_topic_score_gemma":0.0022699004,"teacher_disagreement_score":0.0016671846,"about_ca_system_score_codex":0.0009048114,"about_ca_system_score_gemma":0.0005778113,"threshold_uncertainty_score":0.008680701},"labels":[],"label_agreement":null},{"id":"W3138725098","doi":"10.1016/j.clgc.2021.03.015","title":"Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Interquartile range; Prostate cancer; Prostatectomy; Stage (stratigraphy); Epidemiology; Proportional hazards model; Surveillance, Epidemiology, and End Results; Internal medicine; Cancer; Oncology; Urology; Cancer registry","score_opus":0.052553990776346114,"score_gpt":0.39787147044985366,"score_spread":0.34531747967350757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138725098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98002076,0.0017057235,0.00035631776,0.00038588617,0.00003374274,0.000018952944,0.015603663,0.00004698048,0.0018280067],"genre_scores_gemma":[0.99255025,0.00026698623,0.000093088536,0.000083233885,0.000021544749,0.000009690248,0.006598505,0.000011432044,0.0003654091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983,0.00036649598,0.00023633463,0.0005096296,0.00020810521,0.00037933543],"domain_scores_gemma":[0.9949704,0.00068493834,0.0026721784,0.0006923972,0.00038015566,0.00060003635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001852764,0.00025613632,0.00079218723,0.0011895065,0.0005021634,0.001277607,0.00071400387,0.0007245858,0.0046954765],"category_scores_gemma":[0.006922957,0.0004328798,0.0015365471,0.004046926,0.00032535146,0.0016722947,0.0013550847,0.00085234,0.00052344776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013272837,0.000019950605,0.9966822,0.000018288194,0.00028105805,0.000037402035,0.000051573817,0.0001695229,0.000055706972,0.00007744407,0.00093123317,0.0015427708],"study_design_scores_gemma":[0.0000094536945,0.000035581368,0.99878985,0.00001360317,0.00010597925,0.00014053083,0.00017522852,0.00020124277,0.00001942612,0.00007287446,0.00043130555,0.000004928105],"about_ca_topic_score_codex":0.015982555,"about_ca_topic_score_gemma":0.029300367,"teacher_disagreement_score":0.015982555,"about_ca_system_score_codex":0.0005588327,"about_ca_system_score_gemma":0.0012881536,"threshold_uncertainty_score":0.03177905},"labels":[],"label_agreement":null},{"id":"W3146689657","doi":"10.1016/j.clgc.2021.03.010","title":"Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Urology; Lymph node; Hazard ratio; Chemotherapy; Proportional hazards model; Internal medicine; Stage (stratigraphy); Dissection (medical); Surgery; Cancer; Confidence interval","score_opus":0.0627656918527785,"score_gpt":0.4133542788830282,"score_spread":0.35058858703024975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146689657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837095,0.0008878652,0.00010647546,0.000037163212,0.000025243631,0.000007986505,0.00027430608,0.0000036911424,0.00028649328],"genre_scores_gemma":[0.99910706,0.00022712204,0.000038825256,0.00004473237,0.000039567873,0.00000926585,0.00027165507,0.0000047751573,0.00025700295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887425,0.00034079538,0.00008263979,0.00038500974,0.00010114313,0.0002161817],"domain_scores_gemma":[0.99888676,0.00047318527,0.0002898553,0.00011855342,0.00006587256,0.000165788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010845667,0.000489313,0.0009609844,0.00052262493,0.00041163925,0.0009833918,0.0005697208,0.00121002,0.0024940928],"category_scores_gemma":[0.002190955,0.00053057226,0.0025359266,0.00090549747,0.00036385015,0.0008121445,0.0005479998,0.0012136301,0.00031992228],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045728814,0.0006380949,0.935296,0.000166526,0.0059925155,0.0005226471,0.00023161955,0.00052902434,0.0023330287,0.00014238768,0.0007470427,0.007672421],"study_design_scores_gemma":[0.0007150901,0.0031746444,0.98997235,0.000022040485,0.0029175382,0.00040415156,0.00048115518,0.0014377591,0.00017010588,0.00016803946,0.00050652336,0.000030636515],"about_ca_topic_score_codex":0.003449941,"about_ca_topic_score_gemma":0.0044266884,"teacher_disagreement_score":0.003449941,"about_ca_system_score_codex":0.00034628843,"about_ca_system_score_gemma":0.00036386936,"threshold_uncertainty_score":0.008343577},"labels":[],"label_agreement":null},{"id":"W3152739953","doi":"10.1016/j.clgc.2021.04.008","title":"Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; National Institutes of Health; Bavarian Nordic; Bayer Schering; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Virginia Marine Resources Commission; Advanced Accelerator Applications; Bayer Fund; Clovis Oncology; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Jounce Therapeutics; Merck Sharp and Dohme; Genzyme; National Institute on Handicapped Research; Exelixis; Sanofi; Novartis; Merck; Heron Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Internal medicine; Pembrolizumab; Durvalumab; Oncology; Atezolizumab; Metastatic Urothelial Carcinoma; Carboplatin; Cisplatin; Response Evaluation Criteria in Solid Tumors; Retrospective cohort study; Urology; Bladder cancer; Urothelial carcinoma; Cancer; Chemotherapy; Progressive disease; Immunotherapy","score_opus":0.03517358340460927,"score_gpt":0.3511806430000108,"score_spread":0.31600705959540154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152739953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687237,0.0009866809,0.000054989854,0.00019276993,0.000021070591,0.00001176437,0.0007438336,0.0000040816944,0.0011124908],"genre_scores_gemma":[0.99854267,0.00021234878,0.000016494854,0.000080641556,0.000016256481,0.00000590755,0.0009015326,0.0000012833466,0.00022282121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974746,0.00005748122,0.000031576536,0.000055833232,0.00003420081,0.000073439776],"domain_scores_gemma":[0.99901545,0.0001984624,0.000410805,0.00004173254,0.00006463329,0.00026897376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038141245,0.00014057098,0.0004966756,0.0002717579,0.00030573286,0.00080953987,0.00027067986,0.00038228917,0.001296284],"category_scores_gemma":[0.0018183888,0.0001094378,0.00064968556,0.00048121696,0.00024866668,0.0005682741,0.0003808961,0.00065789785,0.0001815555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072727175,0.00028919202,0.97422713,0.000075408665,0.0002726243,0.00049256574,0.00011647077,0.00064745743,0.000745781,0.000131893,0.0009012455,0.014827545],"study_design_scores_gemma":[0.00026312444,0.0021456338,0.99425006,0.00003238099,0.00025346575,0.0007140735,0.00024105002,0.0006779031,0.0001702354,0.0002626541,0.0009745629,0.000014761357],"about_ca_topic_score_codex":0.0014095985,"about_ca_topic_score_gemma":0.002283809,"teacher_disagreement_score":0.0014095985,"about_ca_system_score_codex":0.0004584381,"about_ca_system_score_gemma":0.00039191844,"threshold_uncertainty_score":0.0043364763},"labels":[],"label_agreement":null},{"id":"W3154739493","doi":"10.1016/j.clgc.2021.04.002","title":"Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"National Cancer Institute; EMD Serono; Exelixis; Boehringer Ingelheim; Gilead Sciences; Sanofi; Roche; Janssen Pharmaceuticals; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blockade; Odds ratio; Internal medicine; Oncology; Confidence interval; Logistic regression; Cancer; Angiotensin receptor; Angiotensin II; Receptor","score_opus":0.07895815771233301,"score_gpt":0.3820731702178508,"score_spread":0.3031150125055178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154739493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892287,0.008446131,0.00013171819,0.00023761338,0.000040871186,0.000031844294,0.000082712984,0.000017227681,0.0017831868],"genre_scores_gemma":[0.99775827,0.0015530369,0.0000696639,0.000076793076,0.000042070224,0.00000809295,0.00008139822,0.0000024305423,0.00040825587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999826,0.000074087904,0.00001171843,0.000018073308,0.00003230293,0.00003781987],"domain_scores_gemma":[0.999741,0.000099613855,0.00005016658,0.00001681263,0.000021832546,0.000070573304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042271437,0.0002293912,0.00056732516,0.00019501107,0.00014552804,0.0005048172,0.00017698342,0.00023622272,0.0011496225],"category_scores_gemma":[0.00073236274,0.00010186084,0.00025743022,0.00024000197,0.00020894383,0.0002535796,0.000108106455,0.0007940324,0.0001599406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1027149,0.007013352,0.11182806,0.0009464639,0.001178558,0.0011216077,0.00041001927,0.0024809598,0.4068683,0.000786142,0.0033238255,0.36132777],"study_design_scores_gemma":[0.008206125,0.19233702,0.5577114,0.00014789842,0.0018279353,0.0028996111,0.0005589928,0.0053921137,0.20784323,0.0006371034,0.022363836,0.00007464995],"about_ca_topic_score_codex":0.0006198838,"about_ca_topic_score_gemma":0.0014971102,"teacher_disagreement_score":0.0011496225,"about_ca_system_score_codex":0.00042853472,"about_ca_system_score_gemma":0.00034590223,"threshold_uncertainty_score":0.0038458705},"labels":[],"label_agreement":null},{"id":"W3155835287","doi":"10.1016/j.clgc.2021.04.004","title":"Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"Ministero della Salute","keywords":"Medicine; Prostatectomy; Prostate cancer; Magnetic resonance imaging; Effective diffusion coefficient; Confidence interval; Logistic regression; Prostate; Univariate analysis; Urology; Radiology; Nuclear medicine; Youden's J statistic; Cancer; Receiver operating characteristic; Internal medicine; Multivariate analysis","score_opus":0.020981356460879,"score_gpt":0.3276683650322122,"score_spread":0.3066870085713332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155835287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813485,0.0009146977,0.00007678375,0.00011492185,0.000021041016,0.0000064577393,0.00009258815,0.000004285722,0.0006342812],"genre_scores_gemma":[0.99957746,0.0001328457,0.00006197166,0.000018483674,0.000018935307,0.0000022853703,0.00008026698,0.0000010711847,0.00010663891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997842,0.00006641439,0.000028230823,0.000029749692,0.000052086016,0.000039400857],"domain_scores_gemma":[0.9987649,0.0004600122,0.000281203,0.000040952804,0.00010747049,0.00034546602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005389425,0.00036519446,0.00038560218,0.00076854636,0.000330623,0.00069394003,0.00043029326,0.00068262714,0.0012966767],"category_scores_gemma":[0.0031685503,0.00021639421,0.00041034498,0.00050535664,0.00040436833,0.0005747596,0.00043995425,0.00067562325,0.00017823545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041707905,0.00005330418,0.9968359,0.000013155313,0.00006690243,0.00007624846,0.00003407552,0.00015269159,0.00025603457,0.000017188979,0.00008883382,0.0019886156],"study_design_scores_gemma":[0.000016424423,0.00023768922,0.9975424,0.000012245797,0.000098449425,0.00030180934,0.00021512069,0.0011999623,0.00014791149,0.00006056016,0.00015881167,0.000008672315],"about_ca_topic_score_codex":0.0031545775,"about_ca_topic_score_gemma":0.007345252,"teacher_disagreement_score":0.0031545775,"about_ca_system_score_codex":0.0002744654,"about_ca_system_score_gemma":0.0005184925,"threshold_uncertainty_score":0.006272435},"labels":[],"label_agreement":null},{"id":"W3196657023","doi":"10.1016/j.clgc.2021.08.003","title":"Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Cohort; Urology; Chemotherapy; Radiation therapy; Internal medicine; Confidence interval; Concomitant; Urothelial carcinoma; Oncology; Cancer","score_opus":0.027970536787984952,"score_gpt":0.35711583299522026,"score_spread":0.3291452962072353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196657023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856332,0.012587692,0.00005801663,0.00034846086,0.00010505726,0.000012668003,0.00012549915,0.0000027105127,0.0011267322],"genre_scores_gemma":[0.99765754,0.001694724,0.00003535294,0.00021727568,0.00011224068,0.0000053457484,0.00007772787,0.0000010782002,0.00019857197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996743,0.0001312709,0.000030227658,0.0000376684,0.000032129832,0.00009425686],"domain_scores_gemma":[0.9993623,0.00030394254,0.00012874021,0.000016187765,0.000020696629,0.00016802341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007129371,0.00015137818,0.0005599017,0.00025683668,0.00027187428,0.00047098644,0.00020667752,0.00041692032,0.0015306219],"category_scores_gemma":[0.0018889451,0.00010231,0.00100039,0.0003411602,0.00019806426,0.0004908055,0.0003527206,0.0004896786,0.000107432315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077715866,0.0009009722,0.8090777,0.00069868006,0.001898446,0.0010066262,0.0005440926,0.0015061955,0.0021665557,0.00043867438,0.0019502945,0.102095924],"study_design_scores_gemma":[0.0011062454,0.009690342,0.9826666,0.00015753873,0.0013191595,0.00064624887,0.0011253263,0.0008052168,0.00031534876,0.00038707102,0.0017549753,0.000026000374],"about_ca_topic_score_codex":0.0021980132,"about_ca_topic_score_gemma":0.007719933,"teacher_disagreement_score":0.0021980132,"about_ca_system_score_codex":0.00041526608,"about_ca_system_score_gemma":0.00047940805,"threshold_uncertainty_score":0.0051203966},"labels":[],"label_agreement":null},{"id":"W3199482111","doi":"10.1016/j.clgc.2021.08.009","title":"Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Prostate cancer; Castration; Oncology; Hormone; Internal medicine; Hormonal therapy; Cancer","score_opus":0.4711515689813758,"score_gpt":0.5250952329655744,"score_spread":0.05394366398419859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199482111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872364,0.003925649,0.0011648064,0.00014894237,0.000037293525,0.000093554045,0.004599728,0.00001996563,0.0012865106],"genre_scores_gemma":[0.9925242,0.0009841322,0.0005094181,0.00006626507,0.00005394366,0.00006343847,0.005638365,0.000012135639,0.00014817137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629223,0.0024913098,0.00024093845,0.00043254773,0.00041804765,0.0001248639],"domain_scores_gemma":[0.9817726,0.01283673,0.0026367384,0.0015632664,0.000805808,0.00038490508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073655015,0.00046186996,0.0009601996,0.0006921616,0.00019447239,0.0012892565,0.0005407067,0.0005744192,0.0024664702],"category_scores_gemma":[0.013742269,0.0001853464,0.0019876144,0.001109186,0.00054447865,0.00095686625,0.00043719896,0.00091327267,0.00029123426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3373858,0.0033100294,0.46123818,0.0026471864,0.026006278,0.00054601766,0.00049191737,0.036841262,0.008309407,0.0021768715,0.005024462,0.116022535],"study_design_scores_gemma":[0.011771936,0.059671436,0.85525703,0.00035379938,0.017781207,0.0016865886,0.00068750203,0.034179963,0.005713091,0.0018481435,0.010770893,0.0002785276],"about_ca_topic_score_codex":0.0012560574,"about_ca_topic_score_gemma":0.0015837785,"teacher_disagreement_score":0.0073655015,"about_ca_system_score_codex":0.00061869633,"about_ca_system_score_gemma":0.00047676283,"threshold_uncertainty_score":0.038952947},"labels":[],"label_agreement":null},{"id":"W3202899348","doi":"10.1016/j.clgc.2021.09.004","title":"The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments","year":2021,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Androgen deprivation therapy; Dose fractionation; Cyberknife; Prostate; Oncology; Cancer; Radiology; Internal medicine; Radiosurgery","score_opus":0.07510440788300249,"score_gpt":0.4424829346515171,"score_spread":0.3673785267685146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202899348","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036388476,0.99938774,0.000047102043,0.00016592858,0.000068188914,0.0000027046895,0.000009107631,0.000002763967,0.00027997847],"genre_scores_gemma":[0.0003308704,0.9991208,0.00013527604,0.00019069032,0.000060291153,0.000003236817,0.000011892985,0.000001175479,0.0001458109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962056,0.000109937275,0.00006711786,0.000058646183,0.00012174054,0.000021947879],"domain_scores_gemma":[0.9991953,0.0004919456,0.0001202872,0.000014632433,0.00014681587,0.00003093249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281905,0.00065221236,0.0018456444,0.0019051098,0.00024520015,0.0014165174,0.00096869364,0.0008817024,0.0035989338],"category_scores_gemma":[0.0019286934,0.0003512969,0.0007492633,0.0024360977,0.0005079163,0.0013946653,0.0005787649,0.002173096,0.0010847775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008453015,0.000040337443,0.00012601505,0.043079685,0.00018526331,0.00007995883,0.00008466545,0.00055753737,0.00047866444,0.0030110835,0.023237359,0.929035],"study_design_scores_gemma":[0.000052852272,0.00013945051,0.0010877349,0.023145735,0.00047156293,0.0008113751,0.000098456505,0.00018285954,0.00019170388,0.0017316657,0.9720596,0.000026883185],"about_ca_topic_score_codex":0.0034498002,"about_ca_topic_score_gemma":0.007529892,"teacher_disagreement_score":0.0035989338,"about_ca_system_score_codex":0.0012324161,"about_ca_system_score_gemma":0.0019441062,"threshold_uncertainty_score":0.012039602},"labels":[],"label_agreement":null},{"id":"W3207290793","doi":"10.1016/j.clgc.2021.10.002","title":"Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"European Association of Urology; Uehara Memorial Foundation","keywords":"Medicine; Urothelial carcinoma; Pathological; Grading (engineering); Urothelial cancer; Oncology; Carcinoma; Internal medicine; Bladder cancer; Cancer","score_opus":0.10614644549365204,"score_gpt":0.4237975035817943,"score_spread":0.31765105808814226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207290793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991571,0.00025975864,0.00015709219,0.000030674186,0.000006039713,0.000004729963,0.00011578004,0.000005116758,0.00026370812],"genre_scores_gemma":[0.9997321,0.000026601141,0.000077972145,0.0000064945593,0.000005113145,0.000001813095,0.00012815246,9.903514e-7,0.000020730708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971853,0.001232094,0.00046637104,0.00030369492,0.0006140319,0.000198616],"domain_scores_gemma":[0.98484725,0.006392283,0.0057748477,0.0011537309,0.0014547887,0.00037717924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003307543,0.00016536319,0.00027693412,0.0009895675,0.00029986093,0.0008179192,0.00056616537,0.00032184407,0.00072375865],"category_scores_gemma":[0.018858748,0.00017678255,0.00025961897,0.00092221535,0.00044950543,0.0002949127,0.0005465856,0.00022022282,0.00017134561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035733443,0.0000030573487,0.9990043,0.0000062714657,0.000009569184,0.000033653312,0.000028210872,0.000029140183,0.00006406241,0.0000056940294,0.000020762884,0.0007596751],"study_design_scores_gemma":[0.000003081774,0.000040497896,0.9980861,0.000009521927,0.000016797609,0.000773784,0.00009778557,0.0005523859,0.00025511187,0.000034280063,0.0001274146,0.0000032897203],"about_ca_topic_score_codex":0.001787998,"about_ca_topic_score_gemma":0.0021751844,"teacher_disagreement_score":0.003307543,"about_ca_system_score_codex":0.00032494785,"about_ca_system_score_gemma":0.00033166795,"threshold_uncertainty_score":0.017492115},"labels":[],"label_agreement":null},{"id":"W3213383090","doi":"10.1016/j.clgc.2021.10.010","title":"Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Lymph node; Bladder cancer; Stage (stratigraphy); Urology; Dissection (medical); Urinary bladder; Carcinoma; Proportional hazards model; Hazard ratio; Adenocarcinoma; Internal medicine; Oncology; Cancer; Surgery; Confidence interval","score_opus":0.050856143172672355,"score_gpt":0.35134109118836987,"score_spread":0.30048494801569753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213383090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255296,0.06167996,0.00044739738,0.0032694964,0.00017850564,0.000015370773,0.0017711533,0.000013828718,0.007094633],"genre_scores_gemma":[0.98580915,0.011727952,0.00013539176,0.00046334416,0.0002726546,0.0000074158606,0.0011707051,0.000008864534,0.00040452345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998912,0.00018420274,0.00020634274,0.0002364989,0.00025599057,0.00020490045],"domain_scores_gemma":[0.9938846,0.0017780636,0.0023405186,0.00025987014,0.0010526127,0.0006843844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018540942,0.00010190019,0.00029973805,0.001467326,0.00027651436,0.001041192,0.00062285824,0.00070088345,0.0018282676],"category_scores_gemma":[0.007507788,0.00015516322,0.0005618337,0.0030547597,0.0006579634,0.0010999343,0.00038048238,0.00079329655,0.00037560952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044082716,0.000056289595,0.9735103,0.0000986531,0.00010931062,0.000056021505,0.0001337627,0.00024269134,0.0002619399,0.00023795871,0.00046393415,0.02438819],"study_design_scores_gemma":[0.00000950878,0.00013987195,0.9968887,0.000068102905,0.0000790514,0.00019399659,0.0003265942,0.00017326472,0.00009904266,0.0000995359,0.0019161353,0.0000061882542],"about_ca_topic_score_codex":0.008395683,"about_ca_topic_score_gemma":0.017533222,"teacher_disagreement_score":0.008395683,"about_ca_system_score_codex":0.0013676338,"about_ca_system_score_gemma":0.0012001393,"threshold_uncertainty_score":0.016693592},"labels":[],"label_agreement":null},{"id":"W4200262376","doi":"10.1016/j.clgc.2021.12.003","title":"Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; University of Ottawa; Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Foothills Medical Centre; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Renal cell carcinoma; Internal medicine; Cohort; Oncology; Kidney cancer; Adverse effect; Expanded access; Cancer; Surgery; Immunotherapy","score_opus":0.07943066627634919,"score_gpt":0.3662064179276324,"score_spread":0.2867757516512832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200262376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870694,0.00046510264,0.00003374345,0.00009322732,0.000006831342,0.0000042407664,0.00033721369,0.0000025015536,0.00035027208],"genre_scores_gemma":[0.9993932,0.00014348679,0.000023761218,0.000055717188,0.00001328014,0.000003839005,0.00030006634,0.0000016456224,0.00006509702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994917,0.0001128542,0.000054858257,0.00013760017,0.00008496427,0.000118096614],"domain_scores_gemma":[0.99897885,0.00017992336,0.0004916508,0.000056324265,0.00009169469,0.00020163399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039802765,0.00014327408,0.00033319902,0.0004187011,0.00039440635,0.0009067243,0.0002706311,0.00039370373,0.0012426795],"category_scores_gemma":[0.0017047623,0.0001773517,0.00049559877,0.00089094427,0.00027941944,0.00055202626,0.00033143308,0.0006082953,0.00016797996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004895351,0.000053057516,0.9965065,0.000015801219,0.00012014109,0.00010363074,0.000048195387,0.00010502444,0.00027635705,0.000035817546,0.00020246577,0.002043441],"study_design_scores_gemma":[0.000029303968,0.00033462993,0.99715304,0.000011094331,0.00010380573,0.000603672,0.00033075234,0.0006594381,0.000121290606,0.000051283136,0.00059124635,0.000010463808],"about_ca_topic_score_codex":0.0059693786,"about_ca_topic_score_gemma":0.006207743,"teacher_disagreement_score":0.0059693786,"about_ca_system_score_codex":0.00083219283,"about_ca_system_score_gemma":0.0006409055,"threshold_uncertainty_score":0.011869252},"labels":[],"label_agreement":null},{"id":"W4205349880","doi":"10.1016/j.clgc.2022.01.003","title":"Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Sinai Health System; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"Prostate Cancer Canada","keywords":"Medicine; Capra; Cohort; Nomogram; Biochemical recurrence; Prostate cancer; Oncology; Internal medicine; Cancer; Metastasis; Prostatectomy; Retrospective cohort study","score_opus":0.025291342321551374,"score_gpt":0.34153732938166614,"score_spread":0.31624598706011475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205349880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854393,0.0074232942,0.00070316,0.00067504024,0.00020462008,0.000044092663,0.00094735634,0.00012928151,0.004433891],"genre_scores_gemma":[0.9976305,0.00043831312,0.00046117065,0.00012695506,0.00016190435,0.00001016862,0.00065529946,0.000011344337,0.0005043659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993918,0.00019175175,0.000047626974,0.00013386187,0.00013394652,0.00010097497],"domain_scores_gemma":[0.99862957,0.00034902059,0.0003095376,0.00012353084,0.0002474117,0.00034104448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010456069,0.0008061039,0.0012112758,0.0011666851,0.0004650346,0.0014508388,0.0006123284,0.00076048,0.0021522278],"category_scores_gemma":[0.0025970368,0.0002417912,0.0007865836,0.00095077255,0.00034294656,0.00071046146,0.00065410224,0.0009086317,0.00056358235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028012842,0.00018620382,0.9548878,0.000087102024,0.00044684717,0.00011404403,0.00004657569,0.00083297264,0.0021124815,0.000057420075,0.0013285133,0.037098702],"study_design_scores_gemma":[0.00009870628,0.0016324123,0.98281085,0.000065035434,0.00084281433,0.00074486603,0.00015737895,0.008053643,0.0020925219,0.00046162689,0.0029858216,0.000054256394],"about_ca_topic_score_codex":0.0020569095,"about_ca_topic_score_gemma":0.0037752127,"teacher_disagreement_score":0.0021522278,"about_ca_system_score_codex":0.000385946,"about_ca_system_score_gemma":0.0005057019,"threshold_uncertainty_score":0.007199943},"labels":[],"label_agreement":null},{"id":"W4206405356","doi":"10.1016/j.clgc.2021.11.018","title":"Establishing metastatic prostate cancer quality indicators using a modified Delphi approach","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Princess Margaret Cancer Centre; University of Toronto","funders":"Movember Foundation","keywords":"Medicine; Prostate cancer; Oncology; Cancer; Delphi method; Quality (philosophy); Prostate; Internal medicine; Artificial intelligence","score_opus":0.5175260287163131,"score_gpt":0.568070829747509,"score_spread":0.05054480103119585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206405356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06417582,0.50073326,0.29221335,0.012907072,0.0014271392,0.061019536,0.006863002,0.00045766024,0.060203146],"genre_scores_gemma":[0.1963706,0.19412902,0.5641055,0.0024427339,0.00018019398,0.034922034,0.0038846121,0.000068966045,0.003896288],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.95612013,0.028663754,0.006599616,0.0011623607,0.0065950295,0.0008591448],"domain_scores_gemma":[0.9482037,0.037613355,0.0031490785,0.0010737691,0.009585197,0.00037494968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.066282034,0.0012907861,0.0030646387,0.010559777,0.0010144869,0.0027453143,0.0017374221,0.0007484758,0.0040496774],"category_scores_gemma":[0.05277868,0.0006432781,0.0036278765,0.009511253,0.0008008609,0.0022233773,0.0033032214,0.001508127,0.00054383057],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023141598,0.0001594601,0.005755416,0.08659189,0.0016547184,0.00010418309,0.0034837923,0.0014757884,0.0009685548,0.009485378,0.0051851287,0.8849042],"study_design_scores_gemma":[0.0009524342,0.0028472517,0.08917715,0.33106592,0.020974807,0.0022910463,0.038405612,0.013328112,0.007710017,0.038849257,0.45371765,0.0006807136],"about_ca_topic_score_codex":0.0039759655,"about_ca_topic_score_gemma":0.0061816103,"teacher_disagreement_score":0.066282034,"about_ca_system_score_codex":0.0033570935,"about_ca_system_score_gemma":0.011750955,"threshold_uncertainty_score":0.35053706},"labels":[],"label_agreement":null},{"id":"W4206793550","doi":"10.1016/j.clgc.2022.01.004","title":"Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Association of Urology","keywords":"Medicine; Gemcitabine; Internal medicine; Chemotherapy; Oncology; Cisplatin; Vinblastine; Hazard ratio; Proportional hazards model; Cancer; Cohort; Urology; Confidence interval","score_opus":0.04488737502863818,"score_gpt":0.3753688852645977,"score_spread":0.3304815102359595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206793550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987801,0.0007011486,0.000026333035,0.000047099362,0.0000050539034,0.0000111046675,0.00021613369,9.526698e-7,0.00021222838],"genre_scores_gemma":[0.9987808,0.00038490104,0.000054708256,0.000091989255,0.00002755659,0.000015384137,0.00056912634,0.0000015053145,0.000074221236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994654,0.00021359778,0.00008017368,0.00009478471,0.000057812013,0.00008827133],"domain_scores_gemma":[0.99849856,0.00021250005,0.0007569653,0.0000863256,0.00013408487,0.000311633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010169612,0.00032119852,0.00056507473,0.0004526426,0.0004084954,0.0007277126,0.00022747066,0.00037059266,0.0008577131],"category_scores_gemma":[0.0017670023,0.00016292505,0.0006851057,0.0010288111,0.00032072025,0.0005681406,0.00057316985,0.00029384956,0.00013506139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028285573,0.00020927435,0.9917887,0.000055107976,0.00050805387,0.00011992267,0.00015641341,0.00006121389,0.0006978027,0.00002880217,0.00026591774,0.0032803472],"study_design_scores_gemma":[0.00023571486,0.0008419976,0.9969382,0.000027016093,0.00047719586,0.00026470155,0.00038732035,0.0000927445,0.00013857055,0.000020289674,0.0005671039,0.000009049948],"about_ca_topic_score_codex":0.002094805,"about_ca_topic_score_gemma":0.0039434154,"teacher_disagreement_score":0.002094805,"about_ca_system_score_codex":0.00052322383,"about_ca_system_score_gemma":0.0005012545,"threshold_uncertainty_score":0.0053782463},"labels":[],"label_agreement":null},{"id":"W4210695409","doi":"10.1016/j.clgc.2022.01.011","title":"Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; Cystectomy; Proportional hazards model; Perioperative; Bladder cancer; Urothelial carcinoma; Urology; Oncology; Carcinoma; Cancer; Database; Internal medicine; Surgery","score_opus":0.07033369076109303,"score_gpt":0.4018111346463198,"score_spread":0.33147744388522676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210695409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932486,0.0016613227,0.00006498029,0.00009971691,0.000013026918,0.000008469958,0.004387829,0.000005092631,0.00051096454],"genre_scores_gemma":[0.9959372,0.0005832264,0.00007589576,0.00007062823,0.000013919479,0.000011564617,0.0031784496,0.0000027187355,0.00012633808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928916,0.00018342282,0.00014284601,0.00016563461,0.000115801864,0.00010313658],"domain_scores_gemma":[0.99765813,0.0005026306,0.0012739574,0.00018129489,0.00018565348,0.00019825912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353157,0.00016325411,0.00048030936,0.0009901663,0.0002802166,0.0006441855,0.00038473782,0.00040883114,0.0009343406],"category_scores_gemma":[0.002789275,0.00023865091,0.00076826947,0.002436158,0.00019865757,0.00046704212,0.0005130278,0.00049839716,0.00010613739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014438626,0.000016328242,0.9985964,0.000018972347,0.00018787014,0.000028345843,0.000020742416,0.000039818427,0.000059266342,0.000012422297,0.00017509787,0.00070040015],"study_design_scores_gemma":[0.000008872009,0.000028674533,0.99928516,0.0000089978885,0.00010587832,0.00009424703,0.000081190556,0.00013788976,0.000029607905,0.00000805603,0.00020827503,0.0000031776444],"about_ca_topic_score_codex":0.016310517,"about_ca_topic_score_gemma":0.025944756,"teacher_disagreement_score":0.016310517,"about_ca_system_score_codex":0.00049859507,"about_ca_system_score_gemma":0.0007051183,"threshold_uncertainty_score":0.032431126},"labels":[],"label_agreement":null},{"id":"W4213176808","doi":"10.1016/j.clgc.2022.02.004","title":"Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University Health Network; Princess Margaret Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Oncology; Internal medicine; Androgen deprivation therapy; Cohort; Cancer; Cancer research","score_opus":0.08870405857679521,"score_gpt":0.40095933957297974,"score_spread":0.31225528099618455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213176808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857151,0.0050252522,0.0022326554,0.00030595213,0.000016990169,0.000017506989,0.0044707116,0.00010531517,0.0021104224],"genre_scores_gemma":[0.99444276,0.000896071,0.000678575,0.00014492421,0.000014294423,0.000013415695,0.0028936025,0.000020901938,0.0008953872],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998135,0.000020371997,0.000007862295,0.000052019484,0.00007405236,0.000032221335],"domain_scores_gemma":[0.9997873,0.0000674006,0.00006271131,0.000022598217,0.000029873801,0.000030175452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001273125,0.00014778378,0.0003321312,0.000526082,0.00017098199,0.00045684865,0.00012434008,0.00022218574,0.0016412211],"category_scores_gemma":[0.0004790054,0.000107784064,0.00017291086,0.00063806237,0.00014876015,0.000107391854,0.00019352144,0.000320008,0.00027138455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009751898,0.00006395967,0.14484207,0.00029946564,0.00026184152,0.00047621125,0.00021629148,0.0015430253,0.7880316,0.00059053005,0.0019833974,0.060716473],"study_design_scores_gemma":[0.000022824628,0.00046564377,0.94447184,0.000021734575,0.00025854533,0.0024705061,0.00020757866,0.0020119187,0.040816996,0.00056071265,0.008676333,0.000015397356],"about_ca_topic_score_codex":0.0009121434,"about_ca_topic_score_gemma":0.0019439851,"teacher_disagreement_score":0.0016412211,"about_ca_system_score_codex":0.0001645028,"about_ca_system_score_gemma":0.00019510256,"threshold_uncertainty_score":0.0054904222},"labels":[],"label_agreement":null},{"id":"W4220970449","doi":"10.1016/j.clgc.2022.03.011","title":"Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC)","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Varian Medical Systems","keywords":"Medicine; Radiofrequency ablation; Renal cell carcinoma; Cost-effectiveness analysis; Stage (stratigraphy); Cohort; Radiology; Cost effectiveness; Ablation; Oncology; Internal medicine","score_opus":0.11082511121681382,"score_gpt":0.4046624807217256,"score_spread":0.2938373695049118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220970449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711429,0.015825493,0.0029263766,0.0017530611,0.0002900591,0.00069185335,0.0016846649,0.00006743403,0.0056181983],"genre_scores_gemma":[0.9974354,0.0010316791,0.0005739161,0.00016705791,0.000042904714,0.000097131255,0.00027035276,0.000007688394,0.00037394173],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99723756,0.0018977076,0.00012547155,0.00016353372,0.0002158637,0.0003598475],"domain_scores_gemma":[0.9962625,0.0028466869,0.00037705316,0.00007078754,0.00014561247,0.00029731414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029353749,0.0011305322,0.0019248475,0.0012917091,0.00024766015,0.0015490426,0.0011993798,0.001222596,0.006686213],"category_scores_gemma":[0.008962148,0.0005595477,0.005671309,0.0011545159,0.00054221496,0.0013828514,0.0007737837,0.0015607807,0.00020921457],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4406785,0.0063686017,0.030462373,0.005022711,0.022903243,0.0005408264,0.00018588321,0.3386232,0.0036737246,0.0066329353,0.003532458,0.14137559],"study_design_scores_gemma":[0.088570304,0.116616,0.14774176,0.0014846676,0.06322536,0.0014416231,0.0013971156,0.5598007,0.003982108,0.009084203,0.00626323,0.00039293978],"about_ca_topic_score_codex":0.013692872,"about_ca_topic_score_gemma":0.0086903265,"teacher_disagreement_score":0.013692872,"about_ca_system_score_codex":0.0052643893,"about_ca_system_score_gemma":0.0024339396,"threshold_uncertainty_score":0.038195968},"labels":[],"label_agreement":null},{"id":"W4224301051","doi":"10.1016/j.clgc.2022.04.003","title":"Physical Activity in Patients With Kidney Cancer: A Scoping Review","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Randomized controlled trial; Quality of life (healthcare); Cochrane Library; Systematic review; MEDLINE; Cohort; Population; Cohort study; Cancer; Gerontology; Family medicine; Physical therapy; Internal medicine; Environmental health; Nursing","score_opus":0.12704742887252504,"score_gpt":0.47176413437025727,"score_spread":0.34471670549773226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224301051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013947056,0.99954814,0.00002242578,0.00006428591,0.000044578956,0.000015384947,0.000072426934,0.000001671699,0.000091589754],"genre_scores_gemma":[0.001660366,0.997968,0.00008235641,0.00014907077,0.000027750066,0.00002384948,0.00004728492,9.973464e-7,0.000040405346],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9983917,0.00032826315,0.00066100224,0.00022835456,0.00030176138,0.00008890537],"domain_scores_gemma":[0.9949845,0.0037163435,0.00085979846,0.000051834137,0.0003177537,0.00006972073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002690492,0.0012225646,0.005866181,0.006939453,0.00047346985,0.002852792,0.0012853269,0.0021719248,0.0047290763],"category_scores_gemma":[0.009113633,0.0009672224,0.0054069953,0.008632572,0.000626264,0.0017068418,0.0015857334,0.0016139861,0.00043243298],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020758083,0.000052118045,0.001524637,0.7971283,0.0069411676,0.00010377164,0.00020405526,0.00019205925,0.00018603007,0.00034942117,0.005242667,0.18786813],"study_design_scores_gemma":[0.00019287299,0.00018924731,0.007694372,0.87886745,0.044080377,0.0006014227,0.00039142676,0.00012926363,0.00014615296,0.00046294506,0.06717264,0.00007190201],"about_ca_topic_score_codex":0.012260027,"about_ca_topic_score_gemma":0.031359892,"teacher_disagreement_score":0.012260027,"about_ca_system_score_codex":0.0015906247,"about_ca_system_score_gemma":0.0050708316,"threshold_uncertainty_score":0.024377346},"labels":[],"label_agreement":null},{"id":"W4224305740","doi":"10.1016/j.clgc.2022.04.005","title":"Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Stage (stratigraphy); Urology; Lymph node; Lymph; Biopsy; Pathological; Prostate; Cancer; Internal medicine; Gynecology; Oncology; Pathology","score_opus":0.02828518460997291,"score_gpt":0.3324095367179585,"score_spread":0.30412435210798555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224305740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968258,0.00084129226,0.00005202801,0.0001506131,0.000016096235,0.000004429886,0.00056408806,0.000005455498,0.0015403209],"genre_scores_gemma":[0.9991792,0.00019449202,0.000013499971,0.000035211426,0.000015828813,0.0000022897163,0.00039605505,0.0000018510161,0.00016167283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996635,0.00005905319,0.0000308601,0.00008045185,0.000061019324,0.000105092535],"domain_scores_gemma":[0.99893516,0.00018573392,0.0004022914,0.000045701523,0.00014052702,0.00029064776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003091944,0.00015422537,0.00027567835,0.0012166527,0.00061737775,0.0007639985,0.00043233484,0.00051660946,0.0024172843],"category_scores_gemma":[0.0014775321,0.00016781219,0.0004403279,0.002025928,0.00042358728,0.0007311232,0.00047652316,0.00047890493,0.00027317263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001429247,0.00001856988,0.99773455,0.000006225631,0.000029507542,0.00005365522,0.00008706702,0.00006655871,0.000086292705,0.00003226932,0.00019320937,0.0015492854],"study_design_scores_gemma":[0.0000017692372,0.000021891954,0.9994116,0.0000028587951,0.000008998966,0.000076827215,0.0002426205,0.00007233173,0.00000954742,0.00002081827,0.0001286166,0.0000020986183],"about_ca_topic_score_codex":0.02561394,"about_ca_topic_score_gemma":0.051447753,"teacher_disagreement_score":0.02561394,"about_ca_system_score_codex":0.0007811929,"about_ca_system_score_gemma":0.00072397524,"threshold_uncertainty_score":0.050929666},"labels":[],"label_agreement":null},{"id":"W4224880568","doi":"10.1016/j.clgc.2022.04.009","title":"Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Sanofi Genzyme; Sanofi","keywords":"Cabazitaxel; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.25056824733698807,"score_gpt":0.5262210880224615,"score_spread":0.2756528406854734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224880568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027155745,0.9994684,0.000011757743,0.00007469697,0.000027825414,0.0000018152668,0.000027951482,0.000001039448,0.00011497173],"genre_scores_gemma":[0.00433555,0.9952728,0.00006353758,0.00011669966,0.00007288698,0.0000046992523,0.000068190966,8.582772e-7,0.000064674256],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996537,0.00009224217,0.000075893855,0.000059385533,0.000097642485,0.00002121592],"domain_scores_gemma":[0.9986467,0.00093180145,0.0002572297,0.000016702972,0.00011315661,0.000034309294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011347871,0.00046415685,0.002434161,0.0010561082,0.00012598348,0.0010058848,0.00073597213,0.00062413083,0.0025194846],"category_scores_gemma":[0.0027362835,0.00020878074,0.0019150448,0.0017040735,0.00024210261,0.0004879529,0.00034818592,0.0012197004,0.00032882305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087225635,0.00009071047,0.0035289547,0.07740872,0.0049901376,0.00009731256,0.00005417355,0.0006114534,0.00030148742,0.0008148378,0.010377022,0.900853],"study_design_scores_gemma":[0.0019543995,0.0025527382,0.115618646,0.16403614,0.047812518,0.0034603002,0.0005173117,0.0015916377,0.00090120616,0.0043378095,0.656924,0.00029331958],"about_ca_topic_score_codex":0.0040294454,"about_ca_topic_score_gemma":0.00990233,"teacher_disagreement_score":0.0040294454,"about_ca_system_score_codex":0.0007212819,"about_ca_system_score_gemma":0.0012269499,"threshold_uncertainty_score":0.008428514},"labels":[],"label_agreement":null},{"id":"W4249692483","doi":"10.1016/j.clgc.2020.06.002","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Guardant Health; Janssen Pharmaceuticals; Janssen Biotech; Bristol-Myers Squibb Canada; EMD Serono; Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Aileron Therapeutics; CTI Biopharma; ImmunoGen; Mirati Therapeutics; Bayer Fund; Five Prime Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Sanofi Genzyme; Takeda Pharmaceuticals U.S.A.; Immunocore; AbbVie; Karyopharm Therapeutics; Exelixis; MedImmune; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; Roche; Foundation Medicine; Astellas Pharma US; American Society of Clinical Oncology; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Boston Biomedical; Pfizer; Amgen; Boehringer Ingelheim; Calithera Biosciences; Bayer; Sarah Cannon Research Institute","keywords":"Medicine; Internal medicine; Nivolumab; Renal cell carcinoma; Rash; Clinical endpoint; Regimen; Clear cell renal cell carcinoma; Progression-free survival; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Toxicity; Chemotherapy; Clinical trial; Immunotherapy","score_opus":0.038017893248143676,"score_gpt":0.32126363076328307,"score_spread":0.2832457375151394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249692483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954998,0.0022894493,0.00013965178,0.00010917826,0.000018765077,0.00026257226,0.00077407906,0.000020481693,0.0008859588],"genre_scores_gemma":[0.9957444,0.00067284185,0.00036517397,0.00028669188,0.00003310812,0.00018823888,0.0021898719,0.000008456814,0.00051109475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999585,0.00020054223,0.000027847298,0.0000580949,0.00008540237,0.000043072818],"domain_scores_gemma":[0.99910283,0.0001911851,0.0002414309,0.000077944766,0.00013379929,0.00025285844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001786221,0.00035902162,0.00070093054,0.00015725891,0.00022695614,0.00056869135,0.00041776954,0.00046712696,0.0014551323],"category_scores_gemma":[0.0010482206,0.00015189726,0.0006612984,0.00018543073,0.00029752046,0.00025426134,0.00019282392,0.0006973871,0.00031874652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42825288,0.014653503,0.25804284,0.0018613865,0.004983058,0.00040815774,0.00042965822,0.0046044434,0.071826555,0.00035904252,0.010357028,0.20422144],"study_design_scores_gemma":[0.17521478,0.24864964,0.528685,0.00022013774,0.003507047,0.0011027833,0.00017168706,0.0049166726,0.017941328,0.00038448686,0.019103011,0.000103455415],"about_ca_topic_score_codex":0.001784506,"about_ca_topic_score_gemma":0.0034837737,"teacher_disagreement_score":0.001786221,"about_ca_system_score_codex":0.0010825307,"about_ca_system_score_gemma":0.0014076064,"threshold_uncertainty_score":0.009446561},"labels":[],"label_agreement":null},{"id":"W4286510751","doi":"10.1016/j.clgc.2022.07.008","title":"CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; Alberta Cancer Foundation","funders":"Ipsen; Ipsen Biopharmaceuticals","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Refractory (planetary science); Oncology; Internal medicine; Carcinoma; Clear cell; Urology","score_opus":0.040498504198724965,"score_gpt":0.3156316967992041,"score_spread":0.27513319260047914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286510751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95007616,0.005009962,0.00025847842,0.00035056565,0.000019806259,0.00020793901,0.0425207,0.000046562847,0.0015098383],"genre_scores_gemma":[0.96751773,0.0009863015,0.00035592742,0.00023655279,0.00003313906,0.00013173505,0.03037427,0.0000106234,0.00035372874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987948,0.00042410305,0.00019839795,0.00023385708,0.00025889152,0.0000900071],"domain_scores_gemma":[0.9971641,0.00066864904,0.0015170367,0.00016682797,0.00022972934,0.00025357862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016624406,0.00025850677,0.00074464467,0.0009175867,0.00018386047,0.00079734664,0.0005746679,0.000343418,0.0019874962],"category_scores_gemma":[0.0031369284,0.00011822003,0.00085789006,0.0017527888,0.00020307233,0.00054423505,0.0005979899,0.00032271823,0.00026369753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029806037,0.00042709548,0.91656977,0.0014007308,0.0025076983,0.00012717496,0.0001566796,0.0013895486,0.00074010977,0.00022976856,0.008605987,0.038039315],"study_design_scores_gemma":[0.00534162,0.0022357015,0.9756068,0.00019848581,0.0016959726,0.00045496353,0.0002249542,0.0036561096,0.00064350414,0.00017205729,0.009727712,0.00004206998],"about_ca_topic_score_codex":0.007257282,"about_ca_topic_score_gemma":0.0132602295,"teacher_disagreement_score":0.007257282,"about_ca_system_score_codex":0.0009326333,"about_ca_system_score_gemma":0.00071729015,"threshold_uncertainty_score":0.014430106},"labels":[],"label_agreement":null},{"id":"W4293217252","doi":"10.1016/j.clgc.2022.08.010","title":"Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Université de Montréal","funders":"","keywords":"Medicine; Proportional hazards model; Internal medicine; Renal cell carcinoma; Concomitant; Cohort; Epidemiology; Nephrectomy; Gastroenterology; Surgery; Urology; Kidney","score_opus":0.17532934324454227,"score_gpt":0.42396707200482325,"score_spread":0.24863772876028098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293217252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167573,0.0020224731,0.0002880088,0.00032876868,0.000052102518,0.000008832194,0.002183166,0.000029143363,0.0034116835],"genre_scores_gemma":[0.9979226,0.00028320547,0.000033073797,0.000048080434,0.000059497754,0.0000055188425,0.0012043247,0.000007335094,0.00043637512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935645,0.00016998228,0.000052577416,0.00011667624,0.00005833542,0.00024600895],"domain_scores_gemma":[0.9985897,0.00033781218,0.00048666183,0.0000921403,0.00011359247,0.0003801533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005498278,0.00035816425,0.0006582029,0.0011216566,0.0004291197,0.0006133363,0.00046587514,0.0006913023,0.0031809744],"category_scores_gemma":[0.002205008,0.00023442732,0.0017257171,0.0012549142,0.00031858368,0.00055498455,0.00064034475,0.0009589677,0.00027049799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036179451,0.00008895062,0.9863559,0.00005249778,0.00046636042,0.00022287345,0.00006137946,0.0011436652,0.00056555413,0.00028365504,0.0012134957,0.005927802],"study_design_scores_gemma":[0.000035503523,0.0002612921,0.9973853,0.00001531443,0.00013756895,0.0002756793,0.00014620804,0.0009725248,0.00010718397,0.000256786,0.00039008187,0.00001644745],"about_ca_topic_score_codex":0.006214044,"about_ca_topic_score_gemma":0.0069861882,"teacher_disagreement_score":0.006214044,"about_ca_system_score_codex":0.00075355783,"about_ca_system_score_gemma":0.00049403595,"threshold_uncertainty_score":0.012355745},"labels":[],"label_agreement":null},{"id":"W4295942277","doi":"10.1016/j.clgc.2022.09.004","title":"Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Docetaxel; Gemcitabine; Bladder cancer; Urology; Bacillus (shape); Oncology; Internal medicine; Cancer; Microbiology","score_opus":0.08438223880145321,"score_gpt":0.38274343369118446,"score_spread":0.29836119488973123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295942277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763644,0.0014437428,0.000117383584,0.00009722776,0.00002345447,0.00014255986,0.00012581439,0.000018949284,0.00039450225],"genre_scores_gemma":[0.9985172,0.00047382648,0.0004098654,0.000098804885,0.000020843843,0.00006165075,0.0002196529,0.0000050541826,0.00019308654],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992205,0.00034894547,0.000071614835,0.00017078129,0.000079611396,0.00010857652],"domain_scores_gemma":[0.999131,0.00013782969,0.00023451682,0.00008068368,0.000082140024,0.0003338182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013953535,0.0004659378,0.0014445906,0.00032952256,0.0004199184,0.0010042972,0.0006188847,0.0005982926,0.0010173435],"category_scores_gemma":[0.001703123,0.0004077002,0.0009857283,0.0005767741,0.00041203972,0.0007658504,0.00043271767,0.0015314493,0.00022440503],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45512992,0.039045,0.15553941,0.0006092248,0.0045628375,0.0003310062,0.00052291213,0.010484475,0.017509438,0.00019404867,0.0014622085,0.31460953],"study_design_scores_gemma":[0.051032588,0.5062484,0.41894937,0.00014455573,0.0038506896,0.0008479067,0.00036128028,0.007412223,0.0065673357,0.00018506742,0.004280168,0.00012041051],"about_ca_topic_score_codex":0.0029567778,"about_ca_topic_score_gemma":0.01105003,"teacher_disagreement_score":0.0029567778,"about_ca_system_score_codex":0.0017897144,"about_ca_system_score_gemma":0.002097527,"threshold_uncertainty_score":0.012985408},"labels":[],"label_agreement":null},{"id":"W4304891956","doi":"10.1016/j.clgc.2022.10.003","title":"Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Population; Hazard ratio; Prostate cancer; Proportional hazards model; Cancer; Urology","score_opus":0.05194096266369281,"score_gpt":0.39466579880682723,"score_spread":0.3427248361431344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304891956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871016,0.00024049234,0.00008093849,0.000021648686,0.0000029912433,0.0000065059007,0.0006422196,0.0000053929693,0.00028965235],"genre_scores_gemma":[0.9992974,0.00008638626,0.000040319843,0.000014522081,0.000005332373,0.000005288944,0.00044175677,0.0000022324302,0.00010669976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993716,0.00017407768,0.00006286363,0.00021395939,0.00009399674,0.00008349335],"domain_scores_gemma":[0.99907684,0.00016210043,0.00034296702,0.00012612733,0.00010744503,0.00018446802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006736889,0.00031702395,0.00052194414,0.0009926632,0.0004783401,0.0007288727,0.00052647083,0.00069223123,0.0018235093],"category_scores_gemma":[0.001567238,0.0005854791,0.0011685131,0.0013882325,0.00034603168,0.00070059195,0.00055062,0.00073107966,0.00026819657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013425527,0.000039084858,0.9989869,0.0000061460764,0.00015993584,0.00004346671,0.000040400144,0.000030229985,0.00015212431,0.000009676524,0.00005294701,0.0003447362],"study_design_scores_gemma":[0.0000043052673,0.00006560195,0.9994867,0.0000013499972,0.000041330386,0.00015531381,0.00009350534,0.000087270004,0.000011617494,0.0000067806714,0.0000432118,0.0000028705695],"about_ca_topic_score_codex":0.010097128,"about_ca_topic_score_gemma":0.008698287,"teacher_disagreement_score":0.010097128,"about_ca_system_score_codex":0.00037293087,"about_ca_system_score_gemma":0.0003209937,"threshold_uncertainty_score":0.020076692},"labels":[],"label_agreement":null},{"id":"W4304892112","doi":"10.1016/j.clgc.2022.10.002","title":"Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Clinical trial; Expanded access; Intensive care medicine; Cabozantinib; Cancer; Urothelial carcinoma; Disease; Clinical Practice; Oncology; Bladder cancer; Internal medicine; Family medicine","score_opus":0.05980277892417523,"score_gpt":0.38068527785311157,"score_spread":0.32088249892893633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304892112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566669,0.0034882345,0.00061866175,0.022469651,0.00013642461,0.00004347388,0.0027490794,0.000012057073,0.013815589],"genre_scores_gemma":[0.997577,0.0005583718,0.00013229539,0.0010363527,0.00004084048,0.000011353307,0.00036259438,0.0000036307322,0.0002775106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780816,0.0006824153,0.00020897776,0.00024695843,0.00036369095,0.0006897161],"domain_scores_gemma":[0.9916889,0.0025190986,0.0032145532,0.00037533673,0.0006948715,0.0015072244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017279267,0.0000712777,0.00023040829,0.0007615304,0.0006998752,0.0012045164,0.0003769646,0.00053444755,0.0036311927],"category_scores_gemma":[0.01621541,0.00011723194,0.00044362003,0.002281333,0.00047228436,0.0012545334,0.0016536044,0.0012016887,0.00011372761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001288997,0.00014116296,0.9644233,0.00006603121,0.0001588522,0.000062739935,0.000845555,0.00039457154,0.00013360631,0.006739944,0.0037306906,0.02317461],"study_design_scores_gemma":[0.00003088846,0.00007724543,0.9841212,0.00027696436,0.00012621754,0.00010331889,0.0027390246,0.0009242965,0.0001301562,0.005064046,0.006385917,0.000020743464],"about_ca_topic_score_codex":0.054376327,"about_ca_topic_score_gemma":0.07767235,"teacher_disagreement_score":0.054376327,"about_ca_system_score_codex":0.0017013687,"about_ca_system_score_gemma":0.0056225844,"threshold_uncertainty_score":0.10811967},"labels":[],"label_agreement":null},{"id":"W4309341654","doi":"10.1016/j.clgc.2022.11.005","title":"Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Oncology; Internal medicine; Quartile; Disease; Prospective cohort study; Proportional hazards model; Gene expression profiling; Biomarker; DNA repair; Bioinformatics; Gene; Cancer; Gene expression; Genetics; Confidence interval; Biology","score_opus":0.07357477446378567,"score_gpt":0.3947500217146571,"score_spread":0.32117524725087143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309341654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659234,0.00052447274,0.00044653425,0.00008597291,0.000008642361,0.000017797827,0.00047572778,0.00002296227,0.0018255208],"genre_scores_gemma":[0.9986091,0.00011372085,0.00015104537,0.000032547654,0.000012044644,0.0000065936665,0.00069303217,0.000014268993,0.00036766913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994723,0.00008543746,0.000043629654,0.000109174616,0.00009061741,0.0001988685],"domain_scores_gemma":[0.9987696,0.00020576843,0.00041166664,0.00008927384,0.00018057956,0.00034300415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042877867,0.00034846837,0.000648558,0.0014144045,0.0005249695,0.0012091392,0.00058401946,0.0005886239,0.0034892638],"category_scores_gemma":[0.002072338,0.00017087947,0.0004641732,0.0010203501,0.0004983774,0.0004388968,0.00093624624,0.0006239111,0.00078066904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008232921,0.000059072598,0.9827429,0.000024098217,0.00009997239,0.000116589894,0.00018607183,0.00015412206,0.007595688,0.0003438313,0.00023578639,0.0076185693],"study_design_scores_gemma":[0.000012422586,0.0002479206,0.99500245,0.000011066689,0.00006210351,0.00093643257,0.0005802587,0.00037637938,0.0012039103,0.0009262075,0.0006270573,0.0000137788375],"about_ca_topic_score_codex":0.0016913774,"about_ca_topic_score_gemma":0.0020110474,"teacher_disagreement_score":0.0034892638,"about_ca_system_score_codex":0.0004499674,"about_ca_system_score_gemma":0.00047411886,"threshold_uncertainty_score":0.011672735},"labels":[],"label_agreement":null},{"id":"W4310353441","doi":"10.1016/j.clgc.2022.11.020","title":"Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic","year":2022,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; Juravinski Cancer Centre; University of Calgary; St. Michael's Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network","funders":"","keywords":"Docetaxel; Medicine; Pandemic; Prostate cancer; Oncology; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Cancer; Family medicine; Gynecology; Disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.22629383110741824,"score_gpt":0.5035467576751977,"score_spread":0.2772529265677795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310353441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93534315,0.0047188415,0.00048791012,0.011309322,0.00016428811,0.00020356254,0.03606808,0.000091059985,0.011613775],"genre_scores_gemma":[0.9855839,0.0028034754,0.00049458287,0.0016511979,0.00004687864,0.000052698226,0.007073356,0.000024448334,0.0022695085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701023,0.00017049976,0.00021164592,0.00027863294,0.0009885717,0.0013402943],"domain_scores_gemma":[0.9911349,0.00032853047,0.0014711826,0.0001014243,0.004915479,0.002048379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012751743,0.00032464316,0.0005197238,0.0020758584,0.0026263848,0.0025079479,0.0020487537,0.00092883117,0.003139093],"category_scores_gemma":[0.0068828356,0.00033150674,0.00084264757,0.006662159,0.0008030289,0.0008051083,0.0012899184,0.0016782283,0.0002446206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031448074,0.00008249129,0.9730443,0.00015498331,0.00013667892,0.00011243481,0.0011073127,0.00082758255,0.0002455535,0.00068268203,0.0075048674,0.015786747],"study_design_scores_gemma":[0.000008915328,0.000062826766,0.99062634,0.00010308862,0.000034110628,0.000072131676,0.0032383273,0.00070618297,0.000108594475,0.00004701385,0.0049744924,0.000018009956],"about_ca_topic_score_codex":0.9950795,"about_ca_topic_score_gemma":0.99647456,"teacher_disagreement_score":0.9315469,"about_ca_system_score_codex":0.068453096,"about_ca_system_score_gemma":0.09195423,"threshold_uncertainty_score":0.4966643},"labels":[],"label_agreement":null},{"id":"W4312143504","doi":"10.1016/j.clgc.2022.12.006","title":"Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Internal medicine; Meta-analysis; Relative risk; Diabetes mellitus; Confidence interval; Metabolic syndrome; Oncology; Random effects model; Cancer; Endocrinology; Obesity","score_opus":0.19316705373262885,"score_gpt":0.4690140193793063,"score_spread":0.27584696564667743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312143504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008814785,0.98883456,0.00068695156,0.00017926135,0.000246263,0.000035021647,0.00081961264,0.000038816335,0.00034473182],"genre_scores_gemma":[0.30905423,0.683521,0.0020616355,0.0016395444,0.0005362216,0.00014779672,0.0018898902,0.000080238984,0.001069496],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99822086,0.00065248593,0.0004182576,0.00036934784,0.00020973117,0.00012930161],"domain_scores_gemma":[0.99752504,0.0016506648,0.00038345667,0.00016723857,0.00020262555,0.00007091031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028311657,0.0019693363,0.008409227,0.0018267644,0.00029642446,0.0017534246,0.001306582,0.0014391266,0.0040186075],"category_scores_gemma":[0.0061030607,0.0010924808,0.025340248,0.0034489792,0.00030265236,0.0009885558,0.0011406161,0.0020531064,0.00047697558],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032588083,0.00002871815,0.014767085,0.075527035,0.8836642,0.00014588595,0.00005134595,0.00061467884,0.00053648633,0.00013225363,0.0016472084,0.01962632],"study_design_scores_gemma":[0.00051649904,0.00011156826,0.010695136,0.0026226023,0.9833799,0.00008330456,0.000025568264,0.00015610731,0.00007789849,0.00018465593,0.0021223973,0.000024399062],"about_ca_topic_score_codex":0.007873741,"about_ca_topic_score_gemma":0.018793661,"teacher_disagreement_score":0.008409227,"about_ca_system_score_codex":0.0008227198,"about_ca_system_score_gemma":0.0011037467,"threshold_uncertainty_score":0.015655816},"labels":[],"label_agreement":null},{"id":"W4313216173","doi":"10.1016/j.clgc.2022.12.005","title":"The Importance of Repeat Imaging Prior to Treatment Decision-making in Testicular Cancer: Commentary From the Inaugural Global Society of Rare Genitourinary Tumors Summit","year":2022,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Summit; Testicular cancer; Genitourinary system; Cancer; Prostate cancer; Gynecology; Internal medicine","score_opus":0.07201843192627884,"score_gpt":0.44156567897869503,"score_spread":0.3695472470524162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313216173","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008557691,0.6499921,0.00015763754,0.29817313,0.05064725,0.00001131576,0.0002035166,0.000021175067,0.00070838694],"genre_scores_gemma":[0.0021113772,0.46851447,0.0005734539,0.446191,0.081349954,0.000051818584,0.00018071255,0.000029887367,0.0009973291],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954755,0.0018773802,0.00084735674,0.00051178527,0.0010521115,0.00023590497],"domain_scores_gemma":[0.9567754,0.030116674,0.0025552663,0.00041633376,0.008969974,0.0011662256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077186,0.00097183953,0.003893001,0.001726995,0.0009581225,0.0033682832,0.0028464333,0.015345992,0.0037894119],"category_scores_gemma":[0.0414876,0.00069576834,0.0024524843,0.0021821724,0.001990596,0.0050312607,0.0020110616,0.018457003,0.0018692903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012497877,0.000012504691,0.00019781975,0.009378326,0.00027977544,0.00018658153,0.00015963122,0.00015234355,0.00010173182,0.0018260282,0.90305704,0.08452318],"study_design_scores_gemma":[0.00018673265,0.00005582108,0.0009400132,0.048870396,0.00072932674,0.00064205326,0.000345254,0.00016141063,0.000079685735,0.0036147388,0.94428766,0.00008684487],"about_ca_topic_score_codex":0.012011446,"about_ca_topic_score_gemma":0.04219919,"teacher_disagreement_score":0.015345992,"about_ca_system_score_codex":0.004372839,"about_ca_system_score_gemma":0.011427348,"threshold_uncertainty_score":0.0408203},"labels":[],"label_agreement":null},{"id":"W4313627518","doi":"10.1016/j.clgc.2023.01.001","title":"Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Foundation Medicine; Ipsen; National Institute for Health and Care Research; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Pfizer; Genentech; Medical Research Council; PharmaMar; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Discontinuation; Placebo; Prostate cancer; Internal medicine; Prednisone; Rash; Adverse effect; Prednisolone; Gastroenterology; Cancer; Oncology; Urology; Pathology","score_opus":0.1045101810834043,"score_gpt":0.4297782096430927,"score_spread":0.3252680285596884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313627518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850096,0.0114750685,0.0003696363,0.00027679466,0.00011196118,0.000522118,0.00068555074,0.000065763685,0.0014835339],"genre_scores_gemma":[0.99516135,0.0026412108,0.000373276,0.00022487425,0.00014442495,0.00032749228,0.0004775464,0.000007781989,0.00064204994],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991999,0.00042674478,0.00007597539,0.000097476026,0.00014565456,0.000054158205],"domain_scores_gemma":[0.9989772,0.00027924465,0.00046530794,0.000053064072,0.00005686606,0.00016832525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014229261,0.0005176885,0.001726358,0.00031888788,0.00019130322,0.0006215832,0.00042074546,0.00060637214,0.002793553],"category_scores_gemma":[0.0018817543,0.00021444625,0.0014181101,0.00044517897,0.0004183673,0.0004793365,0.00023818582,0.0015804357,0.0004572658],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8617528,0.003686878,0.0049640853,0.0019024801,0.0025264113,0.00015937301,0.00014836057,0.0014155546,0.017922478,0.00012270117,0.0008955961,0.1045033],"study_design_scores_gemma":[0.39370403,0.55459017,0.035497066,0.00029942594,0.0031663994,0.0010511626,0.000114623355,0.0017887361,0.005008116,0.00054250273,0.004178071,0.000059636415],"about_ca_topic_score_codex":0.00032180818,"about_ca_topic_score_gemma":0.00093541836,"teacher_disagreement_score":0.002793553,"about_ca_system_score_codex":0.0004119225,"about_ca_system_score_gemma":0.0006659228,"threshold_uncertainty_score":0.009345353},"labels":[],"label_agreement":null},{"id":"W4318064951","doi":"10.1016/j.clgc.2023.01.009","title":"Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Niagara Health System; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"Joseph and Silvana Melara Cancer Research Fund","keywords":"Medicine; Prostate cancer; Sarcopenia; Castration; Internal medicine; Oncology; Cancer; Urology; Hormone","score_opus":0.13355121096114417,"score_gpt":0.4533313267624982,"score_spread":0.319780115801354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318064951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984363,0.0006966522,0.000030960207,0.000056326753,0.000011743439,0.00000997207,0.00019024627,0.0000034146851,0.0005642385],"genre_scores_gemma":[0.9995034,0.00014963408,0.000017992643,0.000023837472,0.000012086465,0.0000036066574,0.00016004233,6.336594e-7,0.00012893227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998542,0.0000306777,0.00001701061,0.000029889365,0.000027873904,0.000040219464],"domain_scores_gemma":[0.99975187,0.000027388729,0.00010275128,0.000009082097,0.000023642622,0.00008533333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018746789,0.00029662772,0.00045219387,0.0004786405,0.00035442738,0.0004272399,0.0001862311,0.0004231314,0.0011298981],"category_scores_gemma":[0.0006980235,0.00019266127,0.00059565366,0.00074439385,0.00017598773,0.00024605237,0.000317339,0.00039108784,0.00011399209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010627161,0.00008086939,0.99389136,0.000026035104,0.00013395508,0.000273533,0.00006167598,0.00008418883,0.00034848673,0.000009948522,0.00012493419,0.0039023291],"study_design_scores_gemma":[0.000014621069,0.00035167686,0.99904126,0.0000068200675,0.000053389256,0.00023662923,0.00006952118,0.00009090492,0.000025258558,0.00000779441,0.0000997087,0.0000023819714],"about_ca_topic_score_codex":0.006550532,"about_ca_topic_score_gemma":0.013234549,"teacher_disagreement_score":0.006550532,"about_ca_system_score_codex":0.00030678575,"about_ca_system_score_gemma":0.0002694943,"threshold_uncertainty_score":0.013024807},"labels":[],"label_agreement":null},{"id":"W4318065001","doi":"10.1016/j.clgc.2023.01.008","title":"Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Receiver operating characteristic; Oncology; Internal medicine; Youden's J statistic; Urology; Area under the curve; Neoadjuvant therapy; Proportional hazards model; Logistic regression; Retrospective cohort study; Cancer; Gastroenterology","score_opus":0.017831391182377688,"score_gpt":0.30661674822825696,"score_spread":0.28878535704587927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318065001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997322,0.0013332316,0.00014104748,0.00012551736,0.00003597532,0.0000072918283,0.000118533084,0.0000061146234,0.0009102864],"genre_scores_gemma":[0.99953115,0.00013035048,0.0000836472,0.000022360584,0.000025934973,0.0000047422864,0.000083545005,0.0000014329462,0.00011693783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996817,0.0001247542,0.000045772944,0.00004288904,0.00005156796,0.00005329799],"domain_scores_gemma":[0.9983822,0.0006503151,0.0004682043,0.0000736292,0.00014255273,0.0002830283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007073696,0.00028147103,0.0004258231,0.000620884,0.000262515,0.000665584,0.00029370727,0.0005264778,0.0011611069],"category_scores_gemma":[0.0034977149,0.00016514039,0.00026629577,0.00067680125,0.00042261078,0.0004715084,0.00029732168,0.00068314356,0.00018856933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065922574,0.000031991854,0.9963168,0.000010106015,0.000043578268,0.000087292414,0.000025901885,0.00012219962,0.00046622154,0.00002048492,0.00007012503,0.0021460736],"study_design_scores_gemma":[0.000019258123,0.00028658763,0.99610305,0.000014116739,0.0001277372,0.00061064836,0.0002289251,0.0016030013,0.00041973827,0.000099145705,0.0004779338,0.000009825576],"about_ca_topic_score_codex":0.00092601194,"about_ca_topic_score_gemma":0.0014790758,"teacher_disagreement_score":0.0011611069,"about_ca_system_score_codex":0.00028221268,"about_ca_system_score_gemma":0.00040897506,"threshold_uncertainty_score":0.003884256},"labels":[],"label_agreement":null},{"id":"W4327692917","doi":"10.1016/j.clgc.2023.03.005","title":"Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods Research","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Psychological intervention; Nursing; Health care; Family medicine","score_opus":0.19710779382864,"score_gpt":0.510845723783789,"score_spread":0.31373792995514904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327692917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852659,0.002587172,0.0036155176,0.0023972094,0.000058166224,0.0036557713,0.00030328127,0.0000081264425,0.0021088785],"genre_scores_gemma":[0.9769092,0.002878038,0.010700304,0.001906366,0.000046792215,0.00681969,0.00018984383,0.000010008385,0.00053975027],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9684092,0.024120934,0.0023086187,0.0012197943,0.0022607576,0.0016807896],"domain_scores_gemma":[0.9549968,0.034945447,0.0043279743,0.0008699208,0.0037512316,0.0011085653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.048897278,0.0004445672,0.0007232953,0.0024656714,0.0044254255,0.0045124455,0.0014511276,0.0014996784,0.002202607],"category_scores_gemma":[0.04712809,0.00074551406,0.0009456659,0.0024629708,0.0018859656,0.0032546408,0.0039004378,0.0013882185,0.00022068483],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022319188,0.0011631942,0.15440871,0.005625529,0.000197266,0.0010184823,0.76017445,0.00018935384,0.00086672837,0.0021594965,0.0013323483,0.07264124],"study_design_scores_gemma":[0.000072428535,0.000776206,0.045718864,0.0029642857,0.00009737443,0.00037500917,0.94248134,0.000572932,0.0004656785,0.0011453948,0.0052878587,0.00004269821],"about_ca_topic_score_codex":0.007201543,"about_ca_topic_score_gemma":0.012850415,"teacher_disagreement_score":0.048897278,"about_ca_system_score_codex":0.005022384,"about_ca_system_score_gemma":0.010878156,"threshold_uncertainty_score":0.25859666},"labels":[],"label_agreement":null},{"id":"W4360874540","doi":"10.1016/j.clgc.2023.03.009","title":"Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Enzalutamide; Docetaxel; Concomitant; Prostate cancer; Urology; Testosterone (patch); Internal medicine; Oncology; Prostate; Adverse effect; Cancer; Androgen receptor","score_opus":0.06496777092265317,"score_gpt":0.45894922739006777,"score_spread":0.3939814564674146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919978,0.006534506,0.000066072025,0.00021037633,0.000080172074,0.000025854912,0.00011966231,0.000012250627,0.000953214],"genre_scores_gemma":[0.9985297,0.00075672835,0.00009113738,0.00011880141,0.00009423184,0.000010684185,0.0001020227,0.0000031664545,0.00029342982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999132,0.00049290975,0.00006284809,0.00008549989,0.00009981337,0.00012689574],"domain_scores_gemma":[0.99849296,0.0006989998,0.00037340476,0.00006016765,0.000056179735,0.00031825106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012471665,0.0002703577,0.0011566888,0.00018786834,0.00019822446,0.0006379791,0.00024345327,0.00033999895,0.001978433],"category_scores_gemma":[0.0028035094,0.00016096412,0.001620198,0.00021565847,0.0003612777,0.0007094155,0.00028541285,0.0011928509,0.0001487928],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7691521,0.0035927608,0.06462464,0.0006123731,0.0048276237,0.00012660942,0.0001982745,0.0017867993,0.0049423124,0.00024530446,0.00072155637,0.14916968],"study_design_scores_gemma":[0.056880787,0.4010341,0.5224317,0.00021647765,0.0075022695,0.0004762749,0.00046487257,0.003887187,0.0031518915,0.00058204273,0.0032812783,0.000091187314],"about_ca_topic_score_codex":0.0008214321,"about_ca_topic_score_gemma":0.0026637374,"teacher_disagreement_score":0.001978433,"about_ca_system_score_codex":0.00039796374,"about_ca_system_score_gemma":0.0006373485,"threshold_uncertainty_score":0.0066184998},"labels":[],"label_agreement":null},{"id":"W4361228771","doi":"10.1016/j.clgc.2023.03.012","title":"Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Foundation of Korea","keywords":"Medicine; Prostate cancer; Precision medicine; Decision support system; Oncology; Cancer; Internal medicine; Machine learning; Artificial intelligence; Pathology; Computer science","score_opus":0.1484363886325666,"score_gpt":0.4358126648759478,"score_spread":0.28737627624338113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361228771","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16907112,0.0017770902,0.81374323,0.0013562192,0.00026009226,0.0004917609,0.0012828386,0.0099777365,0.0020399434],"genre_scores_gemma":[0.4566091,0.00034407733,0.5396544,0.0006164206,0.000102399594,0.00028907025,0.0009830375,0.00012925007,0.0012722628],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983217,0.00057246693,0.00020000382,0.00034881217,0.00047583668,0.0000811293],"domain_scores_gemma":[0.9935057,0.004157844,0.0004589084,0.00033737926,0.0013966816,0.00014344788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046736947,0.00068108446,0.00075999537,0.0009097119,0.0005000665,0.0017234143,0.00096563896,0.0011965015,0.0014709634],"category_scores_gemma":[0.011299798,0.00033360906,0.0005105535,0.0005345986,0.0003021585,0.00070662005,0.00064194173,0.001046313,0.0005862237],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019559166,0.00058221305,0.018481588,0.00048889377,0.00039268626,0.00026109917,0.00024631512,0.1272565,0.045388628,0.0033848167,0.008621308,0.79293996],"study_design_scores_gemma":[0.00021646338,0.00062515296,0.005367541,0.00007711956,0.00016098254,0.00023270176,0.00004382238,0.95034,0.034218997,0.0038812933,0.004796028,0.00004005743],"about_ca_topic_score_codex":0.004040633,"about_ca_topic_score_gemma":0.004058686,"teacher_disagreement_score":0.0046736947,"about_ca_system_score_codex":0.0008082318,"about_ca_system_score_gemma":0.0022027306,"threshold_uncertainty_score":0.024717152},"labels":[],"label_agreement":null},{"id":"W4366754119","doi":"10.1016/j.clgc.2023.04.007","title":"Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs","year":2023,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hypokalemia; Cardiotoxicity; Internal medicine; Prostate cancer; Randomized controlled trial; Placebo; Abiraterone acetate; Odds ratio; Meta-analysis; Cancer; Gastroenterology; Androgen deprivation therapy; Chemotherapy; Pathology","score_opus":0.36135703015794335,"score_gpt":0.5240024488816203,"score_spread":0.16264541872367694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366754119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01895311,0.9754877,0.0030177522,0.00032994084,0.0004125028,0.00046723438,0.0006661468,0.000072376715,0.0005932352],"genre_scores_gemma":[0.6228138,0.3616809,0.008449024,0.0022732867,0.00043986997,0.0013655436,0.0014881766,0.00020066649,0.0012887369],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9756916,0.014936887,0.0057505304,0.0018393521,0.0013200179,0.00046158512],"domain_scores_gemma":[0.9510541,0.039100688,0.005969449,0.0021110147,0.0013628372,0.00040199267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027022244,0.0025894186,0.011428113,0.002051664,0.0005748985,0.003759119,0.0019135233,0.0025954305,0.004251978],"category_scores_gemma":[0.06210351,0.0017335684,0.043597676,0.0031990756,0.0010001904,0.0019665726,0.0019697524,0.003071323,0.0004149703],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004661824,0.000016170474,0.005060369,0.063994154,0.9198335,0.000049108185,0.00007658883,0.00027046955,0.0001781532,0.00010664332,0.00029134273,0.0054617887],"study_design_scores_gemma":[0.0013686336,0.00018991705,0.002981079,0.003941635,0.99009293,0.00004788986,0.00003227815,0.00012491668,0.00007205826,0.00024832887,0.0008839584,0.000016458434],"about_ca_topic_score_codex":0.005189708,"about_ca_topic_score_gemma":0.012238647,"teacher_disagreement_score":0.027022244,"about_ca_system_score_codex":0.00214025,"about_ca_system_score_gemma":0.0024163395,"threshold_uncertainty_score":0.14290899},"labels":[],"label_agreement":null},{"id":"W4366814658","doi":"10.1016/j.clgc.2023.04.008","title":"Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Prostate cancer; Chemotherapy; Internal medicine; Oncology; Taxane; Cancer; Breast cancer","score_opus":0.10718751538685452,"score_gpt":0.4346031280357007,"score_spread":0.3274156126488462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366814658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998701,0.00038787053,0.000044390763,0.000042752432,0.0000065857007,0.000011653185,0.0004728742,0.0000019162119,0.00033099452],"genre_scores_gemma":[0.9987207,0.0001498761,0.000036416106,0.000050536968,0.000018012877,0.000011026015,0.0009150749,0.0000024437743,0.0000959175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991509,0.00017885253,0.0000961686,0.00022399568,0.0001275504,0.00022257303],"domain_scores_gemma":[0.9975527,0.0002691091,0.0012648745,0.00013830083,0.00021132773,0.00056365447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070008636,0.00036394713,0.000735281,0.00085908966,0.00077244034,0.0014944909,0.0006287783,0.00060564204,0.0014485546],"category_scores_gemma":[0.0021004055,0.00025945046,0.0015533654,0.0016980303,0.000394916,0.0012534108,0.0011647104,0.0009975624,0.00015587693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005039209,0.00011635671,0.9977598,0.000014914679,0.00023111887,0.00008840015,0.00006178768,0.000059152917,0.00010615607,0.000022295768,0.00011591446,0.0009201721],"study_design_scores_gemma":[0.000054425942,0.00037786024,0.99812466,0.000013579547,0.00015631015,0.00035985923,0.00044842114,0.00016472086,0.000060682603,0.000033510165,0.00019337027,0.000012589608],"about_ca_topic_score_codex":0.005888439,"about_ca_topic_score_gemma":0.007796466,"teacher_disagreement_score":0.005888439,"about_ca_system_score_codex":0.0013079179,"about_ca_system_score_gemma":0.0009783729,"threshold_uncertainty_score":0.011708319},"labels":[],"label_agreement":null},{"id":"W4377023748","doi":"10.1016/j.clgc.2023.05.010","title":"Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Lymph node; Lymph; Proportional hazards model; Dissection (medical); Internal medicine; Urology; Subgroup analysis; Oncology; Cancer; Surveillance, Epidemiology, and End Results; Surgery; Pathology; Cancer registry; Confidence interval","score_opus":0.12734387318785548,"score_gpt":0.39714999251112304,"score_spread":0.2698061193232676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377023748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981438,0.00027479633,0.0000854634,0.000041054933,0.000010412745,0.0000031529148,0.0005663212,0.0000071743,0.0008677466],"genre_scores_gemma":[0.99928755,0.000046784135,0.000015560729,0.000013361329,0.000009106067,0.0000016154532,0.0003791876,0.0000027300594,0.00024424648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997515,0.000036038135,0.000022649727,0.00007433957,0.000022790697,0.000092758986],"domain_scores_gemma":[0.99898654,0.0003289804,0.00024771478,0.00008069949,0.00006624342,0.0002898414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027128056,0.0002821126,0.00041953492,0.00055519014,0.00022057796,0.00044530525,0.0004049846,0.00041228157,0.0041432166],"category_scores_gemma":[0.0016847999,0.0002493975,0.0008305178,0.00055101875,0.00027490486,0.00046933562,0.0005784561,0.00064045674,0.0003231147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014942626,0.000035137116,0.99399734,0.000017800121,0.00023963384,0.00012783079,0.00009311301,0.00029626634,0.0009806498,0.00008261126,0.00023078505,0.0024044467],"study_design_scores_gemma":[0.000008949202,0.00010793311,0.9990926,0.000002626082,0.00005382934,0.00013272467,0.0001275454,0.0002555231,0.000058241098,0.00006732319,0.00008732983,0.0000054277425],"about_ca_topic_score_codex":0.003532229,"about_ca_topic_score_gemma":0.0065647536,"teacher_disagreement_score":0.0041432166,"about_ca_system_score_codex":0.00023302807,"about_ca_system_score_gemma":0.00040246182,"threshold_uncertainty_score":0.0138604045},"labels":[],"label_agreement":null},{"id":"W4377826791","doi":"10.1016/j.clgc.2023.05.012","title":"Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation","keywords":"Medicine; Prostate cancer; Germline; Gene; DNA repair; Cancer; Oncology; Genetics; Internal medicine; Cancer research; Biology","score_opus":0.034704448532788965,"score_gpt":0.3476029334437013,"score_spread":0.3128984849109123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377826791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987607,0.0001369853,0.000038937436,0.0001058394,0.000008384632,0.0000025980914,0.00016461752,0.0000022540708,0.00077972154],"genre_scores_gemma":[0.9994265,0.000100780104,0.00003140195,0.000060332433,0.000010357615,0.0000029542798,0.00013875341,0.000002102993,0.00022687875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998828,0.000021246156,0.000008305995,0.000038201742,0.000017318775,0.000032068812],"domain_scores_gemma":[0.99975985,0.00004096898,0.00011654204,0.000014390107,0.000025675827,0.00004265832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014404008,0.00022386413,0.00015150683,0.00057406514,0.0005711466,0.0003785946,0.00019309328,0.0002951639,0.0037270573],"category_scores_gemma":[0.00088804605,0.00015989531,0.00021176136,0.00069483934,0.0002480477,0.00014902097,0.00021089532,0.000333771,0.00017924164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028298487,0.000074144926,0.9932161,0.000017227996,0.000067571695,0.0010737401,0.00038718528,0.00004040092,0.0016446024,0.00011765094,0.00044127417,0.0026371242],"study_design_scores_gemma":[0.00003316817,0.00008888291,0.993251,0.000023736298,0.000093181894,0.0038070185,0.0012304498,0.00013100874,0.00016460098,0.00008827536,0.0010815883,0.000007074084],"about_ca_topic_score_codex":0.0073393206,"about_ca_topic_score_gemma":0.006988563,"teacher_disagreement_score":0.0073393206,"about_ca_system_score_codex":0.0002159109,"about_ca_system_score_gemma":0.00020302179,"threshold_uncertainty_score":0.014593244},"labels":[],"label_agreement":null},{"id":"W4380318667","doi":"10.1016/j.clgc.2023.06.003","title":"Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Hazard ratio; Proportional hazards model; Propensity score matching; Confidence interval; Internal medicine; Nephrectomy; Urology; Surveillance, Epidemiology, and End Results; Oncology; Incidence (geometry); Cancer; Surgery; Cancer registry; Kidney","score_opus":0.10840050343005263,"score_gpt":0.3723783414142304,"score_spread":0.26397783798417773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380318667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974916,0.00078369706,0.00013852771,0.0000828446,0.000028659313,0.0000053468066,0.000214397,0.000004767691,0.001250166],"genre_scores_gemma":[0.99941957,0.00008759709,0.000015068815,0.0000248438,0.000020732725,0.0000024611602,0.00019105794,0.000002002436,0.00023677685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955124,0.0001204768,0.000035058005,0.00009176735,0.000055889075,0.0001455623],"domain_scores_gemma":[0.9986192,0.00061378005,0.00024097275,0.00008185872,0.000090469286,0.00035376984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069781765,0.0002296597,0.00058569177,0.00040442537,0.00016429022,0.00039254513,0.00025869143,0.00049455656,0.0020749734],"category_scores_gemma":[0.0021957397,0.00010322981,0.0010829603,0.00036886137,0.0003466653,0.0004368929,0.00035636182,0.00053005386,0.00020720197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056982294,0.00032184835,0.8889176,0.00012329422,0.0014576715,0.0006508991,0.00044032186,0.0024144119,0.010457215,0.0005645305,0.0010929827,0.036576975],"study_design_scores_gemma":[0.00011983537,0.0028560022,0.9943879,0.000011287706,0.00023493751,0.00032663383,0.00021614083,0.0008117551,0.00038424655,0.00027606002,0.00036031633,0.000014923079],"about_ca_topic_score_codex":0.0017350982,"about_ca_topic_score_gemma":0.0030720748,"teacher_disagreement_score":0.0020749734,"about_ca_system_score_codex":0.00039432518,"about_ca_system_score_gemma":0.00038565067,"threshold_uncertainty_score":0.0069414973},"labels":[],"label_agreement":null},{"id":"W4385454243","doi":"10.1016/j.clgc.2023.07.013","title":"Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Concordance; Hazard ratio; Biopsy; Internal medicine; Oncology; Proportional hazards model; Lymphovascular invasion; Biochemical recurrence; Cancer; Prostatectomy; Confidence interval; Metastasis","score_opus":0.1461759309016695,"score_gpt":0.41726883086174177,"score_spread":0.27109289996007224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385454243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8777242,0.011203213,0.025609633,0.00423626,0.0009589102,0.0008955124,0.00793709,0.0008727235,0.07056246],"genre_scores_gemma":[0.9695076,0.0010778233,0.023124449,0.0005235574,0.00032697277,0.00014710793,0.0035243148,0.00010322636,0.0016649208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942502,0.0019182096,0.0011405575,0.00077920774,0.001497257,0.00041453284],"domain_scores_gemma":[0.9791387,0.00658323,0.004460375,0.0031517386,0.005593208,0.0010727475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009458231,0.0009004939,0.0010612432,0.00491612,0.0009670684,0.0029776036,0.0015783012,0.0007617101,0.0043626702],"category_scores_gemma":[0.03200838,0.00045245345,0.0012810262,0.002938019,0.00072715664,0.002465384,0.0023230752,0.0012321749,0.0009422613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003285115,0.000069274654,0.9339348,0.00034270764,0.0002578229,0.00028219252,0.00025457988,0.0007401391,0.0022444099,0.00054344494,0.0033243874,0.05767769],"study_design_scores_gemma":[0.000029388782,0.00045269812,0.9521087,0.0005634696,0.00077815325,0.0033671889,0.00077164854,0.010394051,0.0051153065,0.00171859,0.024603209,0.000097533884],"about_ca_topic_score_codex":0.00808568,"about_ca_topic_score_gemma":0.02232041,"teacher_disagreement_score":0.009458231,"about_ca_system_score_codex":0.0007862778,"about_ca_system_score_gemma":0.0021589366,"threshold_uncertainty_score":0.050020516},"labels":[],"label_agreement":null},{"id":"W4385752997","doi":"10.1016/j.clgc.2023.08.004","title":"Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Lung; Lymph node; Prostate cancer; Lymph; Internal medicine; Prostate; Proportional hazards model; Oncology; Gastroenterology; Cancer; Pathology","score_opus":0.13186869164170348,"score_gpt":0.45688983475261163,"score_spread":0.32502114311090813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385752997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939414,0.0011624633,0.00022156275,0.00009238875,0.00001809035,0.0000057851116,0.0017942006,0.000015441801,0.0027485401],"genre_scores_gemma":[0.99814,0.00016345693,0.00002968157,0.000029604113,0.000013716944,0.0000033292401,0.0009312181,0.0000039601287,0.0006850161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998049,0.000027231355,0.000011057498,0.000045593762,0.000019588231,0.000091650865],"domain_scores_gemma":[0.99948597,0.00014441197,0.00012815867,0.00002882491,0.000051243846,0.00016129919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029221046,0.00026212883,0.00036481032,0.0006077807,0.00024222866,0.0003961799,0.00026731862,0.00033877252,0.004863709],"category_scores_gemma":[0.0008810926,0.0001474506,0.0007641096,0.0005577235,0.00022650843,0.00048782318,0.00051921036,0.00045223374,0.00037472276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004619911,0.000054700864,0.9761572,0.00005398774,0.00050127285,0.00032934494,0.00014449797,0.0013160009,0.0022467622,0.00019296471,0.0011482097,0.013235175],"study_design_scores_gemma":[0.000025184461,0.0004326985,0.9971029,0.000010385521,0.00018701027,0.0005332947,0.000175024,0.00062118843,0.00014132465,0.00017339454,0.0005862674,0.000011365067],"about_ca_topic_score_codex":0.0033434946,"about_ca_topic_score_gemma":0.005549167,"teacher_disagreement_score":0.004863709,"about_ca_system_score_codex":0.0002769077,"about_ca_system_score_gemma":0.00022498067,"threshold_uncertainty_score":0.016270757},"labels":[],"label_agreement":null},{"id":"W4388099416","doi":"10.1016/j.clgc.2023.10.007","title":"Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Proportional hazards model; Stage (stratigraphy); Lymph node; Radiography; Internal medicine; Cohort; Nephrectomy; Oncology; Cancer; Metastasis; Histology; Clear cell; Radiology; Kidney","score_opus":0.11458592131447154,"score_gpt":0.35041434628872703,"score_spread":0.2358284249742555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388099416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739766,0.0009653887,0.00008680411,0.000090937305,0.000012324092,0.0000030958263,0.00021035032,0.0000040625,0.001229379],"genre_scores_gemma":[0.9995371,0.0001365232,0.000021951635,0.000012108356,0.000019345887,0.0000019313359,0.00016210352,0.0000014959717,0.00010741971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998141,0.00003828351,0.000019674551,0.000036455556,0.000039213326,0.000052258685],"domain_scores_gemma":[0.9992654,0.00017594926,0.00028259223,0.000034690074,0.00006290565,0.00017851428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003136398,0.00022230337,0.00030351058,0.000501004,0.00035637186,0.00070155604,0.00037219675,0.00039261833,0.002131789],"category_scores_gemma":[0.0021393267,0.0001464405,0.0003311596,0.00095067103,0.00039250887,0.00047301833,0.00043060165,0.00056762696,0.00018855675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023405868,0.000012830539,0.9971155,0.000009803593,0.00003780499,0.000117239855,0.000044580913,0.00011232593,0.00028609968,0.000036782712,0.00007689408,0.001916097],"study_design_scores_gemma":[0.0000061160076,0.0000767498,0.9987778,0.0000042831853,0.00004021093,0.00036206513,0.00014865444,0.00021844517,0.000068741414,0.000042459706,0.00025124333,0.0000032630157],"about_ca_topic_score_codex":0.0034928734,"about_ca_topic_score_gemma":0.0066975127,"teacher_disagreement_score":0.0034928734,"about_ca_system_score_codex":0.00042246137,"about_ca_system_score_gemma":0.0003928853,"threshold_uncertainty_score":0.0071315765},"labels":[],"label_agreement":null},{"id":"W4388210755","doi":"10.1016/j.clgc.2023.10.011","title":"Other-Cause Mortality, According to Partial vs. Radical Nephrectomy: Age and Stage Analyses","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nephrectomy; Medicine; Renal cell carcinoma; Stage (stratigraphy); Incidence (geometry); Surgery; Urology; Internal medicine; Kidney","score_opus":0.3514332743406447,"score_gpt":0.5119868355715679,"score_spread":0.16055356123092318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388210755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587655,0.0011798759,0.00031237563,0.00007611976,0.000038638944,0.000009173563,0.001311669,0.0000130671915,0.0011825102],"genre_scores_gemma":[0.99784565,0.0002558763,0.000087347275,0.000044835862,0.000047223522,0.000010807235,0.0009209641,0.000009411291,0.00077783794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993217,0.00016368525,0.00005859768,0.00018231977,0.00008498831,0.00018879124],"domain_scores_gemma":[0.998279,0.00077754894,0.000370885,0.0001757687,0.00008076293,0.00031599862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010823486,0.00044821197,0.00094997126,0.00059699756,0.00020124752,0.00060205336,0.00050080154,0.0006349292,0.003724698],"category_scores_gemma":[0.002413409,0.00027934246,0.0025571368,0.00080456765,0.00027361,0.0008597674,0.00050778996,0.0010267642,0.00032239992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017477185,0.00019905235,0.96875685,0.000090412046,0.0021902525,0.00016155101,0.00010177377,0.00087495375,0.0016526148,0.00014902574,0.00094738195,0.007398938],"study_design_scores_gemma":[0.0001562332,0.0013718503,0.9943762,0.00001205633,0.00091266865,0.00019018193,0.00024179809,0.0017858538,0.00025278793,0.0001830368,0.00049516343,0.000022251648],"about_ca_topic_score_codex":0.003312413,"about_ca_topic_score_gemma":0.0054139257,"teacher_disagreement_score":0.003724698,"about_ca_system_score_codex":0.00031255264,"about_ca_system_score_gemma":0.0005152242,"threshold_uncertainty_score":0.012460351},"labels":[],"label_agreement":null},{"id":"W4388498795","doi":"10.1016/j.clgc.2023.11.001","title":"Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence","year":2023,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ipsen; Ipsen Fund","keywords":"Cabozantinib; Medicine; Tolerability; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Kidney cancer; Adverse effect; Systematic review; MEDLINE","score_opus":0.2021130837119291,"score_gpt":0.46081948946590984,"score_spread":0.25870640575398074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388498795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085796404,0.9972677,0.0001970331,0.00036456808,0.000108780885,0.00041117915,0.0005106723,0.00000967322,0.00027234922],"genre_scores_gemma":[0.014501963,0.9820318,0.0010440078,0.00090163696,0.00010900547,0.0008899338,0.00041283946,0.000009981582,0.00009881154],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9822916,0.005903601,0.007588374,0.0011168722,0.002707982,0.00039158837],"domain_scores_gemma":[0.94178826,0.03961442,0.011146392,0.001079544,0.005831545,0.0005398302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017851045,0.0017156459,0.0094841495,0.0149522405,0.00083481375,0.0033518267,0.0023249448,0.002118755,0.0053563993],"category_scores_gemma":[0.06518032,0.0012243488,0.0083877435,0.014115605,0.0011622765,0.0028786587,0.002215,0.0014589396,0.0005125336],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015974644,0.0000088335155,0.0004894452,0.97335875,0.00712373,0.00005323879,0.00012913969,0.000058047608,0.000108534434,0.00012713805,0.0008305787,0.017552817],"study_design_scores_gemma":[0.00020670444,0.00011330098,0.0021624574,0.9274738,0.057662133,0.00018683185,0.00018831839,0.00006134612,0.00011752183,0.00024273858,0.011557192,0.000027679884],"about_ca_topic_score_codex":0.008990381,"about_ca_topic_score_gemma":0.027132535,"teacher_disagreement_score":0.017851045,"about_ca_system_score_codex":0.0049522347,"about_ca_system_score_gemma":0.018650562,"threshold_uncertainty_score":0.094406426},"labels":[],"label_agreement":null},{"id":"W4388752480","doi":"10.1016/j.clgc.2023.11.006","title":"The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ Prostate Cancer: A Multicenter Study","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Lymph node; Biochemical recurrence; Radiology; PET-CT; Proportional hazards model; Nuclear medicine; Positron emission tomography; Internal medicine; Cancer","score_opus":0.046225874543025944,"score_gpt":0.39990364442914156,"score_spread":0.3536777698861156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388752480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781966,0.0014928004,0.00007258121,0.00006607951,0.000006282797,0.000017585186,0.00027129028,0.0000025061454,0.00025120683],"genre_scores_gemma":[0.9990644,0.00035125331,0.000097562865,0.000031879434,0.0000288896,0.000016499698,0.00034189344,0.0000023993998,0.00006508901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879384,0.00059746666,0.00010220864,0.00025757198,0.00014222131,0.00010672698],"domain_scores_gemma":[0.996938,0.0006226786,0.0013884692,0.00036778703,0.0002882755,0.00039476532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025796045,0.0005178262,0.00046145407,0.00060168334,0.00043345254,0.0008165556,0.0006024879,0.0005204007,0.0015467494],"category_scores_gemma":[0.0044986405,0.00037558767,0.0004519734,0.0010533675,0.00050839246,0.00049710233,0.00059611653,0.00039102655,0.00025568224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064514275,0.000042389194,0.9964965,0.000023584726,0.00014297407,0.00006165744,0.00004109967,0.000035266163,0.00017200089,0.000010327555,0.000075140546,0.0022538952],"study_design_scores_gemma":[0.00007786244,0.00036578375,0.99802375,0.000021118076,0.00021249482,0.00050032884,0.00010667083,0.00020783505,0.00008362978,0.00002494652,0.00036863488,0.0000069734197],"about_ca_topic_score_codex":0.0024777162,"about_ca_topic_score_gemma":0.0032225256,"teacher_disagreement_score":0.0025796045,"about_ca_system_score_codex":0.000435539,"about_ca_system_score_gemma":0.00037628156,"threshold_uncertainty_score":0.013642371},"labels":[],"label_agreement":null},{"id":"W4389751876","doi":"10.1016/j.clgc.2023.12.004","title":"Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval","funders":"Fonds de Recherche du Québec - Santé; University of British Columbia; Centre Hospitalier Universitaire de Québec","keywords":"Medicine; Internal medicine; Bacillus (shape); Oncology; Immunology; Microbiology","score_opus":0.1080198090621359,"score_gpt":0.44221844007046646,"score_spread":0.3341986310083306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389751876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433535,0.0035800198,0.00020108988,0.00019835948,0.000073479154,0.000021755704,0.0001838526,0.000018933975,0.001387071],"genre_scores_gemma":[0.9986382,0.00039278434,0.0001999955,0.000076900316,0.00008077644,0.000020780013,0.0002191752,0.0000025996615,0.000368642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995728,0.00016461976,0.000026714091,0.000053808857,0.00009160975,0.00009041208],"domain_scores_gemma":[0.9990225,0.00031800105,0.0003176125,0.000044127195,0.00012764853,0.00017012103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005606854,0.0002763897,0.0005759068,0.00057384634,0.00018541959,0.0005321844,0.00019105493,0.0004911754,0.001116672],"category_scores_gemma":[0.0016316754,0.0001016466,0.00022100259,0.0005402461,0.00021028853,0.00024250272,0.00022190418,0.0007468481,0.0002694761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073392647,0.00039132455,0.93366194,0.000118310905,0.00027974494,0.00047568476,0.00009174561,0.00027034644,0.012313516,0.000064176915,0.0010048585,0.04398925],"study_design_scores_gemma":[0.00020180864,0.003097969,0.98839825,0.00004557195,0.00023734417,0.0013293382,0.00015350038,0.0015679818,0.0033156164,0.000116310686,0.0015203787,0.000015828355],"about_ca_topic_score_codex":0.0004752446,"about_ca_topic_score_gemma":0.0006527873,"teacher_disagreement_score":0.001116672,"about_ca_system_score_codex":0.00021059794,"about_ca_system_score_gemma":0.00017287229,"threshold_uncertainty_score":0.003735602},"labels":[],"label_agreement":null},{"id":"W4390024431","doi":"10.1016/j.clgc.2023.12.010","title":"Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Incorporated; Eisai Canada","keywords":"Medicine; Lenvatinib; Adverse effect; Pembrolizumab; Sunitinib; Internal medicine; Rash; Renal cell carcinoma; Oncology; Intensive care medicine; Cancer; Thyroid cancer; Immunotherapy","score_opus":0.03796370185734156,"score_gpt":0.34374328476668353,"score_spread":0.305779582909342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390024431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97383696,0.016330488,0.0007343307,0.0014367532,0.00009920889,0.00014112667,0.00011732774,0.000028822215,0.0072748642],"genre_scores_gemma":[0.9964264,0.0019559453,0.0005165924,0.00059143733,0.000094298994,0.000028635972,0.00007109398,0.000003522387,0.00031202394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995295,0.0002278354,0.000072891926,0.000026599377,0.00010101798,0.00004208912],"domain_scores_gemma":[0.99933606,0.00021479264,0.0002632824,0.000015678508,0.00008060971,0.00008955443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544271,0.00012230141,0.0003434154,0.00025582002,0.00037523714,0.00042511773,0.00014747,0.00021198699,0.00067754707],"category_scores_gemma":[0.0028638137,0.00007408592,0.00037065698,0.00026799514,0.00006851532,0.00019300051,0.00015196345,0.00052946765,0.000099843826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005250208,0.00083611335,0.6396668,0.00072797027,0.000831185,0.0051534427,0.00055204093,0.001092519,0.007507187,0.00016075392,0.0041997,0.33402216],"study_design_scores_gemma":[0.0006792945,0.006430962,0.94995856,0.00038609808,0.0009935007,0.019019822,0.0008842177,0.0033584668,0.003959321,0.00027015174,0.01402717,0.00003244058],"about_ca_topic_score_codex":0.00089020643,"about_ca_topic_score_gemma":0.0023051086,"teacher_disagreement_score":0.00089020643,"about_ca_system_score_codex":0.0004939844,"about_ca_system_score_gemma":0.0004083256,"threshold_uncertainty_score":0.0035841465},"labels":[],"label_agreement":null},{"id":"W4390246136","doi":"10.1016/j.clgc.2023.12.013","title":"The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Clear cell renal cell carcinoma; Internal medicine","score_opus":0.10167405571182835,"score_gpt":0.3936564586000451,"score_spread":0.29198240288821675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390246136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354184,0.003876373,0.00007097333,0.00078076846,0.00006510078,0.00003352162,0.00016865869,0.000007387646,0.0014553925],"genre_scores_gemma":[0.99858475,0.0005617628,0.00007957448,0.00027052034,0.000081090875,0.000016435628,0.0001973345,0.0000021149287,0.00020652534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994692,0.00026852477,0.000037465223,0.0000612459,0.00004557376,0.00011801121],"domain_scores_gemma":[0.9986785,0.00049048074,0.00038266825,0.000054098047,0.0000687728,0.00032548938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007434864,0.00018739048,0.00057761645,0.00016046225,0.00022250545,0.00041400778,0.00027622664,0.0003631323,0.0018898993],"category_scores_gemma":[0.003371565,0.00008284355,0.0012847265,0.00028542514,0.00014766377,0.00043239605,0.00026796243,0.00087647303,0.00008745662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15351117,0.007391378,0.5521588,0.0008064051,0.0038675878,0.0003704837,0.00043777205,0.006680716,0.004636869,0.00095242873,0.003983009,0.26520342],"study_design_scores_gemma":[0.0039761085,0.02182859,0.96746504,0.00011788962,0.001280916,0.00017024888,0.00026642648,0.0017980366,0.0006208387,0.0003655798,0.0020910709,0.000019330593],"about_ca_topic_score_codex":0.0032162825,"about_ca_topic_score_gemma":0.004718219,"teacher_disagreement_score":0.0032162825,"about_ca_system_score_codex":0.0009403882,"about_ca_system_score_gemma":0.0010697065,"threshold_uncertainty_score":0.0068230033},"labels":[],"label_agreement":null},{"id":"W4391234973","doi":"10.1016/j.clgc.2023.12.006","title":"Corrigendum","year":2024,"lang":"en","type":"erratum","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.15522069340825687,"score_gpt":0.4697687129662767,"score_spread":0.3145480195580198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391234973","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011724564,0.0024854965,0.0005267128,0.0623374,0.8795551,0.00010571522,0.003883957,0.0008133029,0.050175156],"genre_scores_gemma":[0.0035313012,0.007994594,0.0018610957,0.06929461,0.15286933,0.00026439785,0.00740088,0.0013754447,0.75540835],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943355,0.0006449825,0.0005469429,0.0007436613,0.0032837014,0.00044522638],"domain_scores_gemma":[0.9685801,0.0033853916,0.00089390867,0.0013405421,0.024469944,0.0013299925],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026249802,0.0013353048,0.0018882414,0.0029697616,0.0025991437,0.004299868,0.0022926182,0.0043251254,0.315334],"category_scores_gemma":[0.04686799,0.0007908477,0.0015514289,0.0020554066,0.0010024122,0.0017114996,0.0021661434,0.0053518894,0.23328924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004217621,0.0000023547045,0.000014154174,0.000028314302,0.0000011964559,0.00002599627,0.000003447717,0.000007610821,0.00000805363,0.00013203657,0.9969222,0.0028504522],"study_design_scores_gemma":[0.00000948886,0.00000886632,0.00020760682,0.00012122712,0.000006849499,0.000091757574,0.000016539605,0.000038278056,0.0000676565,0.000329401,0.9990921,0.000010220119],"about_ca_topic_score_codex":0.019383196,"about_ca_topic_score_gemma":0.029407142,"teacher_disagreement_score":0.315334,"about_ca_system_score_codex":0.0047637424,"about_ca_system_score_gemma":0.005539001,"threshold_uncertainty_score":0.97659296},"labels":[],"label_agreement":null},{"id":"W4391431106","doi":"10.1016/j.clgc.2024.01.016","title":"Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nephrectomy; Renal cell carcinoma; Demography; Proportional hazards model; Logistic regression; Marital status; Internal medicine; Performance status; Stage (stratigraphy); Epidemiology; Cancer; Kidney; Population; Biology","score_opus":0.06728784782878564,"score_gpt":0.41100857975809013,"score_spread":0.3437207319293045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391431106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977768,0.0006726782,0.00005459528,0.00013375278,0.000011507947,0.0000049719883,0.00037859828,0.000003005144,0.00096409424],"genre_scores_gemma":[0.9994246,0.00015016836,0.000013924461,0.00002852189,0.0000047663816,0.0000012942235,0.00013584693,0.0000010189001,0.00023993723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997067,0.00008030822,0.000030469151,0.000039745784,0.0000473431,0.000095445066],"domain_scores_gemma":[0.99893135,0.0001781827,0.00053677417,0.000041112253,0.00007704044,0.00023546981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031613506,0.00010797974,0.00020070311,0.0005072402,0.00038066178,0.00055737357,0.00025154604,0.00029004776,0.0024106049],"category_scores_gemma":[0.002808868,0.00015291598,0.00057015783,0.00074312836,0.0002249882,0.00039445376,0.0006095129,0.00035663543,0.00019217691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064942185,0.000010886567,0.9981054,0.0000035105402,0.000035132784,0.000020102942,0.000048648908,0.000025542586,0.000053251977,0.000015766931,0.00005111902,0.0015655127],"study_design_scores_gemma":[0.0000020697742,0.000029991981,0.9995432,0.0000029527123,0.000017068573,0.000058028683,0.00015839285,0.0000564444,0.000015145918,0.00001762729,0.0000978346,0.0000012804835],"about_ca_topic_score_codex":0.015165793,"about_ca_topic_score_gemma":0.02656308,"teacher_disagreement_score":0.015165793,"about_ca_system_score_codex":0.000287526,"about_ca_system_score_gemma":0.0003472286,"threshold_uncertainty_score":0.030155063},"labels":[],"label_agreement":null},{"id":"W4391743861","doi":"10.1016/j.clgc.2024.02.003","title":"Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; University of Toronto; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CHEK2; Genetic testing; Germline mutation; Prostate cancer; PMS2; Oncology; Germline; Internal medicine; Cancer; Malignancy; Gynecology; Mutation; DNA mismatch repair; Genetics; Gene; Colorectal cancer; Biology","score_opus":0.09665042977454873,"score_gpt":0.4267790101597776,"score_spread":0.33012858038522885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391743861","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2484386,0.0013384566,0.16673881,0.37907106,0.0021747903,0.00152851,0.0034524356,0.0012622204,0.19599518],"genre_scores_gemma":[0.86597794,0.0008953801,0.039292157,0.029011326,0.0009532403,0.0006894968,0.0005845626,0.00021911274,0.06237672],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9947807,0.0018823021,0.00015581783,0.001357485,0.0009802508,0.00084335834],"domain_scores_gemma":[0.9914561,0.0022632394,0.00036449893,0.00060918333,0.0017126411,0.0035943307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048762807,0.00045853335,0.00053211086,0.0010231785,0.0024579396,0.005600705,0.003186872,0.0032125318,0.02721396],"category_scores_gemma":[0.011384388,0.0005072013,0.0007621312,0.0012386439,0.004301965,0.003224577,0.0034797534,0.0036418184,0.0045000305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017635069,0.001532612,0.059057854,0.00032846173,0.00018191489,0.004325954,0.0043073916,0.02193424,0.006783487,0.7026969,0.09737512,0.09971257],"study_design_scores_gemma":[0.002182587,0.0031608024,0.041373614,0.00055051345,0.0002222079,0.00519948,0.008124246,0.14910416,0.0047679627,0.6333923,0.15150738,0.00041483153],"about_ca_topic_score_codex":0.050752908,"about_ca_topic_score_gemma":0.052593064,"teacher_disagreement_score":0.050752908,"about_ca_system_score_codex":0.01063754,"about_ca_system_score_gemma":0.016292578,"threshold_uncertainty_score":0.100915015},"labels":[],"label_agreement":null},{"id":"W4392126042","doi":"10.1016/j.clgc.2024.02.011","title":"Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; University of Calgary; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; CancerCare Manitoba; University Health Network; McMaster University Medical Centre; Hôtel-Dieu de Québec; McGill University; University of Ottawa; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Toxicity; Tyrosine-kinase inhibitor; Kidney cancer; Oncology; Drug; Cancer; Internal medicine; Clinical trial; Tyrosine kinase; Pharmacology; Receptor","score_opus":0.059389763356065835,"score_gpt":0.36273070475990254,"score_spread":0.3033409414038367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392126042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92975444,0.018903486,0.00039482026,0.0015930646,0.000058765218,0.00015839608,0.04001429,0.000114067196,0.009008721],"genre_scores_gemma":[0.98769206,0.0015246462,0.00029273133,0.0002455936,0.000035503133,0.000024690531,0.009244585,0.000020286609,0.0009198354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977264,0.0005120383,0.00021547494,0.00031440763,0.0010096666,0.00022203325],"domain_scores_gemma":[0.9917652,0.003401648,0.002619871,0.0003880818,0.0011533077,0.0006718036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031861828,0.00036606658,0.00094177667,0.0008942403,0.00032990857,0.0007379766,0.0007161648,0.0004561896,0.0030631109],"category_scores_gemma":[0.011320391,0.00015047612,0.0024195702,0.0020036432,0.00025032824,0.00039974527,0.0003601072,0.0008729409,0.00022168571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03243146,0.00019519073,0.90274197,0.00063599437,0.00607516,0.000042476822,0.00009425917,0.0021898574,0.0005838005,0.00015289462,0.0069923494,0.04786463],"study_design_scores_gemma":[0.00042036,0.00077620085,0.99385756,0.000040164505,0.0019776546,0.000038352697,0.000032477295,0.00084881054,0.00018556742,0.000051279552,0.0017538645,0.000017769431],"about_ca_topic_score_codex":0.39317894,"about_ca_topic_score_gemma":0.5357152,"teacher_disagreement_score":0.39317894,"about_ca_system_score_codex":0.0053709303,"about_ca_system_score_gemma":0.0053718877,"threshold_uncertainty_score":0.7817808},"labels":[],"label_agreement":null},{"id":"W4394008881","doi":"10.1016/j.clgc.2024.102087","title":"Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bladder cancer; Honing; Oncology; Cancer; Neoadjuvant therapy; Internal medicine; Breast cancer","score_opus":0.13661444070638556,"score_gpt":0.46326579593080336,"score_spread":0.3266513552244178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394008881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040618816,0.99954945,0.000040695784,0.00014741912,0.000083678744,0.0000046561995,0.000023291681,0.0000022387933,0.000107961874],"genre_scores_gemma":[0.00038209345,0.9989287,0.0001025923,0.00035817758,0.000085631,0.000006855299,0.000033616445,0.0000013063145,0.00010092396],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99950254,0.00013993023,0.00012869689,0.00008000877,0.0001184087,0.000030445823],"domain_scores_gemma":[0.9984452,0.001084146,0.00018185194,0.000024335512,0.00022366592,0.000040851126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018793815,0.00096440385,0.0034150437,0.002591026,0.00019055972,0.0014388292,0.0012098639,0.0012366775,0.0031038886],"category_scores_gemma":[0.0031706323,0.000517486,0.0018103565,0.0024729536,0.00051971665,0.0015083065,0.0008517364,0.002104426,0.00096024026],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022805146,0.000056678644,0.0003388976,0.09914703,0.0008343439,0.00009276537,0.000071131304,0.00029879043,0.0006664745,0.001296336,0.026773458,0.8701961],"study_design_scores_gemma":[0.00029895056,0.0006119553,0.0033323593,0.07416717,0.0051547266,0.0010303084,0.00014455339,0.0002589502,0.0005907891,0.0020452684,0.9122593,0.000105816835],"about_ca_topic_score_codex":0.0023734155,"about_ca_topic_score_gemma":0.0053700716,"teacher_disagreement_score":0.0034150437,"about_ca_system_score_codex":0.0007553905,"about_ca_system_score_gemma":0.0020490647,"threshold_uncertainty_score":0.010383546},"labels":[],"label_agreement":null},{"id":"W4395070926","doi":"10.1016/j.clgc.2024.102105","title":"Unmarried Status Effect on Stage at Presentation and Treatment Patterns in Non-Metastatic Upper Tract Urothelial Carcinoma Patients","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Urothelial carcinoma; Oncology; Urothelial cancer; Presentation (obstetrics); Metastatic Urothelial Carcinoma; Internal medicine; Cancer; Bladder cancer; Surgery","score_opus":0.04021238607358731,"score_gpt":0.38709177310232806,"score_spread":0.34687938702874077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395070926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99880004,0.00032487465,0.000016683185,0.000091963135,0.000010340328,0.0000023869875,0.00019245468,0.0000015125748,0.0005597691],"genre_scores_gemma":[0.99954635,0.000069780035,0.0000069714347,0.000022363141,0.0000069947564,8.245937e-7,0.00009775824,9.4808286e-7,0.00024792264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979407,0.000054412827,0.000017495388,0.000028095254,0.000018676443,0.00008726281],"domain_scores_gemma":[0.99902654,0.0002300656,0.00036355053,0.00003333101,0.000044650085,0.00030185972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027021728,0.00013477952,0.0002390305,0.0003175112,0.000330075,0.0006044101,0.00020883691,0.0002765302,0.004195077],"category_scores_gemma":[0.0023362692,0.00012916517,0.00057230896,0.0005003988,0.00016994141,0.00043710103,0.00042468216,0.00050952303,0.00023744573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007418948,0.00008554652,0.9956143,0.000011337953,0.00006983568,0.00011788768,0.000109338995,0.00006459995,0.00017820194,0.000028465824,0.00011942391,0.002859249],"study_design_scores_gemma":[0.000010209253,0.0002107152,0.9988734,0.000007750296,0.00003320703,0.00013353022,0.00034821467,0.00014386051,0.000035774145,0.000037801572,0.00016171818,0.0000038866233],"about_ca_topic_score_codex":0.0043634116,"about_ca_topic_score_gemma":0.0062038433,"teacher_disagreement_score":0.0043634116,"about_ca_system_score_codex":0.00023126685,"about_ca_system_score_gemma":0.00029940673,"threshold_uncertainty_score":0.014033914},"labels":[],"label_agreement":null},{"id":"W4396776424","doi":"10.1016/j.clgc.2024.102115","title":"A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; AstraZeneca (Canada); University of Alberta; University of Calgary","funders":"AstraZeneca","keywords":"Medicine; Prostate cancer; Androgen receptor; Observational study; Oncology; Management of prostate cancer; Internal medicine; Androgen; Cancer; Androgen Receptor Antagonists; Hormone","score_opus":0.07166703167350277,"score_gpt":0.3801032690257118,"score_spread":0.30843623735220904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396776424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98817897,0.0012468412,0.00020523848,0.00067957776,0.00004768901,0.0001384006,0.0077219107,0.00001553434,0.0017657736],"genre_scores_gemma":[0.99327093,0.0006549182,0.00028757553,0.00045948086,0.00002468653,0.00004359815,0.0043694037,0.000011838899,0.00087768387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997359,0.00040163883,0.00018401285,0.00044980965,0.00062377984,0.0009816486],"domain_scores_gemma":[0.99519277,0.0004054353,0.0008745355,0.00020299468,0.0018614813,0.0014627024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013733434,0.00081389036,0.0012278722,0.0013045067,0.00371537,0.0025510301,0.003028022,0.0011934321,0.0022954962],"category_scores_gemma":[0.0032649082,0.00079288776,0.0012631912,0.006861139,0.0016150544,0.00061300985,0.0016557398,0.0017096186,0.0003204861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004259315,0.00013892449,0.9942094,0.00006028453,0.00024730142,0.00026282403,0.000597986,0.00025865014,0.00017659261,0.00018298552,0.0018300001,0.0016091312],"study_design_scores_gemma":[0.00009991608,0.00009080906,0.99507385,0.00005936877,0.00012308959,0.0001470681,0.002575313,0.0005986286,0.00003484958,0.000045436173,0.0011207135,0.000030871102],"about_ca_topic_score_codex":0.99510336,"about_ca_topic_score_gemma":0.99622536,"teacher_disagreement_score":0.04691442,"about_ca_system_score_codex":0.04691442,"about_ca_system_score_gemma":0.060882222,"threshold_uncertainty_score":0.34038955},"labels":[],"label_agreement":null},{"id":"W4396809848","doi":"10.1016/j.clgc.2024.102119","title":"Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Bladder cancer; Urothelial carcinoma; Urology; Urothelial cancer; Metastatic Urothelial Carcinoma; Cancer; Oncology; Urinary bladder; Internal medicine","score_opus":0.07550536402370836,"score_gpt":0.37294869773629125,"score_spread":0.2974433337125829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396809848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462306,0.0017001214,0.00012198757,0.00017269661,0.000014848603,0.000004206984,0.002166921,0.000010443433,0.0011857323],"genre_scores_gemma":[0.99820733,0.00039983878,0.000030311032,0.000029079196,0.000018280753,0.0000042826664,0.0010550215,0.0000024915428,0.0002533266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997701,0.00003372353,0.000029379476,0.000060026567,0.000026600426,0.00008013543],"domain_scores_gemma":[0.9989285,0.00022193643,0.0005124186,0.000060975504,0.00014964174,0.00012646124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003702226,0.000105657025,0.00022310154,0.00054016523,0.00017467121,0.00045687368,0.00025725158,0.00038465604,0.0019495812],"category_scores_gemma":[0.0019388961,0.00012916319,0.0005512704,0.0011806575,0.00013312277,0.0005553637,0.0002500277,0.00052383187,0.00015190276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015490545,0.00004684724,0.9898891,0.000046636793,0.00021533151,0.000073600335,0.0000903135,0.00059498724,0.0004913715,0.00014639225,0.00056243443,0.0062939893],"study_design_scores_gemma":[0.000013449085,0.00015418621,0.9979565,0.000012400374,0.0001174526,0.00011950467,0.00018717394,0.0006805824,0.00013325938,0.00004880549,0.000571297,0.000005481588],"about_ca_topic_score_codex":0.008918722,"about_ca_topic_score_gemma":0.010701868,"teacher_disagreement_score":0.008918722,"about_ca_system_score_codex":0.00047784907,"about_ca_system_score_gemma":0.00043697038,"threshold_uncertainty_score":0.017733634},"labels":[],"label_agreement":null},{"id":"W4396887599","doi":"10.1016/j.clgc.2024.102120","title":"Hydronephrosis as a Prognostic Factor in Primary Bladder Adenocarcinoma: Insights from a 15-Year Tertiary Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Hydronephrosis; Oncology; Adenocarcinoma; Bladder cancer; Center (category theory); Internal medicine; Urology; Cancer; Urinary system","score_opus":0.044912572032890875,"score_gpt":0.3677872979111405,"score_spread":0.3228747258782496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396887599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990907,0.0004247651,0.000025496942,0.00004743944,0.000003564159,0.0000028660081,0.00005531579,0.0000010309592,0.00034889512],"genre_scores_gemma":[0.9995253,0.00026335387,0.000028799557,0.000023452132,0.000012039609,0.0000011254253,0.00007228424,6.4210104e-7,0.00007306324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966383,0.00009307001,0.000036083256,0.000049988874,0.00005698688,0.00009999983],"domain_scores_gemma":[0.9987393,0.0003167929,0.00031089142,0.000054328473,0.00017777404,0.000401003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007918865,0.00015701694,0.00032437246,0.00078603654,0.0006753641,0.0008453477,0.00031972898,0.00029626512,0.0010147749],"category_scores_gemma":[0.0022353162,0.00010116717,0.00027809697,0.0010465847,0.00050119864,0.00061212014,0.0007343356,0.00028061733,0.00014270307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007691652,0.000043595897,0.99564445,0.000010647545,0.000014699541,0.0009116318,0.00048262818,0.00003060511,0.00018654003,0.000027862869,0.00006993277,0.002500536],"study_design_scores_gemma":[0.0000030263789,0.00020773217,0.9948886,0.000015042043,0.000023305749,0.0026378569,0.0016826402,0.00009428698,0.000120211254,0.000031806096,0.00028838997,0.000006961916],"about_ca_topic_score_codex":0.008619943,"about_ca_topic_score_gemma":0.012232877,"teacher_disagreement_score":0.008619943,"about_ca_system_score_codex":0.00064513565,"about_ca_system_score_gemma":0.00090122776,"threshold_uncertainty_score":0.017139494},"labels":[],"label_agreement":null},{"id":"W4399240896","doi":"10.1016/j.clgc.2024.102132","title":"Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystectomy; Stage (stratigraphy); Incidence (geometry); Cumulative incidence; Internal medicine; Adjuvant; Chemotherapy; Overall survival; Urology; Oncology; Gastroenterology; Surgery; Bladder cancer; Cohort; Cancer","score_opus":0.04327223786571829,"score_gpt":0.4050090018454212,"score_spread":0.36173676397970295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399240896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888524,0.0064710677,0.00014484249,0.00085600844,0.00016818874,0.00005536325,0.00017688247,0.000008611241,0.003266577],"genre_scores_gemma":[0.9974331,0.0013268201,0.00011468761,0.00025934927,0.00008978809,0.00004010092,0.00018528813,0.0000028528718,0.0005480116],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998061,0.00009203672,0.000017673407,0.000027489079,0.000015815154,0.00004088867],"domain_scores_gemma":[0.99953794,0.00021185009,0.00007078779,0.000015138533,0.000014596579,0.00014966851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028649686,0.00012366267,0.00046476116,0.00010680656,0.00017297287,0.0004135289,0.00013103693,0.0002826187,0.0029394708],"category_scores_gemma":[0.0016591398,0.00008096849,0.0004322265,0.0001455401,0.00021539709,0.00035846364,0.00016845812,0.0004747178,0.0001944025],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44923297,0.0056415303,0.18551157,0.0018025837,0.0009166532,0.0009242602,0.0005166328,0.004920964,0.013888313,0.0012485363,0.0055468148,0.32984915],"study_design_scores_gemma":[0.019995045,0.20030776,0.736837,0.001234095,0.0029257392,0.0019463035,0.0012293468,0.0054351236,0.005460381,0.00224726,0.022305848,0.00007601701],"about_ca_topic_score_codex":0.00078072934,"about_ca_topic_score_gemma":0.004169882,"teacher_disagreement_score":0.0029394708,"about_ca_system_score_codex":0.00045339225,"about_ca_system_score_gemma":0.00061415485,"threshold_uncertainty_score":0.009833455},"labels":[],"label_agreement":null},{"id":"W4399361696","doi":"10.1016/j.clgc.2024.102133","title":"Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Urothelial carcinoma; Medicine; Urology; Insulin-like growth factor; Insulin-like growth factor-binding protein; Internal medicine; Oncology; Risk stratification; Insulin; Growth factor; Endocrinology; Cancer; Receptor; Bladder cancer","score_opus":0.040373999970872654,"score_gpt":0.3333764279400442,"score_spread":0.29300242796917153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990565,0.00026624993,0.00037750386,0.000036895104,0.0000044230214,0.000004049583,0.0001332838,0.000005313257,0.00011578595],"genre_scores_gemma":[0.99961674,0.000039830655,0.00016868715,0.000009129843,0.0000048163593,0.0000024819417,0.00013667178,0.0000010580482,0.000020539172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996593,0.00013421476,0.00004176652,0.00007018537,0.00006271177,0.00003196431],"domain_scores_gemma":[0.9986908,0.00054862804,0.0004802789,0.0000869956,0.000063351334,0.00012996445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878722,0.00029501054,0.00031627918,0.0004493178,0.0001894954,0.0006055081,0.00032333136,0.0002935127,0.0005909047],"category_scores_gemma":[0.002994238,0.0001601764,0.00056511106,0.00051280163,0.00021551581,0.00025451067,0.00028072062,0.00035295996,0.000098528784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011877659,0.000010934581,0.9980564,0.000004698148,0.000046149802,0.000025284462,0.000010863496,0.00026446904,0.00013037382,0.000005977724,0.000033057793,0.0012931083],"study_design_scores_gemma":[0.000017597527,0.0001811206,0.99144137,0.000009387773,0.00011630131,0.0004219345,0.00006633034,0.0071499557,0.00034581238,0.00006353252,0.0001805303,0.0000062274667],"about_ca_topic_score_codex":0.0014730043,"about_ca_topic_score_gemma":0.0022098233,"teacher_disagreement_score":0.0014730043,"about_ca_system_score_codex":0.00028301156,"about_ca_system_score_gemma":0.00039759063,"threshold_uncertainty_score":0.0046471953},"labels":[],"label_agreement":null},{"id":"W4399556172","doi":"10.1016/j.clgc.2024.102137","title":"Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Surrogate endpoint; Oncology; Internal medicine; Clinical trial; Castration; Clinical endpoint; Cancer; Hormone","score_opus":0.3290512161179735,"score_gpt":0.5274228000287672,"score_spread":0.19837158391079368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399556172","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067113934,0.9973658,0.0012754742,0.00012625786,0.00005530894,0.00003783317,0.000090357804,0.0000125102615,0.0003654042],"genre_scores_gemma":[0.01704178,0.98025954,0.0019953677,0.00019298797,0.000069097776,0.000090741,0.00017497475,0.0000072170924,0.00016829772],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971718,0.0019335415,0.00033078977,0.00018039269,0.00033692404,0.000046533067],"domain_scores_gemma":[0.98732346,0.011347621,0.00083486695,0.0001567725,0.00028580756,0.000051519615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008579444,0.001255793,0.0039114277,0.0014448335,0.00010072735,0.0013957104,0.0011532003,0.000995645,0.0018154347],"category_scores_gemma":[0.013146376,0.00039239004,0.003998462,0.0017391788,0.00029867832,0.0009971319,0.0004944088,0.0016608578,0.00037903388],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006729901,0.00007350236,0.0009846754,0.08206621,0.0054185325,0.000050641156,0.000047787635,0.011726578,0.00050029624,0.0030443387,0.0037053186,0.8917092],"study_design_scores_gemma":[0.0027430276,0.0065277037,0.026327679,0.24290851,0.071602605,0.0021629033,0.00033208032,0.040123243,0.0049173282,0.038957413,0.56288004,0.0005174097],"about_ca_topic_score_codex":0.0010226021,"about_ca_topic_score_gemma":0.0021217007,"teacher_disagreement_score":0.008579444,"about_ca_system_score_codex":0.0007986219,"about_ca_system_score_gemma":0.001235745,"threshold_uncertainty_score":0.045373023},"labels":[],"label_agreement":null},{"id":"W4399605698","doi":"10.1016/j.clgc.2024.102139","title":"Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Urothelial carcinoma; Urology; Urinary bladder; Metastatic Urothelial Carcinoma; Urinary system; Carcinoma; Urothelial cancer; Bladder cancer; Oncology; Internal medicine; Cancer","score_opus":0.07465514347380514,"score_gpt":0.41600303817888884,"score_spread":0.3413478947050837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399605698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993869,0.00018671143,0.000070169874,0.00002384638,0.0000024012365,0.0000021365252,0.00021521427,0.000002372112,0.00011031461],"genre_scores_gemma":[0.9996617,0.000037316273,0.000030748415,0.0000070404185,0.000004262971,0.0000018954418,0.00020786548,6.0412793e-7,0.000048618887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977547,0.00006452154,0.000016684357,0.00005879483,0.00003581967,0.000048615522],"domain_scores_gemma":[0.9987925,0.000335155,0.0005308177,0.000060818656,0.00007827747,0.00020239507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005744107,0.00019851176,0.00018887794,0.0003031777,0.00014117181,0.00027747353,0.00028164926,0.0002785319,0.0014865262],"category_scores_gemma":[0.002207901,0.000118470336,0.00035978053,0.00029845798,0.00016525647,0.00032238424,0.00042304775,0.00029286172,0.00014746902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024409324,0.000015933798,0.9980665,0.000007526959,0.00003638656,0.000020809572,0.00000971277,0.00010110126,0.00013711651,0.0000074001655,0.00005275485,0.0013006957],"study_design_scores_gemma":[0.000010527308,0.00018451535,0.9987929,0.0000045038714,0.000039017836,0.00018921426,0.00003421883,0.00055605423,0.00007986699,0.000018755343,0.00008836947,0.000002133236],"about_ca_topic_score_codex":0.0019912594,"about_ca_topic_score_gemma":0.003048229,"teacher_disagreement_score":0.0019912594,"about_ca_system_score_codex":0.00021177084,"about_ca_system_score_gemma":0.00023348666,"threshold_uncertainty_score":0.0049729943},"labels":[],"label_agreement":null},{"id":"W4400016505","doi":"10.1016/j.clgc.2024.102143","title":"Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Medicine; Chemotherapy; Bladder cancer; Oncology; Cancer; Angiotensin-converting enzyme; Neoadjuvant therapy; Internal medicine; Urology; Pathology; Breast cancer","score_opus":0.08896954853584528,"score_gpt":0.41624653728751193,"score_spread":0.32727698875166666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400016505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714247,0.022734985,0.00026649606,0.0009184242,0.00017740906,0.00004382923,0.00027523024,0.0000116589,0.004147245],"genre_scores_gemma":[0.9972843,0.0017811044,0.000097108765,0.00016375598,0.00010233632,0.000011150528,0.00019298961,0.0000037354648,0.00036352064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915946,0.0005057993,0.0000811829,0.00006230151,0.000120172015,0.00007107466],"domain_scores_gemma":[0.9967527,0.0021103977,0.0005297614,0.00014508389,0.00017559757,0.00028644624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018391721,0.00022131487,0.0006850401,0.00023115377,0.00016651713,0.0004793249,0.00021233778,0.0002691687,0.0009219842],"category_scores_gemma":[0.0056258487,0.00009276213,0.00063281896,0.00037078385,0.00026635695,0.0005580266,0.00023179756,0.00066709256,0.00009373965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08370785,0.00086491357,0.6760613,0.0005748992,0.0024659026,0.00047374237,0.00018122036,0.0034566019,0.0072153676,0.0002208812,0.0011595569,0.22361778],"study_design_scores_gemma":[0.00038416585,0.015343958,0.9754489,0.00008441612,0.0017279165,0.0003793125,0.00016681061,0.0010224988,0.0018831212,0.00017642336,0.0033652869,0.000017067418],"about_ca_topic_score_codex":0.0008856543,"about_ca_topic_score_gemma":0.0030443163,"teacher_disagreement_score":0.0018391721,"about_ca_system_score_codex":0.00047737514,"about_ca_system_score_gemma":0.00061038753,"threshold_uncertainty_score":0.009726584},"labels":[],"label_agreement":null},{"id":"W4400624727","doi":"10.1016/j.clgc.2024.102161","title":"Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Epidemiology; Proportional hazards model; Cancer registry; Internal medicine; Surveillance, Epidemiology, and End Results; Stage (stratigraphy); Oncology; Hazard ratio; Cancer; Gynecology; Confidence interval","score_opus":0.06848158676397974,"score_gpt":0.3984688936577359,"score_spread":0.32998730689375616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400624727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529123,0.00094005396,0.0006384243,0.00017108,0.000012594664,0.0000192405,0.0021610593,0.000012446175,0.00075385807],"genre_scores_gemma":[0.9983858,0.00017835137,0.00016227218,0.000038613845,0.000010425276,0.00001326192,0.0011290852,0.0000058769438,0.00007624688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959103,0.0017885271,0.00049831514,0.0010191089,0.00039075993,0.00039309863],"domain_scores_gemma":[0.9914737,0.0013533877,0.005368795,0.0008401344,0.0006493396,0.00031461308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00376743,0.00018331902,0.00044213652,0.00092723564,0.00027286782,0.0006723227,0.000486614,0.00020856765,0.0013676208],"category_scores_gemma":[0.007848433,0.00020368744,0.00062894553,0.0022050594,0.000321284,0.0005371166,0.0009201203,0.0003314906,0.00019991223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006719119,0.000008661853,0.9974094,0.000018577744,0.00016176538,0.000021721513,0.00013087824,0.00017202289,0.00011807715,0.00009807844,0.00019714436,0.0015964301],"study_design_scores_gemma":[0.0000070025417,0.000034375047,0.9985511,0.000012330721,0.00006477067,0.00011881155,0.00026416368,0.0002841554,0.00010786627,0.000052020732,0.00049841864,0.0000050367094],"about_ca_topic_score_codex":0.010673749,"about_ca_topic_score_gemma":0.016457027,"teacher_disagreement_score":0.010673749,"about_ca_system_score_codex":0.0005370964,"about_ca_system_score_gemma":0.00056198874,"threshold_uncertainty_score":0.021223247},"labels":[],"label_agreement":null},{"id":"W4400798284","doi":"10.1016/j.clgc.2024.102166","title":"Rates of Systemic Therapy for Metastatic Bladder Cancer Are Lower in Unmarried Males and Females","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Systemic therapy; Bladder cancer; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.14799061125416446,"score_gpt":0.4574729877468923,"score_spread":0.30948237649272786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400798284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237,0.001954666,0.00019341748,0.00035423695,0.000049481383,0.000005917243,0.0007996708,0.000013806725,0.0042588147],"genre_scores_gemma":[0.99601126,0.0010533179,0.00008073115,0.00018936674,0.000050573435,0.0000037468628,0.00037840585,0.000008923414,0.0022236828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985886,0.000030514679,0.000012660745,0.000029015991,0.000025356203,0.000043582015],"domain_scores_gemma":[0.9991736,0.00010993507,0.00048259005,0.000034659708,0.000054855806,0.00014420379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018265567,0.0001227915,0.00024069542,0.00056556996,0.00040640472,0.0005576475,0.00012710496,0.00024457814,0.0090212],"category_scores_gemma":[0.001451997,0.00012817075,0.00042814377,0.00069447455,0.00013012956,0.0003296448,0.00025222328,0.00039782378,0.000762413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100471334,0.000036205918,0.9882572,0.000022759106,0.000050229417,0.00006308092,0.00012207919,0.000018441136,0.00034202976,0.000049456296,0.00047106566,0.010466953],"study_design_scores_gemma":[0.0000023599403,0.000039932343,0.9986664,0.000009599165,0.000016767144,0.00019091633,0.00027982442,0.000037641836,0.00005266427,0.00002014801,0.00068196387,0.0000018810993],"about_ca_topic_score_codex":0.003556118,"about_ca_topic_score_gemma":0.0059032873,"teacher_disagreement_score":0.0090212,"about_ca_system_score_codex":0.00013878176,"about_ca_system_score_gemma":0.00013355595,"threshold_uncertainty_score":0.030178905},"labels":[],"label_agreement":null},{"id":"W4401002134","doi":"10.1016/j.clgc.2024.102176","title":"Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck KGaA","keywords":"Medicine; Cisplatin; Gemcitabine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Regimen; Meta-analysis; Internal medicine; Urothelial cancer; Chemotherapy; Cancer; Bladder cancer","score_opus":0.11901612622383809,"score_gpt":0.4274046873142976,"score_spread":0.30838856109045953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401002134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013992408,0.9833484,0.0005793503,0.00024627952,0.00013501543,0.00028193544,0.0009914931,0.000026482012,0.0003985965],"genre_scores_gemma":[0.3840701,0.6094868,0.0021430345,0.0014107649,0.00023802479,0.00095678953,0.0013391998,0.000043827353,0.00031137548],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99195695,0.003883829,0.0021656423,0.0010589462,0.00070081046,0.00023393374],"domain_scores_gemma":[0.98408705,0.010609232,0.0033288402,0.0005390605,0.0011594304,0.00027646078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010092368,0.0019307367,0.012401719,0.0062492406,0.0004891185,0.0024514778,0.001859294,0.0018435542,0.0029801754],"category_scores_gemma":[0.022694705,0.0012196777,0.026110584,0.008799203,0.0006827302,0.0016399068,0.0014816801,0.0013982301,0.0002573176],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002842609,0.000035245357,0.0100475475,0.27859885,0.6962714,0.00019337937,0.00008748219,0.00084404164,0.00030791736,0.00012272858,0.0007487381,0.009899956],"study_design_scores_gemma":[0.0006472484,0.00017473633,0.0072824205,0.015878055,0.97381103,0.00010406079,0.00005150906,0.00027257027,0.00011438416,0.00017140909,0.0014680608,0.000024487426],"about_ca_topic_score_codex":0.007938448,"about_ca_topic_score_gemma":0.017343136,"teacher_disagreement_score":0.012401719,"about_ca_system_score_codex":0.0023483369,"about_ca_system_score_gemma":0.0026780434,"threshold_uncertainty_score":0.05337417},"labels":[],"label_agreement":null},{"id":"W4401542816","doi":"10.1016/j.clgc.2024.102194","title":"The Incidence of Extreme Serum Prostate Specific Antigen Levels During the COVID-19 Pandemic","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; Incidence (geometry); 2019-20 coronavirus outbreak; Prostate cancer; Prostate-specific antigen; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Betacoronavirus; Virology; Immunology; Coronavirus Infections; Internal medicine; Oncology; Cancer; Outbreak; Disease","score_opus":0.19616703783216913,"score_gpt":0.4284442812121122,"score_spread":0.23227724337994307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401542816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371625,0.0024324555,0.00030487025,0.0017956143,0.00018909002,0.000030049236,0.0038564962,0.000026253036,0.0076489095],"genre_scores_gemma":[0.99765766,0.0005886398,0.00007156095,0.00025485165,0.000067093926,0.0000074536933,0.0010786133,0.0000039981032,0.0002700934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935156,0.00012260153,0.000052343566,0.00010757855,0.00013530807,0.00023059279],"domain_scores_gemma":[0.99861217,0.00014602175,0.0006121789,0.00006266963,0.0002516635,0.00031533747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046972433,0.00014627639,0.00021392792,0.0005446525,0.00045979916,0.0009802175,0.00031363347,0.000628291,0.0017158256],"category_scores_gemma":[0.0030603763,0.00016909411,0.0002843848,0.0009094714,0.00031982776,0.0005544281,0.0008961991,0.0012737997,0.00019336227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022244937,0.000028126551,0.98801744,0.00004294242,0.000056889632,0.00015102923,0.00022476759,0.00027073314,0.00045222757,0.00022348449,0.0018860678,0.008423975],"study_design_scores_gemma":[0.000002899626,0.000047759513,0.9976549,0.000026765454,0.000007213889,0.00023637096,0.00046842865,0.00017305065,0.000065143686,0.00006904215,0.001241358,0.000006982546],"about_ca_topic_score_codex":0.015743116,"about_ca_topic_score_gemma":0.019116292,"teacher_disagreement_score":0.015743116,"about_ca_system_score_codex":0.00072818575,"about_ca_system_score_gemma":0.0007486395,"threshold_uncertainty_score":0.03130293},"labels":[],"label_agreement":null},{"id":"W4401833551","doi":"10.1016/j.clgc.2024.102210","title":"Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Advanced Research Projects Agency for Health; Bladder Cancer Advocacy Network; American Society of Clinical Oncology; Prostate Cancer Fight Foundation","keywords":"Medicine; Clinical trial; Clinical Oncology; Genitourinary system; Alternative medicine; Family medicine; Oncology; Medical physics; Internal medicine; Cancer; Pathology","score_opus":0.7695312986740319,"score_gpt":0.6581462062715825,"score_spread":0.11138509240244943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401833551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8954545,0.0773249,0.0012774877,0.0040545473,0.0003619086,0.0004267356,0.005478239,0.00007813942,0.0155436145],"genre_scores_gemma":[0.99107516,0.0042952285,0.00035785034,0.0011205403,0.00024420337,0.00008660994,0.0020747639,0.000021347128,0.00072418584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97380495,0.020996844,0.0012062321,0.0010115366,0.0017762671,0.0012041737],"domain_scores_gemma":[0.9271692,0.04701072,0.0127108805,0.0017393682,0.007894737,0.0034751387],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017225703,0.00034704577,0.001992905,0.0012829315,0.00031444064,0.0019791063,0.0005399822,0.0011053961,0.001602314],"category_scores_gemma":[0.04434255,0.00016742988,0.0024429255,0.0023983766,0.00080564857,0.0010729347,0.0005330426,0.0011903407,0.00009097626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2802663,0.0008410936,0.48196468,0.004607163,0.021271965,0.00032114875,0.00076038565,0.013562918,0.0018133435,0.005488614,0.010898947,0.17820342],"study_design_scores_gemma":[0.023435958,0.032053724,0.9120015,0.00077641447,0.008275938,0.00034370238,0.0007635522,0.003784274,0.00072305003,0.0010430188,0.016705258,0.000093729905],"about_ca_topic_score_codex":0.051375423,"about_ca_topic_score_gemma":0.09403164,"teacher_disagreement_score":0.9953941,"about_ca_system_score_codex":0.0046058716,"about_ca_system_score_gemma":0.0066295248,"threshold_uncertainty_score":0.102152765},"labels":[],"label_agreement":null},{"id":"W4402327929","doi":"10.1016/j.clgc.2024.102215","title":"Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Tremelimumab; Metastatic Urothelial Carcinoma; Bone metastasis; Oncology; Urothelial carcinoma; Metastasis; Internal medicine; Carcinoma; Cancer; Immunotherapy; Bladder cancer","score_opus":0.061469192054745055,"score_gpt":0.3951481070672198,"score_spread":0.33367891501247476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402327929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950198,0.0025519198,0.000052650164,0.0003017233,0.000035569818,0.000014650696,0.00083850644,0.0000033907004,0.0011817272],"genre_scores_gemma":[0.997498,0.0007290789,0.00006216998,0.00011552498,0.00004031155,0.000017970162,0.0009809912,0.0000041641956,0.00055178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995796,0.00014655653,0.000027549713,0.000082466286,0.00008734656,0.00007651742],"domain_scores_gemma":[0.99953365,0.00009380027,0.00014305944,0.000035769775,0.000042464253,0.00015122241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005767648,0.00038972608,0.0008672135,0.00035816405,0.0003395521,0.00096033554,0.0007658996,0.00048968813,0.0012662382],"category_scores_gemma":[0.0009736935,0.0001999597,0.0007819612,0.0007732239,0.00034311265,0.00045007758,0.0005617049,0.0007783574,0.0001672952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013603998,0.00027656165,0.96469384,0.0001208998,0.0016764783,0.00042151762,0.0000752618,0.0006298195,0.0023188535,0.00020340578,0.0014848574,0.014494521],"study_design_scores_gemma":[0.0011013406,0.0011892624,0.99226177,0.000037132886,0.001037344,0.00046170398,0.00023164116,0.0008048264,0.00040955294,0.00014565271,0.0023010126,0.000018715551],"about_ca_topic_score_codex":0.009722537,"about_ca_topic_score_gemma":0.02493936,"teacher_disagreement_score":0.009722537,"about_ca_system_score_codex":0.0010502903,"about_ca_system_score_gemma":0.0008408245,"threshold_uncertainty_score":0.019331872},"labels":[],"label_agreement":null},{"id":"W4402667368","doi":"10.1016/j.clgc.2024.102214","title":"Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Associazione Italiana per la Ricerca sul Cancro; Deutsche Forschungsgemeinschaft; Merck","keywords":"Medicine; Cystectomy; Pembrolizumab; Oncology; Internal medicine; Neoadjuvant therapy; Bladder cancer; Cancer; Immunotherapy","score_opus":0.03257032447753763,"score_gpt":0.3766893100353639,"score_spread":0.3441189855578263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402667368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889296,0.0002462598,0.00004643121,0.000037721067,0.000006590392,0.000007835192,0.0003490697,0.0000024586905,0.0004108177],"genre_scores_gemma":[0.9985435,0.000120731485,0.0000697581,0.00007021183,0.000014103146,0.0000143390835,0.0007980865,0.0000039075503,0.00036542688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977833,0.000052026928,0.000019710393,0.00006689812,0.00003103738,0.000052155792],"domain_scores_gemma":[0.99969876,0.00006743172,0.000097686745,0.000033016582,0.000033673783,0.00006934054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030779853,0.00020684193,0.0004054116,0.0003979569,0.00025280158,0.0008457771,0.00022664736,0.0003325862,0.0012736025],"category_scores_gemma":[0.00063353137,0.0001678751,0.00036851448,0.00043194272,0.00024811155,0.00031240188,0.00032020302,0.00034106054,0.00024681247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030226854,0.0001468808,0.97722214,0.000040382474,0.0002720998,0.00015423127,0.00012652525,0.00007047962,0.011452028,0.00006367595,0.00046490587,0.0069638384],"study_design_scores_gemma":[0.000042176816,0.00027979093,0.99766445,0.0000062057275,0.000106337015,0.00030815948,0.0002593397,0.00014419072,0.0005313848,0.000039942,0.0006123943,0.000005579541],"about_ca_topic_score_codex":0.0009413653,"about_ca_topic_score_gemma":0.0027657289,"teacher_disagreement_score":0.0012736025,"about_ca_system_score_codex":0.00021412139,"about_ca_system_score_gemma":0.00021538395,"threshold_uncertainty_score":0.0042605996},"labels":[],"label_agreement":null},{"id":"W4403499706","doi":"10.1016/j.clgc.2024.102237","title":"The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Concomitant; Renal cell carcinoma; Systemic therapy; Oncology; Meta-analysis; Internal medicine; Overall survival; Intensive care medicine; Cancer","score_opus":0.1818844136184329,"score_gpt":0.4447486379091504,"score_spread":0.26286422429071754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403499706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052898843,0.99292773,0.0004258267,0.000184514,0.0001192295,0.00010814204,0.0006904088,0.00001786587,0.00023630327],"genre_scores_gemma":[0.21454248,0.7802107,0.0016466578,0.00097233086,0.0002871922,0.0005957879,0.001368955,0.000037563364,0.0003384161],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99392045,0.002518743,0.001942295,0.0007330351,0.00066248205,0.00022306293],"domain_scores_gemma":[0.9875075,0.009205525,0.0018062972,0.00044119288,0.0008702173,0.00016926117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00841903,0.001976946,0.013970811,0.0050812806,0.00055570976,0.0026385954,0.0015945261,0.0018428382,0.0023319833],"category_scores_gemma":[0.020035679,0.0012077343,0.039748758,0.007204456,0.00050220505,0.0012463406,0.0011527323,0.0014722862,0.00026227284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011962187,0.000017562394,0.007565196,0.23558709,0.7451732,0.00013687307,0.000066845954,0.0005746653,0.00018555716,0.00011492282,0.00056473206,0.00881713],"study_design_scores_gemma":[0.0002032039,0.000085191234,0.0044125672,0.013251779,0.98028356,0.00008126105,0.00002795433,0.00017398846,0.00006830779,0.00014234733,0.0012512233,0.000018622148],"about_ca_topic_score_codex":0.008635512,"about_ca_topic_score_gemma":0.01815065,"teacher_disagreement_score":0.013970811,"about_ca_system_score_codex":0.0017919393,"about_ca_system_score_gemma":0.002669199,"threshold_uncertainty_score":0.04452467},"labels":[],"label_agreement":null},{"id":"W4403727295","doi":"10.1016/j.clgc.2024.102251","title":"Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Innovációs és Technológiai Minisztérium; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; European Association of Urology","keywords":"Medicine; Meta-analysis; Prostate cancer; Androgen receptor; Oncology; Central nervous system; Toxicity; Bioinformatics; Cancer; Internal medicine; Biology","score_opus":0.11726088546034366,"score_gpt":0.3980136414811087,"score_spread":0.280752756020765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403727295","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011171541,0.9854909,0.0009484257,0.00028154856,0.00014891836,0.0002745289,0.0012928175,0.000046328423,0.00034493944],"genre_scores_gemma":[0.4070411,0.5837846,0.003689781,0.0012351593,0.00032503763,0.0014468654,0.0019814344,0.00005308741,0.0004429403],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99036425,0.005640364,0.0019865397,0.000993735,0.00072684797,0.00028821308],"domain_scores_gemma":[0.98288155,0.013095927,0.0022698927,0.00061352743,0.0009390994,0.00019996907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013484174,0.0027345575,0.014478173,0.0050496696,0.0005308917,0.0025309692,0.0020070986,0.00176809,0.0027705454],"category_scores_gemma":[0.0273841,0.0013400709,0.04322755,0.0057642,0.0005422007,0.0012423074,0.0014412552,0.0017568292,0.0002242179],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018254222,0.000021666398,0.005732774,0.13135153,0.8529115,0.000091789654,0.00004345216,0.0009983166,0.000151823,0.00010355552,0.00054023555,0.0062278775],"study_design_scores_gemma":[0.00039983462,0.000103261445,0.0029337807,0.0061761807,0.98910123,0.0000499384,0.000016308553,0.00028041838,0.000058084068,0.00014417915,0.00072331715,0.000013513497],"about_ca_topic_score_codex":0.008124424,"about_ca_topic_score_gemma":0.015807008,"teacher_disagreement_score":0.014478173,"about_ca_system_score_codex":0.002177932,"about_ca_system_score_gemma":0.0021640307,"threshold_uncertainty_score":0.07131201},"labels":[],"label_agreement":null},{"id":"W4403914498","doi":"10.1016/j.clgc.2024.102249","title":"Reevaluating the Role of Extended Pelvic Lymphadenectomy in Muscle-Invasive Bladder Cancer: Insights From SWOG S1011 and LEA AB 25-02 Trials","year":2024,"lang":"en","type":"editorial","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bladder cancer; Lymphadenectomy; Oncology; Internal medicine; Urology; Cancer","score_opus":0.0636659490453141,"score_gpt":0.41644178006503174,"score_spread":0.35277583101971766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403914498","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016654348,0.059130773,0.0003235119,0.10601833,0.8311415,0.00007353946,0.00022983218,0.000087036846,0.0028289503],"genre_scores_gemma":[0.0013667912,0.038717266,0.000415184,0.10511519,0.84722835,0.00007550956,0.00011210877,0.00006765187,0.00690186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943974,0.0019301848,0.00086456584,0.0005314568,0.0019519652,0.0003244417],"domain_scores_gemma":[0.9653118,0.022830326,0.001725494,0.00051993696,0.0073315245,0.0022809475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019445248,0.0022552235,0.004084274,0.0016930776,0.0013573917,0.005351349,0.0039573954,0.011941503,0.0056871953],"category_scores_gemma":[0.033476,0.0009985289,0.003366526,0.0013321241,0.001879317,0.0036653674,0.0012104425,0.022769308,0.003874721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030626028,0.000022157596,0.000047777634,0.0010960388,0.00016113791,0.000076598226,0.000017652404,0.000057302546,0.00008640486,0.00056804286,0.9751492,0.022411436],"study_design_scores_gemma":[0.0010717071,0.00023443108,0.00062969216,0.002372721,0.0007817965,0.00017553706,0.000047047906,0.00032218077,0.00020653833,0.0023350914,0.9917714,0.00005183613],"about_ca_topic_score_codex":0.0024437774,"about_ca_topic_score_gemma":0.007813534,"teacher_disagreement_score":0.019445248,"about_ca_system_score_codex":0.0031894296,"about_ca_system_score_gemma":0.005111835,"threshold_uncertainty_score":0.10283756},"labels":[],"label_agreement":null},{"id":"W4403978554","doi":"10.1016/j.clgc.2024.102261","title":"Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Wilfrid Laurier University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Carboplatin; Pembrolizumab; Medicine; Cisplatin; Gemcitabine; Chemotherapy; Regimen; Internal medicine; Oncology; Chemotherapy regimen; Phases of clinical research; Progression-free survival; Urology; Cancer; Immunotherapy","score_opus":0.08280996112484124,"score_gpt":0.4458786824423694,"score_spread":0.36306872131752815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403978554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98529565,0.0077497456,0.0005005218,0.00040950355,0.00007333513,0.00111412,0.003351142,0.000049543956,0.0014565923],"genre_scores_gemma":[0.98767346,0.0035260164,0.0009929395,0.00067640655,0.000119500946,0.00089066545,0.0050202236,0.000040736086,0.0010600074],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99784815,0.0013227226,0.00008319302,0.00027409865,0.00017280047,0.00029900332],"domain_scores_gemma":[0.99795914,0.00059374806,0.00055055367,0.00023856307,0.00013132767,0.0005266204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053592785,0.001667037,0.0030463429,0.0005394853,0.00045636942,0.0015186346,0.0011204104,0.0010265338,0.0030514984],"category_scores_gemma":[0.0026455203,0.00060633686,0.0050427965,0.0012326555,0.00090728165,0.0013803896,0.00067898753,0.0030004636,0.0005885925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87273216,0.011778867,0.022007372,0.0016133562,0.011574564,0.00010457045,0.00020777463,0.0052588573,0.006811022,0.0002325455,0.0033616798,0.06431722],"study_design_scores_gemma":[0.48834985,0.3265478,0.15290287,0.00033011034,0.017799553,0.0004009294,0.00033364916,0.0030580775,0.002573128,0.0008699746,0.006707159,0.00012694171],"about_ca_topic_score_codex":0.0019524011,"about_ca_topic_score_gemma":0.006936309,"teacher_disagreement_score":0.0053592785,"about_ca_system_score_codex":0.0016972399,"about_ca_system_score_gemma":0.0025366358,"threshold_uncertainty_score":0.028342903},"labels":[],"label_agreement":null},{"id":"W4404195234","doi":"10.1016/j.clgc.2024.102259","title":"Robot-Assisted Cystectomy in Patients With Previous Pelvic Irradiation: A Comprehensive Systematic Review and Single-Arm Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Medicine; Cystectomy; Meta-analysis; Bladder cancer; Urology; Surgery; General surgery; Oncology; Internal medicine; Cancer","score_opus":0.1854983916649068,"score_gpt":0.4282979106529379,"score_spread":0.24279951898803107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404195234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008256788,0.99032825,0.00033680513,0.000111300345,0.00013391397,0.000098161814,0.00048621107,0.000020079251,0.00022855432],"genre_scores_gemma":[0.2621844,0.7330901,0.0013896009,0.0013012913,0.00025002408,0.0003133369,0.00092003413,0.000038528844,0.0005127351],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99696916,0.0011829971,0.0008579215,0.0005519157,0.00027780238,0.00016022635],"domain_scores_gemma":[0.99561536,0.002900824,0.00094503054,0.0001695001,0.0002625066,0.00010684937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042038225,0.0020003086,0.012498448,0.0022670557,0.00048090718,0.0020684465,0.0014958213,0.0018345822,0.0039274767],"category_scores_gemma":[0.010153064,0.0011916301,0.026084129,0.0035399948,0.0006158917,0.00152968,0.0013423433,0.0022224276,0.0003650575],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004514553,0.00004618418,0.005856513,0.29821298,0.67478746,0.00010758049,0.00011030154,0.00041346534,0.00033571423,0.00009393275,0.0008677469,0.014653533],"study_design_scores_gemma":[0.0014120877,0.00023091832,0.0061498987,0.012337097,0.9780935,0.00007079661,0.000061072475,0.000109973866,0.00007020615,0.00013476438,0.0012991956,0.000030420335],"about_ca_topic_score_codex":0.007282038,"about_ca_topic_score_gemma":0.025896147,"teacher_disagreement_score":0.012498448,"about_ca_system_score_codex":0.0014566982,"about_ca_system_score_gemma":0.0018990816,"threshold_uncertainty_score":0.022232234},"labels":[],"label_agreement":null},{"id":"W4404436762","doi":"10.1016/j.clgc.2024.102269","title":"Trends and Disparities in Inpatient Palliative Care Use in Metastatic Renal Cell Carcinoma Patients Receiving Critical Care Therapy","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Palliative care; Intensive care medicine; Internal medicine; Oncology; Nursing","score_opus":0.23133950319896626,"score_gpt":0.4877354794917965,"score_spread":0.2563959762928303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404436762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982857,0.00048188886,0.000049616676,0.0003130388,0.0000055822225,0.000004320111,0.0004765373,0.0000018078614,0.00038150788],"genre_scores_gemma":[0.9992761,0.00023694908,0.000039113886,0.000047130932,0.000008584965,0.000003935096,0.00034716708,9.000934e-7,0.000040141047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955434,0.000095737356,0.00006742507,0.00009149438,0.000077788056,0.00011312334],"domain_scores_gemma":[0.9983754,0.00020913125,0.0009916693,0.00004729205,0.00016835351,0.00020805406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046629854,0.00007672646,0.00020809489,0.0006420757,0.00026189975,0.00040729268,0.00028107225,0.00023815197,0.0010513625],"category_scores_gemma":[0.002375643,0.00010546959,0.00030789452,0.0013854951,0.00020139226,0.00042724703,0.0005119726,0.0004248281,0.00007317029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002162853,0.000016695885,0.9980001,0.000011901928,0.00003014249,0.000018354021,0.00009480474,0.000057302277,0.000052993924,0.00006180332,0.00013831933,0.0014958446],"study_design_scores_gemma":[0.0000022351594,0.0000152137745,0.99908316,0.000016952425,0.000010099188,0.000045919634,0.0002971414,0.00029555615,0.0000242042,0.000028735798,0.00017878378,0.000001910714],"about_ca_topic_score_codex":0.036056463,"about_ca_topic_score_gemma":0.056083534,"teacher_disagreement_score":0.036056463,"about_ca_system_score_codex":0.00075147575,"about_ca_system_score_gemma":0.00079897087,"threshold_uncertainty_score":0.07169318},"labels":[],"label_agreement":null},{"id":"W4404630453","doi":"10.1016/j.clgc.2024.102274","title":"Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Neuroendocrine tumors; Cancer; Prostate","score_opus":0.11318034506068382,"score_gpt":0.48364685449129363,"score_spread":0.3704665094306098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404630453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99809223,0.0007431135,0.00017252278,0.00007449253,0.000007497192,0.0000057256134,0.0005539736,0.00000432389,0.0003461378],"genre_scores_gemma":[0.9995431,0.00007172341,0.00005226111,0.000006547099,0.0000074168124,0.0000037143682,0.00029795594,9.901096e-7,0.000016395597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919003,0.00033797708,0.00009460446,0.00013834263,0.00014708431,0.00009200878],"domain_scores_gemma":[0.995004,0.0012505772,0.0026896086,0.00019205704,0.00032926296,0.0005345337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001199705,0.00020186057,0.0002430277,0.0007945392,0.0002939227,0.00069893803,0.00039381275,0.00036751124,0.0011662791],"category_scores_gemma":[0.004988559,0.00011537941,0.0002696264,0.0012007933,0.00042842486,0.0005503104,0.0004883936,0.00045803643,0.00019159456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060618,0.0000062194777,0.998899,0.000008369749,0.00002105142,0.000060066537,0.000019697734,0.0000775492,0.000035299578,0.000013898729,0.00004997431,0.00074834574],"study_design_scores_gemma":[0.0000039763695,0.00006298248,0.9984346,0.0000057266434,0.000021131262,0.0007294201,0.00011304296,0.0002809254,0.00005481482,0.00007320002,0.00021380832,0.00000645615],"about_ca_topic_score_codex":0.0008580446,"about_ca_topic_score_gemma":0.0012500838,"teacher_disagreement_score":0.001199705,"about_ca_system_score_codex":0.000392527,"about_ca_system_score_gemma":0.00032491874,"threshold_uncertainty_score":0.0063447356},"labels":[],"label_agreement":null},{"id":"W4406169109","doi":"10.1016/j.clgc.2025.102300","title":"Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostatectomy; Prostate cancer; Urology; Stage (stratigraphy); Cancer; Internal medicine","score_opus":0.019467790870964785,"score_gpt":0.36674264614547786,"score_spread":0.3472748552745131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406169109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99660194,0.00048654078,0.00007739442,0.000089715584,0.000016633743,0.0000072525027,0.0002872123,0.0000075058715,0.002425698],"genre_scores_gemma":[0.99966824,0.000052110478,0.000022792776,0.000013036506,0.000011837363,0.0000012661851,0.00013882776,9.494327e-7,0.000091021066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998118,0.000031473555,0.000016637485,0.000034095865,0.00003760595,0.00006829218],"domain_scores_gemma":[0.9992483,0.000118617485,0.0002592045,0.00003062247,0.00004661667,0.00029668192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018980227,0.00024697912,0.00024584157,0.0006682201,0.00042135088,0.0006645949,0.00027782161,0.0003274597,0.0023348983],"category_scores_gemma":[0.00149956,0.0001333231,0.0003193083,0.0006078928,0.00033120692,0.00035206048,0.00048360837,0.00056471507,0.00017843422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032395023,0.000017191885,0.9965604,0.000008946608,0.000016474172,0.00019363,0.000030883213,0.00006235053,0.0003254775,0.00003879845,0.00011841535,0.0023035142],"study_design_scores_gemma":[0.000004902528,0.0000786052,0.998904,0.000004178401,0.000026722557,0.00044144643,0.00011964529,0.00012153905,0.00007606524,0.00008728162,0.0001322134,0.000003457788],"about_ca_topic_score_codex":0.0030679666,"about_ca_topic_score_gemma":0.0072196415,"teacher_disagreement_score":0.0030679666,"about_ca_system_score_codex":0.00027529118,"about_ca_system_score_gemma":0.00042744275,"threshold_uncertainty_score":0.00781101},"labels":[],"label_agreement":null},{"id":"W4406771426","doi":"10.1016/j.clgc.2025.102306","title":"Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Bladder cancer; Meta-analysis; Urology; Oncology; Cancer; Internal medicine","score_opus":0.14743990973766827,"score_gpt":0.4676024706977903,"score_spread":0.3201625609601221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406771426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030677542,0.9955515,0.00033040604,0.00014218516,0.00009649279,0.00018678216,0.0003946282,0.00001740914,0.0002127163],"genre_scores_gemma":[0.11752313,0.8779198,0.0016117251,0.00087779737,0.00022645245,0.0007005669,0.00079825066,0.00002515709,0.00031714482],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936505,0.0028677646,0.0019207529,0.0006224563,0.00070083153,0.00023768196],"domain_scores_gemma":[0.98864204,0.008320143,0.001678339,0.00030538542,0.00087178516,0.00018230634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009371339,0.0024685618,0.01617623,0.0059340415,0.000584811,0.002795036,0.0018036402,0.0020815865,0.0036190297],"category_scores_gemma":[0.01995473,0.0013271739,0.037780035,0.0064279656,0.0005437715,0.0014470691,0.0012984631,0.0017189214,0.0003258335],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021693846,0.000039721595,0.002585878,0.43626064,0.5416066,0.00011810836,0.00006032522,0.00041894015,0.00023231002,0.00012389175,0.00059290254,0.015791304],"study_design_scores_gemma":[0.00061995356,0.0002150184,0.002629951,0.026950877,0.9673708,0.000076534656,0.000033856948,0.00015541037,0.00010213126,0.00014485132,0.0016814615,0.000019159319],"about_ca_topic_score_codex":0.006956789,"about_ca_topic_score_gemma":0.01725859,"teacher_disagreement_score":0.01617623,"about_ca_system_score_codex":0.0020488005,"about_ca_system_score_gemma":0.0033000328,"threshold_uncertainty_score":0.049560964},"labels":[],"label_agreement":null},{"id":"W4407122004","doi":"10.1016/j.clgc.2025.102313","title":"Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi; Cégep de Chicoutimi; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck Sharp and Dohme; EMD Serono; Astellas Pharma; Natera; Bladder Cancer Advocacy Network; American Association for Cancer Research; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Bladder cancer; Urothelial cancer; Chart; Oncology; Cancer; Internal medicine; Bacillus (shape); Urology","score_opus":0.021617643058209353,"score_gpt":0.3654198877687889,"score_spread":0.3438022447105796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407122004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835154,0.0075392765,0.0004856573,0.0003188334,0.000018925713,0.00011653341,0.006383513,0.000030190498,0.0015916575],"genre_scores_gemma":[0.9929147,0.0026329043,0.00062508637,0.000093527764,0.000021383285,0.00006162424,0.0034989244,0.0000061057767,0.00014567572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987973,0.00023898282,0.00035009003,0.00022405184,0.00029451592,0.000095010946],"domain_scores_gemma":[0.99258196,0.0013281237,0.004564307,0.00023738154,0.0009839716,0.00030425124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010142602,0.00011812267,0.00025360065,0.0025673723,0.000344818,0.0005442452,0.0003677478,0.00023210187,0.00065388565],"category_scores_gemma":[0.003741057,0.00014286317,0.00024138487,0.0032634577,0.00024491604,0.0005651108,0.0004125316,0.00019268737,0.00011214605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028409855,0.000007950468,0.99391454,0.00011967854,0.000033324264,0.00022788624,0.0002326838,0.000034259614,0.00013909378,0.000028514902,0.0005202529,0.004713416],"study_design_scores_gemma":[0.0000033136869,0.000025473846,0.99690515,0.00010656215,0.000025439906,0.00080330926,0.00056216435,0.00011603406,0.00014278562,0.0000133996,0.0012899414,0.0000065959134],"about_ca_topic_score_codex":0.009623349,"about_ca_topic_score_gemma":0.013149477,"teacher_disagreement_score":0.009623349,"about_ca_system_score_codex":0.00077475695,"about_ca_system_score_gemma":0.0011888309,"threshold_uncertainty_score":0.01913464},"labels":[],"label_agreement":null},{"id":"W4407790476","doi":"10.1016/j.clgc.2025.102320","title":"Lymphovascular Invasion Predicts Cancer-specific Mortality in Penile Localized Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Lymphovascular invasion; Penile cancer; Oncology; Basal cell; Cancer; Internal medicine; Metastasis","score_opus":0.06391110629489691,"score_gpt":0.3895034241149258,"score_spread":0.32559231782002884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407790476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983259,0.000829152,0.00013976509,0.00005282137,0.000004871103,0.0000049128857,0.0003678824,0.0000064909555,0.00026817078],"genre_scores_gemma":[0.9995054,0.0001540306,0.000045347664,0.0000075036273,0.000007970622,0.0000026554749,0.00020022776,0.0000010061433,0.00007592422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998672,0.000035139492,0.000012293971,0.000032401727,0.000031491418,0.000021531718],"domain_scores_gemma":[0.9989266,0.0002918237,0.00041972107,0.000059173595,0.00009509487,0.00020750135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003675568,0.00024129673,0.00024027925,0.00043790406,0.00014197448,0.00040715467,0.00025335365,0.0002065666,0.0021275755],"category_scores_gemma":[0.0016977733,0.00011677716,0.00033394096,0.0005290673,0.00016346517,0.000216669,0.00032532788,0.00041760507,0.0001927469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000633395,0.000010366815,0.9980426,0.000012648923,0.000031138447,0.00003815188,0.000008962119,0.0001123593,0.00010311289,0.000004420488,0.00005913837,0.0015137646],"study_design_scores_gemma":[0.0000048319557,0.00005137661,0.99895346,0.000010109363,0.000038080037,0.00021202568,0.000028472012,0.0005066395,0.00009033824,0.000028557972,0.00007366754,0.0000023456232],"about_ca_topic_score_codex":0.001992466,"about_ca_topic_score_gemma":0.0032772245,"teacher_disagreement_score":0.0021275755,"about_ca_system_score_codex":0.00021688025,"about_ca_system_score_gemma":0.00031638594,"threshold_uncertainty_score":0.00711751},"labels":[],"label_agreement":null},{"id":"W4409197276","doi":"10.1016/j.clgc.2025.102342","title":"Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; London Health Sciences Centre; Western University; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; McMaster University; BC Cancer Agency; Alberta Health Services; University of Calgary; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; University Health Network; Dalhousie University; University of Manitoba; Juravinski Cancer Centre; McGill University; McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Renal cell carcinoma; Nephrectomy; Oncology; Internal medicine; Urology; Pathology; Kidney","score_opus":0.06990687001142348,"score_gpt":0.38939416906212765,"score_spread":0.31948729905070417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409197276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564725,0.0028748345,0.0003687696,0.00011778011,0.000039095547,0.000029968047,0.0002884976,0.0000040555333,0.00062975247],"genre_scores_gemma":[0.9987326,0.0007124219,0.00020793447,0.000042057247,0.000028068798,0.000012221418,0.00021773459,0.0000025661348,0.00004440123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995435,0.00015470218,0.00005282304,0.00010519523,0.00006289556,0.00008091747],"domain_scores_gemma":[0.9986168,0.00042145213,0.00058522826,0.00004705476,0.00010341918,0.00022597941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007152839,0.00024688826,0.0005920147,0.00036295512,0.0002740742,0.00067563227,0.0002599457,0.0003788401,0.0011928004],"category_scores_gemma":[0.0030350722,0.00014119643,0.000618337,0.00069964345,0.00027404676,0.0005181953,0.00024642685,0.0004673922,0.00013731247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011994804,0.00046749972,0.950842,0.0002650824,0.00047856747,0.0006966858,0.00022432485,0.0016653716,0.0013261833,0.00022024108,0.00077113224,0.03104803],"study_design_scores_gemma":[0.00044572723,0.004401709,0.9839505,0.00013498425,0.0008828897,0.0015130911,0.0010507152,0.0027179103,0.00070469035,0.00054794055,0.0036035231,0.00004624366],"about_ca_topic_score_codex":0.0018254085,"about_ca_topic_score_gemma":0.0027782314,"teacher_disagreement_score":0.0018254085,"about_ca_system_score_codex":0.0008684997,"about_ca_system_score_gemma":0.0008628112,"threshold_uncertainty_score":0.006301403},"labels":[],"label_agreement":null},{"id":"W4411275540","doi":"10.1016/j.clgc.2025.102385","title":"Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Discontinuation; Comorbidity; Internal medicine; Hazard ratio; Renal cell carcinoma; Nivolumab; Adverse effect; Oncology; Confidence interval; Cancer; Immunotherapy","score_opus":0.04757200492122552,"score_gpt":0.38146650259542847,"score_spread":0.33389449767420293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411275540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923942,0.004831492,0.000096878226,0.000598855,0.000032841013,0.0000057030556,0.0005009821,0.000004641927,0.0015342733],"genre_scores_gemma":[0.99879634,0.0005711431,0.000041479667,0.000064385116,0.00005010895,0.0000024666253,0.00036325766,0.0000017895007,0.00010907082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947566,0.00018005526,0.00007450272,0.000059396876,0.00010127607,0.000109140936],"domain_scores_gemma":[0.9976539,0.0005078118,0.0011581216,0.00008349234,0.0001367774,0.0004598964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005036998,0.00012235204,0.0004978855,0.0003805105,0.00034678314,0.00063451723,0.0002380364,0.0003322474,0.0018906271],"category_scores_gemma":[0.0054535535,0.00010627584,0.0008139477,0.0009973994,0.00017856562,0.00043641345,0.00049556664,0.00055001205,0.00011740623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016745994,0.00010613753,0.98235357,0.000059426686,0.00046993414,0.000076885066,0.000029554727,0.0007841301,0.00033482534,0.0001677698,0.00045199523,0.013491191],"study_design_scores_gemma":[0.000026600648,0.00023787761,0.9980075,0.00001886565,0.0001453745,0.00020200448,0.00006353134,0.00073657255,0.000055051056,0.00012948671,0.00037183746,0.000005382595],"about_ca_topic_score_codex":0.005158517,"about_ca_topic_score_gemma":0.008320829,"teacher_disagreement_score":0.005158517,"about_ca_system_score_codex":0.0008383392,"about_ca_system_score_gemma":0.00065910595,"threshold_uncertainty_score":0.010256946},"labels":[],"label_agreement":null},{"id":"W4414089879","doi":"10.1016/j.clgc.2025.102431","title":"CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Therapure Biopharma (Canada); Institute of Cancer Research; Alberta Cancer Foundation; University of Calgary","funders":"Ipsen; Ipsen Biopharmaceuticals","keywords":"Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Metastatic melanoma; Emulation; Clinical trial; Expanded access","score_opus":0.282927175586458,"score_gpt":0.4596656794035395,"score_spread":0.17673850381708145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414089879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873017,0.0037581178,0.0012771088,0.00041897674,0.00022555717,0.0027676038,0.002497024,0.00010155621,0.0016524991],"genre_scores_gemma":[0.99336666,0.00061621,0.0010839583,0.00029225025,0.000088837915,0.0019894547,0.001591645,0.000018650995,0.00095246977],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99538785,0.003524743,0.00028824728,0.00034678492,0.00022863664,0.00022374085],"domain_scores_gemma":[0.99679875,0.0015570665,0.0008917006,0.00024027622,0.00018087012,0.0003313526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00721959,0.0012489603,0.0025200944,0.00043540183,0.00022967943,0.0010730277,0.0011527494,0.0013617637,0.0045303255],"category_scores_gemma":[0.0065452713,0.00047802334,0.00513652,0.00038991112,0.0007060098,0.001121663,0.000595342,0.0021071136,0.0005734141],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97924656,0.0017795805,0.0019822791,0.0006034481,0.0035780526,0.000033233526,0.000054843797,0.0020050968,0.0012190341,0.00016327786,0.0004540482,0.0088805575],"study_design_scores_gemma":[0.78349173,0.1834608,0.013262306,0.000120910925,0.0059625595,0.00013235532,0.00008215182,0.00905835,0.0014594861,0.00074664596,0.002171242,0.000051494673],"about_ca_topic_score_codex":0.0014162523,"about_ca_topic_score_gemma":0.0022674517,"teacher_disagreement_score":0.00721959,"about_ca_system_score_codex":0.0014140126,"about_ca_system_score_gemma":0.0010496761,"threshold_uncertainty_score":0.038181245},"labels":[],"label_agreement":null},{"id":"W4414113945","doi":"10.1016/j.clgc.2025.102429","title":"Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D’amico Risk Groups in A Contemporary Cohort","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"","keywords":"Prostate cancer; External beam radiation; Cohort; External beam radiotherapy; Bladder cancer; Prostate; Radiation therapy; Affect (linguistics)","score_opus":0.03408347317099797,"score_gpt":0.38332738780107994,"score_spread":0.349243914630082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414113945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985813,0.00020317735,0.00006342478,0.0000425826,0.000005427811,0.0000034725535,0.00050522777,0.0000044813646,0.00059091253],"genre_scores_gemma":[0.9990602,0.00010862932,0.000032527132,0.000019292245,0.000009418417,0.000004383397,0.00043708264,0.0000041201697,0.00032445512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995672,0.00005454157,0.000038334187,0.00015891898,0.00005122016,0.00012969029],"domain_scores_gemma":[0.99913245,0.00014072726,0.00031294592,0.00011928411,0.00008700469,0.00020770609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031341228,0.00020023691,0.00036001453,0.0011352829,0.00045887876,0.0007173373,0.0004021529,0.0005496408,0.0029069134],"category_scores_gemma":[0.0015895519,0.00049197196,0.00096073817,0.0010321145,0.00029240362,0.0005588884,0.00076125836,0.0006915676,0.0003440416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011090823,0.000017178561,0.99884415,0.0000025237623,0.00005061412,0.000038272752,0.00006672621,0.000038251845,0.000105218314,0.000022254384,0.00008854213,0.00061534793],"study_design_scores_gemma":[0.0000027351086,0.000032765245,0.99935,0.0000018694916,0.00001599858,0.00014655587,0.00016342815,0.00010624235,0.000025775144,0.000019992047,0.00013129055,0.0000032853434],"about_ca_topic_score_codex":0.016722264,"about_ca_topic_score_gemma":0.014219932,"teacher_disagreement_score":0.016722264,"about_ca_system_score_codex":0.0004339193,"about_ca_system_score_gemma":0.00034600397,"threshold_uncertainty_score":0.033249855},"labels":[],"label_agreement":null},{"id":"W4416397242","doi":"10.1016/j.clgc.2025.102467","title":"Transperineal versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Clinical Genitourinary Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Prostate cancer; Randomized controlled trial; Prostate; Urinary retention; Odds ratio; Confidence interval; Prostate biopsy; Meta-analysis; Complication","score_opus":0.24107333823660282,"score_gpt":0.5052030998858291,"score_spread":0.2641297616492263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416397242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048057176,0.9935895,0.0004970743,0.0001221036,0.0001420146,0.0002626231,0.00037952635,0.00002560546,0.00017585701],"genre_scores_gemma":[0.18010546,0.81312335,0.0031295284,0.0013971651,0.0002570221,0.00078888546,0.0006685938,0.00005525966,0.00047469692],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9914903,0.004319759,0.0021888958,0.001075026,0.0006386379,0.00028744133],"domain_scores_gemma":[0.9874061,0.009399407,0.0021795747,0.00033866873,0.00048012464,0.00019609027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01004735,0.0032206818,0.021236837,0.0036413304,0.00062172074,0.0031445902,0.0025326612,0.0026594526,0.0060125003],"category_scores_gemma":[0.026599564,0.0018154391,0.030144567,0.0046935854,0.0010108757,0.0025265494,0.0019114864,0.00320497,0.00041329602],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054988684,0.000031638778,0.0016808717,0.38021016,0.6018995,0.000079500736,0.00008601419,0.0003085058,0.00020102826,0.000101942045,0.0004832301,0.009418767],"study_design_scores_gemma":[0.0029302894,0.00022142452,0.0019003971,0.017205512,0.9762422,0.00006456665,0.000055516848,0.00010575926,0.00006555404,0.00020148035,0.0009824722,0.000024711197],"about_ca_topic_score_codex":0.00698862,"about_ca_topic_score_gemma":0.020175213,"teacher_disagreement_score":0.021236837,"about_ca_system_score_codex":0.0023871707,"about_ca_system_score_gemma":0.002816506,"threshold_uncertainty_score":0.05313611},"labels":[],"label_agreement":null},{"id":"W4417259318","doi":"10.1016/j.clgc.2025.102484","title":"Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache","funders":"","keywords":"Renal cell carcinoma; First line; Attrition; First line therapy; Second line; Line (geometry); Expanded access","score_opus":0.0958034315958499,"score_gpt":0.38373461358010946,"score_spread":0.28793118198425954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417259318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8976076,0.003858079,0.00022417842,0.0006187944,0.000032036263,0.00014212678,0.095698245,0.000048199207,0.0017707889],"genre_scores_gemma":[0.93123686,0.00143318,0.00023239003,0.00041999013,0.00004894695,0.0002001786,0.06559029,0.000022138816,0.0008159303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944208,0.0014126082,0.0012608096,0.00088453956,0.0013108877,0.0007103149],"domain_scores_gemma":[0.97771543,0.0032509256,0.012891069,0.0015901056,0.0031880592,0.0013643666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048754546,0.0002536478,0.0012212268,0.0021220995,0.000650178,0.001753797,0.00167435,0.000858146,0.0018218177],"category_scores_gemma":[0.02212841,0.00025835005,0.0020917254,0.006668249,0.00024425305,0.0009803169,0.0018016616,0.00089470134,0.00047145673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012990369,0.00006885149,0.9889592,0.00018552729,0.0003731335,0.00002314598,0.00012386193,0.0002400242,0.000027240267,0.000051504914,0.0027107585,0.005937756],"study_design_scores_gemma":[0.000073983574,0.00016111303,0.9975672,0.00006600045,0.00027408105,0.00006370548,0.00016413817,0.00037878018,0.00007411697,0.000021212947,0.0011427093,0.00001311464],"about_ca_topic_score_codex":0.093431816,"about_ca_topic_score_gemma":0.07205285,"teacher_disagreement_score":0.093431816,"about_ca_system_score_codex":0.0034223641,"about_ca_system_score_gemma":0.0032960298,"threshold_uncertainty_score":0.185776},"labels":[],"label_agreement":null},{"id":"W7116661595","doi":"10.1016/j.clgc.2025.102491","title":"Efficacy and Safety of Immune Checkpoint Blockade in Locally Advanced or Metastatic Penile Cancer: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Genital Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blockade; Adverse effect; Immune checkpoint; Hazard ratio; Meta-analysis; Malignancy; Incidence (geometry); Immunotherapy; Penile cancer","score_opus":0.07886086246731193,"score_gpt":0.4474153223984749,"score_spread":0.368554459931163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116661595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018042106,0.9800245,0.0005186732,0.00016611927,0.00016552088,0.00012700236,0.0006545647,0.000026399344,0.0002751431],"genre_scores_gemma":[0.5176678,0.47669247,0.0016302099,0.0016154553,0.0003633125,0.00039585226,0.0010620337,0.000042039148,0.00053091627],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9953585,0.0017979397,0.001321543,0.00085382216,0.00043674913,0.00023134013],"domain_scores_gemma":[0.9920047,0.0053790496,0.0016673874,0.00035248522,0.0004387879,0.00015762715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068883463,0.0021367823,0.013958934,0.0023363594,0.00046237715,0.002371093,0.0016886427,0.002263398,0.0033202844],"category_scores_gemma":[0.014793384,0.0012247569,0.033951677,0.0034832605,0.0007341023,0.0016124692,0.0013318857,0.0020649277,0.0003183147],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060583134,0.000040551684,0.008100563,0.15059476,0.8258908,0.000104159306,0.00006651766,0.00048701785,0.00037861156,0.00007738764,0.00042418964,0.007777178],"study_design_scores_gemma":[0.001086548,0.0002373977,0.004860048,0.004365207,0.9884477,0.00005477833,0.000032102926,0.00010671493,0.00006891788,0.00009057849,0.00062996405,0.000020095878],"about_ca_topic_score_codex":0.00491859,"about_ca_topic_score_gemma":0.012895375,"teacher_disagreement_score":0.013958934,"about_ca_system_score_codex":0.0013940791,"about_ca_system_score_gemma":0.0015869795,"threshold_uncertainty_score":0.036429465},"labels":[],"label_agreement":null}]}